Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
Diagnose is an umlsterm, Glykogenose is an umlsterm, Enzymassay is an umlsterm, Lebergewebe is an umlsterm, Gens is an umlsterm, Mutationen is an umlsterm, Patienten is an umlsterm, Glykogenose is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Enzymassays is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm
MonatsschriftKinderheilkunde.81460660.ger.abstr_task0
Sentence: Hintergrund : Als Goldstandard fuer die Diagnose der Glykogenose Typ Ia gilt noch der Enzymassay in frischem Lebergewebe . 1993 gelang die Isolation des Gens , welches fuer die menschliche Phosphatase ( G-6-Pase) des Glukose-6-Phosphatase-Systems kodiert , und die ersten Mutationen sind bei Glykogenose-Typ-Ia-Patienten gefunden worden . Wir haben das G-6-Pase-Gen von 18 Patienten mit Glykogenose Typ Ia analysiert . Die Diagnose war bei 13 Patienten bereits frueher mittels des Enzymassays gesichert worden . Bei den uebrigen 5 Patienten basierte die Diagnose auf dem klinischen Bild . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Hintergrund : Als Goldstandard fuer die Diagnose der Glykogenose Typ Ia gilt noch der Enzymassay in frischem Lebergewebe . 1993 gelang die Isolation des Gens , welches fuer die menschliche Phosphatase ( G-6-Pase) des Glukose-6-Phosphatase-Systems kodiert , und die ersten Mutationen sind bei Glykogenose-Typ-Ia-Patienten gefunden worden . Wir haben das G-6-Pase-Gen von 18 Patienten mit Glykogenose Typ Ia analysiert . Die Diagnose war bei 13 Patienten bereits frueher mittels des Enzymassays gesichert worden . Bei den uebrigen 5 Patienten basierte die Diagnose auf dem klinischen Bild .
[ "Hintergrund", ":", "Als", "Goldstandard", "fuer", "die", "Diagnose", "der", "Glykogenose", "Typ", "Ia", "gilt", "noch", "der", "Enzymassay", "in", "frischem", "Lebergewebe", ".", "1993", "gelang", "die", "Isolation", "des", "Gens", ",", "welches", "fuer", "die", "menschliche", "Phosphatase", "(", "G-6-Pase", ")", "des", "Glukose-6-Phosphatase", "-", "Systems", "kodiert", ",", "und", "die", "ersten", "Mutationen", "sind", "bei", "Glykogenose", "-", "Typ", "-", "Ia", "-", "Patienten", "gefunden", "worden", ".", "Wir", "haben", "das", "G-6-Pase", "-", "Gen", "von", "18", "Patienten", "mit", "Glykogenose", "Typ", "Ia", "analysiert", ".", "Die", "Diagnose", "war", "bei", "13", "Patienten", "bereits", "frueher", "mittels", "des", "Enzymassays", "gesichert", "worden", ".", "Bei", "den", "uebrigen", "5", "Patienten", "basierte", "die", "Diagnose", "auf", "dem", "klinischen", "Bild", "." ]
[ "umlsterm" ]
Diagnose is an umlsterm, Glykogenose is an umlsterm, Enzymassay is an umlsterm, Lebergewebe is an umlsterm, Gens is an umlsterm, Mutationen is an umlsterm, Patienten is an umlsterm, Glykogenose is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Enzymassays is an umlsterm, Patienten is an umlsterm, Diagnose is an umlsterm
MonatsschriftKinderheilkunde.81460660.ger.abstr_task1
Sentence: Hintergrund : Als Goldstandard fuer die Diagnose der Glykogenose Typ Ia gilt noch der Enzymassay in frischem Lebergewebe . 1993 gelang die Isolation des Gens , welches fuer die menschliche Phosphatase ( G-6-Pase) des Glukose-6-Phosphatase-Systems kodiert , und die ersten Mutationen sind bei Glykogenose-Typ-Ia-Patienten gefunden worden . Wir haben das G-6-Pase-Gen von 18 Patienten mit Glykogenose Typ Ia analysiert . Die Diagnose war bei 13 Patienten bereits frueher mittels des Enzymassays gesichert worden . Bei den uebrigen 5 Patienten basierte die Diagnose auf dem klinischen Bild . Instructions: please typing these entity words according to sentence: Diagnose, Glykogenose, Enzymassay, Lebergewebe, Gens, Mutationen, Patienten, Glykogenose, Diagnose, Patienten, Enzymassays, Patienten, Diagnose Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Hintergrund : Als Goldstandard fuer die Diagnose der Glykogenose Typ Ia gilt noch der Enzymassay in frischem Lebergewebe . 1993 gelang die Isolation des Gens , welches fuer die menschliche Phosphatase ( G-6-Pase) des Glukose-6-Phosphatase-Systems kodiert , und die ersten Mutationen sind bei Glykogenose-Typ-Ia-Patienten gefunden worden . Wir haben das G-6-Pase-Gen von 18 Patienten mit Glykogenose Typ Ia analysiert . Die Diagnose war bei 13 Patienten bereits frueher mittels des Enzymassays gesichert worden . Bei den uebrigen 5 Patienten basierte die Diagnose auf dem klinischen Bild .
[ "Hintergrund", ":", "Als", "Goldstandard", "fuer", "die", "Diagnose", "der", "Glykogenose", "Typ", "Ia", "gilt", "noch", "der", "Enzymassay", "in", "frischem", "Lebergewebe", ".", "1993", "gelang", "die", "Isolation", "des", "Gens", ",", "welches", "fuer", "die", "menschliche", "Phosphatase", "(", "G-6-Pase", ")", "des", "Glukose-6-Phosphatase", "-", "Systems", "kodiert", ",", "und", "die", "ersten", "Mutationen", "sind", "bei", "Glykogenose", "-", "Typ", "-", "Ia", "-", "Patienten", "gefunden", "worden", ".", "Wir", "haben", "das", "G-6-Pase", "-", "Gen", "von", "18", "Patienten", "mit", "Glykogenose", "Typ", "Ia", "analysiert", ".", "Die", "Diagnose", "war", "bei", "13", "Patienten", "bereits", "frueher", "mittels", "des", "Enzymassays", "gesichert", "worden", ".", "Bei", "den", "uebrigen", "5", "Patienten", "basierte", "die", "Diagnose", "auf", "dem", "klinischen", "Bild", "." ]
[ "umlsterm" ]
Diagnose, Glykogenose, Enzymassay, Lebergewebe, Gens, Mutationen, Patienten, Glykogenose, Diagnose, Patienten, Enzymassays, Patienten, Diagnose
MonatsschriftKinderheilkunde.81460660.ger.abstr_task2
Sentence: Hintergrund : Als Goldstandard fuer die Diagnose der Glykogenose Typ Ia gilt noch der Enzymassay in frischem Lebergewebe . 1993 gelang die Isolation des Gens , welches fuer die menschliche Phosphatase ( G-6-Pase) des Glukose-6-Phosphatase-Systems kodiert , und die ersten Mutationen sind bei Glykogenose-Typ-Ia-Patienten gefunden worden . Wir haben das G-6-Pase-Gen von 18 Patienten mit Glykogenose Typ Ia analysiert . Die Diagnose war bei 13 Patienten bereits frueher mittels des Enzymassays gesichert worden . Bei den uebrigen 5 Patienten basierte die Diagnose auf dem klinischen Bild . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Hintergrund : Als Goldstandard fuer die Diagnose der Glykogenose Typ Ia gilt noch der Enzymassay in frischem Lebergewebe . 1993 gelang die Isolation des Gens , welches fuer die menschliche Phosphatase ( G-6-Pase) des Glukose-6-Phosphatase-Systems kodiert , und die ersten Mutationen sind bei Glykogenose-Typ-Ia-Patienten gefunden worden . Wir haben das G-6-Pase-Gen von 18 Patienten mit Glykogenose Typ Ia analysiert . Die Diagnose war bei 13 Patienten bereits frueher mittels des Enzymassays gesichert worden . Bei den uebrigen 5 Patienten basierte die Diagnose auf dem klinischen Bild .
[ "Hintergrund", ":", "Als", "Goldstandard", "fuer", "die", "Diagnose", "der", "Glykogenose", "Typ", "Ia", "gilt", "noch", "der", "Enzymassay", "in", "frischem", "Lebergewebe", ".", "1993", "gelang", "die", "Isolation", "des", "Gens", ",", "welches", "fuer", "die", "menschliche", "Phosphatase", "(", "G-6-Pase", ")", "des", "Glukose-6-Phosphatase", "-", "Systems", "kodiert", ",", "und", "die", "ersten", "Mutationen", "sind", "bei", "Glykogenose", "-", "Typ", "-", "Ia", "-", "Patienten", "gefunden", "worden", ".", "Wir", "haben", "das", "G-6-Pase", "-", "Gen", "von", "18", "Patienten", "mit", "Glykogenose", "Typ", "Ia", "analysiert", ".", "Die", "Diagnose", "war", "bei", "13", "Patienten", "bereits", "frueher", "mittels", "des", "Enzymassays", "gesichert", "worden", ".", "Bei", "den", "uebrigen", "5", "Patienten", "basierte", "die", "Diagnose", "auf", "dem", "klinischen", "Bild", "." ]
[ "umlsterm" ]
JNK / SAPK is a protein, MEKK1 Peptides is a peptide
1.0alpha7.train.1026_task0
Sentence: Endogenous JNK/SAPK Isoforms Bind to MEKK1 Peptides Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: peptide, protein
[ "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "B-peptide", "I-peptide" ]
Endogenous JNK/SAPK Isoforms Bind to MEKK1 Peptides
[ "Endogenous", "JNK", "/", "SAPK", "Isoforms", "Bind", "to", "MEKK1", "Peptides" ]
[ "peptide", "protein" ]
JNK / SAPK is a protein, MEKK1 Peptides is a peptide
1.0alpha7.train.1026_task1
Sentence: Endogenous JNK/SAPK Isoforms Bind to MEKK1 Peptides Instructions: please typing these entity words according to sentence: JNK / SAPK, MEKK1 Peptides Options: peptide, protein
[ "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "B-peptide", "I-peptide" ]
Endogenous JNK/SAPK Isoforms Bind to MEKK1 Peptides
[ "Endogenous", "JNK", "/", "SAPK", "Isoforms", "Bind", "to", "MEKK1", "Peptides" ]
[ "peptide", "protein" ]
JNK / SAPK, MEKK1 Peptides
1.0alpha7.train.1026_task2
Sentence: Endogenous JNK/SAPK Isoforms Bind to MEKK1 Peptides Instructions: please extract entity words from the input sentence
[ "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "B-peptide", "I-peptide" ]
Endogenous JNK/SAPK Isoforms Bind to MEKK1 Peptides
[ "Endogenous", "JNK", "/", "SAPK", "Isoforms", "Bind", "to", "MEKK1", "Peptides" ]
[ "peptide", "protein" ]
Dynamin 2 is a protein, SH3 is a protein-domain, amphiphysin is a protein, M - amphiphysin 2 is a protein-isoform, BAR * is a protein-domain
1.0alpha7.train.437_task0
Sentence: Dynamin 2, a binding partner of the SH3 domain of amphiphysin (9), was recruited to the tubules when coexpressed with M-amphiphysin 2 (Fig. 2D), but not when coexpressed with its BAR* domain, which was sufficient to induce tubulation (Fig. 2, B and E). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-domain, protein-isoform, protein
[ "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-isoform", "I-protein-isoform", "I-protein-isoform", "I-protein-isoform", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Dynamin 2, a binding partner of the SH3 domain of amphiphysin (9), was recruited to the tubules when coexpressed with M-amphiphysin 2 (Fig. 2D), but not when coexpressed with its BAR* domain, which was sufficient to induce tubulation (Fig. 2, B and E).
[ "Dynamin", "2", ",", "a", "binding", "partner", "of", "the", "SH3", "domain", "of", "amphiphysin", "(", "9", ")", ",", "was", "recruited", "to", "the", "tubules", "when", "coexpressed", "with", "M", "-", "amphiphysin", "2", "(", "Fig", ".", "2D", ")", ",", "but", "not", "when", "coexpressed", "with", "its", "BAR", "*", "domain", ",", "which", "was", "sufficient", "to", "induce", "tubulation", "(", "Fig", ".", "2", ",", "B", "and", "E", ")", "." ]
[ "protein-isoform", "protein", "protein-domain" ]
Dynamin 2 is a protein, SH3 is a protein-domain, amphiphysin is a protein, M - amphiphysin 2 is a protein-isoform, BAR * is a protein-domain
1.0alpha7.train.437_task1
Sentence: Dynamin 2, a binding partner of the SH3 domain of amphiphysin (9), was recruited to the tubules when coexpressed with M-amphiphysin 2 (Fig. 2D), but not when coexpressed with its BAR* domain, which was sufficient to induce tubulation (Fig. 2, B and E). Instructions: please typing these entity words according to sentence: Dynamin 2, SH3, amphiphysin, M - amphiphysin 2, BAR * Options: protein-domain, protein-isoform, protein
[ "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-isoform", "I-protein-isoform", "I-protein-isoform", "I-protein-isoform", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Dynamin 2, a binding partner of the SH3 domain of amphiphysin (9), was recruited to the tubules when coexpressed with M-amphiphysin 2 (Fig. 2D), but not when coexpressed with its BAR* domain, which was sufficient to induce tubulation (Fig. 2, B and E).
[ "Dynamin", "2", ",", "a", "binding", "partner", "of", "the", "SH3", "domain", "of", "amphiphysin", "(", "9", ")", ",", "was", "recruited", "to", "the", "tubules", "when", "coexpressed", "with", "M", "-", "amphiphysin", "2", "(", "Fig", ".", "2D", ")", ",", "but", "not", "when", "coexpressed", "with", "its", "BAR", "*", "domain", ",", "which", "was", "sufficient", "to", "induce", "tubulation", "(", "Fig", ".", "2", ",", "B", "and", "E", ")", "." ]
[ "protein-isoform", "protein", "protein-domain" ]
Dynamin 2, SH3, amphiphysin, M - amphiphysin 2, BAR *
1.0alpha7.train.437_task2
Sentence: Dynamin 2, a binding partner of the SH3 domain of amphiphysin (9), was recruited to the tubules when coexpressed with M-amphiphysin 2 (Fig. 2D), but not when coexpressed with its BAR* domain, which was sufficient to induce tubulation (Fig. 2, B and E). Instructions: please extract entity words from the input sentence
[ "B-protein", "I-protein", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-isoform", "I-protein-isoform", "I-protein-isoform", "I-protein-isoform", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-domain", "I-protein-domain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Dynamin 2, a binding partner of the SH3 domain of amphiphysin (9), was recruited to the tubules when coexpressed with M-amphiphysin 2 (Fig. 2D), but not when coexpressed with its BAR* domain, which was sufficient to induce tubulation (Fig. 2, B and E).
[ "Dynamin", "2", ",", "a", "binding", "partner", "of", "the", "SH3", "domain", "of", "amphiphysin", "(", "9", ")", ",", "was", "recruited", "to", "the", "tubules", "when", "coexpressed", "with", "M", "-", "amphiphysin", "2", "(", "Fig", ".", "2D", ")", ",", "but", "not", "when", "coexpressed", "with", "its", "BAR", "*", "domain", ",", "which", "was", "sufficient", "to", "induce", "tubulation", "(", "Fig", ".", "2", ",", "B", "and", "E", ")", "." ]
[ "protein-isoform", "protein", "protein-domain" ]
neutropenia is an umlsterm, hematologic disorder is an umlsterm, origin is an umlsterm, blood leukocytes is an umlsterm, relative is an umlsterm, neutropenia is an umlsterm, lymphocytosis is an umlsterm, weakness is an umlsterm, fever is an umlsterm, complications is an umlsterm, necrosis is an umlsterm, mucous membranes is an umlsterm, patients is an umlsterm, laboratory is an umlsterm, patient is an umlsterm, neutropenia is an umlsterm, oral mucosa is an umlsterm
DerHautarzt.90500503.eng.abstr_task0
Sentence: Cyclic neutropenia is a rare hematologic disorder of unknown origin . Periodic decreases in blood leukocytes with relative neutropenia and lymphocytosis are typical . These episodes appear in regular intervals of 15-35 days and last three to seven days . They are associated with physical weakness , fever , septic complications and necrosis of mucous membranes . Between the episodes , the patients are in complete clinical and laboratory remission . We report the case of a 34 year-old patient suffering from cyclic neutropenia with ulcerous lesions of the oral mucosa . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Cyclic neutropenia is a rare hematologic disorder of unknown origin . Periodic decreases in blood leukocytes with relative neutropenia and lymphocytosis are typical . These episodes appear in regular intervals of 15-35 days and last three to seven days . They are associated with physical weakness , fever , septic complications and necrosis of mucous membranes . Between the episodes , the patients are in complete clinical and laboratory remission . We report the case of a 34 year-old patient suffering from cyclic neutropenia with ulcerous lesions of the oral mucosa .
[ "Cyclic", "neutropenia", "is", "a", "rare", "hematologic", "disorder", "of", "unknown", "origin", ".", "Periodic", "decreases", "in", "blood", "leukocytes", "with", "relative", "neutropenia", "and", "lymphocytosis", "are", "typical", ".", "These", "episodes", "appear", "in", "regular", "intervals", "of", "15", "-", "35", "days", "and", "last", "three", "to", "seven", "days", ".", "They", "are", "associated", "with", "physical", "weakness", ",", "fever", ",", "septic", "complications", "and", "necrosis", "of", "mucous", "membranes", ".", "Between", "the", "episodes", ",", "the", "patients", "are", "in", "complete", "clinical", "and", "laboratory", "remission", ".", "We", "report", "the", "case", "of", "a", "34", "year", "-", "old", "patient", "suffering", "from", "cyclic", "neutropenia", "with", "ulcerous", "lesions", "of", "the", "oral", "mucosa", "." ]
[ "umlsterm" ]
neutropenia is an umlsterm, hematologic disorder is an umlsterm, origin is an umlsterm, blood leukocytes is an umlsterm, relative is an umlsterm, neutropenia is an umlsterm, lymphocytosis is an umlsterm, weakness is an umlsterm, fever is an umlsterm, complications is an umlsterm, necrosis is an umlsterm, mucous membranes is an umlsterm, patients is an umlsterm, laboratory is an umlsterm, patient is an umlsterm, neutropenia is an umlsterm, oral mucosa is an umlsterm
DerHautarzt.90500503.eng.abstr_task1
Sentence: Cyclic neutropenia is a rare hematologic disorder of unknown origin . Periodic decreases in blood leukocytes with relative neutropenia and lymphocytosis are typical . These episodes appear in regular intervals of 15-35 days and last three to seven days . They are associated with physical weakness , fever , septic complications and necrosis of mucous membranes . Between the episodes , the patients are in complete clinical and laboratory remission . We report the case of a 34 year-old patient suffering from cyclic neutropenia with ulcerous lesions of the oral mucosa . Instructions: please typing these entity words according to sentence: neutropenia, hematologic disorder, origin, blood leukocytes, relative, neutropenia, lymphocytosis, weakness, fever, complications, necrosis, mucous membranes, patients, laboratory, patient, neutropenia, oral mucosa Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Cyclic neutropenia is a rare hematologic disorder of unknown origin . Periodic decreases in blood leukocytes with relative neutropenia and lymphocytosis are typical . These episodes appear in regular intervals of 15-35 days and last three to seven days . They are associated with physical weakness , fever , septic complications and necrosis of mucous membranes . Between the episodes , the patients are in complete clinical and laboratory remission . We report the case of a 34 year-old patient suffering from cyclic neutropenia with ulcerous lesions of the oral mucosa .
[ "Cyclic", "neutropenia", "is", "a", "rare", "hematologic", "disorder", "of", "unknown", "origin", ".", "Periodic", "decreases", "in", "blood", "leukocytes", "with", "relative", "neutropenia", "and", "lymphocytosis", "are", "typical", ".", "These", "episodes", "appear", "in", "regular", "intervals", "of", "15", "-", "35", "days", "and", "last", "three", "to", "seven", "days", ".", "They", "are", "associated", "with", "physical", "weakness", ",", "fever", ",", "septic", "complications", "and", "necrosis", "of", "mucous", "membranes", ".", "Between", "the", "episodes", ",", "the", "patients", "are", "in", "complete", "clinical", "and", "laboratory", "remission", ".", "We", "report", "the", "case", "of", "a", "34", "year", "-", "old", "patient", "suffering", "from", "cyclic", "neutropenia", "with", "ulcerous", "lesions", "of", "the", "oral", "mucosa", "." ]
[ "umlsterm" ]
neutropenia, hematologic disorder, origin, blood leukocytes, relative, neutropenia, lymphocytosis, weakness, fever, complications, necrosis, mucous membranes, patients, laboratory, patient, neutropenia, oral mucosa
DerHautarzt.90500503.eng.abstr_task2
Sentence: Cyclic neutropenia is a rare hematologic disorder of unknown origin . Periodic decreases in blood leukocytes with relative neutropenia and lymphocytosis are typical . These episodes appear in regular intervals of 15-35 days and last three to seven days . They are associated with physical weakness , fever , septic complications and necrosis of mucous membranes . Between the episodes , the patients are in complete clinical and laboratory remission . We report the case of a 34 year-old patient suffering from cyclic neutropenia with ulcerous lesions of the oral mucosa . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Cyclic neutropenia is a rare hematologic disorder of unknown origin . Periodic decreases in blood leukocytes with relative neutropenia and lymphocytosis are typical . These episodes appear in regular intervals of 15-35 days and last three to seven days . They are associated with physical weakness , fever , septic complications and necrosis of mucous membranes . Between the episodes , the patients are in complete clinical and laboratory remission . We report the case of a 34 year-old patient suffering from cyclic neutropenia with ulcerous lesions of the oral mucosa .
[ "Cyclic", "neutropenia", "is", "a", "rare", "hematologic", "disorder", "of", "unknown", "origin", ".", "Periodic", "decreases", "in", "blood", "leukocytes", "with", "relative", "neutropenia", "and", "lymphocytosis", "are", "typical", ".", "These", "episodes", "appear", "in", "regular", "intervals", "of", "15", "-", "35", "days", "and", "last", "three", "to", "seven", "days", ".", "They", "are", "associated", "with", "physical", "weakness", ",", "fever", ",", "septic", "complications", "and", "necrosis", "of", "mucous", "membranes", ".", "Between", "the", "episodes", ",", "the", "patients", "are", "in", "complete", "clinical", "and", "laboratory", "remission", ".", "We", "report", "the", "case", "of", "a", "34", "year", "-", "old", "patient", "suffering", "from", "cyclic", "neutropenia", "with", "ulcerous", "lesions", "of", "the", "oral", "mucosa", "." ]
[ "umlsterm" ]
Abstract is an umlsterm, syndrome is an umlsterm, antibody is an umlsterm, hematologic disorders is an umlsterm, recurrent abortion is an umlsterm, cerebral ischemia is an umlsterm, skin disorders is an umlsterm, female is an umlsterm, time is an umlsterm, ulcers is an umlsterm, legs is an umlsterm, livedo racemosa is an umlsterm, arms is an umlsterm, disease is an umlsterm, treatment is an umlsterm, methylprednisolone is an umlsterm, hydrocolloid is an umlsterm, dressings is an umlsterm, scar tissue is an umlsterm, maintenance is an umlsterm, acetylsalicylic acid is an umlsterm, signs is an umlsterm
DerHautarzt.40450394.eng.abstr_task0
Sentence: Abstract . In anticardiolin syndrome ( ACS ) a typical antibody constellation is associated with thrombotic and hematologic disorders . Furthermore , recurrent abortion , cerebral ischemia and different skin disorders occur . We report the case of a 29-year-old female suffering for the first time from painful , necrotic deep ulcers on the upper and lower legs and livedo racemosa on the arms as a rare example of a merely cutaneous manifestation of ACS with no demonstrable underlying disease . After systemic treatment with high-dose methylprednisolone , azathioprin and hydrocolloid dressings , healing of the scar tissue occurred . Simultaneously , a maintenance dose of acetylsalicylic acid ( 100 mg/day ) was administered . So far , neither cutaneous relapse nor other signs of ACS have occurred . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Abstract . In anticardiolin syndrome ( ACS ) a typical antibody constellation is associated with thrombotic and hematologic disorders . Furthermore , recurrent abortion , cerebral ischemia and different skin disorders occur . We report the case of a 29-year-old female suffering for the first time from painful , necrotic deep ulcers on the upper and lower legs and livedo racemosa on the arms as a rare example of a merely cutaneous manifestation of ACS with no demonstrable underlying disease . After systemic treatment with high-dose methylprednisolone , azathioprin and hydrocolloid dressings , healing of the scar tissue occurred . Simultaneously , a maintenance dose of acetylsalicylic acid ( 100 mg/day ) was administered . So far , neither cutaneous relapse nor other signs of ACS have occurred .
[ "Abstract", ".", "In", "anticardiolin", "syndrome", "(", "ACS", ")", "a", "typical", "antibody", "constellation", "is", "associated", "with", "thrombotic", "and", "hematologic", "disorders", ".", "Furthermore", ",", "recurrent", "abortion", ",", "cerebral", "ischemia", "and", "different", "skin", "disorders", "occur", ".", "We", "report", "the", "case", "of", "a", "29-year", "-", "old", "female", "suffering", "for", "the", "first", "time", "from", "painful", ",", "necrotic", "deep", "ulcers", "on", "the", "upper", "and", "lower", "legs", "and", "livedo", "racemosa", "on", "the", "arms", "as", "a", "rare", "example", "of", "a", "merely", "cutaneous", "manifestation", "of", "ACS", "with", "no", "demonstrable", "underlying", "disease", ".", "After", "systemic", "treatment", "with", "high", "-", "dose", "methylprednisolone", ",", "azathioprin", "and", "hydrocolloid", "dressings", ",", "healing", "of", "the", "scar", "tissue", "occurred", ".", "Simultaneously", ",", "a", "maintenance", "dose", "of", "acetylsalicylic", "acid", "(", "100", "mg", "/", "day", ")", "was", "administered", ".", "So", "far", ",", "neither", "cutaneous", "relapse", "nor", "other", "signs", "of", "ACS", "have", "occurred", "." ]
[ "umlsterm" ]
Abstract is an umlsterm, syndrome is an umlsterm, antibody is an umlsterm, hematologic disorders is an umlsterm, recurrent abortion is an umlsterm, cerebral ischemia is an umlsterm, skin disorders is an umlsterm, female is an umlsterm, time is an umlsterm, ulcers is an umlsterm, legs is an umlsterm, livedo racemosa is an umlsterm, arms is an umlsterm, disease is an umlsterm, treatment is an umlsterm, methylprednisolone is an umlsterm, hydrocolloid is an umlsterm, dressings is an umlsterm, scar tissue is an umlsterm, maintenance is an umlsterm, acetylsalicylic acid is an umlsterm, signs is an umlsterm
DerHautarzt.40450394.eng.abstr_task1
Sentence: Abstract . In anticardiolin syndrome ( ACS ) a typical antibody constellation is associated with thrombotic and hematologic disorders . Furthermore , recurrent abortion , cerebral ischemia and different skin disorders occur . We report the case of a 29-year-old female suffering for the first time from painful , necrotic deep ulcers on the upper and lower legs and livedo racemosa on the arms as a rare example of a merely cutaneous manifestation of ACS with no demonstrable underlying disease . After systemic treatment with high-dose methylprednisolone , azathioprin and hydrocolloid dressings , healing of the scar tissue occurred . Simultaneously , a maintenance dose of acetylsalicylic acid ( 100 mg/day ) was administered . So far , neither cutaneous relapse nor other signs of ACS have occurred . Instructions: please typing these entity words according to sentence: Abstract, syndrome, antibody, hematologic disorders, recurrent abortion, cerebral ischemia, skin disorders, female, time, ulcers, legs, livedo racemosa, arms, disease, treatment, methylprednisolone, hydrocolloid, dressings, scar tissue, maintenance, acetylsalicylic acid, signs Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Abstract . In anticardiolin syndrome ( ACS ) a typical antibody constellation is associated with thrombotic and hematologic disorders . Furthermore , recurrent abortion , cerebral ischemia and different skin disorders occur . We report the case of a 29-year-old female suffering for the first time from painful , necrotic deep ulcers on the upper and lower legs and livedo racemosa on the arms as a rare example of a merely cutaneous manifestation of ACS with no demonstrable underlying disease . After systemic treatment with high-dose methylprednisolone , azathioprin and hydrocolloid dressings , healing of the scar tissue occurred . Simultaneously , a maintenance dose of acetylsalicylic acid ( 100 mg/day ) was administered . So far , neither cutaneous relapse nor other signs of ACS have occurred .
[ "Abstract", ".", "In", "anticardiolin", "syndrome", "(", "ACS", ")", "a", "typical", "antibody", "constellation", "is", "associated", "with", "thrombotic", "and", "hematologic", "disorders", ".", "Furthermore", ",", "recurrent", "abortion", ",", "cerebral", "ischemia", "and", "different", "skin", "disorders", "occur", ".", "We", "report", "the", "case", "of", "a", "29-year", "-", "old", "female", "suffering", "for", "the", "first", "time", "from", "painful", ",", "necrotic", "deep", "ulcers", "on", "the", "upper", "and", "lower", "legs", "and", "livedo", "racemosa", "on", "the", "arms", "as", "a", "rare", "example", "of", "a", "merely", "cutaneous", "manifestation", "of", "ACS", "with", "no", "demonstrable", "underlying", "disease", ".", "After", "systemic", "treatment", "with", "high", "-", "dose", "methylprednisolone", ",", "azathioprin", "and", "hydrocolloid", "dressings", ",", "healing", "of", "the", "scar", "tissue", "occurred", ".", "Simultaneously", ",", "a", "maintenance", "dose", "of", "acetylsalicylic", "acid", "(", "100", "mg", "/", "day", ")", "was", "administered", ".", "So", "far", ",", "neither", "cutaneous", "relapse", "nor", "other", "signs", "of", "ACS", "have", "occurred", "." ]
[ "umlsterm" ]
Abstract, syndrome, antibody, hematologic disorders, recurrent abortion, cerebral ischemia, skin disorders, female, time, ulcers, legs, livedo racemosa, arms, disease, treatment, methylprednisolone, hydrocolloid, dressings, scar tissue, maintenance, acetylsalicylic acid, signs
DerHautarzt.40450394.eng.abstr_task2
Sentence: Abstract . In anticardiolin syndrome ( ACS ) a typical antibody constellation is associated with thrombotic and hematologic disorders . Furthermore , recurrent abortion , cerebral ischemia and different skin disorders occur . We report the case of a 29-year-old female suffering for the first time from painful , necrotic deep ulcers on the upper and lower legs and livedo racemosa on the arms as a rare example of a merely cutaneous manifestation of ACS with no demonstrable underlying disease . After systemic treatment with high-dose methylprednisolone , azathioprin and hydrocolloid dressings , healing of the scar tissue occurred . Simultaneously , a maintenance dose of acetylsalicylic acid ( 100 mg/day ) was administered . So far , neither cutaneous relapse nor other signs of ACS have occurred . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Abstract . In anticardiolin syndrome ( ACS ) a typical antibody constellation is associated with thrombotic and hematologic disorders . Furthermore , recurrent abortion , cerebral ischemia and different skin disorders occur . We report the case of a 29-year-old female suffering for the first time from painful , necrotic deep ulcers on the upper and lower legs and livedo racemosa on the arms as a rare example of a merely cutaneous manifestation of ACS with no demonstrable underlying disease . After systemic treatment with high-dose methylprednisolone , azathioprin and hydrocolloid dressings , healing of the scar tissue occurred . Simultaneously , a maintenance dose of acetylsalicylic acid ( 100 mg/day ) was administered . So far , neither cutaneous relapse nor other signs of ACS have occurred .
[ "Abstract", ".", "In", "anticardiolin", "syndrome", "(", "ACS", ")", "a", "typical", "antibody", "constellation", "is", "associated", "with", "thrombotic", "and", "hematologic", "disorders", ".", "Furthermore", ",", "recurrent", "abortion", ",", "cerebral", "ischemia", "and", "different", "skin", "disorders", "occur", ".", "We", "report", "the", "case", "of", "a", "29-year", "-", "old", "female", "suffering", "for", "the", "first", "time", "from", "painful", ",", "necrotic", "deep", "ulcers", "on", "the", "upper", "and", "lower", "legs", "and", "livedo", "racemosa", "on", "the", "arms", "as", "a", "rare", "example", "of", "a", "merely", "cutaneous", "manifestation", "of", "ACS", "with", "no", "demonstrable", "underlying", "disease", ".", "After", "systemic", "treatment", "with", "high", "-", "dose", "methylprednisolone", ",", "azathioprin", "and", "hydrocolloid", "dressings", ",", "healing", "of", "the", "scar", "tissue", "occurred", ".", "Simultaneously", ",", "a", "maintenance", "dose", "of", "acetylsalicylic", "acid", "(", "100", "mg", "/", "day", ")", "was", "administered", ".", "So", "far", ",", "neither", "cutaneous", "relapse", "nor", "other", "signs", "of", "ACS", "have", "occurred", "." ]
[ "umlsterm" ]
FK506 is an other_organic_compound, ciclosporin is an other_organic_compound, intracellular signal transduction is an other_name
81408_task0
Sentence: FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, other_name
[ "B-other_organic_compound", "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]
FK506 and ciclosporin: molecular probes for studying intracellular signal transduction.
[ "FK506", "and", "ciclosporin", ":", "molecular", "probes", "for", "studying", "intracellular", "signal", "transduction", "." ]
[ "other_name", "protein_molecule", "protein_family_or_group", "protein_subunit", "protein_complex", "atom", "cell_type", "other_organic_compound", "cell_component" ]
FK506 is an other_organic_compound, ciclosporin is an other_organic_compound, intracellular signal transduction is an other_name
81408_task1
Sentence: FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. Instructions: please typing these entity words according to sentence: FK506, ciclosporin, intracellular signal transduction Options: other_organic_compound, other_name
[ "B-other_organic_compound", "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]
FK506 and ciclosporin: molecular probes for studying intracellular signal transduction.
[ "FK506", "and", "ciclosporin", ":", "molecular", "probes", "for", "studying", "intracellular", "signal", "transduction", "." ]
[ "other_name", "protein_molecule", "protein_family_or_group", "protein_subunit", "protein_complex", "atom", "cell_type", "other_organic_compound", "cell_component" ]
FK506, ciclosporin, intracellular signal transduction
81408_task2
Sentence: FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. Instructions: please extract entity words from the input sentence
[ "B-other_organic_compound", "O", "B-other_organic_compound", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]
FK506 and ciclosporin: molecular probes for studying intracellular signal transduction.
[ "FK506", "and", "ciclosporin", ":", "molecular", "probes", "for", "studying", "intracellular", "signal", "transduction", "." ]
[ "other_name", "protein_molecule", "protein_family_or_group", "protein_subunit", "protein_complex", "atom", "cell_type", "other_organic_compound", "cell_component" ]
play is an umlsterm, emergency is an umlsterm, patients is an umlsterm, functions is an umlsterm, policies is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, measures is an umlsterm, transport is an umlsterm, emergency is an umlsterm
DerAnaesthesist.70460126.eng.abstr_task0
Sentence: " Stay and play , " especially in emergency patients with unstable vital functions , offers definite advantages compared to " scoop and run " policies . Typical medical and tactical aspects can be identified to judge the amount of diagnostic and therapeutic measures necessary at the site and during transport . Scoop and run seems to be appropriate only rarely in a area with an emergency medical system in the German style . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
" Stay and play , " especially in emergency patients with unstable vital functions , offers definite advantages compared to " scoop and run " policies . Typical medical and tactical aspects can be identified to judge the amount of diagnostic and therapeutic measures necessary at the site and during transport . Scoop and run seems to be appropriate only rarely in a area with an emergency medical system in the German style .
[ "\"", "Stay", "and", "play", ",", "\"", "especially", "in", "emergency", "patients", "with", "unstable", "vital", "functions", ",", "offers", "definite", "advantages", "compared", "to", "\"", "scoop", "and", "run", "\"", "policies", ".", "Typical", "medical", "and", "tactical", "aspects", "can", "be", "identified", "to", "judge", "the", "amount", "of", "diagnostic", "and", "therapeutic", "measures", "necessary", "at", "the", "site", "and", "during", "transport", ".", "Scoop", "and", "run", "seems", "to", "be", "appropriate", "only", "rarely", "in", "a", "area", "with", "an", "emergency", "medical", "system", "in", "the", "German", "style", "." ]
[ "umlsterm" ]
play is an umlsterm, emergency is an umlsterm, patients is an umlsterm, functions is an umlsterm, policies is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, measures is an umlsterm, transport is an umlsterm, emergency is an umlsterm
DerAnaesthesist.70460126.eng.abstr_task1
Sentence: " Stay and play , " especially in emergency patients with unstable vital functions , offers definite advantages compared to " scoop and run " policies . Typical medical and tactical aspects can be identified to judge the amount of diagnostic and therapeutic measures necessary at the site and during transport . Scoop and run seems to be appropriate only rarely in a area with an emergency medical system in the German style . Instructions: please typing these entity words according to sentence: play, emergency, patients, functions, policies, diagnostic, therapeutic, measures, transport, emergency Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
" Stay and play , " especially in emergency patients with unstable vital functions , offers definite advantages compared to " scoop and run " policies . Typical medical and tactical aspects can be identified to judge the amount of diagnostic and therapeutic measures necessary at the site and during transport . Scoop and run seems to be appropriate only rarely in a area with an emergency medical system in the German style .
[ "\"", "Stay", "and", "play", ",", "\"", "especially", "in", "emergency", "patients", "with", "unstable", "vital", "functions", ",", "offers", "definite", "advantages", "compared", "to", "\"", "scoop", "and", "run", "\"", "policies", ".", "Typical", "medical", "and", "tactical", "aspects", "can", "be", "identified", "to", "judge", "the", "amount", "of", "diagnostic", "and", "therapeutic", "measures", "necessary", "at", "the", "site", "and", "during", "transport", ".", "Scoop", "and", "run", "seems", "to", "be", "appropriate", "only", "rarely", "in", "a", "area", "with", "an", "emergency", "medical", "system", "in", "the", "German", "style", "." ]
[ "umlsterm" ]
play, emergency, patients, functions, policies, diagnostic, therapeutic, measures, transport, emergency
DerAnaesthesist.70460126.eng.abstr_task2
Sentence: " Stay and play , " especially in emergency patients with unstable vital functions , offers definite advantages compared to " scoop and run " policies . Typical medical and tactical aspects can be identified to judge the amount of diagnostic and therapeutic measures necessary at the site and during transport . Scoop and run seems to be appropriate only rarely in a area with an emergency medical system in the German style . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
" Stay and play , " especially in emergency patients with unstable vital functions , offers definite advantages compared to " scoop and run " policies . Typical medical and tactical aspects can be identified to judge the amount of diagnostic and therapeutic measures necessary at the site and during transport . Scoop and run seems to be appropriate only rarely in a area with an emergency medical system in the German style .
[ "\"", "Stay", "and", "play", ",", "\"", "especially", "in", "emergency", "patients", "with", "unstable", "vital", "functions", ",", "offers", "definite", "advantages", "compared", "to", "\"", "scoop", "and", "run", "\"", "policies", ".", "Typical", "medical", "and", "tactical", "aspects", "can", "be", "identified", "to", "judge", "the", "amount", "of", "diagnostic", "and", "therapeutic", "measures", "necessary", "at", "the", "site", "and", "during", "transport", ".", "Scoop", "and", "run", "seems", "to", "be", "appropriate", "only", "rarely", "in", "a", "area", "with", "an", "emergency", "medical", "system", "in", "the", "German", "style", "." ]
[ "umlsterm" ]
Diagnostik is an umlsterm, Magenbiopsien is an umlsterm, Lymphknotenpathologie is an umlsterm, Patienten is an umlsterm, Magenbiopsien is an umlsterm, Biopsie is an umlsterm, Biopsie is an umlsterm, Immunhistologie is an umlsterm, Molekularbiologie is an umlsterm, Lymphomen is an umlsterm, Tumorkomponente is an umlsterm, Magenbiopsien is an umlsterm, Lymphomen is an umlsterm, Biopsieartefakte is an umlsterm, Lymphome is an umlsterm, Biopsien is an umlsterm
DerPathologe.80190209.ger.abstr_task0
Sentence: Die Diagnostik gastraler MALT-Typ-Lymphome stuetzt sich heute fast ausschliesslich auf Magenbiopsien . Um deren diagostische Aussagekraft zu bestimmen , wurden im Referenzzentrum fuer Lymphknotenpathologie Wuerzburg bei 64 Patienten mit gastralem MALT-Typ-Lymphom durchschnittlich 6 praeoperative Magenbiopsien mit dem konsekutiven Gastrektomieproaeparat verglichen . Anhand der Biopsie wurde durch den primaer befundenden Pathologen ein MALT-Typ-Lymphom in 69% der Faelle richtig diagnostiziert , in 41% korrekt in niedrigmaligne , hochmaligne und sekundaer hochmaligne graduiert . Am Referenzzentrum erhoehte sich die Treffsicherheit der Biopsie durch Anwendung zusaetzlicher Verfahren ( Immunhistologie Molekularbiologie ) , auf 95% beziehungsweise 73% . Dennoch wurden bei den sekundaer hochmalignen Lymphomen auch hier nur in 33% sowohl die hoch- als auch die niedrigmaligne Tumorkomponente erfasst . Die diagnostische Aussagekraft von Magenbiopsien in gastralen Lymphomen ist durch Biopsieartefakte eingeschraenkt , kann jedoch durch immunhistochemische und molekularbiologische Verfahren erhoeht werden . Insbesondere sekundaer hochmaligne Lymphome lassen sich aufgrund der limitierten Anzahl von Biopsien praeoperativ oft nicht hinreichend erkennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Die Diagnostik gastraler MALT-Typ-Lymphome stuetzt sich heute fast ausschliesslich auf Magenbiopsien . Um deren diagostische Aussagekraft zu bestimmen , wurden im Referenzzentrum fuer Lymphknotenpathologie Wuerzburg bei 64 Patienten mit gastralem MALT-Typ-Lymphom durchschnittlich 6 praeoperative Magenbiopsien mit dem konsekutiven Gastrektomieproaeparat verglichen . Anhand der Biopsie wurde durch den primaer befundenden Pathologen ein MALT-Typ-Lymphom in 69% der Faelle richtig diagnostiziert , in 41% korrekt in niedrigmaligne , hochmaligne und sekundaer hochmaligne graduiert . Am Referenzzentrum erhoehte sich die Treffsicherheit der Biopsie durch Anwendung zusaetzlicher Verfahren ( Immunhistologie Molekularbiologie ) , auf 95% beziehungsweise 73% . Dennoch wurden bei den sekundaer hochmalignen Lymphomen auch hier nur in 33% sowohl die hoch- als auch die niedrigmaligne Tumorkomponente erfasst . Die diagnostische Aussagekraft von Magenbiopsien in gastralen Lymphomen ist durch Biopsieartefakte eingeschraenkt , kann jedoch durch immunhistochemische und molekularbiologische Verfahren erhoeht werden . Insbesondere sekundaer hochmaligne Lymphome lassen sich aufgrund der limitierten Anzahl von Biopsien praeoperativ oft nicht hinreichend erkennen .
[ "Die", "Diagnostik", "gastraler", "MALT", "-", "Typ", "-", "Lymphome", "stuetzt", "sich", "heute", "fast", "ausschliesslich", "auf", "Magenbiopsien", ".", "Um", "deren", "diagostische", "Aussagekraft", "zu", "bestimmen", ",", "wurden", "im", "Referenzzentrum", "fuer", "Lymphknotenpathologie", "Wuerzburg", "bei", "64", "Patienten", "mit", "gastralem", "MALT", "-", "Typ", "-", "Lymphom", "durchschnittlich", "6", "praeoperative", "Magenbiopsien", "mit", "dem", "konsekutiven", "Gastrektomieproaeparat", "verglichen", ".", "Anhand", "der", "Biopsie", "wurde", "durch", "den", "primaer", "befundenden", "Pathologen", "ein", "MALT", "-", "Typ", "-", "Lymphom", "in", "69", "%", "der", "Faelle", "richtig", "diagnostiziert", ",", "in", "41", "%", "korrekt", "in", "niedrigmaligne", ",", "hochmaligne", "und", "sekundaer", "hochmaligne", "graduiert", ".", "Am", "Referenzzentrum", "erhoehte", "sich", "die", "Treffsicherheit", "der", "Biopsie", "durch", "Anwendung", "zusaetzlicher", "Verfahren", "(", "Immunhistologie", "Molekularbiologie", ")", ",", "auf", "95", "%", "beziehungsweise", "73", "%", ".", "Dennoch", "wurden", "bei", "den", "sekundaer", "hochmalignen", "Lymphomen", "auch", "hier", "nur", "in", "33", "%", "sowohl", "die", "hoch-", "als", "auch", "die", "niedrigmaligne", "Tumorkomponente", "erfasst", ".", "Die", "diagnostische", "Aussagekraft", "von", "Magenbiopsien", "in", "gastralen", "Lymphomen", "ist", "durch", "Biopsieartefakte", "eingeschraenkt", ",", "kann", "jedoch", "durch", "immunhistochemische", "und", "molekularbiologische", "Verfahren", "erhoeht", "werden", ".", "Insbesondere", "sekundaer", "hochmaligne", "Lymphome", "lassen", "sich", "aufgrund", "der", "limitierten", "Anzahl", "von", "Biopsien", "praeoperativ", "oft", "nicht", "hinreichend", "erkennen", "." ]
[ "umlsterm" ]
Diagnostik is an umlsterm, Magenbiopsien is an umlsterm, Lymphknotenpathologie is an umlsterm, Patienten is an umlsterm, Magenbiopsien is an umlsterm, Biopsie is an umlsterm, Biopsie is an umlsterm, Immunhistologie is an umlsterm, Molekularbiologie is an umlsterm, Lymphomen is an umlsterm, Tumorkomponente is an umlsterm, Magenbiopsien is an umlsterm, Lymphomen is an umlsterm, Biopsieartefakte is an umlsterm, Lymphome is an umlsterm, Biopsien is an umlsterm
DerPathologe.80190209.ger.abstr_task1
Sentence: Die Diagnostik gastraler MALT-Typ-Lymphome stuetzt sich heute fast ausschliesslich auf Magenbiopsien . Um deren diagostische Aussagekraft zu bestimmen , wurden im Referenzzentrum fuer Lymphknotenpathologie Wuerzburg bei 64 Patienten mit gastralem MALT-Typ-Lymphom durchschnittlich 6 praeoperative Magenbiopsien mit dem konsekutiven Gastrektomieproaeparat verglichen . Anhand der Biopsie wurde durch den primaer befundenden Pathologen ein MALT-Typ-Lymphom in 69% der Faelle richtig diagnostiziert , in 41% korrekt in niedrigmaligne , hochmaligne und sekundaer hochmaligne graduiert . Am Referenzzentrum erhoehte sich die Treffsicherheit der Biopsie durch Anwendung zusaetzlicher Verfahren ( Immunhistologie Molekularbiologie ) , auf 95% beziehungsweise 73% . Dennoch wurden bei den sekundaer hochmalignen Lymphomen auch hier nur in 33% sowohl die hoch- als auch die niedrigmaligne Tumorkomponente erfasst . Die diagnostische Aussagekraft von Magenbiopsien in gastralen Lymphomen ist durch Biopsieartefakte eingeschraenkt , kann jedoch durch immunhistochemische und molekularbiologische Verfahren erhoeht werden . Insbesondere sekundaer hochmaligne Lymphome lassen sich aufgrund der limitierten Anzahl von Biopsien praeoperativ oft nicht hinreichend erkennen . Instructions: please typing these entity words according to sentence: Diagnostik, Magenbiopsien, Lymphknotenpathologie, Patienten, Magenbiopsien, Biopsie, Biopsie, Immunhistologie, Molekularbiologie, Lymphomen, Tumorkomponente, Magenbiopsien, Lymphomen, Biopsieartefakte, Lymphome, Biopsien Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Die Diagnostik gastraler MALT-Typ-Lymphome stuetzt sich heute fast ausschliesslich auf Magenbiopsien . Um deren diagostische Aussagekraft zu bestimmen , wurden im Referenzzentrum fuer Lymphknotenpathologie Wuerzburg bei 64 Patienten mit gastralem MALT-Typ-Lymphom durchschnittlich 6 praeoperative Magenbiopsien mit dem konsekutiven Gastrektomieproaeparat verglichen . Anhand der Biopsie wurde durch den primaer befundenden Pathologen ein MALT-Typ-Lymphom in 69% der Faelle richtig diagnostiziert , in 41% korrekt in niedrigmaligne , hochmaligne und sekundaer hochmaligne graduiert . Am Referenzzentrum erhoehte sich die Treffsicherheit der Biopsie durch Anwendung zusaetzlicher Verfahren ( Immunhistologie Molekularbiologie ) , auf 95% beziehungsweise 73% . Dennoch wurden bei den sekundaer hochmalignen Lymphomen auch hier nur in 33% sowohl die hoch- als auch die niedrigmaligne Tumorkomponente erfasst . Die diagnostische Aussagekraft von Magenbiopsien in gastralen Lymphomen ist durch Biopsieartefakte eingeschraenkt , kann jedoch durch immunhistochemische und molekularbiologische Verfahren erhoeht werden . Insbesondere sekundaer hochmaligne Lymphome lassen sich aufgrund der limitierten Anzahl von Biopsien praeoperativ oft nicht hinreichend erkennen .
[ "Die", "Diagnostik", "gastraler", "MALT", "-", "Typ", "-", "Lymphome", "stuetzt", "sich", "heute", "fast", "ausschliesslich", "auf", "Magenbiopsien", ".", "Um", "deren", "diagostische", "Aussagekraft", "zu", "bestimmen", ",", "wurden", "im", "Referenzzentrum", "fuer", "Lymphknotenpathologie", "Wuerzburg", "bei", "64", "Patienten", "mit", "gastralem", "MALT", "-", "Typ", "-", "Lymphom", "durchschnittlich", "6", "praeoperative", "Magenbiopsien", "mit", "dem", "konsekutiven", "Gastrektomieproaeparat", "verglichen", ".", "Anhand", "der", "Biopsie", "wurde", "durch", "den", "primaer", "befundenden", "Pathologen", "ein", "MALT", "-", "Typ", "-", "Lymphom", "in", "69", "%", "der", "Faelle", "richtig", "diagnostiziert", ",", "in", "41", "%", "korrekt", "in", "niedrigmaligne", ",", "hochmaligne", "und", "sekundaer", "hochmaligne", "graduiert", ".", "Am", "Referenzzentrum", "erhoehte", "sich", "die", "Treffsicherheit", "der", "Biopsie", "durch", "Anwendung", "zusaetzlicher", "Verfahren", "(", "Immunhistologie", "Molekularbiologie", ")", ",", "auf", "95", "%", "beziehungsweise", "73", "%", ".", "Dennoch", "wurden", "bei", "den", "sekundaer", "hochmalignen", "Lymphomen", "auch", "hier", "nur", "in", "33", "%", "sowohl", "die", "hoch-", "als", "auch", "die", "niedrigmaligne", "Tumorkomponente", "erfasst", ".", "Die", "diagnostische", "Aussagekraft", "von", "Magenbiopsien", "in", "gastralen", "Lymphomen", "ist", "durch", "Biopsieartefakte", "eingeschraenkt", ",", "kann", "jedoch", "durch", "immunhistochemische", "und", "molekularbiologische", "Verfahren", "erhoeht", "werden", ".", "Insbesondere", "sekundaer", "hochmaligne", "Lymphome", "lassen", "sich", "aufgrund", "der", "limitierten", "Anzahl", "von", "Biopsien", "praeoperativ", "oft", "nicht", "hinreichend", "erkennen", "." ]
[ "umlsterm" ]
Diagnostik, Magenbiopsien, Lymphknotenpathologie, Patienten, Magenbiopsien, Biopsie, Biopsie, Immunhistologie, Molekularbiologie, Lymphomen, Tumorkomponente, Magenbiopsien, Lymphomen, Biopsieartefakte, Lymphome, Biopsien
DerPathologe.80190209.ger.abstr_task2
Sentence: Die Diagnostik gastraler MALT-Typ-Lymphome stuetzt sich heute fast ausschliesslich auf Magenbiopsien . Um deren diagostische Aussagekraft zu bestimmen , wurden im Referenzzentrum fuer Lymphknotenpathologie Wuerzburg bei 64 Patienten mit gastralem MALT-Typ-Lymphom durchschnittlich 6 praeoperative Magenbiopsien mit dem konsekutiven Gastrektomieproaeparat verglichen . Anhand der Biopsie wurde durch den primaer befundenden Pathologen ein MALT-Typ-Lymphom in 69% der Faelle richtig diagnostiziert , in 41% korrekt in niedrigmaligne , hochmaligne und sekundaer hochmaligne graduiert . Am Referenzzentrum erhoehte sich die Treffsicherheit der Biopsie durch Anwendung zusaetzlicher Verfahren ( Immunhistologie Molekularbiologie ) , auf 95% beziehungsweise 73% . Dennoch wurden bei den sekundaer hochmalignen Lymphomen auch hier nur in 33% sowohl die hoch- als auch die niedrigmaligne Tumorkomponente erfasst . Die diagnostische Aussagekraft von Magenbiopsien in gastralen Lymphomen ist durch Biopsieartefakte eingeschraenkt , kann jedoch durch immunhistochemische und molekularbiologische Verfahren erhoeht werden . Insbesondere sekundaer hochmaligne Lymphome lassen sich aufgrund der limitierten Anzahl von Biopsien praeoperativ oft nicht hinreichend erkennen . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Die Diagnostik gastraler MALT-Typ-Lymphome stuetzt sich heute fast ausschliesslich auf Magenbiopsien . Um deren diagostische Aussagekraft zu bestimmen , wurden im Referenzzentrum fuer Lymphknotenpathologie Wuerzburg bei 64 Patienten mit gastralem MALT-Typ-Lymphom durchschnittlich 6 praeoperative Magenbiopsien mit dem konsekutiven Gastrektomieproaeparat verglichen . Anhand der Biopsie wurde durch den primaer befundenden Pathologen ein MALT-Typ-Lymphom in 69% der Faelle richtig diagnostiziert , in 41% korrekt in niedrigmaligne , hochmaligne und sekundaer hochmaligne graduiert . Am Referenzzentrum erhoehte sich die Treffsicherheit der Biopsie durch Anwendung zusaetzlicher Verfahren ( Immunhistologie Molekularbiologie ) , auf 95% beziehungsweise 73% . Dennoch wurden bei den sekundaer hochmalignen Lymphomen auch hier nur in 33% sowohl die hoch- als auch die niedrigmaligne Tumorkomponente erfasst . Die diagnostische Aussagekraft von Magenbiopsien in gastralen Lymphomen ist durch Biopsieartefakte eingeschraenkt , kann jedoch durch immunhistochemische und molekularbiologische Verfahren erhoeht werden . Insbesondere sekundaer hochmaligne Lymphome lassen sich aufgrund der limitierten Anzahl von Biopsien praeoperativ oft nicht hinreichend erkennen .
[ "Die", "Diagnostik", "gastraler", "MALT", "-", "Typ", "-", "Lymphome", "stuetzt", "sich", "heute", "fast", "ausschliesslich", "auf", "Magenbiopsien", ".", "Um", "deren", "diagostische", "Aussagekraft", "zu", "bestimmen", ",", "wurden", "im", "Referenzzentrum", "fuer", "Lymphknotenpathologie", "Wuerzburg", "bei", "64", "Patienten", "mit", "gastralem", "MALT", "-", "Typ", "-", "Lymphom", "durchschnittlich", "6", "praeoperative", "Magenbiopsien", "mit", "dem", "konsekutiven", "Gastrektomieproaeparat", "verglichen", ".", "Anhand", "der", "Biopsie", "wurde", "durch", "den", "primaer", "befundenden", "Pathologen", "ein", "MALT", "-", "Typ", "-", "Lymphom", "in", "69", "%", "der", "Faelle", "richtig", "diagnostiziert", ",", "in", "41", "%", "korrekt", "in", "niedrigmaligne", ",", "hochmaligne", "und", "sekundaer", "hochmaligne", "graduiert", ".", "Am", "Referenzzentrum", "erhoehte", "sich", "die", "Treffsicherheit", "der", "Biopsie", "durch", "Anwendung", "zusaetzlicher", "Verfahren", "(", "Immunhistologie", "Molekularbiologie", ")", ",", "auf", "95", "%", "beziehungsweise", "73", "%", ".", "Dennoch", "wurden", "bei", "den", "sekundaer", "hochmalignen", "Lymphomen", "auch", "hier", "nur", "in", "33", "%", "sowohl", "die", "hoch-", "als", "auch", "die", "niedrigmaligne", "Tumorkomponente", "erfasst", ".", "Die", "diagnostische", "Aussagekraft", "von", "Magenbiopsien", "in", "gastralen", "Lymphomen", "ist", "durch", "Biopsieartefakte", "eingeschraenkt", ",", "kann", "jedoch", "durch", "immunhistochemische", "und", "molekularbiologische", "Verfahren", "erhoeht", "werden", ".", "Insbesondere", "sekundaer", "hochmaligne", "Lymphome", "lassen", "sich", "aufgrund", "der", "limitierten", "Anzahl", "von", "Biopsien", "praeoperativ", "oft", "nicht", "hinreichend", "erkennen", "." ]
[ "umlsterm" ]
methotrexate is a Diseases & Disorders, urothelial cancer is a Diseases & Disorders
12751_task0
Sentence: Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Diseases & Disorders
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases & Disorders", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "O" ]
Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.
[ "Drug", "related", "genetic", "polymorphisms", "affecting", "adverse", "reactions", "to", "methotrexate", ",", "vinblastine", ",", "doxorubicin", "and", "cisplatin", "in", "patients", "with", "urothelial", "cancer", "." ]
[ "Diseases & Disorders", "SNP & Sequence variations", "Genes & Molecular Sequences", "" ]
methotrexate is a Diseases & Disorders, urothelial cancer is a Diseases & Disorders
12751_task1
Sentence: Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. Instructions: please typing these entity words according to sentence: methotrexate, urothelial cancer Options: Diseases & Disorders
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases & Disorders", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "O" ]
Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.
[ "Drug", "related", "genetic", "polymorphisms", "affecting", "adverse", "reactions", "to", "methotrexate", ",", "vinblastine", ",", "doxorubicin", "and", "cisplatin", "in", "patients", "with", "urothelial", "cancer", "." ]
[ "Diseases & Disorders", "SNP & Sequence variations", "Genes & Molecular Sequences", "" ]
methotrexate, urothelial cancer
12751_task2
Sentence: Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases & Disorders", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "O" ]
Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.
[ "Drug", "related", "genetic", "polymorphisms", "affecting", "adverse", "reactions", "to", "methotrexate", ",", "vinblastine", ",", "doxorubicin", "and", "cisplatin", "in", "patients", "with", "urothelial", "cancer", "." ]
[ "Diseases & Disorders", "SNP & Sequence variations", "Genes & Molecular Sequences", "" ]
quinidine is a Intervention_Pharmacological, amiodarone is a Intervention_Pharmacological, after electric cardioversion ] is a Participant_Condition
79440_task0
Sentence: [ Maintaining sinus rhythm with quinidine and amiodarone after electric cardioversion ] . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]
[ Maintaining sinus rhythm with quinidine and amiodarone after electric cardioversion ] .
[ "[", "Maintaining", "sinus", "rhythm", "with", "quinidine", "and", "amiodarone", "after", "electric", "cardioversion", "]", "." ]
[ "Participant_Condition", "Intervention_Pharmacological" ]
quinidine is a Intervention_Pharmacological, amiodarone is a Intervention_Pharmacological, after electric cardioversion ] is a Participant_Condition
79440_task1
Sentence: [ Maintaining sinus rhythm with quinidine and amiodarone after electric cardioversion ] . Instructions: please typing these entity words according to sentence: quinidine, amiodarone, after electric cardioversion ] Options: Intervention_Pharmacological, Participant_Condition
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]
[ Maintaining sinus rhythm with quinidine and amiodarone after electric cardioversion ] .
[ "[", "Maintaining", "sinus", "rhythm", "with", "quinidine", "and", "amiodarone", "after", "electric", "cardioversion", "]", "." ]
[ "Participant_Condition", "Intervention_Pharmacological" ]
quinidine, amiodarone, after electric cardioversion ]
79440_task2
Sentence: [ Maintaining sinus rhythm with quinidine and amiodarone after electric cardioversion ] . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]
[ Maintaining sinus rhythm with quinidine and amiodarone after electric cardioversion ] .
[ "[", "Maintaining", "sinus", "rhythm", "with", "quinidine", "and", "amiodarone", "after", "electric", "cardioversion", "]", "." ]
[ "Participant_Condition", "Intervention_Pharmacological" ]
Blutung is an umlsterm, Literatur is an umlsterm, Patienten is an umlsterm, Schlaganfallstudie is an umlsterm, Literatur is an umlsterm, Signalverhalten is an umlsterm, Diffusionsgewichtung is an umlsterm, Ischaemie is an umlsterm, Diagnostik is an umlsterm, Schlaganfalls is an umlsterm, Ischaemien is an umlsterm, Computertomographie is an umlsterm, Akutdiagnostik is an umlsterm
DerRadiologe.90390838.ger.abstr_task0
Sentence: In dieser Uebersicht wird das kernspintomographische ( KST ) Erscheinungsbild der intrazerebralen Blutung ( IZB ) anhand eigener Erfahrungen und der Literatur diskutiert . Besonderes Gewicht wurde auf den KST Nachweis der hyperakuten IZB innerhalb der ersten Stunden gelegt . Es wurden einerseits die Befunde von 42 Patienten einer prospektiven , KST randomisierten Schlaganfallstudie ausgewertet , bei denen die KST als Erstuntersuchung innerhalb von 6 Stunden durchgefuehrt worden war . Andererseits werteten wir retrospektiv jene KST Untersuchungen aus , die im Jahr 1998 unter der Fragestellung einer IZB ( n=63) erfolgten . Die KST erwies sich als sensitiv im Nachweis auch der hyperakuten IZB . Es wurden weder falsch-negative noch falsch-positive Befunde erhoben . Die hyperakute IZB kommt in der T2-Gewichtung hyperintens und in der T1-Gewichtung isointens zur Darstellung . Auf den diffusionsgewichteten Sequenzen fuehren minimale Deoxyhaemoglobinkonzentrationen bereits in dieser Phase zu Signalausloeschungen . Das Erscheinungsbild der akuten , subakuten und chronischen IZB entsprach dem , in der Literatur mitgeteilten Signalverhalten . , Zusammenfassend waren alle IZB , unabhaengig vom Stadium in der KST nachweisbar . Die Diffusionsgewichtung war in der hyperakuten Blutungsdiagnose und deren Abgrenzung von der akuten Ischaemie hilfreich . Zumindest bei 1,5T erscheint die KST somit fuer die Diagnostik des akuten Schlaganfalls geeignet und sollte , da Ischaemien besser als mit der Computertomographie charakterisiert werden koennen , fuer die Akutdiagnostik verfuegbar gemacht werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
In dieser Uebersicht wird das kernspintomographische ( KST ) Erscheinungsbild der intrazerebralen Blutung ( IZB ) anhand eigener Erfahrungen und der Literatur diskutiert . Besonderes Gewicht wurde auf den KST Nachweis der hyperakuten IZB innerhalb der ersten Stunden gelegt . Es wurden einerseits die Befunde von 42 Patienten einer prospektiven , KST randomisierten Schlaganfallstudie ausgewertet , bei denen die KST als Erstuntersuchung innerhalb von 6 Stunden durchgefuehrt worden war . Andererseits werteten wir retrospektiv jene KST Untersuchungen aus , die im Jahr 1998 unter der Fragestellung einer IZB ( n=63) erfolgten . Die KST erwies sich als sensitiv im Nachweis auch der hyperakuten IZB . Es wurden weder falsch-negative noch falsch-positive Befunde erhoben . Die hyperakute IZB kommt in der T2-Gewichtung hyperintens und in der T1-Gewichtung isointens zur Darstellung . Auf den diffusionsgewichteten Sequenzen fuehren minimale Deoxyhaemoglobinkonzentrationen bereits in dieser Phase zu Signalausloeschungen . Das Erscheinungsbild der akuten , subakuten und chronischen IZB entsprach dem , in der Literatur mitgeteilten Signalverhalten . , Zusammenfassend waren alle IZB , unabhaengig vom Stadium in der KST nachweisbar . Die Diffusionsgewichtung war in der hyperakuten Blutungsdiagnose und deren Abgrenzung von der akuten Ischaemie hilfreich . Zumindest bei 1,5T erscheint die KST somit fuer die Diagnostik des akuten Schlaganfalls geeignet und sollte , da Ischaemien besser als mit der Computertomographie charakterisiert werden koennen , fuer die Akutdiagnostik verfuegbar gemacht werden .
[ "In", "dieser", "Uebersicht", "wird", "das", "kernspintomographische", "(", "KST", ")", "Erscheinungsbild", "der", "intrazerebralen", "Blutung", "(", "IZB", ")", "anhand", "eigener", "Erfahrungen", "und", "der", "Literatur", "diskutiert", ".", "Besonderes", "Gewicht", "wurde", "auf", "den", "KST", "Nachweis", "der", "hyperakuten", "IZB", "innerhalb", "der", "ersten", "Stunden", "gelegt", ".", "Es", "wurden", "einerseits", "die", "Befunde", "von", "42", "Patienten", "einer", "prospektiven", ",", "KST", "randomisierten", "Schlaganfallstudie", "ausgewertet", ",", "bei", "denen", "die", "KST", "als", "Erstuntersuchung", "innerhalb", "von", "6", "Stunden", "durchgefuehrt", "worden", "war", ".", "Andererseits", "werteten", "wir", "retrospektiv", "jene", "KST", "Untersuchungen", "aus", ",", "die", "im", "Jahr", "1998", "unter", "der", "Fragestellung", "einer", "IZB", "(", "n=63", ")", "erfolgten", ".", "Die", "KST", "erwies", "sich", "als", "sensitiv", "im", "Nachweis", "auch", "der", "hyperakuten", "IZB", ".", "Es", "wurden", "weder", "falsch", "-", "negative", "noch", "falsch", "-", "positive", "Befunde", "erhoben", ".", "Die", "hyperakute", "IZB", "kommt", "in", "der", "T2-Gewichtung", "hyperintens", "und", "in", "der", "T1-Gewichtung", "isointens", "zur", "Darstellung", ".", "Auf", "den", "diffusionsgewichteten", "Sequenzen", "fuehren", "minimale", "Deoxyhaemoglobinkonzentrationen", "bereits", "in", "dieser", "Phase", "zu", "Signalausloeschungen", ".", "Das", "Erscheinungsbild", "der", "akuten", ",", "subakuten", "und", "chronischen", "IZB", "entsprach", "dem", ",", "in", "der", "Literatur", "mitgeteilten", "Signalverhalten", ".", ",", "Zusammenfassend", "waren", "alle", "IZB", ",", "unabhaengig", "vom", "Stadium", "in", "der", "KST", "nachweisbar", ".", "Die", "Diffusionsgewichtung", "war", "in", "der", "hyperakuten", "Blutungsdiagnose", "und", "deren", "Abgrenzung", "von", "der", "akuten", "Ischaemie", "hilfreich", ".", "Zumindest", "bei", "1,5", "T", "erscheint", "die", "KST", "somit", "fuer", "die", "Diagnostik", "des", "akuten", "Schlaganfalls", "geeignet", "und", "sollte", ",", "da", "Ischaemien", "besser", "als", "mit", "der", "Computertomographie", "charakterisiert", "werden", "koennen", ",", "fuer", "die", "Akutdiagnostik", "verfuegbar", "gemacht", "werden", "." ]
[ "umlsterm" ]
Blutung is an umlsterm, Literatur is an umlsterm, Patienten is an umlsterm, Schlaganfallstudie is an umlsterm, Literatur is an umlsterm, Signalverhalten is an umlsterm, Diffusionsgewichtung is an umlsterm, Ischaemie is an umlsterm, Diagnostik is an umlsterm, Schlaganfalls is an umlsterm, Ischaemien is an umlsterm, Computertomographie is an umlsterm, Akutdiagnostik is an umlsterm
DerRadiologe.90390838.ger.abstr_task1
Sentence: In dieser Uebersicht wird das kernspintomographische ( KST ) Erscheinungsbild der intrazerebralen Blutung ( IZB ) anhand eigener Erfahrungen und der Literatur diskutiert . Besonderes Gewicht wurde auf den KST Nachweis der hyperakuten IZB innerhalb der ersten Stunden gelegt . Es wurden einerseits die Befunde von 42 Patienten einer prospektiven , KST randomisierten Schlaganfallstudie ausgewertet , bei denen die KST als Erstuntersuchung innerhalb von 6 Stunden durchgefuehrt worden war . Andererseits werteten wir retrospektiv jene KST Untersuchungen aus , die im Jahr 1998 unter der Fragestellung einer IZB ( n=63) erfolgten . Die KST erwies sich als sensitiv im Nachweis auch der hyperakuten IZB . Es wurden weder falsch-negative noch falsch-positive Befunde erhoben . Die hyperakute IZB kommt in der T2-Gewichtung hyperintens und in der T1-Gewichtung isointens zur Darstellung . Auf den diffusionsgewichteten Sequenzen fuehren minimale Deoxyhaemoglobinkonzentrationen bereits in dieser Phase zu Signalausloeschungen . Das Erscheinungsbild der akuten , subakuten und chronischen IZB entsprach dem , in der Literatur mitgeteilten Signalverhalten . , Zusammenfassend waren alle IZB , unabhaengig vom Stadium in der KST nachweisbar . Die Diffusionsgewichtung war in der hyperakuten Blutungsdiagnose und deren Abgrenzung von der akuten Ischaemie hilfreich . Zumindest bei 1,5T erscheint die KST somit fuer die Diagnostik des akuten Schlaganfalls geeignet und sollte , da Ischaemien besser als mit der Computertomographie charakterisiert werden koennen , fuer die Akutdiagnostik verfuegbar gemacht werden . Instructions: please typing these entity words according to sentence: Blutung, Literatur, Patienten, Schlaganfallstudie, Literatur, Signalverhalten, Diffusionsgewichtung, Ischaemie, Diagnostik, Schlaganfalls, Ischaemien, Computertomographie, Akutdiagnostik Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
In dieser Uebersicht wird das kernspintomographische ( KST ) Erscheinungsbild der intrazerebralen Blutung ( IZB ) anhand eigener Erfahrungen und der Literatur diskutiert . Besonderes Gewicht wurde auf den KST Nachweis der hyperakuten IZB innerhalb der ersten Stunden gelegt . Es wurden einerseits die Befunde von 42 Patienten einer prospektiven , KST randomisierten Schlaganfallstudie ausgewertet , bei denen die KST als Erstuntersuchung innerhalb von 6 Stunden durchgefuehrt worden war . Andererseits werteten wir retrospektiv jene KST Untersuchungen aus , die im Jahr 1998 unter der Fragestellung einer IZB ( n=63) erfolgten . Die KST erwies sich als sensitiv im Nachweis auch der hyperakuten IZB . Es wurden weder falsch-negative noch falsch-positive Befunde erhoben . Die hyperakute IZB kommt in der T2-Gewichtung hyperintens und in der T1-Gewichtung isointens zur Darstellung . Auf den diffusionsgewichteten Sequenzen fuehren minimale Deoxyhaemoglobinkonzentrationen bereits in dieser Phase zu Signalausloeschungen . Das Erscheinungsbild der akuten , subakuten und chronischen IZB entsprach dem , in der Literatur mitgeteilten Signalverhalten . , Zusammenfassend waren alle IZB , unabhaengig vom Stadium in der KST nachweisbar . Die Diffusionsgewichtung war in der hyperakuten Blutungsdiagnose und deren Abgrenzung von der akuten Ischaemie hilfreich . Zumindest bei 1,5T erscheint die KST somit fuer die Diagnostik des akuten Schlaganfalls geeignet und sollte , da Ischaemien besser als mit der Computertomographie charakterisiert werden koennen , fuer die Akutdiagnostik verfuegbar gemacht werden .
[ "In", "dieser", "Uebersicht", "wird", "das", "kernspintomographische", "(", "KST", ")", "Erscheinungsbild", "der", "intrazerebralen", "Blutung", "(", "IZB", ")", "anhand", "eigener", "Erfahrungen", "und", "der", "Literatur", "diskutiert", ".", "Besonderes", "Gewicht", "wurde", "auf", "den", "KST", "Nachweis", "der", "hyperakuten", "IZB", "innerhalb", "der", "ersten", "Stunden", "gelegt", ".", "Es", "wurden", "einerseits", "die", "Befunde", "von", "42", "Patienten", "einer", "prospektiven", ",", "KST", "randomisierten", "Schlaganfallstudie", "ausgewertet", ",", "bei", "denen", "die", "KST", "als", "Erstuntersuchung", "innerhalb", "von", "6", "Stunden", "durchgefuehrt", "worden", "war", ".", "Andererseits", "werteten", "wir", "retrospektiv", "jene", "KST", "Untersuchungen", "aus", ",", "die", "im", "Jahr", "1998", "unter", "der", "Fragestellung", "einer", "IZB", "(", "n=63", ")", "erfolgten", ".", "Die", "KST", "erwies", "sich", "als", "sensitiv", "im", "Nachweis", "auch", "der", "hyperakuten", "IZB", ".", "Es", "wurden", "weder", "falsch", "-", "negative", "noch", "falsch", "-", "positive", "Befunde", "erhoben", ".", "Die", "hyperakute", "IZB", "kommt", "in", "der", "T2-Gewichtung", "hyperintens", "und", "in", "der", "T1-Gewichtung", "isointens", "zur", "Darstellung", ".", "Auf", "den", "diffusionsgewichteten", "Sequenzen", "fuehren", "minimale", "Deoxyhaemoglobinkonzentrationen", "bereits", "in", "dieser", "Phase", "zu", "Signalausloeschungen", ".", "Das", "Erscheinungsbild", "der", "akuten", ",", "subakuten", "und", "chronischen", "IZB", "entsprach", "dem", ",", "in", "der", "Literatur", "mitgeteilten", "Signalverhalten", ".", ",", "Zusammenfassend", "waren", "alle", "IZB", ",", "unabhaengig", "vom", "Stadium", "in", "der", "KST", "nachweisbar", ".", "Die", "Diffusionsgewichtung", "war", "in", "der", "hyperakuten", "Blutungsdiagnose", "und", "deren", "Abgrenzung", "von", "der", "akuten", "Ischaemie", "hilfreich", ".", "Zumindest", "bei", "1,5", "T", "erscheint", "die", "KST", "somit", "fuer", "die", "Diagnostik", "des", "akuten", "Schlaganfalls", "geeignet", "und", "sollte", ",", "da", "Ischaemien", "besser", "als", "mit", "der", "Computertomographie", "charakterisiert", "werden", "koennen", ",", "fuer", "die", "Akutdiagnostik", "verfuegbar", "gemacht", "werden", "." ]
[ "umlsterm" ]
Blutung, Literatur, Patienten, Schlaganfallstudie, Literatur, Signalverhalten, Diffusionsgewichtung, Ischaemie, Diagnostik, Schlaganfalls, Ischaemien, Computertomographie, Akutdiagnostik
DerRadiologe.90390838.ger.abstr_task2
Sentence: In dieser Uebersicht wird das kernspintomographische ( KST ) Erscheinungsbild der intrazerebralen Blutung ( IZB ) anhand eigener Erfahrungen und der Literatur diskutiert . Besonderes Gewicht wurde auf den KST Nachweis der hyperakuten IZB innerhalb der ersten Stunden gelegt . Es wurden einerseits die Befunde von 42 Patienten einer prospektiven , KST randomisierten Schlaganfallstudie ausgewertet , bei denen die KST als Erstuntersuchung innerhalb von 6 Stunden durchgefuehrt worden war . Andererseits werteten wir retrospektiv jene KST Untersuchungen aus , die im Jahr 1998 unter der Fragestellung einer IZB ( n=63) erfolgten . Die KST erwies sich als sensitiv im Nachweis auch der hyperakuten IZB . Es wurden weder falsch-negative noch falsch-positive Befunde erhoben . Die hyperakute IZB kommt in der T2-Gewichtung hyperintens und in der T1-Gewichtung isointens zur Darstellung . Auf den diffusionsgewichteten Sequenzen fuehren minimale Deoxyhaemoglobinkonzentrationen bereits in dieser Phase zu Signalausloeschungen . Das Erscheinungsbild der akuten , subakuten und chronischen IZB entsprach dem , in der Literatur mitgeteilten Signalverhalten . , Zusammenfassend waren alle IZB , unabhaengig vom Stadium in der KST nachweisbar . Die Diffusionsgewichtung war in der hyperakuten Blutungsdiagnose und deren Abgrenzung von der akuten Ischaemie hilfreich . Zumindest bei 1,5T erscheint die KST somit fuer die Diagnostik des akuten Schlaganfalls geeignet und sollte , da Ischaemien besser als mit der Computertomographie charakterisiert werden koennen , fuer die Akutdiagnostik verfuegbar gemacht werden . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
In dieser Uebersicht wird das kernspintomographische ( KST ) Erscheinungsbild der intrazerebralen Blutung ( IZB ) anhand eigener Erfahrungen und der Literatur diskutiert . Besonderes Gewicht wurde auf den KST Nachweis der hyperakuten IZB innerhalb der ersten Stunden gelegt . Es wurden einerseits die Befunde von 42 Patienten einer prospektiven , KST randomisierten Schlaganfallstudie ausgewertet , bei denen die KST als Erstuntersuchung innerhalb von 6 Stunden durchgefuehrt worden war . Andererseits werteten wir retrospektiv jene KST Untersuchungen aus , die im Jahr 1998 unter der Fragestellung einer IZB ( n=63) erfolgten . Die KST erwies sich als sensitiv im Nachweis auch der hyperakuten IZB . Es wurden weder falsch-negative noch falsch-positive Befunde erhoben . Die hyperakute IZB kommt in der T2-Gewichtung hyperintens und in der T1-Gewichtung isointens zur Darstellung . Auf den diffusionsgewichteten Sequenzen fuehren minimale Deoxyhaemoglobinkonzentrationen bereits in dieser Phase zu Signalausloeschungen . Das Erscheinungsbild der akuten , subakuten und chronischen IZB entsprach dem , in der Literatur mitgeteilten Signalverhalten . , Zusammenfassend waren alle IZB , unabhaengig vom Stadium in der KST nachweisbar . Die Diffusionsgewichtung war in der hyperakuten Blutungsdiagnose und deren Abgrenzung von der akuten Ischaemie hilfreich . Zumindest bei 1,5T erscheint die KST somit fuer die Diagnostik des akuten Schlaganfalls geeignet und sollte , da Ischaemien besser als mit der Computertomographie charakterisiert werden koennen , fuer die Akutdiagnostik verfuegbar gemacht werden .
[ "In", "dieser", "Uebersicht", "wird", "das", "kernspintomographische", "(", "KST", ")", "Erscheinungsbild", "der", "intrazerebralen", "Blutung", "(", "IZB", ")", "anhand", "eigener", "Erfahrungen", "und", "der", "Literatur", "diskutiert", ".", "Besonderes", "Gewicht", "wurde", "auf", "den", "KST", "Nachweis", "der", "hyperakuten", "IZB", "innerhalb", "der", "ersten", "Stunden", "gelegt", ".", "Es", "wurden", "einerseits", "die", "Befunde", "von", "42", "Patienten", "einer", "prospektiven", ",", "KST", "randomisierten", "Schlaganfallstudie", "ausgewertet", ",", "bei", "denen", "die", "KST", "als", "Erstuntersuchung", "innerhalb", "von", "6", "Stunden", "durchgefuehrt", "worden", "war", ".", "Andererseits", "werteten", "wir", "retrospektiv", "jene", "KST", "Untersuchungen", "aus", ",", "die", "im", "Jahr", "1998", "unter", "der", "Fragestellung", "einer", "IZB", "(", "n=63", ")", "erfolgten", ".", "Die", "KST", "erwies", "sich", "als", "sensitiv", "im", "Nachweis", "auch", "der", "hyperakuten", "IZB", ".", "Es", "wurden", "weder", "falsch", "-", "negative", "noch", "falsch", "-", "positive", "Befunde", "erhoben", ".", "Die", "hyperakute", "IZB", "kommt", "in", "der", "T2-Gewichtung", "hyperintens", "und", "in", "der", "T1-Gewichtung", "isointens", "zur", "Darstellung", ".", "Auf", "den", "diffusionsgewichteten", "Sequenzen", "fuehren", "minimale", "Deoxyhaemoglobinkonzentrationen", "bereits", "in", "dieser", "Phase", "zu", "Signalausloeschungen", ".", "Das", "Erscheinungsbild", "der", "akuten", ",", "subakuten", "und", "chronischen", "IZB", "entsprach", "dem", ",", "in", "der", "Literatur", "mitgeteilten", "Signalverhalten", ".", ",", "Zusammenfassend", "waren", "alle", "IZB", ",", "unabhaengig", "vom", "Stadium", "in", "der", "KST", "nachweisbar", ".", "Die", "Diffusionsgewichtung", "war", "in", "der", "hyperakuten", "Blutungsdiagnose", "und", "deren", "Abgrenzung", "von", "der", "akuten", "Ischaemie", "hilfreich", ".", "Zumindest", "bei", "1,5", "T", "erscheint", "die", "KST", "somit", "fuer", "die", "Diagnostik", "des", "akuten", "Schlaganfalls", "geeignet", "und", "sollte", ",", "da", "Ischaemien", "besser", "als", "mit", "der", "Computertomographie", "charakterisiert", "werden", "koennen", ",", "fuer", "die", "Akutdiagnostik", "verfuegbar", "gemacht", "werden", "." ]
[ "umlsterm" ]
transplantation is an umlsterm, retinal pigment is an umlsterm, epithelial cells is an umlsterm, patients is an umlsterm, macular degeneration is an umlsterm, future is an umlsterm, therapy is an umlsterm, cornea is an umlsterm, cells is an umlsterm, tissue - compatible is an umlsterm, transplantation is an umlsterm
DerOpthalmologe.90960648.eng.abstr_task0
Sentence: Background : The transplantation of retinal pigment epithelial cells ( RPE ) in patients with age-related macular degeneration is discussed as a future therapy . A cornea bank can serve as a source for cells that can be isolated , cultivated , HLA-typed and cryopreserved for subsequent tissue-compatible transplantation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O" ]
Background : The transplantation of retinal pigment epithelial cells ( RPE ) in patients with age-related macular degeneration is discussed as a future therapy . A cornea bank can serve as a source for cells that can be isolated , cultivated , HLA-typed and cryopreserved for subsequent tissue-compatible transplantation .
[ "Background", ":", "The", "transplantation", "of", "retinal", "pigment", "epithelial", "cells", "(", "RPE", ")", "in", "patients", "with", "age", "-", "related", "macular", "degeneration", "is", "discussed", "as", "a", "future", "therapy", ".", "A", "cornea", "bank", "can", "serve", "as", "a", "source", "for", "cells", "that", "can", "be", "isolated", ",", "cultivated", ",", "HLA", "-", "typed", "and", "cryopreserved", "for", "subsequent", "tissue", "-", "compatible", "transplantation", "." ]
[ "umlsterm" ]
transplantation is an umlsterm, retinal pigment is an umlsterm, epithelial cells is an umlsterm, patients is an umlsterm, macular degeneration is an umlsterm, future is an umlsterm, therapy is an umlsterm, cornea is an umlsterm, cells is an umlsterm, tissue - compatible is an umlsterm, transplantation is an umlsterm
DerOpthalmologe.90960648.eng.abstr_task1
Sentence: Background : The transplantation of retinal pigment epithelial cells ( RPE ) in patients with age-related macular degeneration is discussed as a future therapy . A cornea bank can serve as a source for cells that can be isolated , cultivated , HLA-typed and cryopreserved for subsequent tissue-compatible transplantation . Instructions: please typing these entity words according to sentence: transplantation, retinal pigment, epithelial cells, patients, macular degeneration, future, therapy, cornea, cells, tissue - compatible, transplantation Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O" ]
Background : The transplantation of retinal pigment epithelial cells ( RPE ) in patients with age-related macular degeneration is discussed as a future therapy . A cornea bank can serve as a source for cells that can be isolated , cultivated , HLA-typed and cryopreserved for subsequent tissue-compatible transplantation .
[ "Background", ":", "The", "transplantation", "of", "retinal", "pigment", "epithelial", "cells", "(", "RPE", ")", "in", "patients", "with", "age", "-", "related", "macular", "degeneration", "is", "discussed", "as", "a", "future", "therapy", ".", "A", "cornea", "bank", "can", "serve", "as", "a", "source", "for", "cells", "that", "can", "be", "isolated", ",", "cultivated", ",", "HLA", "-", "typed", "and", "cryopreserved", "for", "subsequent", "tissue", "-", "compatible", "transplantation", "." ]
[ "umlsterm" ]
transplantation, retinal pigment, epithelial cells, patients, macular degeneration, future, therapy, cornea, cells, tissue - compatible, transplantation
DerOpthalmologe.90960648.eng.abstr_task2
Sentence: Background : The transplantation of retinal pigment epithelial cells ( RPE ) in patients with age-related macular degeneration is discussed as a future therapy . A cornea bank can serve as a source for cells that can be isolated , cultivated , HLA-typed and cryopreserved for subsequent tissue-compatible transplantation . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O" ]
Background : The transplantation of retinal pigment epithelial cells ( RPE ) in patients with age-related macular degeneration is discussed as a future therapy . A cornea bank can serve as a source for cells that can be isolated , cultivated , HLA-typed and cryopreserved for subsequent tissue-compatible transplantation .
[ "Background", ":", "The", "transplantation", "of", "retinal", "pigment", "epithelial", "cells", "(", "RPE", ")", "in", "patients", "with", "age", "-", "related", "macular", "degeneration", "is", "discussed", "as", "a", "future", "therapy", ".", "A", "cornea", "bank", "can", "serve", "as", "a", "source", "for", "cells", "that", "can", "be", "isolated", ",", "cultivated", ",", "HLA", "-", "typed", "and", "cryopreserved", "for", "subsequent", "tissue", "-", "compatible", "transplantation", "." ]
[ "umlsterm" ]
p50 is a Protein, CD14 is a Protein, naive Mono Mac 6 cells is a Entity, p50 is a Protein, p50 is a Protein, p105 is a Protein, p50 is a Protein, CD14 is a Protein, p50 is a Protein
354_task0
Sentence: Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. Stimulation of the human monocytic cell line Mono Mac 6 with lipopolysaccharide (LPS) leads to rapid and transient expression of cytokines like tumor necrosis factor (TNF). When such cells are precultured for 2 days with a low dose of LPS (20 ng/ml) followed by stimulation with a high dose of LPS (1 microgram/ml), expression of the TNF gene is minimal, i.e. the cells are tolerant. In nuclear run-on analysis, such tolerant cells show only a low degree of transcription, indicating that tolerance operates at or upstream of the transcription level. The CD14 LPS receptor is, however, up-regulated (not down-regulated) in tolerant cells, and LPS can, in fact, still lead to activation of tolerant cells as evidenced by mobilization of the transcription factor nuclear factor kappa B (NF-kappa B). Resolution of the NF-kappa B complex in gel shift analysis shows that the binding protein, mobilized in naive Mono Mac 6 cells, consists mainly of p50-p65 heterodimers, while in tolerant cells, the p50 homodimer is predominant. This increase in p50 homodimers coincides with an increase in p105 mRNA, suggestive of a transcriptional up-regulation of p50. Reporter gene analysis reveals that the NF-kappa B complex mobilized in tolerant cells is functionally inactive in that NF-kappa B-dependent luciferase constructs containing the human immunodeficiency virus long terminal repeat or the TNF 5'-region show only minimal transactivation after LPS stimulation. Similar to Mono Mac 6 cells, primary blood monocytes, when precultured with a low dose of LPS, also become tolerant and produce little TNF after LPS stimulation. The tolerant blood monocytes also up-regulate CD14, and they mobilize NF-kappa B with a predominance of p50 homodimers. Taken together, these results demonstrate that tolerance to LPS is determined by post-receptor mechanisms that involve an altered composition of the NF-kappa B complex. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. Stimulation of the human monocytic cell line Mono Mac 6 with lipopolysaccharide (LPS) leads to rapid and transient expression of cytokines like tumor necrosis factor (TNF). When such cells are precultured for 2 days with a low dose of LPS (20 ng/ml) followed by stimulation with a high dose of LPS (1 microgram/ml), expression of the TNF gene is minimal, i.e. the cells are tolerant. In nuclear run-on analysis, such tolerant cells show only a low degree of transcription, indicating that tolerance operates at or upstream of the transcription level. The CD14 LPS receptor is, however, up-regulated (not down-regulated) in tolerant cells, and LPS can, in fact, still lead to activation of tolerant cells as evidenced by mobilization of the transcription factor nuclear factor kappa B (NF-kappa B). Resolution of the NF-kappa B complex in gel shift analysis shows that the binding protein, mobilized in naive Mono Mac 6 cells, consists mainly of p50-p65 heterodimers, while in tolerant cells, the p50 homodimer is predominant. This increase in p50 homodimers coincides with an increase in p105 mRNA, suggestive of a transcriptional up-regulation of p50. Reporter gene analysis reveals that the NF-kappa B complex mobilized in tolerant cells is functionally inactive in that NF-kappa B-dependent luciferase constructs containing the human immunodeficiency virus long terminal repeat or the TNF 5'-region show only minimal transactivation after LPS stimulation. Similar to Mono Mac 6 cells, primary blood monocytes, when precultured with a low dose of LPS, also become tolerant and produce little TNF after LPS stimulation. The tolerant blood monocytes also up-regulate CD14, and they mobilize NF-kappa B with a predominance of p50 homodimers. Taken together, these results demonstrate that tolerance to LPS is determined by post-receptor mechanisms that involve an altered composition of the NF-kappa B complex.
[ "Tolerance", "to", "lipopolysaccharide", "involves", "mobilization", "of", "nuclear", "factor", "kappa", "B", "with", "predominance", "of", "p50", "homodimers", ".", "\n", "Stimulation", "of", "the", "human", "monocytic", "cell", "line", "Mono", "Mac", "6", "with", "lipopolysaccharide", "(", "LPS", ")", "leads", "to", "rapid", "and", "transient", "expression", "of", "cytokines", "like", "tumor", "necrosis", "factor", "(", "TNF", ")", ".", "When", "such", "cells", "are", "precultured", "for", "2", "days", "with", "a", "low", "dose", "of", "LPS", "(", "20", "ng", "/", "ml", ")", "followed", "by", "stimulation", "with", "a", "high", "dose", "of", "LPS", "(", "1", "microgram", "/", "ml", ")", ",", "expression", "of", "the", "TNF", "gene", "is", "minimal", ",", "i.e", ".", "the", "cells", "are", "tolerant", ".", "In", "nuclear", "run", "-", "on", "analysis", ",", "such", "tolerant", "cells", "show", "only", "a", "low", "degree", "of", "transcription", ",", "indicating", "that", "tolerance", "operates", "at", "or", "upstream", "of", "the", "transcription", "level", ".", "The", "CD14", "LPS", "receptor", "is", ",", "however", ",", "up", "-", "regulated", "(", "not", "down", "-", "regulated", ")", "in", "tolerant", "cells", ",", "and", "LPS", "can", ",", "in", "fact", ",", "still", "lead", "to", "activation", "of", "tolerant", "cells", "as", "evidenced", "by", "mobilization", "of", "the", "transcription", "factor", "nuclear", "factor", "kappa", "B", "(", "NF", "-", "kappa", "B", ")", ".", "Resolution", "of", "the", "NF", "-", "kappa", "B", "complex", "in", "gel", "shift", "analysis", "shows", "that", "the", "binding", "protein", ",", "mobilized", "in", "naive", "Mono", "Mac", "6", "cells", ",", "consists", "mainly", "of", "p50-p65", "heterodimers", ",", "while", "in", "tolerant", "cells", ",", "the", "p50", "homodimer", "is", "predominant", ".", "This", "increase", "in", "p50", "homodimers", "coincides", "with", "an", "increase", "in", "p105", "mRNA", ",", "suggestive", "of", "a", "transcriptional", "up", "-", "regulation", "of", "p50", ".", "Reporter", "gene", "analysis", "reveals", "that", "the", "NF", "-", "kappa", "B", "complex", "mobilized", "in", "tolerant", "cells", "is", "functionally", "inactive", "in", "that", "NF", "-", "kappa", "B", "-", "dependent", "luciferase", "constructs", "containing", "the", "human", "immunodeficiency", "virus", "long", "terminal", "repeat", "or", "the", "TNF", "5'-region", "show", "only", "minimal", "transactivation", "after", "LPS", "stimulation", ".", "Similar", "to", "Mono", "Mac", "6", "cells", ",", "primary", "blood", "monocytes", ",", "when", "precultured", "with", "a", "low", "dose", "of", "LPS", ",", "also", "become", "tolerant", "and", "produce", "little", "TNF", "after", "LPS", "stimulation", ".", "The", "tolerant", "blood", "monocytes", "also", "up", "-", "regulate", "CD14", ",", "and", "they", "mobilize", "NF", "-", "kappa", "B", "with", "a", "predominance", "of", "p50", "homodimers", ".", "Taken", "together", ",", "these", "results", "demonstrate", "that", "tolerance", "to", "LPS", "is", "determined", "by", "post", "-", "receptor", "mechanisms", "that", "involve", "an", "altered", "composition", "of", "the", "NF", "-", "kappa", "B", "complex", "." ]
[ "Entity", "Protein" ]
p50 is a Protein, CD14 is a Protein, naive Mono Mac 6 cells is a Entity, p50 is a Protein, p50 is a Protein, p105 is a Protein, p50 is a Protein, CD14 is a Protein, p50 is a Protein
354_task1
Sentence: Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. Stimulation of the human monocytic cell line Mono Mac 6 with lipopolysaccharide (LPS) leads to rapid and transient expression of cytokines like tumor necrosis factor (TNF). When such cells are precultured for 2 days with a low dose of LPS (20 ng/ml) followed by stimulation with a high dose of LPS (1 microgram/ml), expression of the TNF gene is minimal, i.e. the cells are tolerant. In nuclear run-on analysis, such tolerant cells show only a low degree of transcription, indicating that tolerance operates at or upstream of the transcription level. The CD14 LPS receptor is, however, up-regulated (not down-regulated) in tolerant cells, and LPS can, in fact, still lead to activation of tolerant cells as evidenced by mobilization of the transcription factor nuclear factor kappa B (NF-kappa B). Resolution of the NF-kappa B complex in gel shift analysis shows that the binding protein, mobilized in naive Mono Mac 6 cells, consists mainly of p50-p65 heterodimers, while in tolerant cells, the p50 homodimer is predominant. This increase in p50 homodimers coincides with an increase in p105 mRNA, suggestive of a transcriptional up-regulation of p50. Reporter gene analysis reveals that the NF-kappa B complex mobilized in tolerant cells is functionally inactive in that NF-kappa B-dependent luciferase constructs containing the human immunodeficiency virus long terminal repeat or the TNF 5'-region show only minimal transactivation after LPS stimulation. Similar to Mono Mac 6 cells, primary blood monocytes, when precultured with a low dose of LPS, also become tolerant and produce little TNF after LPS stimulation. The tolerant blood monocytes also up-regulate CD14, and they mobilize NF-kappa B with a predominance of p50 homodimers. Taken together, these results demonstrate that tolerance to LPS is determined by post-receptor mechanisms that involve an altered composition of the NF-kappa B complex. Instructions: please typing these entity words according to sentence: p50, CD14, naive Mono Mac 6 cells, p50, p50, p105, p50, CD14, p50 Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. Stimulation of the human monocytic cell line Mono Mac 6 with lipopolysaccharide (LPS) leads to rapid and transient expression of cytokines like tumor necrosis factor (TNF). When such cells are precultured for 2 days with a low dose of LPS (20 ng/ml) followed by stimulation with a high dose of LPS (1 microgram/ml), expression of the TNF gene is minimal, i.e. the cells are tolerant. In nuclear run-on analysis, such tolerant cells show only a low degree of transcription, indicating that tolerance operates at or upstream of the transcription level. The CD14 LPS receptor is, however, up-regulated (not down-regulated) in tolerant cells, and LPS can, in fact, still lead to activation of tolerant cells as evidenced by mobilization of the transcription factor nuclear factor kappa B (NF-kappa B). Resolution of the NF-kappa B complex in gel shift analysis shows that the binding protein, mobilized in naive Mono Mac 6 cells, consists mainly of p50-p65 heterodimers, while in tolerant cells, the p50 homodimer is predominant. This increase in p50 homodimers coincides with an increase in p105 mRNA, suggestive of a transcriptional up-regulation of p50. Reporter gene analysis reveals that the NF-kappa B complex mobilized in tolerant cells is functionally inactive in that NF-kappa B-dependent luciferase constructs containing the human immunodeficiency virus long terminal repeat or the TNF 5'-region show only minimal transactivation after LPS stimulation. Similar to Mono Mac 6 cells, primary blood monocytes, when precultured with a low dose of LPS, also become tolerant and produce little TNF after LPS stimulation. The tolerant blood monocytes also up-regulate CD14, and they mobilize NF-kappa B with a predominance of p50 homodimers. Taken together, these results demonstrate that tolerance to LPS is determined by post-receptor mechanisms that involve an altered composition of the NF-kappa B complex.
[ "Tolerance", "to", "lipopolysaccharide", "involves", "mobilization", "of", "nuclear", "factor", "kappa", "B", "with", "predominance", "of", "p50", "homodimers", ".", "\n", "Stimulation", "of", "the", "human", "monocytic", "cell", "line", "Mono", "Mac", "6", "with", "lipopolysaccharide", "(", "LPS", ")", "leads", "to", "rapid", "and", "transient", "expression", "of", "cytokines", "like", "tumor", "necrosis", "factor", "(", "TNF", ")", ".", "When", "such", "cells", "are", "precultured", "for", "2", "days", "with", "a", "low", "dose", "of", "LPS", "(", "20", "ng", "/", "ml", ")", "followed", "by", "stimulation", "with", "a", "high", "dose", "of", "LPS", "(", "1", "microgram", "/", "ml", ")", ",", "expression", "of", "the", "TNF", "gene", "is", "minimal", ",", "i.e", ".", "the", "cells", "are", "tolerant", ".", "In", "nuclear", "run", "-", "on", "analysis", ",", "such", "tolerant", "cells", "show", "only", "a", "low", "degree", "of", "transcription", ",", "indicating", "that", "tolerance", "operates", "at", "or", "upstream", "of", "the", "transcription", "level", ".", "The", "CD14", "LPS", "receptor", "is", ",", "however", ",", "up", "-", "regulated", "(", "not", "down", "-", "regulated", ")", "in", "tolerant", "cells", ",", "and", "LPS", "can", ",", "in", "fact", ",", "still", "lead", "to", "activation", "of", "tolerant", "cells", "as", "evidenced", "by", "mobilization", "of", "the", "transcription", "factor", "nuclear", "factor", "kappa", "B", "(", "NF", "-", "kappa", "B", ")", ".", "Resolution", "of", "the", "NF", "-", "kappa", "B", "complex", "in", "gel", "shift", "analysis", "shows", "that", "the", "binding", "protein", ",", "mobilized", "in", "naive", "Mono", "Mac", "6", "cells", ",", "consists", "mainly", "of", "p50-p65", "heterodimers", ",", "while", "in", "tolerant", "cells", ",", "the", "p50", "homodimer", "is", "predominant", ".", "This", "increase", "in", "p50", "homodimers", "coincides", "with", "an", "increase", "in", "p105", "mRNA", ",", "suggestive", "of", "a", "transcriptional", "up", "-", "regulation", "of", "p50", ".", "Reporter", "gene", "analysis", "reveals", "that", "the", "NF", "-", "kappa", "B", "complex", "mobilized", "in", "tolerant", "cells", "is", "functionally", "inactive", "in", "that", "NF", "-", "kappa", "B", "-", "dependent", "luciferase", "constructs", "containing", "the", "human", "immunodeficiency", "virus", "long", "terminal", "repeat", "or", "the", "TNF", "5'-region", "show", "only", "minimal", "transactivation", "after", "LPS", "stimulation", ".", "Similar", "to", "Mono", "Mac", "6", "cells", ",", "primary", "blood", "monocytes", ",", "when", "precultured", "with", "a", "low", "dose", "of", "LPS", ",", "also", "become", "tolerant", "and", "produce", "little", "TNF", "after", "LPS", "stimulation", ".", "The", "tolerant", "blood", "monocytes", "also", "up", "-", "regulate", "CD14", ",", "and", "they", "mobilize", "NF", "-", "kappa", "B", "with", "a", "predominance", "of", "p50", "homodimers", ".", "Taken", "together", ",", "these", "results", "demonstrate", "that", "tolerance", "to", "LPS", "is", "determined", "by", "post", "-", "receptor", "mechanisms", "that", "involve", "an", "altered", "composition", "of", "the", "NF", "-", "kappa", "B", "complex", "." ]
[ "Entity", "Protein" ]
p50, CD14, naive Mono Mac 6 cells, p50, p50, p105, p50, CD14, p50
354_task2
Sentence: Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. Stimulation of the human monocytic cell line Mono Mac 6 with lipopolysaccharide (LPS) leads to rapid and transient expression of cytokines like tumor necrosis factor (TNF). When such cells are precultured for 2 days with a low dose of LPS (20 ng/ml) followed by stimulation with a high dose of LPS (1 microgram/ml), expression of the TNF gene is minimal, i.e. the cells are tolerant. In nuclear run-on analysis, such tolerant cells show only a low degree of transcription, indicating that tolerance operates at or upstream of the transcription level. The CD14 LPS receptor is, however, up-regulated (not down-regulated) in tolerant cells, and LPS can, in fact, still lead to activation of tolerant cells as evidenced by mobilization of the transcription factor nuclear factor kappa B (NF-kappa B). Resolution of the NF-kappa B complex in gel shift analysis shows that the binding protein, mobilized in naive Mono Mac 6 cells, consists mainly of p50-p65 heterodimers, while in tolerant cells, the p50 homodimer is predominant. This increase in p50 homodimers coincides with an increase in p105 mRNA, suggestive of a transcriptional up-regulation of p50. Reporter gene analysis reveals that the NF-kappa B complex mobilized in tolerant cells is functionally inactive in that NF-kappa B-dependent luciferase constructs containing the human immunodeficiency virus long terminal repeat or the TNF 5'-region show only minimal transactivation after LPS stimulation. Similar to Mono Mac 6 cells, primary blood monocytes, when precultured with a low dose of LPS, also become tolerant and produce little TNF after LPS stimulation. The tolerant blood monocytes also up-regulate CD14, and they mobilize NF-kappa B with a predominance of p50 homodimers. Taken together, these results demonstrate that tolerance to LPS is determined by post-receptor mechanisms that involve an altered composition of the NF-kappa B complex. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. Stimulation of the human monocytic cell line Mono Mac 6 with lipopolysaccharide (LPS) leads to rapid and transient expression of cytokines like tumor necrosis factor (TNF). When such cells are precultured for 2 days with a low dose of LPS (20 ng/ml) followed by stimulation with a high dose of LPS (1 microgram/ml), expression of the TNF gene is minimal, i.e. the cells are tolerant. In nuclear run-on analysis, such tolerant cells show only a low degree of transcription, indicating that tolerance operates at or upstream of the transcription level. The CD14 LPS receptor is, however, up-regulated (not down-regulated) in tolerant cells, and LPS can, in fact, still lead to activation of tolerant cells as evidenced by mobilization of the transcription factor nuclear factor kappa B (NF-kappa B). Resolution of the NF-kappa B complex in gel shift analysis shows that the binding protein, mobilized in naive Mono Mac 6 cells, consists mainly of p50-p65 heterodimers, while in tolerant cells, the p50 homodimer is predominant. This increase in p50 homodimers coincides with an increase in p105 mRNA, suggestive of a transcriptional up-regulation of p50. Reporter gene analysis reveals that the NF-kappa B complex mobilized in tolerant cells is functionally inactive in that NF-kappa B-dependent luciferase constructs containing the human immunodeficiency virus long terminal repeat or the TNF 5'-region show only minimal transactivation after LPS stimulation. Similar to Mono Mac 6 cells, primary blood monocytes, when precultured with a low dose of LPS, also become tolerant and produce little TNF after LPS stimulation. The tolerant blood monocytes also up-regulate CD14, and they mobilize NF-kappa B with a predominance of p50 homodimers. Taken together, these results demonstrate that tolerance to LPS is determined by post-receptor mechanisms that involve an altered composition of the NF-kappa B complex.
[ "Tolerance", "to", "lipopolysaccharide", "involves", "mobilization", "of", "nuclear", "factor", "kappa", "B", "with", "predominance", "of", "p50", "homodimers", ".", "\n", "Stimulation", "of", "the", "human", "monocytic", "cell", "line", "Mono", "Mac", "6", "with", "lipopolysaccharide", "(", "LPS", ")", "leads", "to", "rapid", "and", "transient", "expression", "of", "cytokines", "like", "tumor", "necrosis", "factor", "(", "TNF", ")", ".", "When", "such", "cells", "are", "precultured", "for", "2", "days", "with", "a", "low", "dose", "of", "LPS", "(", "20", "ng", "/", "ml", ")", "followed", "by", "stimulation", "with", "a", "high", "dose", "of", "LPS", "(", "1", "microgram", "/", "ml", ")", ",", "expression", "of", "the", "TNF", "gene", "is", "minimal", ",", "i.e", ".", "the", "cells", "are", "tolerant", ".", "In", "nuclear", "run", "-", "on", "analysis", ",", "such", "tolerant", "cells", "show", "only", "a", "low", "degree", "of", "transcription", ",", "indicating", "that", "tolerance", "operates", "at", "or", "upstream", "of", "the", "transcription", "level", ".", "The", "CD14", "LPS", "receptor", "is", ",", "however", ",", "up", "-", "regulated", "(", "not", "down", "-", "regulated", ")", "in", "tolerant", "cells", ",", "and", "LPS", "can", ",", "in", "fact", ",", "still", "lead", "to", "activation", "of", "tolerant", "cells", "as", "evidenced", "by", "mobilization", "of", "the", "transcription", "factor", "nuclear", "factor", "kappa", "B", "(", "NF", "-", "kappa", "B", ")", ".", "Resolution", "of", "the", "NF", "-", "kappa", "B", "complex", "in", "gel", "shift", "analysis", "shows", "that", "the", "binding", "protein", ",", "mobilized", "in", "naive", "Mono", "Mac", "6", "cells", ",", "consists", "mainly", "of", "p50-p65", "heterodimers", ",", "while", "in", "tolerant", "cells", ",", "the", "p50", "homodimer", "is", "predominant", ".", "This", "increase", "in", "p50", "homodimers", "coincides", "with", "an", "increase", "in", "p105", "mRNA", ",", "suggestive", "of", "a", "transcriptional", "up", "-", "regulation", "of", "p50", ".", "Reporter", "gene", "analysis", "reveals", "that", "the", "NF", "-", "kappa", "B", "complex", "mobilized", "in", "tolerant", "cells", "is", "functionally", "inactive", "in", "that", "NF", "-", "kappa", "B", "-", "dependent", "luciferase", "constructs", "containing", "the", "human", "immunodeficiency", "virus", "long", "terminal", "repeat", "or", "the", "TNF", "5'-region", "show", "only", "minimal", "transactivation", "after", "LPS", "stimulation", ".", "Similar", "to", "Mono", "Mac", "6", "cells", ",", "primary", "blood", "monocytes", ",", "when", "precultured", "with", "a", "low", "dose", "of", "LPS", ",", "also", "become", "tolerant", "and", "produce", "little", "TNF", "after", "LPS", "stimulation", ".", "The", "tolerant", "blood", "monocytes", "also", "up", "-", "regulate", "CD14", ",", "and", "they", "mobilize", "NF", "-", "kappa", "B", "with", "a", "predominance", "of", "p50", "homodimers", ".", "Taken", "together", ",", "these", "results", "demonstrate", "that", "tolerance", "to", "LPS", "is", "determined", "by", "post", "-", "receptor", "mechanisms", "that", "involve", "an", "altered", "composition", "of", "the", "NF", "-", "kappa", "B", "complex", "." ]
[ "Entity", "Protein" ]
VicRK is a Two-component-system, YycFG is a Two-component-system, VicR is a Protein, Bacillus subtilis is a Organism, Staphylococcus aureus is a Organism, Streptococcus pneumoniae is a Organism, Streptococcus pyogenes is a Organism, vicK is a Protein, S. pneumoniae is a Organism, Streptococcus mutans is a Organism, S. pyogenes is a Organism, B. subtilis is a Organism, S. aureus is a Organism, vicRK is a Two-component-system, vicRK is a Two-component-system, Streptococcus equi subspecies equi is a Organism, S. equi is a Organism, equine is a Organism, S. equi is a Organism, S. equi is a Organism, hyaluronic acid is a Chemical, S. equi is a Organism, M - like protein is a Protein, SeM is a Protein, horses is a Organism, S. equi is a Organism, SeM is a Protein, hyaluronic acid is a Chemical, VicRK is a Two-component-system, S. equi is a Organism, vicK deletion mutant is a Organism, mouse is a Organism, vicK is a Protein, S. equi is a Organism, mouse is a Organism, vicK deletion mutant is a Organism, S. equi is a Organism, SeM is a Protein
8_task0
Sentence: INTRODUCTION Bacterial pathogens produce many two-component regulatory systems to regulate gene expression by specific environmental signals [1]. These systems consist of membrane protein sensors and cognate cytoplasmic response regulators. The regulator is phosphorylated by the sensor in response to a specific signal, activating or repressing the transcription of target genes. The two-component regulatory system VicRK or YycFG is specific for Gram-positive bacteria. The regulator component VicR is essential in Bacillus subtilis [2], Staphylococcus aureus [3], and Streptococcus pneumoniae [4-5] but appears not to be essential in Streptococcus pyogenes [6]. The deletion of the vicK gene can be readily inactivated in S. pneumoniae [7], Streptococcus mutans [8], and S. pyogenes [6] but not in B. subtilis [2] and S. aureus [3]. Conditional and unconditional vicRK mutants display various phenotypes, including defects in morphology and cell wall synthesis, decreased competence, sensitivity to antibiotics and fatty acids, defects in biofilm formation, and attenuated virulence, growth defect, and sensitivity to osmotic pressure [3, 6, 8-11]. The vicRK system of Gram-positive bacterium Streptococcus equi subspecies equi (S. equi) has not been studied. This pathogen causes equine strangles, a highly contagious purulent lymphadenitis [12-13]. The infection initially causes nasal discharge and fever and, then, leads to abscess formation in local lymph nodes, causing respiratory difficulty. Although the infection at the lymph nodes cause massive infiltration of polymorphoneuclear leukocytes (PMNs) [14], S. equi resists phagocytosis by PMNs and rapidly multiplies, forming an abscess of large numbers of degenerating PMNs and long chains of S. equi [15]. The hyaluronic acid capsule and S. equi M-like protein (SeM) are both required for the resistance to phagocytosis by PMNs [16-17]. Most horses recovered from strangles have immunity against S. equi reinfection for up to 5 years [18]. It is believed that the immunity is mediated by mucosal antibodies specific to SeM and other protective antigens. An intranasal vaccine made of live attenuated strain has been used in USA, which lacks the hyaluronic acid capsule, and various adverse effects, including pharyngeal lymphadenopathy, limb edema, and bastard strangles abscesses, have been reported [15]. This study aims at evaluating the importance of VicRK to S. equi virulence and the potential of a vicK deletion mutant as a live vaccine using mouse infection models. We found that the vicK deletion attenuated S. equi virulence in mouse models of subcutaneous and intranasal infections and that infection with a vicK deletion mutant confers protection against subsequent infection with wild-type S. equi and induces production of mucosal and systemic immunoglobins to SeM in nasal infection. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism, Chemical, Two-component-system, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "B-Two-component-system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Chemical", "I-Chemical", "O", "O", "B-Organism", "I-Organism", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Chemical", "I-Chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Organism", "I-Organism", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]
INTRODUCTION Bacterial pathogens produce many two-component regulatory systems to regulate gene expression by specific environmental signals [1]. These systems consist of membrane protein sensors and cognate cytoplasmic response regulators. The regulator is phosphorylated by the sensor in response to a specific signal, activating or repressing the transcription of target genes. The two-component regulatory system VicRK or YycFG is specific for Gram-positive bacteria. The regulator component VicR is essential in Bacillus subtilis [2], Staphylococcus aureus [3], and Streptococcus pneumoniae [4-5] but appears not to be essential in Streptococcus pyogenes [6]. The deletion of the vicK gene can be readily inactivated in S. pneumoniae [7], Streptococcus mutans [8], and S. pyogenes [6] but not in B. subtilis [2] and S. aureus [3]. Conditional and unconditional vicRK mutants display various phenotypes, including defects in morphology and cell wall synthesis, decreased competence, sensitivity to antibiotics and fatty acids, defects in biofilm formation, and attenuated virulence, growth defect, and sensitivity to osmotic pressure [3, 6, 8-11]. The vicRK system of Gram-positive bacterium Streptococcus equi subspecies equi (S. equi) has not been studied. This pathogen causes equine strangles, a highly contagious purulent lymphadenitis [12-13]. The infection initially causes nasal discharge and fever and, then, leads to abscess formation in local lymph nodes, causing respiratory difficulty. Although the infection at the lymph nodes cause massive infiltration of polymorphoneuclear leukocytes (PMNs) [14], S. equi resists phagocytosis by PMNs and rapidly multiplies, forming an abscess of large numbers of degenerating PMNs and long chains of S. equi [15]. The hyaluronic acid capsule and S. equi M-like protein (SeM) are both required for the resistance to phagocytosis by PMNs [16-17]. Most horses recovered from strangles have immunity against S. equi reinfection for up to 5 years [18]. It is believed that the immunity is mediated by mucosal antibodies specific to SeM and other protective antigens. An intranasal vaccine made of live attenuated strain has been used in USA, which lacks the hyaluronic acid capsule, and various adverse effects, including pharyngeal lymphadenopathy, limb edema, and bastard strangles abscesses, have been reported [15]. This study aims at evaluating the importance of VicRK to S. equi virulence and the potential of a vicK deletion mutant as a live vaccine using mouse infection models. We found that the vicK deletion attenuated S. equi virulence in mouse models of subcutaneous and intranasal infections and that infection with a vicK deletion mutant confers protection against subsequent infection with wild-type S. equi and induces production of mucosal and systemic immunoglobins to SeM in nasal infection.
[ "INTRODUCTION", "\n", "Bacterial", "pathogens", "produce", "many", "two", "-", "component", "regulatory", "systems", "to", "regulate", "gene", "expression", "by", "specific", "environmental", "signals", "[", "1", "]", ".", "These", "systems", "consist", "of", "membrane", "protein", "sensors", "and", "cognate", "cytoplasmic", "response", "regulators", ".", "The", "regulator", "is", "phosphorylated", "by", "the", "sensor", "in", "response", "to", "a", "specific", "signal", ",", "activating", "or", "repressing", "the", "transcription", "of", "target", "genes", ".", "The", "two", "-", "component", "regulatory", "system", "VicRK", "or", "YycFG", "is", "specific", "for", "Gram", "-", "positive", "bacteria", ".", "The", "regulator", "component", "VicR", "is", "essential", "in", "Bacillus", "subtilis", "[", "2", "]", ",", "Staphylococcus", "aureus", "[", "3", "]", ",", "and", "Streptococcus", "pneumoniae", "[", "4", "-", "5", "]", "but", "appears", "not", "to", "be", "essential", "in", "Streptococcus", "pyogenes", "[", "6", "]", ".", "The", "deletion", "of", "the", "vicK", "gene", "can", "be", "readily", "inactivated", "in", "S.", "pneumoniae", "[", "7", "]", ",", "Streptococcus", "mutans", "[", "8", "]", ",", "and", "S.", "pyogenes", "[", "6", "]", "but", "not", "in", "B.", "subtilis", "[", "2", "]", "and", "S.", "aureus", "[", "3", "]", ".", "Conditional", "and", "unconditional", "vicRK", "mutants", "display", "various", "phenotypes", ",", "including", "defects", "in", "morphology", "and", "cell", "wall", "synthesis", ",", "decreased", "competence", ",", "sensitivity", "to", "antibiotics", "and", "fatty", "acids", ",", "defects", "in", "biofilm", "formation", ",", "and", "attenuated", "virulence", ",", "growth", "defect", ",", "and", "sensitivity", "to", "osmotic", "pressure", "[", "3", ",", "6", ",", "8", "-", "11", "]", ".", "The", "vicRK", "system", "of", "Gram", "-", "positive", "bacterium", "Streptococcus", "equi", "subspecies", "equi", "(", "S.", "equi", ")", "has", "not", "been", "studied", ".", "This", "pathogen", "causes", "equine", "strangles", ",", "a", "highly", "contagious", "purulent", "lymphadenitis", "[", "12", "-", "13", "]", ".", "The", "infection", "initially", "causes", "nasal", "discharge", "and", "fever", "and", ",", "then", ",", "leads", "to", "abscess", "formation", "in", "local", "lymph", "nodes", ",", "causing", "respiratory", "difficulty", ".", "Although", "the", "infection", "at", "the", "lymph", "nodes", "cause", "massive", "infiltration", "of", "polymorphoneuclear", "leukocytes", "(", "PMNs", ")", "[", "14", "]", ",", "S.", "equi", "resists", "phagocytosis", "by", "PMNs", "and", "rapidly", "multiplies", ",", "forming", "an", "abscess", "of", "large", "numbers", "of", "degenerating", "PMNs", "and", "long", "chains", "of", "S.", "equi", "[", "15", "]", ".", "The", "hyaluronic", "acid", "capsule", "and", "S.", "equi", "M", "-", "like", "protein", "(", "SeM", ")", "are", "both", "required", "for", "the", "resistance", "to", "phagocytosis", "by", "PMNs", "[", "16", "-", "17", "]", ".", "Most", "horses", "recovered", "from", "strangles", "have", "immunity", "against", "S.", "equi", "reinfection", "for", "up", "to", "5", "years", "[", "18", "]", ".", "It", "is", "believed", "that", "the", "immunity", "is", "mediated", "by", "mucosal", "antibodies", "specific", "to", "SeM", "and", "other", "protective", "antigens", ".", "An", "intranasal", "vaccine", "made", "of", "live", "attenuated", "strain", "has", "been", "used", "in", "USA", ",", "which", "lacks", "the", "hyaluronic", "acid", "capsule", ",", "and", "various", "adverse", "effects", ",", "including", "pharyngeal", "lymphadenopathy", ",", "limb", "edema", ",", "and", "bastard", "strangles", "abscesses", ",", "have", "been", "reported", "[", "15", "]", ".", "This", "study", "aims", "at", "evaluating", "the", "importance", "of", "VicRK", "to", "S.", "equi", "virulence", "and", "the", "potential", "of", "a", "vicK", "deletion", "mutant", "as", "a", "live", "vaccine", "using", "mouse", "infection", "models", ".", "We", "found", "that", "the", "vicK", "deletion", "attenuated", "S.", "equi", "virulence", "in", "mouse", "models", "of", "subcutaneous", "and", "intranasal", "infections", "and", "that", "infection", "with", "a", "vicK", "deletion", "mutant", "confers", "protection", "against", "subsequent", "infection", "with", "wild", "-", "type", "S.", "equi", "and", "induces", "production", "of", "mucosal", "and", "systemic", "immunoglobins", "to", "SeM", "in", "nasal", "infection", ".", "\n" ]
[ "Organism", "Chemical", "Protein", "Two-component-system" ]
VicRK is a Two-component-system, YycFG is a Two-component-system, VicR is a Protein, Bacillus subtilis is a Organism, Staphylococcus aureus is a Organism, Streptococcus pneumoniae is a Organism, Streptococcus pyogenes is a Organism, vicK is a Protein, S. pneumoniae is a Organism, Streptococcus mutans is a Organism, S. pyogenes is a Organism, B. subtilis is a Organism, S. aureus is a Organism, vicRK is a Two-component-system, vicRK is a Two-component-system, Streptococcus equi subspecies equi is a Organism, S. equi is a Organism, equine is a Organism, S. equi is a Organism, S. equi is a Organism, hyaluronic acid is a Chemical, S. equi is a Organism, M - like protein is a Protein, SeM is a Protein, horses is a Organism, S. equi is a Organism, SeM is a Protein, hyaluronic acid is a Chemical, VicRK is a Two-component-system, S. equi is a Organism, vicK deletion mutant is a Organism, mouse is a Organism, vicK is a Protein, S. equi is a Organism, mouse is a Organism, vicK deletion mutant is a Organism, S. equi is a Organism, SeM is a Protein
8_task1
Sentence: INTRODUCTION Bacterial pathogens produce many two-component regulatory systems to regulate gene expression by specific environmental signals [1]. These systems consist of membrane protein sensors and cognate cytoplasmic response regulators. The regulator is phosphorylated by the sensor in response to a specific signal, activating or repressing the transcription of target genes. The two-component regulatory system VicRK or YycFG is specific for Gram-positive bacteria. The regulator component VicR is essential in Bacillus subtilis [2], Staphylococcus aureus [3], and Streptococcus pneumoniae [4-5] but appears not to be essential in Streptococcus pyogenes [6]. The deletion of the vicK gene can be readily inactivated in S. pneumoniae [7], Streptococcus mutans [8], and S. pyogenes [6] but not in B. subtilis [2] and S. aureus [3]. Conditional and unconditional vicRK mutants display various phenotypes, including defects in morphology and cell wall synthesis, decreased competence, sensitivity to antibiotics and fatty acids, defects in biofilm formation, and attenuated virulence, growth defect, and sensitivity to osmotic pressure [3, 6, 8-11]. The vicRK system of Gram-positive bacterium Streptococcus equi subspecies equi (S. equi) has not been studied. This pathogen causes equine strangles, a highly contagious purulent lymphadenitis [12-13]. The infection initially causes nasal discharge and fever and, then, leads to abscess formation in local lymph nodes, causing respiratory difficulty. Although the infection at the lymph nodes cause massive infiltration of polymorphoneuclear leukocytes (PMNs) [14], S. equi resists phagocytosis by PMNs and rapidly multiplies, forming an abscess of large numbers of degenerating PMNs and long chains of S. equi [15]. The hyaluronic acid capsule and S. equi M-like protein (SeM) are both required for the resistance to phagocytosis by PMNs [16-17]. Most horses recovered from strangles have immunity against S. equi reinfection for up to 5 years [18]. It is believed that the immunity is mediated by mucosal antibodies specific to SeM and other protective antigens. An intranasal vaccine made of live attenuated strain has been used in USA, which lacks the hyaluronic acid capsule, and various adverse effects, including pharyngeal lymphadenopathy, limb edema, and bastard strangles abscesses, have been reported [15]. This study aims at evaluating the importance of VicRK to S. equi virulence and the potential of a vicK deletion mutant as a live vaccine using mouse infection models. We found that the vicK deletion attenuated S. equi virulence in mouse models of subcutaneous and intranasal infections and that infection with a vicK deletion mutant confers protection against subsequent infection with wild-type S. equi and induces production of mucosal and systemic immunoglobins to SeM in nasal infection. Instructions: please typing these entity words according to sentence: VicRK, YycFG, VicR, Bacillus subtilis, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, vicK, S. pneumoniae, Streptococcus mutans, S. pyogenes, B. subtilis, S. aureus, vicRK, vicRK, Streptococcus equi subspecies equi, S. equi, equine, S. equi, S. equi, hyaluronic acid, S. equi, M - like protein, SeM, horses, S. equi, SeM, hyaluronic acid, VicRK, S. equi, vicK deletion mutant, mouse, vicK, S. equi, mouse, vicK deletion mutant, S. equi, SeM Options: Organism, Chemical, Two-component-system, Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "B-Two-component-system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Chemical", "I-Chemical", "O", "O", "B-Organism", "I-Organism", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Chemical", "I-Chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Organism", "I-Organism", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]
INTRODUCTION Bacterial pathogens produce many two-component regulatory systems to regulate gene expression by specific environmental signals [1]. These systems consist of membrane protein sensors and cognate cytoplasmic response regulators. The regulator is phosphorylated by the sensor in response to a specific signal, activating or repressing the transcription of target genes. The two-component regulatory system VicRK or YycFG is specific for Gram-positive bacteria. The regulator component VicR is essential in Bacillus subtilis [2], Staphylococcus aureus [3], and Streptococcus pneumoniae [4-5] but appears not to be essential in Streptococcus pyogenes [6]. The deletion of the vicK gene can be readily inactivated in S. pneumoniae [7], Streptococcus mutans [8], and S. pyogenes [6] but not in B. subtilis [2] and S. aureus [3]. Conditional and unconditional vicRK mutants display various phenotypes, including defects in morphology and cell wall synthesis, decreased competence, sensitivity to antibiotics and fatty acids, defects in biofilm formation, and attenuated virulence, growth defect, and sensitivity to osmotic pressure [3, 6, 8-11]. The vicRK system of Gram-positive bacterium Streptococcus equi subspecies equi (S. equi) has not been studied. This pathogen causes equine strangles, a highly contagious purulent lymphadenitis [12-13]. The infection initially causes nasal discharge and fever and, then, leads to abscess formation in local lymph nodes, causing respiratory difficulty. Although the infection at the lymph nodes cause massive infiltration of polymorphoneuclear leukocytes (PMNs) [14], S. equi resists phagocytosis by PMNs and rapidly multiplies, forming an abscess of large numbers of degenerating PMNs and long chains of S. equi [15]. The hyaluronic acid capsule and S. equi M-like protein (SeM) are both required for the resistance to phagocytosis by PMNs [16-17]. Most horses recovered from strangles have immunity against S. equi reinfection for up to 5 years [18]. It is believed that the immunity is mediated by mucosal antibodies specific to SeM and other protective antigens. An intranasal vaccine made of live attenuated strain has been used in USA, which lacks the hyaluronic acid capsule, and various adverse effects, including pharyngeal lymphadenopathy, limb edema, and bastard strangles abscesses, have been reported [15]. This study aims at evaluating the importance of VicRK to S. equi virulence and the potential of a vicK deletion mutant as a live vaccine using mouse infection models. We found that the vicK deletion attenuated S. equi virulence in mouse models of subcutaneous and intranasal infections and that infection with a vicK deletion mutant confers protection against subsequent infection with wild-type S. equi and induces production of mucosal and systemic immunoglobins to SeM in nasal infection.
[ "INTRODUCTION", "\n", "Bacterial", "pathogens", "produce", "many", "two", "-", "component", "regulatory", "systems", "to", "regulate", "gene", "expression", "by", "specific", "environmental", "signals", "[", "1", "]", ".", "These", "systems", "consist", "of", "membrane", "protein", "sensors", "and", "cognate", "cytoplasmic", "response", "regulators", ".", "The", "regulator", "is", "phosphorylated", "by", "the", "sensor", "in", "response", "to", "a", "specific", "signal", ",", "activating", "or", "repressing", "the", "transcription", "of", "target", "genes", ".", "The", "two", "-", "component", "regulatory", "system", "VicRK", "or", "YycFG", "is", "specific", "for", "Gram", "-", "positive", "bacteria", ".", "The", "regulator", "component", "VicR", "is", "essential", "in", "Bacillus", "subtilis", "[", "2", "]", ",", "Staphylococcus", "aureus", "[", "3", "]", ",", "and", "Streptococcus", "pneumoniae", "[", "4", "-", "5", "]", "but", "appears", "not", "to", "be", "essential", "in", "Streptococcus", "pyogenes", "[", "6", "]", ".", "The", "deletion", "of", "the", "vicK", "gene", "can", "be", "readily", "inactivated", "in", "S.", "pneumoniae", "[", "7", "]", ",", "Streptococcus", "mutans", "[", "8", "]", ",", "and", "S.", "pyogenes", "[", "6", "]", "but", "not", "in", "B.", "subtilis", "[", "2", "]", "and", "S.", "aureus", "[", "3", "]", ".", "Conditional", "and", "unconditional", "vicRK", "mutants", "display", "various", "phenotypes", ",", "including", "defects", "in", "morphology", "and", "cell", "wall", "synthesis", ",", "decreased", "competence", ",", "sensitivity", "to", "antibiotics", "and", "fatty", "acids", ",", "defects", "in", "biofilm", "formation", ",", "and", "attenuated", "virulence", ",", "growth", "defect", ",", "and", "sensitivity", "to", "osmotic", "pressure", "[", "3", ",", "6", ",", "8", "-", "11", "]", ".", "The", "vicRK", "system", "of", "Gram", "-", "positive", "bacterium", "Streptococcus", "equi", "subspecies", "equi", "(", "S.", "equi", ")", "has", "not", "been", "studied", ".", "This", "pathogen", "causes", "equine", "strangles", ",", "a", "highly", "contagious", "purulent", "lymphadenitis", "[", "12", "-", "13", "]", ".", "The", "infection", "initially", "causes", "nasal", "discharge", "and", "fever", "and", ",", "then", ",", "leads", "to", "abscess", "formation", "in", "local", "lymph", "nodes", ",", "causing", "respiratory", "difficulty", ".", "Although", "the", "infection", "at", "the", "lymph", "nodes", "cause", "massive", "infiltration", "of", "polymorphoneuclear", "leukocytes", "(", "PMNs", ")", "[", "14", "]", ",", "S.", "equi", "resists", "phagocytosis", "by", "PMNs", "and", "rapidly", "multiplies", ",", "forming", "an", "abscess", "of", "large", "numbers", "of", "degenerating", "PMNs", "and", "long", "chains", "of", "S.", "equi", "[", "15", "]", ".", "The", "hyaluronic", "acid", "capsule", "and", "S.", "equi", "M", "-", "like", "protein", "(", "SeM", ")", "are", "both", "required", "for", "the", "resistance", "to", "phagocytosis", "by", "PMNs", "[", "16", "-", "17", "]", ".", "Most", "horses", "recovered", "from", "strangles", "have", "immunity", "against", "S.", "equi", "reinfection", "for", "up", "to", "5", "years", "[", "18", "]", ".", "It", "is", "believed", "that", "the", "immunity", "is", "mediated", "by", "mucosal", "antibodies", "specific", "to", "SeM", "and", "other", "protective", "antigens", ".", "An", "intranasal", "vaccine", "made", "of", "live", "attenuated", "strain", "has", "been", "used", "in", "USA", ",", "which", "lacks", "the", "hyaluronic", "acid", "capsule", ",", "and", "various", "adverse", "effects", ",", "including", "pharyngeal", "lymphadenopathy", ",", "limb", "edema", ",", "and", "bastard", "strangles", "abscesses", ",", "have", "been", "reported", "[", "15", "]", ".", "This", "study", "aims", "at", "evaluating", "the", "importance", "of", "VicRK", "to", "S.", "equi", "virulence", "and", "the", "potential", "of", "a", "vicK", "deletion", "mutant", "as", "a", "live", "vaccine", "using", "mouse", "infection", "models", ".", "We", "found", "that", "the", "vicK", "deletion", "attenuated", "S.", "equi", "virulence", "in", "mouse", "models", "of", "subcutaneous", "and", "intranasal", "infections", "and", "that", "infection", "with", "a", "vicK", "deletion", "mutant", "confers", "protection", "against", "subsequent", "infection", "with", "wild", "-", "type", "S.", "equi", "and", "induces", "production", "of", "mucosal", "and", "systemic", "immunoglobins", "to", "SeM", "in", "nasal", "infection", ".", "\n" ]
[ "Organism", "Chemical", "Protein", "Two-component-system" ]
VicRK, YycFG, VicR, Bacillus subtilis, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, vicK, S. pneumoniae, Streptococcus mutans, S. pyogenes, B. subtilis, S. aureus, vicRK, vicRK, Streptococcus equi subspecies equi, S. equi, equine, S. equi, S. equi, hyaluronic acid, S. equi, M - like protein, SeM, horses, S. equi, SeM, hyaluronic acid, VicRK, S. equi, vicK deletion mutant, mouse, vicK, S. equi, mouse, vicK deletion mutant, S. equi, SeM
8_task2
Sentence: INTRODUCTION Bacterial pathogens produce many two-component regulatory systems to regulate gene expression by specific environmental signals [1]. These systems consist of membrane protein sensors and cognate cytoplasmic response regulators. The regulator is phosphorylated by the sensor in response to a specific signal, activating or repressing the transcription of target genes. The two-component regulatory system VicRK or YycFG is specific for Gram-positive bacteria. The regulator component VicR is essential in Bacillus subtilis [2], Staphylococcus aureus [3], and Streptococcus pneumoniae [4-5] but appears not to be essential in Streptococcus pyogenes [6]. The deletion of the vicK gene can be readily inactivated in S. pneumoniae [7], Streptococcus mutans [8], and S. pyogenes [6] but not in B. subtilis [2] and S. aureus [3]. Conditional and unconditional vicRK mutants display various phenotypes, including defects in morphology and cell wall synthesis, decreased competence, sensitivity to antibiotics and fatty acids, defects in biofilm formation, and attenuated virulence, growth defect, and sensitivity to osmotic pressure [3, 6, 8-11]. The vicRK system of Gram-positive bacterium Streptococcus equi subspecies equi (S. equi) has not been studied. This pathogen causes equine strangles, a highly contagious purulent lymphadenitis [12-13]. The infection initially causes nasal discharge and fever and, then, leads to abscess formation in local lymph nodes, causing respiratory difficulty. Although the infection at the lymph nodes cause massive infiltration of polymorphoneuclear leukocytes (PMNs) [14], S. equi resists phagocytosis by PMNs and rapidly multiplies, forming an abscess of large numbers of degenerating PMNs and long chains of S. equi [15]. The hyaluronic acid capsule and S. equi M-like protein (SeM) are both required for the resistance to phagocytosis by PMNs [16-17]. Most horses recovered from strangles have immunity against S. equi reinfection for up to 5 years [18]. It is believed that the immunity is mediated by mucosal antibodies specific to SeM and other protective antigens. An intranasal vaccine made of live attenuated strain has been used in USA, which lacks the hyaluronic acid capsule, and various adverse effects, including pharyngeal lymphadenopathy, limb edema, and bastard strangles abscesses, have been reported [15]. This study aims at evaluating the importance of VicRK to S. equi virulence and the potential of a vicK deletion mutant as a live vaccine using mouse infection models. We found that the vicK deletion attenuated S. equi virulence in mouse models of subcutaneous and intranasal infections and that infection with a vicK deletion mutant confers protection against subsequent infection with wild-type S. equi and induces production of mucosal and systemic immunoglobins to SeM in nasal infection. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "B-Two-component-system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Chemical", "I-Chemical", "O", "O", "B-Organism", "I-Organism", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Chemical", "I-Chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Two-component-system", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Organism", "I-Organism", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O" ]
INTRODUCTION Bacterial pathogens produce many two-component regulatory systems to regulate gene expression by specific environmental signals [1]. These systems consist of membrane protein sensors and cognate cytoplasmic response regulators. The regulator is phosphorylated by the sensor in response to a specific signal, activating or repressing the transcription of target genes. The two-component regulatory system VicRK or YycFG is specific for Gram-positive bacteria. The regulator component VicR is essential in Bacillus subtilis [2], Staphylococcus aureus [3], and Streptococcus pneumoniae [4-5] but appears not to be essential in Streptococcus pyogenes [6]. The deletion of the vicK gene can be readily inactivated in S. pneumoniae [7], Streptococcus mutans [8], and S. pyogenes [6] but not in B. subtilis [2] and S. aureus [3]. Conditional and unconditional vicRK mutants display various phenotypes, including defects in morphology and cell wall synthesis, decreased competence, sensitivity to antibiotics and fatty acids, defects in biofilm formation, and attenuated virulence, growth defect, and sensitivity to osmotic pressure [3, 6, 8-11]. The vicRK system of Gram-positive bacterium Streptococcus equi subspecies equi (S. equi) has not been studied. This pathogen causes equine strangles, a highly contagious purulent lymphadenitis [12-13]. The infection initially causes nasal discharge and fever and, then, leads to abscess formation in local lymph nodes, causing respiratory difficulty. Although the infection at the lymph nodes cause massive infiltration of polymorphoneuclear leukocytes (PMNs) [14], S. equi resists phagocytosis by PMNs and rapidly multiplies, forming an abscess of large numbers of degenerating PMNs and long chains of S. equi [15]. The hyaluronic acid capsule and S. equi M-like protein (SeM) are both required for the resistance to phagocytosis by PMNs [16-17]. Most horses recovered from strangles have immunity against S. equi reinfection for up to 5 years [18]. It is believed that the immunity is mediated by mucosal antibodies specific to SeM and other protective antigens. An intranasal vaccine made of live attenuated strain has been used in USA, which lacks the hyaluronic acid capsule, and various adverse effects, including pharyngeal lymphadenopathy, limb edema, and bastard strangles abscesses, have been reported [15]. This study aims at evaluating the importance of VicRK to S. equi virulence and the potential of a vicK deletion mutant as a live vaccine using mouse infection models. We found that the vicK deletion attenuated S. equi virulence in mouse models of subcutaneous and intranasal infections and that infection with a vicK deletion mutant confers protection against subsequent infection with wild-type S. equi and induces production of mucosal and systemic immunoglobins to SeM in nasal infection.
[ "INTRODUCTION", "\n", "Bacterial", "pathogens", "produce", "many", "two", "-", "component", "regulatory", "systems", "to", "regulate", "gene", "expression", "by", "specific", "environmental", "signals", "[", "1", "]", ".", "These", "systems", "consist", "of", "membrane", "protein", "sensors", "and", "cognate", "cytoplasmic", "response", "regulators", ".", "The", "regulator", "is", "phosphorylated", "by", "the", "sensor", "in", "response", "to", "a", "specific", "signal", ",", "activating", "or", "repressing", "the", "transcription", "of", "target", "genes", ".", "The", "two", "-", "component", "regulatory", "system", "VicRK", "or", "YycFG", "is", "specific", "for", "Gram", "-", "positive", "bacteria", ".", "The", "regulator", "component", "VicR", "is", "essential", "in", "Bacillus", "subtilis", "[", "2", "]", ",", "Staphylococcus", "aureus", "[", "3", "]", ",", "and", "Streptococcus", "pneumoniae", "[", "4", "-", "5", "]", "but", "appears", "not", "to", "be", "essential", "in", "Streptococcus", "pyogenes", "[", "6", "]", ".", "The", "deletion", "of", "the", "vicK", "gene", "can", "be", "readily", "inactivated", "in", "S.", "pneumoniae", "[", "7", "]", ",", "Streptococcus", "mutans", "[", "8", "]", ",", "and", "S.", "pyogenes", "[", "6", "]", "but", "not", "in", "B.", "subtilis", "[", "2", "]", "and", "S.", "aureus", "[", "3", "]", ".", "Conditional", "and", "unconditional", "vicRK", "mutants", "display", "various", "phenotypes", ",", "including", "defects", "in", "morphology", "and", "cell", "wall", "synthesis", ",", "decreased", "competence", ",", "sensitivity", "to", "antibiotics", "and", "fatty", "acids", ",", "defects", "in", "biofilm", "formation", ",", "and", "attenuated", "virulence", ",", "growth", "defect", ",", "and", "sensitivity", "to", "osmotic", "pressure", "[", "3", ",", "6", ",", "8", "-", "11", "]", ".", "The", "vicRK", "system", "of", "Gram", "-", "positive", "bacterium", "Streptococcus", "equi", "subspecies", "equi", "(", "S.", "equi", ")", "has", "not", "been", "studied", ".", "This", "pathogen", "causes", "equine", "strangles", ",", "a", "highly", "contagious", "purulent", "lymphadenitis", "[", "12", "-", "13", "]", ".", "The", "infection", "initially", "causes", "nasal", "discharge", "and", "fever", "and", ",", "then", ",", "leads", "to", "abscess", "formation", "in", "local", "lymph", "nodes", ",", "causing", "respiratory", "difficulty", ".", "Although", "the", "infection", "at", "the", "lymph", "nodes", "cause", "massive", "infiltration", "of", "polymorphoneuclear", "leukocytes", "(", "PMNs", ")", "[", "14", "]", ",", "S.", "equi", "resists", "phagocytosis", "by", "PMNs", "and", "rapidly", "multiplies", ",", "forming", "an", "abscess", "of", "large", "numbers", "of", "degenerating", "PMNs", "and", "long", "chains", "of", "S.", "equi", "[", "15", "]", ".", "The", "hyaluronic", "acid", "capsule", "and", "S.", "equi", "M", "-", "like", "protein", "(", "SeM", ")", "are", "both", "required", "for", "the", "resistance", "to", "phagocytosis", "by", "PMNs", "[", "16", "-", "17", "]", ".", "Most", "horses", "recovered", "from", "strangles", "have", "immunity", "against", "S.", "equi", "reinfection", "for", "up", "to", "5", "years", "[", "18", "]", ".", "It", "is", "believed", "that", "the", "immunity", "is", "mediated", "by", "mucosal", "antibodies", "specific", "to", "SeM", "and", "other", "protective", "antigens", ".", "An", "intranasal", "vaccine", "made", "of", "live", "attenuated", "strain", "has", "been", "used", "in", "USA", ",", "which", "lacks", "the", "hyaluronic", "acid", "capsule", ",", "and", "various", "adverse", "effects", ",", "including", "pharyngeal", "lymphadenopathy", ",", "limb", "edema", ",", "and", "bastard", "strangles", "abscesses", ",", "have", "been", "reported", "[", "15", "]", ".", "This", "study", "aims", "at", "evaluating", "the", "importance", "of", "VicRK", "to", "S.", "equi", "virulence", "and", "the", "potential", "of", "a", "vicK", "deletion", "mutant", "as", "a", "live", "vaccine", "using", "mouse", "infection", "models", ".", "We", "found", "that", "the", "vicK", "deletion", "attenuated", "S.", "equi", "virulence", "in", "mouse", "models", "of", "subcutaneous", "and", "intranasal", "infections", "and", "that", "infection", "with", "a", "vicK", "deletion", "mutant", "confers", "protection", "against", "subsequent", "infection", "with", "wild", "-", "type", "S.", "equi", "and", "induces", "production", "of", "mucosal", "and", "systemic", "immunoglobins", "to", "SeM", "in", "nasal", "infection", ".", "\n" ]
[ "Organism", "Chemical", "Protein", "Two-component-system" ]
topotecan is a CHEMICAL, p53 is a GENE-Y, topotecan is a CHEMICAL, Topotecan is a CHEMICAL, topoisomerase I is a GENE-Y, topotecan is a CHEMICAL, topoisomerase I is a GENE-Y, p53 is a GENE-Y, p53 is a GENE-Y, topotecan is a CHEMICAL, topoisomerase I is a GENE-Y, p53 is a GENE-Y, p53 is a GENE-Y, topotecan is a CHEMICAL, p53 is a GENE-Y, topoisomerase I is a GENE-Y, topotecan is a CHEMICAL
31421_task0
Sentence: Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. Topotecan is a topoisomerase I inhibitor which is currently evaluated as an adjuvant agent for malignant glioma. Here, we analysed the effects of topotecan on 12 human malignant glioma cell lines in vitro. All cell lines expressed topoisomerase I mRNA. High p53 protein levels, but not genetic or functional p53 status, were associated with increased topotecan-induced DNA/topoisomerase I complex formation. Neither functional p53 status, nor p53 protein levels, nor complex formation predicted topotecan-induced growth inhibition. We thus confirm a possible role for p53 protein in modulating topoisomerase I activity but conclude that the major molecular determinants of topotecan sensitivity in glioma cells await identification. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. Topotecan is a topoisomerase I inhibitor which is currently evaluated as an adjuvant agent for malignant glioma. Here, we analysed the effects of topotecan on 12 human malignant glioma cell lines in vitro. All cell lines expressed topoisomerase I mRNA. High p53 protein levels, but not genetic or functional p53 status, were associated with increased topotecan-induced DNA/topoisomerase I complex formation. Neither functional p53 status, nor p53 protein levels, nor complex formation predicted topotecan-induced growth inhibition. We thus confirm a possible role for p53 protein in modulating topoisomerase I activity but conclude that the major molecular determinants of topotecan sensitivity in glioma cells await identification.
[ "Glioma", "cell", "sensitivity", "to", "topotecan", ":", "the", "role", "of", "p53", "and", "topotecan", "-", "induced", "DNA", "damage", ".", "\n", "Topotecan", "is", "a", "topoisomerase", "I", "inhibitor", "which", "is", "currently", "evaluated", "as", "an", "adjuvant", "agent", "for", "malignant", "glioma", ".", "Here", ",", "we", "analysed", "the", "effects", "of", "topotecan", "on", "12", "human", "malignant", "glioma", "cell", "lines", "in", "vitro", ".", "All", "cell", "lines", "expressed", "topoisomerase", "I", "mRNA", ".", "High", "p53", "protein", "levels", ",", "but", "not", "genetic", "or", "functional", "p53", "status", ",", "were", "associated", "with", "increased", "topotecan", "-", "induced", "DNA", "/", "topoisomerase", "I", "complex", "formation", ".", "Neither", "functional", "p53", "status", ",", "nor", "p53", "protein", "levels", ",", "nor", "complex", "formation", "predicted", "topotecan", "-", "induced", "growth", "inhibition", ".", "We", "thus", "confirm", "a", "possible", "role", "for", "p53", "protein", "in", "modulating", "topoisomerase", "I", "activity", "but", "conclude", "that", "the", "major", "molecular", "determinants", "of", "topotecan", "sensitivity", "in", "glioma", "cells", "await", "identification", "." ]
[ "GENE-Y", "CHEMICAL" ]
topotecan is a CHEMICAL, p53 is a GENE-Y, topotecan is a CHEMICAL, Topotecan is a CHEMICAL, topoisomerase I is a GENE-Y, topotecan is a CHEMICAL, topoisomerase I is a GENE-Y, p53 is a GENE-Y, p53 is a GENE-Y, topotecan is a CHEMICAL, topoisomerase I is a GENE-Y, p53 is a GENE-Y, p53 is a GENE-Y, topotecan is a CHEMICAL, p53 is a GENE-Y, topoisomerase I is a GENE-Y, topotecan is a CHEMICAL
31421_task1
Sentence: Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. Topotecan is a topoisomerase I inhibitor which is currently evaluated as an adjuvant agent for malignant glioma. Here, we analysed the effects of topotecan on 12 human malignant glioma cell lines in vitro. All cell lines expressed topoisomerase I mRNA. High p53 protein levels, but not genetic or functional p53 status, were associated with increased topotecan-induced DNA/topoisomerase I complex formation. Neither functional p53 status, nor p53 protein levels, nor complex formation predicted topotecan-induced growth inhibition. We thus confirm a possible role for p53 protein in modulating topoisomerase I activity but conclude that the major molecular determinants of topotecan sensitivity in glioma cells await identification. Instructions: please typing these entity words according to sentence: topotecan, p53, topotecan, Topotecan, topoisomerase I, topotecan, topoisomerase I, p53, p53, topotecan, topoisomerase I, p53, p53, topotecan, p53, topoisomerase I, topotecan Options: GENE-Y, CHEMICAL
[ "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. Topotecan is a topoisomerase I inhibitor which is currently evaluated as an adjuvant agent for malignant glioma. Here, we analysed the effects of topotecan on 12 human malignant glioma cell lines in vitro. All cell lines expressed topoisomerase I mRNA. High p53 protein levels, but not genetic or functional p53 status, were associated with increased topotecan-induced DNA/topoisomerase I complex formation. Neither functional p53 status, nor p53 protein levels, nor complex formation predicted topotecan-induced growth inhibition. We thus confirm a possible role for p53 protein in modulating topoisomerase I activity but conclude that the major molecular determinants of topotecan sensitivity in glioma cells await identification.
[ "Glioma", "cell", "sensitivity", "to", "topotecan", ":", "the", "role", "of", "p53", "and", "topotecan", "-", "induced", "DNA", "damage", ".", "\n", "Topotecan", "is", "a", "topoisomerase", "I", "inhibitor", "which", "is", "currently", "evaluated", "as", "an", "adjuvant", "agent", "for", "malignant", "glioma", ".", "Here", ",", "we", "analysed", "the", "effects", "of", "topotecan", "on", "12", "human", "malignant", "glioma", "cell", "lines", "in", "vitro", ".", "All", "cell", "lines", "expressed", "topoisomerase", "I", "mRNA", ".", "High", "p53", "protein", "levels", ",", "but", "not", "genetic", "or", "functional", "p53", "status", ",", "were", "associated", "with", "increased", "topotecan", "-", "induced", "DNA", "/", "topoisomerase", "I", "complex", "formation", ".", "Neither", "functional", "p53", "status", ",", "nor", "p53", "protein", "levels", ",", "nor", "complex", "formation", "predicted", "topotecan", "-", "induced", "growth", "inhibition", ".", "We", "thus", "confirm", "a", "possible", "role", "for", "p53", "protein", "in", "modulating", "topoisomerase", "I", "activity", "but", "conclude", "that", "the", "major", "molecular", "determinants", "of", "topotecan", "sensitivity", "in", "glioma", "cells", "await", "identification", "." ]
[ "GENE-Y", "CHEMICAL" ]
topotecan, p53, topotecan, Topotecan, topoisomerase I, topotecan, topoisomerase I, p53, p53, topotecan, topoisomerase I, p53, p53, topotecan, p53, topoisomerase I, topotecan
31421_task2
Sentence: Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. Topotecan is a topoisomerase I inhibitor which is currently evaluated as an adjuvant agent for malignant glioma. Here, we analysed the effects of topotecan on 12 human malignant glioma cell lines in vitro. All cell lines expressed topoisomerase I mRNA. High p53 protein levels, but not genetic or functional p53 status, were associated with increased topotecan-induced DNA/topoisomerase I complex formation. Neither functional p53 status, nor p53 protein levels, nor complex formation predicted topotecan-induced growth inhibition. We thus confirm a possible role for p53 protein in modulating topoisomerase I activity but conclude that the major molecular determinants of topotecan sensitivity in glioma cells await identification. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. Topotecan is a topoisomerase I inhibitor which is currently evaluated as an adjuvant agent for malignant glioma. Here, we analysed the effects of topotecan on 12 human malignant glioma cell lines in vitro. All cell lines expressed topoisomerase I mRNA. High p53 protein levels, but not genetic or functional p53 status, were associated with increased topotecan-induced DNA/topoisomerase I complex formation. Neither functional p53 status, nor p53 protein levels, nor complex formation predicted topotecan-induced growth inhibition. We thus confirm a possible role for p53 protein in modulating topoisomerase I activity but conclude that the major molecular determinants of topotecan sensitivity in glioma cells await identification.
[ "Glioma", "cell", "sensitivity", "to", "topotecan", ":", "the", "role", "of", "p53", "and", "topotecan", "-", "induced", "DNA", "damage", ".", "\n", "Topotecan", "is", "a", "topoisomerase", "I", "inhibitor", "which", "is", "currently", "evaluated", "as", "an", "adjuvant", "agent", "for", "malignant", "glioma", ".", "Here", ",", "we", "analysed", "the", "effects", "of", "topotecan", "on", "12", "human", "malignant", "glioma", "cell", "lines", "in", "vitro", ".", "All", "cell", "lines", "expressed", "topoisomerase", "I", "mRNA", ".", "High", "p53", "protein", "levels", ",", "but", "not", "genetic", "or", "functional", "p53", "status", ",", "were", "associated", "with", "increased", "topotecan", "-", "induced", "DNA", "/", "topoisomerase", "I", "complex", "formation", ".", "Neither", "functional", "p53", "status", ",", "nor", "p53", "protein", "levels", ",", "nor", "complex", "formation", "predicted", "topotecan", "-", "induced", "growth", "inhibition", ".", "We", "thus", "confirm", "a", "possible", "role", "for", "p53", "protein", "in", "modulating", "topoisomerase", "I", "activity", "but", "conclude", "that", "the", "major", "molecular", "determinants", "of", "topotecan", "sensitivity", "in", "glioma", "cells", "await", "identification", "." ]
[ "GENE-Y", "CHEMICAL" ]
cAMP response element binding protein is a GENE-N, cocaine is a CHEMICAL
17324065_task0
Sentence: Differential activation of cAMP response element binding protein in discrete nucleus accumbens subregions during early and late cocaine sensitization. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL
[ "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O" ]
Differential activation of cAMP response element binding protein in discrete nucleus accumbens subregions during early and late cocaine sensitization.
[ "Differential", "activation", "of", "cAMP", "response", "element", "binding", "protein", "in", "discrete", "nucleus", "accumbens", "subregions", "during", "early", "and", "late", "cocaine", "sensitization", "." ]
[ "GENE-N", "CHEMICAL" ]
cAMP response element binding protein is a GENE-N, cocaine is a CHEMICAL
17324065_task1
Sentence: Differential activation of cAMP response element binding protein in discrete nucleus accumbens subregions during early and late cocaine sensitization. Instructions: please typing these entity words according to sentence: cAMP response element binding protein, cocaine Options: GENE-N, CHEMICAL
[ "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O" ]
Differential activation of cAMP response element binding protein in discrete nucleus accumbens subregions during early and late cocaine sensitization.
[ "Differential", "activation", "of", "cAMP", "response", "element", "binding", "protein", "in", "discrete", "nucleus", "accumbens", "subregions", "during", "early", "and", "late", "cocaine", "sensitization", "." ]
[ "GENE-N", "CHEMICAL" ]
cAMP response element binding protein, cocaine
17324065_task2
Sentence: Differential activation of cAMP response element binding protein in discrete nucleus accumbens subregions during early and late cocaine sensitization. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O" ]
Differential activation of cAMP response element binding protein in discrete nucleus accumbens subregions during early and late cocaine sensitization.
[ "Differential", "activation", "of", "cAMP", "response", "element", "binding", "protein", "in", "discrete", "nucleus", "accumbens", "subregions", "during", "early", "and", "late", "cocaine", "sensitization", "." ]
[ "GENE-N", "CHEMICAL" ]
Paromomycin is a Intervention_Pharmacological, AIDS : is a Participant_Condition, paromomycin is a Intervention_Pharmacological, placebo is a Intervention_Control, number and character of each stool is a Outcome_Physical, stool specimens for weight is a Outcome_Physical, oocyst excretion is a Outcome_Physical, Oocyst excretion is a Outcome_Physical, drug is a Intervention_Pharmacological, Stool frequency is a Outcome_Other, stool weight , stool character is a Outcome_Physical, Karnofsky score is a Outcome_Other
83746_task0
Sentence: Paromomycin for cryptosporidiosis in AIDS : a prospective , double-blind trial . To test the effects of paromomycin , 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double-blind trial . After 14 days , patients were switched to the other treatment for 14 additional days . Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion . During the paromomycin treatment phase , oocyst excretion decreased from 314 x 10 ( 6 ) to 109 x 10 ( 6 ) 24 h ( P < .02 ) . Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 10 ( 6 ) /24 h for the 6 initially treated with drug ( P < .02 ) . Stool frequency also decreased more in those treated with drug ( 3.6 fewer vs. 1.25 fewer/24 h , P < .05 ) . Trends favored drug over placebo for stool weight , stool character , and Karnofsky score . Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other
[ "B-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Paromomycin for cryptosporidiosis in AIDS : a prospective , double-blind trial . To test the effects of paromomycin , 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double-blind trial . After 14 days , patients were switched to the other treatment for 14 additional days . Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion . During the paromomycin treatment phase , oocyst excretion decreased from 314 x 10 ( 6 ) to 109 x 10 ( 6 ) 24 h ( P < .02 ) . Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 10 ( 6 ) /24 h for the 6 initially treated with drug ( P < .02 ) . Stool frequency also decreased more in those treated with drug ( 3.6 fewer vs. 1.25 fewer/24 h , P < .05 ) . Trends favored drug over placebo for stool weight , stool character , and Karnofsky score . Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS .
[ "Paromomycin", "for", "cryptosporidiosis", "in", "AIDS", ":", "a", "prospective", ",", "double", "-", "blind", "trial", ".", "To", "test", "the", "effects", "of", "paromomycin", ",", "10", "patients", "with", "AIDS", "and", "cryptosporidiosis", "were", "randomized", "to", "paromomycin", "or", "placebo", "in", "a", "double", "-", "blind", "trial", ".", "After", "14", "days", ",", "patients", "were", "switched", "to", "the", "other", "treatment", "for", "14", "additional", "days", ".", "Measures", "included", "the", "number", "and", "character", "of", "each", "stool", "and", "weekly", "24-h", "stool", "specimens", "for", "weight", "and", "oocyst", "excretion", ".", "During", "the", "paromomycin", "treatment", "phase", ",", "oocyst", "excretion", "decreased", "from", "314", "x", "10", "(", "6", ")", "to", "109", "x", "10", "(", "6", ")", "24", "h", "(", "P", "<", ".02", ")", ".", "Oocyst", "excretion", "increased", "for", "the", "4", "patients", "initially", "on", "placebo", "compared", "to", "a", "median", "decrease", "of", "128", "x", "10", "(", "6", ")", "/24", "h", "for", "the", "6", "initially", "treated", "with", "drug", "(", "P", "<", ".02", ")", ".", "Stool", "frequency", "also", "decreased", "more", "in", "those", "treated", "with", "drug", "(", "3.6", "fewer", "vs", ".", "1.25", "fewer/24", "h", ",", "P", "<", ".05", ")", ".", "Trends", "favored", "drug", "over", "placebo", "for", "stool", "weight", ",", "stool", "character", ",", "and", "Karnofsky", "score", ".", "Paromomycin", "treatment", "resulted", "in", "improvement", "in", "both", "clinical", "and", "parasitologic", "parameters", "in", "cryptosporidiosis", "in", "AIDS", "." ]
[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Condition" ]
Paromomycin is a Intervention_Pharmacological, AIDS : is a Participant_Condition, paromomycin is a Intervention_Pharmacological, placebo is a Intervention_Control, number and character of each stool is a Outcome_Physical, stool specimens for weight is a Outcome_Physical, oocyst excretion is a Outcome_Physical, Oocyst excretion is a Outcome_Physical, drug is a Intervention_Pharmacological, Stool frequency is a Outcome_Other, stool weight , stool character is a Outcome_Physical, Karnofsky score is a Outcome_Other
83746_task1
Sentence: Paromomycin for cryptosporidiosis in AIDS : a prospective , double-blind trial . To test the effects of paromomycin , 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double-blind trial . After 14 days , patients were switched to the other treatment for 14 additional days . Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion . During the paromomycin treatment phase , oocyst excretion decreased from 314 x 10 ( 6 ) to 109 x 10 ( 6 ) 24 h ( P < .02 ) . Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 10 ( 6 ) /24 h for the 6 initially treated with drug ( P < .02 ) . Stool frequency also decreased more in those treated with drug ( 3.6 fewer vs. 1.25 fewer/24 h , P < .05 ) . Trends favored drug over placebo for stool weight , stool character , and Karnofsky score . Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS . Instructions: please typing these entity words according to sentence: Paromomycin, AIDS :, paromomycin, placebo, number and character of each stool, stool specimens for weight, oocyst excretion, Oocyst excretion, drug, Stool frequency, stool weight , stool character, Karnofsky score Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other
[ "B-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Paromomycin for cryptosporidiosis in AIDS : a prospective , double-blind trial . To test the effects of paromomycin , 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double-blind trial . After 14 days , patients were switched to the other treatment for 14 additional days . Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion . During the paromomycin treatment phase , oocyst excretion decreased from 314 x 10 ( 6 ) to 109 x 10 ( 6 ) 24 h ( P < .02 ) . Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 10 ( 6 ) /24 h for the 6 initially treated with drug ( P < .02 ) . Stool frequency also decreased more in those treated with drug ( 3.6 fewer vs. 1.25 fewer/24 h , P < .05 ) . Trends favored drug over placebo for stool weight , stool character , and Karnofsky score . Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS .
[ "Paromomycin", "for", "cryptosporidiosis", "in", "AIDS", ":", "a", "prospective", ",", "double", "-", "blind", "trial", ".", "To", "test", "the", "effects", "of", "paromomycin", ",", "10", "patients", "with", "AIDS", "and", "cryptosporidiosis", "were", "randomized", "to", "paromomycin", "or", "placebo", "in", "a", "double", "-", "blind", "trial", ".", "After", "14", "days", ",", "patients", "were", "switched", "to", "the", "other", "treatment", "for", "14", "additional", "days", ".", "Measures", "included", "the", "number", "and", "character", "of", "each", "stool", "and", "weekly", "24-h", "stool", "specimens", "for", "weight", "and", "oocyst", "excretion", ".", "During", "the", "paromomycin", "treatment", "phase", ",", "oocyst", "excretion", "decreased", "from", "314", "x", "10", "(", "6", ")", "to", "109", "x", "10", "(", "6", ")", "24", "h", "(", "P", "<", ".02", ")", ".", "Oocyst", "excretion", "increased", "for", "the", "4", "patients", "initially", "on", "placebo", "compared", "to", "a", "median", "decrease", "of", "128", "x", "10", "(", "6", ")", "/24", "h", "for", "the", "6", "initially", "treated", "with", "drug", "(", "P", "<", ".02", ")", ".", "Stool", "frequency", "also", "decreased", "more", "in", "those", "treated", "with", "drug", "(", "3.6", "fewer", "vs", ".", "1.25", "fewer/24", "h", ",", "P", "<", ".05", ")", ".", "Trends", "favored", "drug", "over", "placebo", "for", "stool", "weight", ",", "stool", "character", ",", "and", "Karnofsky", "score", ".", "Paromomycin", "treatment", "resulted", "in", "improvement", "in", "both", "clinical", "and", "parasitologic", "parameters", "in", "cryptosporidiosis", "in", "AIDS", "." ]
[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Condition" ]
Paromomycin, AIDS :, paromomycin, placebo, number and character of each stool, stool specimens for weight, oocyst excretion, Oocyst excretion, drug, Stool frequency, stool weight , stool character, Karnofsky score
83746_task2
Sentence: Paromomycin for cryptosporidiosis in AIDS : a prospective , double-blind trial . To test the effects of paromomycin , 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double-blind trial . After 14 days , patients were switched to the other treatment for 14 additional days . Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion . During the paromomycin treatment phase , oocyst excretion decreased from 314 x 10 ( 6 ) to 109 x 10 ( 6 ) 24 h ( P < .02 ) . Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 10 ( 6 ) /24 h for the 6 initially treated with drug ( P < .02 ) . Stool frequency also decreased more in those treated with drug ( 3.6 fewer vs. 1.25 fewer/24 h , P < .05 ) . Trends favored drug over placebo for stool weight , stool character , and Karnofsky score . Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Paromomycin for cryptosporidiosis in AIDS : a prospective , double-blind trial . To test the effects of paromomycin , 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double-blind trial . After 14 days , patients were switched to the other treatment for 14 additional days . Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion . During the paromomycin treatment phase , oocyst excretion decreased from 314 x 10 ( 6 ) to 109 x 10 ( 6 ) 24 h ( P < .02 ) . Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 x 10 ( 6 ) /24 h for the 6 initially treated with drug ( P < .02 ) . Stool frequency also decreased more in those treated with drug ( 3.6 fewer vs. 1.25 fewer/24 h , P < .05 ) . Trends favored drug over placebo for stool weight , stool character , and Karnofsky score . Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS .
[ "Paromomycin", "for", "cryptosporidiosis", "in", "AIDS", ":", "a", "prospective", ",", "double", "-", "blind", "trial", ".", "To", "test", "the", "effects", "of", "paromomycin", ",", "10", "patients", "with", "AIDS", "and", "cryptosporidiosis", "were", "randomized", "to", "paromomycin", "or", "placebo", "in", "a", "double", "-", "blind", "trial", ".", "After", "14", "days", ",", "patients", "were", "switched", "to", "the", "other", "treatment", "for", "14", "additional", "days", ".", "Measures", "included", "the", "number", "and", "character", "of", "each", "stool", "and", "weekly", "24-h", "stool", "specimens", "for", "weight", "and", "oocyst", "excretion", ".", "During", "the", "paromomycin", "treatment", "phase", ",", "oocyst", "excretion", "decreased", "from", "314", "x", "10", "(", "6", ")", "to", "109", "x", "10", "(", "6", ")", "24", "h", "(", "P", "<", ".02", ")", ".", "Oocyst", "excretion", "increased", "for", "the", "4", "patients", "initially", "on", "placebo", "compared", "to", "a", "median", "decrease", "of", "128", "x", "10", "(", "6", ")", "/24", "h", "for", "the", "6", "initially", "treated", "with", "drug", "(", "P", "<", ".02", ")", ".", "Stool", "frequency", "also", "decreased", "more", "in", "those", "treated", "with", "drug", "(", "3.6", "fewer", "vs", ".", "1.25", "fewer/24", "h", ",", "P", "<", ".05", ")", ".", "Trends", "favored", "drug", "over", "placebo", "for", "stool", "weight", ",", "stool", "character", ",", "and", "Karnofsky", "score", ".", "Paromomycin", "treatment", "resulted", "in", "improvement", "in", "both", "clinical", "and", "parasitologic", "parameters", "in", "cryptosporidiosis", "in", "AIDS", "." ]
[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control", "Participant_Condition" ]
DSM - IV - TR is a Qualifier, major depressive disorder is a Condition, aged is a Person, between 20 and 80 is a Value, durg is a Drug, naive is a Negation, drug is a Drug, free is a Negation
NCT01997580_inc_task0
Sentence: DSM-IV-TR major depressive disorder aged between 20 and 80 durg-naive or drug-free Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Negation, Drug
[ "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Drug", "O", "B-Negation", "O", "B-Drug", "O", "B-Negation", "O" ]
DSM-IV-TR major depressive disorder aged between 20 and 80 durg-naive or drug-free
[ "DSM", "-", "IV", "-", "TR", "major", "depressive", "disorder", "\n", "aged", "between", "20", "and", "80", "\n", "durg", "-", "naive", "or", "drug", "-", "free", "\n" ]
[ "Condition", "Value", "Qualifier", "Negation", "Person", "Drug" ]
DSM - IV - TR is a Qualifier, major depressive disorder is a Condition, aged is a Person, between 20 and 80 is a Value, durg is a Drug, naive is a Negation, drug is a Drug, free is a Negation
NCT01997580_inc_task1
Sentence: DSM-IV-TR major depressive disorder aged between 20 and 80 durg-naive or drug-free Instructions: please typing these entity words according to sentence: DSM - IV - TR, major depressive disorder, aged, between 20 and 80, durg, naive, drug, free Options: Condition, Qualifier, Value, Person, Negation, Drug
[ "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Drug", "O", "B-Negation", "O", "B-Drug", "O", "B-Negation", "O" ]
DSM-IV-TR major depressive disorder aged between 20 and 80 durg-naive or drug-free
[ "DSM", "-", "IV", "-", "TR", "major", "depressive", "disorder", "\n", "aged", "between", "20", "and", "80", "\n", "durg", "-", "naive", "or", "drug", "-", "free", "\n" ]
[ "Condition", "Value", "Qualifier", "Negation", "Person", "Drug" ]
DSM - IV - TR, major depressive disorder, aged, between 20 and 80, durg, naive, drug, free
NCT01997580_inc_task2
Sentence: DSM-IV-TR major depressive disorder aged between 20 and 80 durg-naive or drug-free Instructions: please extract entity words from the input sentence
[ "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "B-Condition", "I-Condition", "I-Condition", "O", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Drug", "O", "B-Negation", "O", "B-Drug", "O", "B-Negation", "O" ]
DSM-IV-TR major depressive disorder aged between 20 and 80 durg-naive or drug-free
[ "DSM", "-", "IV", "-", "TR", "major", "depressive", "disorder", "\n", "aged", "between", "20", "and", "80", "\n", "durg", "-", "naive", "or", "drug", "-", "free", "\n" ]
[ "Condition", "Value", "Qualifier", "Negation", "Person", "Drug" ]
LMP-1 is a Protein, I kappa B alpha is a Protein, LMP-1 is a Protein, LMP-1 is a Protein, bcl2 is a Protein, LMP-1 is a Protein, LMP-1 is a Protein, LMP-1 is a Protein, LMP-1 is a Protein, I kappa B alpha is a Protein, I kappa B alpha is a Protein, p105 is a Protein, I kappa B alpha is a Protein, MAD3 is a Protein, LMP-1 is a Protein, I kappa B alpha is a Protein, LMP-1 is a Protein, I kappa B alpha is a Protein
447_task0
Sentence: LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha. LMP-1, an Epstein-Barr virus membrane protein expressed during latent infection, has oncogenic properties, as judged from its ability to transform B lymphocytes and rodent fibroblasts. LMP-1 induces the expression of bcl2, an oncogene which protects cells from apoptosis, as well as of genes encoding other proteins involved in cell regulation and growth control. The mechanisms by which LMP-1 upregulates these proteins is unknown, but it is plausible that LMP-1 modifies signal transduction pathways that result in the activation of one or more transcription factors that ultimately regulate transcription of oncogenic genes. NF-kappa B, a transcription factor controlling the expression of genes involved in cell activation and growth control, has been shown to be activated by LMP-1. The mechanism(s) regulating this activation remains unknown. Our data indicate that increased NF-kappa B DNA binding and functional activity are present in B-lymphoid cells stably or transiently expressing LMP-1. I kappa B alpha is selectively modified in LMP-1-expressing B cells. A phosphorylated form of I kappa B alpha and increased protein turnover-degradation correlate with increased NF-kappa B nuclear translocation. This results in increased transcription of NF-kappa B-dependent-genes, including those encoding p105 and I kappa B alpha (MAD3). These results indicate that LMP-1 activates NF-kappa B in B-cell lines by targeting I kappa B alpha. Identification of the pathways activated by LMP-1 to result in posttranslational modifications of I kappa B alpha will aid in determining the role of this virus-host cell protein interaction in Epstein-Barr virus-mediated oncogenesis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha. LMP-1, an Epstein-Barr virus membrane protein expressed during latent infection, has oncogenic properties, as judged from its ability to transform B lymphocytes and rodent fibroblasts. LMP-1 induces the expression of bcl2, an oncogene which protects cells from apoptosis, as well as of genes encoding other proteins involved in cell regulation and growth control. The mechanisms by which LMP-1 upregulates these proteins is unknown, but it is plausible that LMP-1 modifies signal transduction pathways that result in the activation of one or more transcription factors that ultimately regulate transcription of oncogenic genes. NF-kappa B, a transcription factor controlling the expression of genes involved in cell activation and growth control, has been shown to be activated by LMP-1. The mechanism(s) regulating this activation remains unknown. Our data indicate that increased NF-kappa B DNA binding and functional activity are present in B-lymphoid cells stably or transiently expressing LMP-1. I kappa B alpha is selectively modified in LMP-1-expressing B cells. A phosphorylated form of I kappa B alpha and increased protein turnover-degradation correlate with increased NF-kappa B nuclear translocation. This results in increased transcription of NF-kappa B-dependent-genes, including those encoding p105 and I kappa B alpha (MAD3). These results indicate that LMP-1 activates NF-kappa B in B-cell lines by targeting I kappa B alpha. Identification of the pathways activated by LMP-1 to result in posttranslational modifications of I kappa B alpha will aid in determining the role of this virus-host cell protein interaction in Epstein-Barr virus-mediated oncogenesis.
[ "LMP-1", "activates", "NF", "-", "kappa", "B", "by", "targeting", "the", "inhibitory", "molecule", "I", "kappa", "B", "alpha", ".", "\n", "LMP-1", ",", "an", "Epstein", "-", "Barr", "virus", "membrane", "protein", "expressed", "during", "latent", "infection", ",", "has", "oncogenic", "properties", ",", "as", "judged", "from", "its", "ability", "to", "transform", "B", "lymphocytes", "and", "rodent", "fibroblasts", ".", "LMP-1", "induces", "the", "expression", "of", "bcl2", ",", "an", "oncogene", "which", "protects", "cells", "from", "apoptosis", ",", "as", "well", "as", "of", "genes", "encoding", "other", "proteins", "involved", "in", "cell", "regulation", "and", "growth", "control", ".", "The", "mechanisms", "by", "which", "LMP-1", "upregulates", "these", "proteins", "is", "unknown", ",", "but", "it", "is", "plausible", "that", "LMP-1", "modifies", "signal", "transduction", "pathways", "that", "result", "in", "the", "activation", "of", "one", "or", "more", "transcription", "factors", "that", "ultimately", "regulate", "transcription", "of", "oncogenic", "genes", ".", "NF", "-", "kappa", "B", ",", "a", "transcription", "factor", "controlling", "the", "expression", "of", "genes", "involved", "in", "cell", "activation", "and", "growth", "control", ",", "has", "been", "shown", "to", "be", "activated", "by", "LMP-1", ".", "The", "mechanism(s", ")", "regulating", "this", "activation", "remains", "unknown", ".", "Our", "data", "indicate", "that", "increased", "NF", "-", "kappa", "B", "DNA", "binding", "and", "functional", "activity", "are", "present", "in", "B", "-", "lymphoid", "cells", "stably", "or", "transiently", "expressing", "LMP-1", ".", "I", "kappa", "B", "alpha", "is", "selectively", "modified", "in", "LMP-1-expressing", "B", "cells", ".", "A", "phosphorylated", "form", "of", "I", "kappa", "B", "alpha", "and", "increased", "protein", "turnover", "-", "degradation", "correlate", "with", "increased", "NF", "-", "kappa", "B", "nuclear", "translocation", ".", "This", "results", "in", "increased", "transcription", "of", "NF", "-", "kappa", "B", "-", "dependent", "-", "genes", ",", "including", "those", "encoding", "p105", "and", "I", "kappa", "B", "alpha", "(", "MAD3", ")", ".", "These", "results", "indicate", "that", "LMP-1", "activates", "NF", "-", "kappa", "B", "in", "B", "-", "cell", "lines", "by", "targeting", "I", "kappa", "B", "alpha", ".", "Identification", "of", "the", "pathways", "activated", "by", "LMP-1", "to", "result", "in", "posttranslational", "modifications", "of", "I", "kappa", "B", "alpha", "will", "aid", "in", "determining", "the", "role", "of", "this", "virus", "-", "host", "cell", "protein", "interaction", "in", "Epstein", "-", "Barr", "virus", "-", "mediated", "oncogenesis", "." ]
[ "Protein" ]
LMP-1 is a Protein, I kappa B alpha is a Protein, LMP-1 is a Protein, LMP-1 is a Protein, bcl2 is a Protein, LMP-1 is a Protein, LMP-1 is a Protein, LMP-1 is a Protein, LMP-1 is a Protein, I kappa B alpha is a Protein, I kappa B alpha is a Protein, p105 is a Protein, I kappa B alpha is a Protein, MAD3 is a Protein, LMP-1 is a Protein, I kappa B alpha is a Protein, LMP-1 is a Protein, I kappa B alpha is a Protein
447_task1
Sentence: LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha. LMP-1, an Epstein-Barr virus membrane protein expressed during latent infection, has oncogenic properties, as judged from its ability to transform B lymphocytes and rodent fibroblasts. LMP-1 induces the expression of bcl2, an oncogene which protects cells from apoptosis, as well as of genes encoding other proteins involved in cell regulation and growth control. The mechanisms by which LMP-1 upregulates these proteins is unknown, but it is plausible that LMP-1 modifies signal transduction pathways that result in the activation of one or more transcription factors that ultimately regulate transcription of oncogenic genes. NF-kappa B, a transcription factor controlling the expression of genes involved in cell activation and growth control, has been shown to be activated by LMP-1. The mechanism(s) regulating this activation remains unknown. Our data indicate that increased NF-kappa B DNA binding and functional activity are present in B-lymphoid cells stably or transiently expressing LMP-1. I kappa B alpha is selectively modified in LMP-1-expressing B cells. A phosphorylated form of I kappa B alpha and increased protein turnover-degradation correlate with increased NF-kappa B nuclear translocation. This results in increased transcription of NF-kappa B-dependent-genes, including those encoding p105 and I kappa B alpha (MAD3). These results indicate that LMP-1 activates NF-kappa B in B-cell lines by targeting I kappa B alpha. Identification of the pathways activated by LMP-1 to result in posttranslational modifications of I kappa B alpha will aid in determining the role of this virus-host cell protein interaction in Epstein-Barr virus-mediated oncogenesis. Instructions: please typing these entity words according to sentence: LMP-1, I kappa B alpha, LMP-1, LMP-1, bcl2, LMP-1, LMP-1, LMP-1, LMP-1, I kappa B alpha, I kappa B alpha, p105, I kappa B alpha, MAD3, LMP-1, I kappa B alpha, LMP-1, I kappa B alpha Options: Protein
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha. LMP-1, an Epstein-Barr virus membrane protein expressed during latent infection, has oncogenic properties, as judged from its ability to transform B lymphocytes and rodent fibroblasts. LMP-1 induces the expression of bcl2, an oncogene which protects cells from apoptosis, as well as of genes encoding other proteins involved in cell regulation and growth control. The mechanisms by which LMP-1 upregulates these proteins is unknown, but it is plausible that LMP-1 modifies signal transduction pathways that result in the activation of one or more transcription factors that ultimately regulate transcription of oncogenic genes. NF-kappa B, a transcription factor controlling the expression of genes involved in cell activation and growth control, has been shown to be activated by LMP-1. The mechanism(s) regulating this activation remains unknown. Our data indicate that increased NF-kappa B DNA binding and functional activity are present in B-lymphoid cells stably or transiently expressing LMP-1. I kappa B alpha is selectively modified in LMP-1-expressing B cells. A phosphorylated form of I kappa B alpha and increased protein turnover-degradation correlate with increased NF-kappa B nuclear translocation. This results in increased transcription of NF-kappa B-dependent-genes, including those encoding p105 and I kappa B alpha (MAD3). These results indicate that LMP-1 activates NF-kappa B in B-cell lines by targeting I kappa B alpha. Identification of the pathways activated by LMP-1 to result in posttranslational modifications of I kappa B alpha will aid in determining the role of this virus-host cell protein interaction in Epstein-Barr virus-mediated oncogenesis.
[ "LMP-1", "activates", "NF", "-", "kappa", "B", "by", "targeting", "the", "inhibitory", "molecule", "I", "kappa", "B", "alpha", ".", "\n", "LMP-1", ",", "an", "Epstein", "-", "Barr", "virus", "membrane", "protein", "expressed", "during", "latent", "infection", ",", "has", "oncogenic", "properties", ",", "as", "judged", "from", "its", "ability", "to", "transform", "B", "lymphocytes", "and", "rodent", "fibroblasts", ".", "LMP-1", "induces", "the", "expression", "of", "bcl2", ",", "an", "oncogene", "which", "protects", "cells", "from", "apoptosis", ",", "as", "well", "as", "of", "genes", "encoding", "other", "proteins", "involved", "in", "cell", "regulation", "and", "growth", "control", ".", "The", "mechanisms", "by", "which", "LMP-1", "upregulates", "these", "proteins", "is", "unknown", ",", "but", "it", "is", "plausible", "that", "LMP-1", "modifies", "signal", "transduction", "pathways", "that", "result", "in", "the", "activation", "of", "one", "or", "more", "transcription", "factors", "that", "ultimately", "regulate", "transcription", "of", "oncogenic", "genes", ".", "NF", "-", "kappa", "B", ",", "a", "transcription", "factor", "controlling", "the", "expression", "of", "genes", "involved", "in", "cell", "activation", "and", "growth", "control", ",", "has", "been", "shown", "to", "be", "activated", "by", "LMP-1", ".", "The", "mechanism(s", ")", "regulating", "this", "activation", "remains", "unknown", ".", "Our", "data", "indicate", "that", "increased", "NF", "-", "kappa", "B", "DNA", "binding", "and", "functional", "activity", "are", "present", "in", "B", "-", "lymphoid", "cells", "stably", "or", "transiently", "expressing", "LMP-1", ".", "I", "kappa", "B", "alpha", "is", "selectively", "modified", "in", "LMP-1-expressing", "B", "cells", ".", "A", "phosphorylated", "form", "of", "I", "kappa", "B", "alpha", "and", "increased", "protein", "turnover", "-", "degradation", "correlate", "with", "increased", "NF", "-", "kappa", "B", "nuclear", "translocation", ".", "This", "results", "in", "increased", "transcription", "of", "NF", "-", "kappa", "B", "-", "dependent", "-", "genes", ",", "including", "those", "encoding", "p105", "and", "I", "kappa", "B", "alpha", "(", "MAD3", ")", ".", "These", "results", "indicate", "that", "LMP-1", "activates", "NF", "-", "kappa", "B", "in", "B", "-", "cell", "lines", "by", "targeting", "I", "kappa", "B", "alpha", ".", "Identification", "of", "the", "pathways", "activated", "by", "LMP-1", "to", "result", "in", "posttranslational", "modifications", "of", "I", "kappa", "B", "alpha", "will", "aid", "in", "determining", "the", "role", "of", "this", "virus", "-", "host", "cell", "protein", "interaction", "in", "Epstein", "-", "Barr", "virus", "-", "mediated", "oncogenesis", "." ]
[ "Protein" ]
LMP-1, I kappa B alpha, LMP-1, LMP-1, bcl2, LMP-1, LMP-1, LMP-1, LMP-1, I kappa B alpha, I kappa B alpha, p105, I kappa B alpha, MAD3, LMP-1, I kappa B alpha, LMP-1, I kappa B alpha
447_task2
Sentence: LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha. LMP-1, an Epstein-Barr virus membrane protein expressed during latent infection, has oncogenic properties, as judged from its ability to transform B lymphocytes and rodent fibroblasts. LMP-1 induces the expression of bcl2, an oncogene which protects cells from apoptosis, as well as of genes encoding other proteins involved in cell regulation and growth control. The mechanisms by which LMP-1 upregulates these proteins is unknown, but it is plausible that LMP-1 modifies signal transduction pathways that result in the activation of one or more transcription factors that ultimately regulate transcription of oncogenic genes. NF-kappa B, a transcription factor controlling the expression of genes involved in cell activation and growth control, has been shown to be activated by LMP-1. The mechanism(s) regulating this activation remains unknown. Our data indicate that increased NF-kappa B DNA binding and functional activity are present in B-lymphoid cells stably or transiently expressing LMP-1. I kappa B alpha is selectively modified in LMP-1-expressing B cells. A phosphorylated form of I kappa B alpha and increased protein turnover-degradation correlate with increased NF-kappa B nuclear translocation. This results in increased transcription of NF-kappa B-dependent-genes, including those encoding p105 and I kappa B alpha (MAD3). These results indicate that LMP-1 activates NF-kappa B in B-cell lines by targeting I kappa B alpha. Identification of the pathways activated by LMP-1 to result in posttranslational modifications of I kappa B alpha will aid in determining the role of this virus-host cell protein interaction in Epstein-Barr virus-mediated oncogenesis. Instructions: please extract entity words from the input sentence
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha. LMP-1, an Epstein-Barr virus membrane protein expressed during latent infection, has oncogenic properties, as judged from its ability to transform B lymphocytes and rodent fibroblasts. LMP-1 induces the expression of bcl2, an oncogene which protects cells from apoptosis, as well as of genes encoding other proteins involved in cell regulation and growth control. The mechanisms by which LMP-1 upregulates these proteins is unknown, but it is plausible that LMP-1 modifies signal transduction pathways that result in the activation of one or more transcription factors that ultimately regulate transcription of oncogenic genes. NF-kappa B, a transcription factor controlling the expression of genes involved in cell activation and growth control, has been shown to be activated by LMP-1. The mechanism(s) regulating this activation remains unknown. Our data indicate that increased NF-kappa B DNA binding and functional activity are present in B-lymphoid cells stably or transiently expressing LMP-1. I kappa B alpha is selectively modified in LMP-1-expressing B cells. A phosphorylated form of I kappa B alpha and increased protein turnover-degradation correlate with increased NF-kappa B nuclear translocation. This results in increased transcription of NF-kappa B-dependent-genes, including those encoding p105 and I kappa B alpha (MAD3). These results indicate that LMP-1 activates NF-kappa B in B-cell lines by targeting I kappa B alpha. Identification of the pathways activated by LMP-1 to result in posttranslational modifications of I kappa B alpha will aid in determining the role of this virus-host cell protein interaction in Epstein-Barr virus-mediated oncogenesis.
[ "LMP-1", "activates", "NF", "-", "kappa", "B", "by", "targeting", "the", "inhibitory", "molecule", "I", "kappa", "B", "alpha", ".", "\n", "LMP-1", ",", "an", "Epstein", "-", "Barr", "virus", "membrane", "protein", "expressed", "during", "latent", "infection", ",", "has", "oncogenic", "properties", ",", "as", "judged", "from", "its", "ability", "to", "transform", "B", "lymphocytes", "and", "rodent", "fibroblasts", ".", "LMP-1", "induces", "the", "expression", "of", "bcl2", ",", "an", "oncogene", "which", "protects", "cells", "from", "apoptosis", ",", "as", "well", "as", "of", "genes", "encoding", "other", "proteins", "involved", "in", "cell", "regulation", "and", "growth", "control", ".", "The", "mechanisms", "by", "which", "LMP-1", "upregulates", "these", "proteins", "is", "unknown", ",", "but", "it", "is", "plausible", "that", "LMP-1", "modifies", "signal", "transduction", "pathways", "that", "result", "in", "the", "activation", "of", "one", "or", "more", "transcription", "factors", "that", "ultimately", "regulate", "transcription", "of", "oncogenic", "genes", ".", "NF", "-", "kappa", "B", ",", "a", "transcription", "factor", "controlling", "the", "expression", "of", "genes", "involved", "in", "cell", "activation", "and", "growth", "control", ",", "has", "been", "shown", "to", "be", "activated", "by", "LMP-1", ".", "The", "mechanism(s", ")", "regulating", "this", "activation", "remains", "unknown", ".", "Our", "data", "indicate", "that", "increased", "NF", "-", "kappa", "B", "DNA", "binding", "and", "functional", "activity", "are", "present", "in", "B", "-", "lymphoid", "cells", "stably", "or", "transiently", "expressing", "LMP-1", ".", "I", "kappa", "B", "alpha", "is", "selectively", "modified", "in", "LMP-1-expressing", "B", "cells", ".", "A", "phosphorylated", "form", "of", "I", "kappa", "B", "alpha", "and", "increased", "protein", "turnover", "-", "degradation", "correlate", "with", "increased", "NF", "-", "kappa", "B", "nuclear", "translocation", ".", "This", "results", "in", "increased", "transcription", "of", "NF", "-", "kappa", "B", "-", "dependent", "-", "genes", ",", "including", "those", "encoding", "p105", "and", "I", "kappa", "B", "alpha", "(", "MAD3", ")", ".", "These", "results", "indicate", "that", "LMP-1", "activates", "NF", "-", "kappa", "B", "in", "B", "-", "cell", "lines", "by", "targeting", "I", "kappa", "B", "alpha", ".", "Identification", "of", "the", "pathways", "activated", "by", "LMP-1", "to", "result", "in", "posttranslational", "modifications", "of", "I", "kappa", "B", "alpha", "will", "aid", "in", "determining", "the", "role", "of", "this", "virus", "-", "host", "cell", "protein", "interaction", "in", "Epstein", "-", "Barr", "virus", "-", "mediated", "oncogenesis", "." ]
[ "Protein" ]
Propofol is an umlsterm, Zeit is an umlsterm, Patienten is an umlsterm, Kindern is an umlsterm, Kurzzeithypnotikum is an umlsterm
DerAnaesthesist.80470229.ger.abstr_task0
Sentence: Seit mehr als 10 Jahren ist Propofol in die Klinik eingefuehrt und hat in dieser Zeit weltweit eine sehr gute Akzeptanz erfahren . Es ist allerdings nur bei Patienten oberhalb des 3. Lebensjahres zugelassen , obwohl es weder pharmakokinetische noch pharmakodynamische Gruende gibt , wie anhand umfangreicher Daten belegt werden kann , Propofol Kindern unterhalb des vollendeten 3. Lebensjahres fuer anaesthesiologische Zwecke - sei es als Narkoseadjuvans oder als Kurzzeithypnotikum fuer therapeutische oder diagnostische Interventionen - vorzuenthalten . Dies gilt um so mehr , als ansonsten oftmals auf weniger geeignete Narkoseverfahren zurueckgegriffen werden muss . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Seit mehr als 10 Jahren ist Propofol in die Klinik eingefuehrt und hat in dieser Zeit weltweit eine sehr gute Akzeptanz erfahren . Es ist allerdings nur bei Patienten oberhalb des 3. Lebensjahres zugelassen , obwohl es weder pharmakokinetische noch pharmakodynamische Gruende gibt , wie anhand umfangreicher Daten belegt werden kann , Propofol Kindern unterhalb des vollendeten 3. Lebensjahres fuer anaesthesiologische Zwecke - sei es als Narkoseadjuvans oder als Kurzzeithypnotikum fuer therapeutische oder diagnostische Interventionen - vorzuenthalten . Dies gilt um so mehr , als ansonsten oftmals auf weniger geeignete Narkoseverfahren zurueckgegriffen werden muss .
[ "Seit", "mehr", "als", "10", "Jahren", "ist", "Propofol", "in", "die", "Klinik", "eingefuehrt", "und", "hat", "in", "dieser", "Zeit", "weltweit", "eine", "sehr", "gute", "Akzeptanz", "erfahren", ".", "Es", "ist", "allerdings", "nur", "bei", "Patienten", "oberhalb", "des", "3", ".", "Lebensjahres", "zugelassen", ",", "obwohl", "es", "weder", "pharmakokinetische", "noch", "pharmakodynamische", "Gruende", "gibt", ",", "wie", "anhand", "umfangreicher", "Daten", "belegt", "werden", "kann", ",", "Propofol", "Kindern", "unterhalb", "des", "vollendeten", "3", ".", "Lebensjahres", "fuer", "anaesthesiologische", "Zwecke", "-", "sei", "es", "als", "Narkoseadjuvans", "oder", "als", "Kurzzeithypnotikum", "fuer", "therapeutische", "oder", "diagnostische", "Interventionen", "-", "vorzuenthalten", ".", "Dies", "gilt", "um", "so", "mehr", ",", "als", "ansonsten", "oftmals", "auf", "weniger", "geeignete", "Narkoseverfahren", "zurueckgegriffen", "werden", "muss", "." ]
[ "umlsterm" ]
Propofol is an umlsterm, Zeit is an umlsterm, Patienten is an umlsterm, Kindern is an umlsterm, Kurzzeithypnotikum is an umlsterm
DerAnaesthesist.80470229.ger.abstr_task1
Sentence: Seit mehr als 10 Jahren ist Propofol in die Klinik eingefuehrt und hat in dieser Zeit weltweit eine sehr gute Akzeptanz erfahren . Es ist allerdings nur bei Patienten oberhalb des 3. Lebensjahres zugelassen , obwohl es weder pharmakokinetische noch pharmakodynamische Gruende gibt , wie anhand umfangreicher Daten belegt werden kann , Propofol Kindern unterhalb des vollendeten 3. Lebensjahres fuer anaesthesiologische Zwecke - sei es als Narkoseadjuvans oder als Kurzzeithypnotikum fuer therapeutische oder diagnostische Interventionen - vorzuenthalten . Dies gilt um so mehr , als ansonsten oftmals auf weniger geeignete Narkoseverfahren zurueckgegriffen werden muss . Instructions: please typing these entity words according to sentence: Propofol, Zeit, Patienten, Kindern, Kurzzeithypnotikum Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Seit mehr als 10 Jahren ist Propofol in die Klinik eingefuehrt und hat in dieser Zeit weltweit eine sehr gute Akzeptanz erfahren . Es ist allerdings nur bei Patienten oberhalb des 3. Lebensjahres zugelassen , obwohl es weder pharmakokinetische noch pharmakodynamische Gruende gibt , wie anhand umfangreicher Daten belegt werden kann , Propofol Kindern unterhalb des vollendeten 3. Lebensjahres fuer anaesthesiologische Zwecke - sei es als Narkoseadjuvans oder als Kurzzeithypnotikum fuer therapeutische oder diagnostische Interventionen - vorzuenthalten . Dies gilt um so mehr , als ansonsten oftmals auf weniger geeignete Narkoseverfahren zurueckgegriffen werden muss .
[ "Seit", "mehr", "als", "10", "Jahren", "ist", "Propofol", "in", "die", "Klinik", "eingefuehrt", "und", "hat", "in", "dieser", "Zeit", "weltweit", "eine", "sehr", "gute", "Akzeptanz", "erfahren", ".", "Es", "ist", "allerdings", "nur", "bei", "Patienten", "oberhalb", "des", "3", ".", "Lebensjahres", "zugelassen", ",", "obwohl", "es", "weder", "pharmakokinetische", "noch", "pharmakodynamische", "Gruende", "gibt", ",", "wie", "anhand", "umfangreicher", "Daten", "belegt", "werden", "kann", ",", "Propofol", "Kindern", "unterhalb", "des", "vollendeten", "3", ".", "Lebensjahres", "fuer", "anaesthesiologische", "Zwecke", "-", "sei", "es", "als", "Narkoseadjuvans", "oder", "als", "Kurzzeithypnotikum", "fuer", "therapeutische", "oder", "diagnostische", "Interventionen", "-", "vorzuenthalten", ".", "Dies", "gilt", "um", "so", "mehr", ",", "als", "ansonsten", "oftmals", "auf", "weniger", "geeignete", "Narkoseverfahren", "zurueckgegriffen", "werden", "muss", "." ]
[ "umlsterm" ]
Propofol, Zeit, Patienten, Kindern, Kurzzeithypnotikum
DerAnaesthesist.80470229.ger.abstr_task2
Sentence: Seit mehr als 10 Jahren ist Propofol in die Klinik eingefuehrt und hat in dieser Zeit weltweit eine sehr gute Akzeptanz erfahren . Es ist allerdings nur bei Patienten oberhalb des 3. Lebensjahres zugelassen , obwohl es weder pharmakokinetische noch pharmakodynamische Gruende gibt , wie anhand umfangreicher Daten belegt werden kann , Propofol Kindern unterhalb des vollendeten 3. Lebensjahres fuer anaesthesiologische Zwecke - sei es als Narkoseadjuvans oder als Kurzzeithypnotikum fuer therapeutische oder diagnostische Interventionen - vorzuenthalten . Dies gilt um so mehr , als ansonsten oftmals auf weniger geeignete Narkoseverfahren zurueckgegriffen werden muss . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Seit mehr als 10 Jahren ist Propofol in die Klinik eingefuehrt und hat in dieser Zeit weltweit eine sehr gute Akzeptanz erfahren . Es ist allerdings nur bei Patienten oberhalb des 3. Lebensjahres zugelassen , obwohl es weder pharmakokinetische noch pharmakodynamische Gruende gibt , wie anhand umfangreicher Daten belegt werden kann , Propofol Kindern unterhalb des vollendeten 3. Lebensjahres fuer anaesthesiologische Zwecke - sei es als Narkoseadjuvans oder als Kurzzeithypnotikum fuer therapeutische oder diagnostische Interventionen - vorzuenthalten . Dies gilt um so mehr , als ansonsten oftmals auf weniger geeignete Narkoseverfahren zurueckgegriffen werden muss .
[ "Seit", "mehr", "als", "10", "Jahren", "ist", "Propofol", "in", "die", "Klinik", "eingefuehrt", "und", "hat", "in", "dieser", "Zeit", "weltweit", "eine", "sehr", "gute", "Akzeptanz", "erfahren", ".", "Es", "ist", "allerdings", "nur", "bei", "Patienten", "oberhalb", "des", "3", ".", "Lebensjahres", "zugelassen", ",", "obwohl", "es", "weder", "pharmakokinetische", "noch", "pharmakodynamische", "Gruende", "gibt", ",", "wie", "anhand", "umfangreicher", "Daten", "belegt", "werden", "kann", ",", "Propofol", "Kindern", "unterhalb", "des", "vollendeten", "3", ".", "Lebensjahres", "fuer", "anaesthesiologische", "Zwecke", "-", "sei", "es", "als", "Narkoseadjuvans", "oder", "als", "Kurzzeithypnotikum", "fuer", "therapeutische", "oder", "diagnostische", "Interventionen", "-", "vorzuenthalten", ".", "Dies", "gilt", "um", "so", "mehr", ",", "als", "ansonsten", "oftmals", "auf", "weniger", "geeignete", "Narkoseverfahren", "zurueckgegriffen", "werden", "muss", "." ]
[ "umlsterm" ]
Abstract is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, risks of is an umlsterm, obesity is an umlsterm, morbid obesity is an umlsterm, BMI is an umlsterm, obese is an umlsterm, diabetes mellitus is an umlsterm, hypertension is an umlsterm, syndrome is an umlsterm, obstructive sleep apnea is an umlsterm, syndrome is an umlsterm, pressure is an umlsterm, obese is an umlsterm, persons is an umlsterm, society is an umlsterm, Weight reduction is an umlsterm, therapeutic is an umlsterm, overweight is an umlsterm, patients is an umlsterm, type 2 diabetes is an umlsterm, hypertension is an umlsterm, syndrome is an umlsterm, obstructive sleep apnea is an umlsterm, primary prevention is an umlsterm, diseases is an umlsterm, obesity is an umlsterm, excess mortality is an umlsterm, men is an umlsterm, obesity is an umlsterm, weight reduction is an umlsterm, excess mortality is an umlsterm, therapeutic is an umlsterm, weight reduction is an umlsterm, safety is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, risks is an umlsterm, therapeutic is an umlsterm, safety is an umlsterm, surgical is an umlsterm, methods is an umlsterm, obesity is an umlsterm
DerChirurg.00710129.eng.abstr_task0
Sentence: Abstract . The widely propagated morbidity and mortality risks of obesity appear somewhat exaggerated , except for morbid obesity ( BMI > 40 kg/m2) and for high-risk obese subgroups concerning diabetes mellitus , hypertension , metabolic syndrome and obstructive sleep apnea syndrome . Non-medical reasons represent a major component of the social pressure that is presently experienced by obese persons in our society . Weight reduction represents the primary therapeutic approach in overweight patients with type 2 diabetes , hypertension , metabolic syndrome and obstructive sleep apnea , and it may be recommended in high-risk individuals for primary prevention of these diseases . Massive obesity is associated with excess mortality , especially in younger , physically inactive men with upper-body-segment obesity . It is widely assumed that weight reduction will lead to a reduction of excess mortality in these individuals ; so far , however , there is no proof for this assumption . Non-medicamentous conservative therapeutic approaches to weight reduction have the advantage of safety , even though their long-term efficacy is generally disappointing . There are no randomized , controlled trials to prove a reduction of morbidity or mortality risks and of therapeutic safety for pharmacological , invasive or surgical methods to treat obesity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Abstract . The widely propagated morbidity and mortality risks of obesity appear somewhat exaggerated , except for morbid obesity ( BMI > 40 kg/m2) and for high-risk obese subgroups concerning diabetes mellitus , hypertension , metabolic syndrome and obstructive sleep apnea syndrome . Non-medical reasons represent a major component of the social pressure that is presently experienced by obese persons in our society . Weight reduction represents the primary therapeutic approach in overweight patients with type 2 diabetes , hypertension , metabolic syndrome and obstructive sleep apnea , and it may be recommended in high-risk individuals for primary prevention of these diseases . Massive obesity is associated with excess mortality , especially in younger , physically inactive men with upper-body-segment obesity . It is widely assumed that weight reduction will lead to a reduction of excess mortality in these individuals ; so far , however , there is no proof for this assumption . Non-medicamentous conservative therapeutic approaches to weight reduction have the advantage of safety , even though their long-term efficacy is generally disappointing . There are no randomized , controlled trials to prove a reduction of morbidity or mortality risks and of therapeutic safety for pharmacological , invasive or surgical methods to treat obesity .
[ "Abstract", ".", "The", "widely", "propagated", "morbidity", "and", "mortality", "risks", "of", "obesity", "appear", "somewhat", "exaggerated", ",", "except", "for", "morbid", "obesity", "(", "BMI", ">", "40", "kg", "/", "m2", ")", "and", "for", "high", "-", "risk", "obese", "subgroups", "concerning", "diabetes", "mellitus", ",", "hypertension", ",", "metabolic", "syndrome", "and", "obstructive", "sleep", "apnea", "syndrome", ".", "Non", "-", "medical", "reasons", "represent", "a", "major", "component", "of", "the", "social", "pressure", "that", "is", "presently", "experienced", "by", "obese", "persons", "in", "our", "society", ".", "Weight", "reduction", "represents", "the", "primary", "therapeutic", "approach", "in", "overweight", "patients", "with", "type", "2", "diabetes", ",", "hypertension", ",", "metabolic", "syndrome", "and", "obstructive", "sleep", "apnea", ",", "and", "it", "may", "be", "recommended", "in", "high", "-", "risk", "individuals", "for", "primary", "prevention", "of", "these", "diseases", ".", "Massive", "obesity", "is", "associated", "with", "excess", "mortality", ",", "especially", "in", "younger", ",", "physically", "inactive", "men", "with", "upper", "-", "body", "-", "segment", "obesity", ".", "It", "is", "widely", "assumed", "that", "weight", "reduction", "will", "lead", "to", "a", "reduction", "of", "excess", "mortality", "in", "these", "individuals", ";", "so", "far", ",", "however", ",", "there", "is", "no", "proof", "for", "this", "assumption", ".", "Non", "-", "medicamentous", "conservative", "therapeutic", "approaches", "to", "weight", "reduction", "have", "the", "advantage", "of", "safety", ",", "even", "though", "their", "long", "-", "term", "efficacy", "is", "generally", "disappointing", ".", "There", "are", "no", "randomized", ",", "controlled", "trials", "to", "prove", "a", "reduction", "of", "morbidity", "or", "mortality", "risks", "and", "of", "therapeutic", "safety", "for", "pharmacological", ",", "invasive", "or", "surgical", "methods", "to", "treat", "obesity", "." ]
[ "umlsterm" ]
Abstract is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, risks of is an umlsterm, obesity is an umlsterm, morbid obesity is an umlsterm, BMI is an umlsterm, obese is an umlsterm, diabetes mellitus is an umlsterm, hypertension is an umlsterm, syndrome is an umlsterm, obstructive sleep apnea is an umlsterm, syndrome is an umlsterm, pressure is an umlsterm, obese is an umlsterm, persons is an umlsterm, society is an umlsterm, Weight reduction is an umlsterm, therapeutic is an umlsterm, overweight is an umlsterm, patients is an umlsterm, type 2 diabetes is an umlsterm, hypertension is an umlsterm, syndrome is an umlsterm, obstructive sleep apnea is an umlsterm, primary prevention is an umlsterm, diseases is an umlsterm, obesity is an umlsterm, excess mortality is an umlsterm, men is an umlsterm, obesity is an umlsterm, weight reduction is an umlsterm, excess mortality is an umlsterm, therapeutic is an umlsterm, weight reduction is an umlsterm, safety is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, risks is an umlsterm, therapeutic is an umlsterm, safety is an umlsterm, surgical is an umlsterm, methods is an umlsterm, obesity is an umlsterm
DerChirurg.00710129.eng.abstr_task1
Sentence: Abstract . The widely propagated morbidity and mortality risks of obesity appear somewhat exaggerated , except for morbid obesity ( BMI > 40 kg/m2) and for high-risk obese subgroups concerning diabetes mellitus , hypertension , metabolic syndrome and obstructive sleep apnea syndrome . Non-medical reasons represent a major component of the social pressure that is presently experienced by obese persons in our society . Weight reduction represents the primary therapeutic approach in overweight patients with type 2 diabetes , hypertension , metabolic syndrome and obstructive sleep apnea , and it may be recommended in high-risk individuals for primary prevention of these diseases . Massive obesity is associated with excess mortality , especially in younger , physically inactive men with upper-body-segment obesity . It is widely assumed that weight reduction will lead to a reduction of excess mortality in these individuals ; so far , however , there is no proof for this assumption . Non-medicamentous conservative therapeutic approaches to weight reduction have the advantage of safety , even though their long-term efficacy is generally disappointing . There are no randomized , controlled trials to prove a reduction of morbidity or mortality risks and of therapeutic safety for pharmacological , invasive or surgical methods to treat obesity . Instructions: please typing these entity words according to sentence: Abstract, morbidity, mortality, risks of, obesity, morbid obesity, BMI, obese, diabetes mellitus, hypertension, syndrome, obstructive sleep apnea, syndrome, pressure, obese, persons, society, Weight reduction, therapeutic, overweight, patients, type 2 diabetes, hypertension, syndrome, obstructive sleep apnea, primary prevention, diseases, obesity, excess mortality, men, obesity, weight reduction, excess mortality, therapeutic, weight reduction, safety, morbidity, mortality, risks, therapeutic, safety, surgical, methods, obesity Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Abstract . The widely propagated morbidity and mortality risks of obesity appear somewhat exaggerated , except for morbid obesity ( BMI > 40 kg/m2) and for high-risk obese subgroups concerning diabetes mellitus , hypertension , metabolic syndrome and obstructive sleep apnea syndrome . Non-medical reasons represent a major component of the social pressure that is presently experienced by obese persons in our society . Weight reduction represents the primary therapeutic approach in overweight patients with type 2 diabetes , hypertension , metabolic syndrome and obstructive sleep apnea , and it may be recommended in high-risk individuals for primary prevention of these diseases . Massive obesity is associated with excess mortality , especially in younger , physically inactive men with upper-body-segment obesity . It is widely assumed that weight reduction will lead to a reduction of excess mortality in these individuals ; so far , however , there is no proof for this assumption . Non-medicamentous conservative therapeutic approaches to weight reduction have the advantage of safety , even though their long-term efficacy is generally disappointing . There are no randomized , controlled trials to prove a reduction of morbidity or mortality risks and of therapeutic safety for pharmacological , invasive or surgical methods to treat obesity .
[ "Abstract", ".", "The", "widely", "propagated", "morbidity", "and", "mortality", "risks", "of", "obesity", "appear", "somewhat", "exaggerated", ",", "except", "for", "morbid", "obesity", "(", "BMI", ">", "40", "kg", "/", "m2", ")", "and", "for", "high", "-", "risk", "obese", "subgroups", "concerning", "diabetes", "mellitus", ",", "hypertension", ",", "metabolic", "syndrome", "and", "obstructive", "sleep", "apnea", "syndrome", ".", "Non", "-", "medical", "reasons", "represent", "a", "major", "component", "of", "the", "social", "pressure", "that", "is", "presently", "experienced", "by", "obese", "persons", "in", "our", "society", ".", "Weight", "reduction", "represents", "the", "primary", "therapeutic", "approach", "in", "overweight", "patients", "with", "type", "2", "diabetes", ",", "hypertension", ",", "metabolic", "syndrome", "and", "obstructive", "sleep", "apnea", ",", "and", "it", "may", "be", "recommended", "in", "high", "-", "risk", "individuals", "for", "primary", "prevention", "of", "these", "diseases", ".", "Massive", "obesity", "is", "associated", "with", "excess", "mortality", ",", "especially", "in", "younger", ",", "physically", "inactive", "men", "with", "upper", "-", "body", "-", "segment", "obesity", ".", "It", "is", "widely", "assumed", "that", "weight", "reduction", "will", "lead", "to", "a", "reduction", "of", "excess", "mortality", "in", "these", "individuals", ";", "so", "far", ",", "however", ",", "there", "is", "no", "proof", "for", "this", "assumption", ".", "Non", "-", "medicamentous", "conservative", "therapeutic", "approaches", "to", "weight", "reduction", "have", "the", "advantage", "of", "safety", ",", "even", "though", "their", "long", "-", "term", "efficacy", "is", "generally", "disappointing", ".", "There", "are", "no", "randomized", ",", "controlled", "trials", "to", "prove", "a", "reduction", "of", "morbidity", "or", "mortality", "risks", "and", "of", "therapeutic", "safety", "for", "pharmacological", ",", "invasive", "or", "surgical", "methods", "to", "treat", "obesity", "." ]
[ "umlsterm" ]
Abstract, morbidity, mortality, risks of, obesity, morbid obesity, BMI, obese, diabetes mellitus, hypertension, syndrome, obstructive sleep apnea, syndrome, pressure, obese, persons, society, Weight reduction, therapeutic, overweight, patients, type 2 diabetes, hypertension, syndrome, obstructive sleep apnea, primary prevention, diseases, obesity, excess mortality, men, obesity, weight reduction, excess mortality, therapeutic, weight reduction, safety, morbidity, mortality, risks, therapeutic, safety, surgical, methods, obesity
DerChirurg.00710129.eng.abstr_task2
Sentence: Abstract . The widely propagated morbidity and mortality risks of obesity appear somewhat exaggerated , except for morbid obesity ( BMI > 40 kg/m2) and for high-risk obese subgroups concerning diabetes mellitus , hypertension , metabolic syndrome and obstructive sleep apnea syndrome . Non-medical reasons represent a major component of the social pressure that is presently experienced by obese persons in our society . Weight reduction represents the primary therapeutic approach in overweight patients with type 2 diabetes , hypertension , metabolic syndrome and obstructive sleep apnea , and it may be recommended in high-risk individuals for primary prevention of these diseases . Massive obesity is associated with excess mortality , especially in younger , physically inactive men with upper-body-segment obesity . It is widely assumed that weight reduction will lead to a reduction of excess mortality in these individuals ; so far , however , there is no proof for this assumption . Non-medicamentous conservative therapeutic approaches to weight reduction have the advantage of safety , even though their long-term efficacy is generally disappointing . There are no randomized , controlled trials to prove a reduction of morbidity or mortality risks and of therapeutic safety for pharmacological , invasive or surgical methods to treat obesity . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Abstract . The widely propagated morbidity and mortality risks of obesity appear somewhat exaggerated , except for morbid obesity ( BMI > 40 kg/m2) and for high-risk obese subgroups concerning diabetes mellitus , hypertension , metabolic syndrome and obstructive sleep apnea syndrome . Non-medical reasons represent a major component of the social pressure that is presently experienced by obese persons in our society . Weight reduction represents the primary therapeutic approach in overweight patients with type 2 diabetes , hypertension , metabolic syndrome and obstructive sleep apnea , and it may be recommended in high-risk individuals for primary prevention of these diseases . Massive obesity is associated with excess mortality , especially in younger , physically inactive men with upper-body-segment obesity . It is widely assumed that weight reduction will lead to a reduction of excess mortality in these individuals ; so far , however , there is no proof for this assumption . Non-medicamentous conservative therapeutic approaches to weight reduction have the advantage of safety , even though their long-term efficacy is generally disappointing . There are no randomized , controlled trials to prove a reduction of morbidity or mortality risks and of therapeutic safety for pharmacological , invasive or surgical methods to treat obesity .
[ "Abstract", ".", "The", "widely", "propagated", "morbidity", "and", "mortality", "risks", "of", "obesity", "appear", "somewhat", "exaggerated", ",", "except", "for", "morbid", "obesity", "(", "BMI", ">", "40", "kg", "/", "m2", ")", "and", "for", "high", "-", "risk", "obese", "subgroups", "concerning", "diabetes", "mellitus", ",", "hypertension", ",", "metabolic", "syndrome", "and", "obstructive", "sleep", "apnea", "syndrome", ".", "Non", "-", "medical", "reasons", "represent", "a", "major", "component", "of", "the", "social", "pressure", "that", "is", "presently", "experienced", "by", "obese", "persons", "in", "our", "society", ".", "Weight", "reduction", "represents", "the", "primary", "therapeutic", "approach", "in", "overweight", "patients", "with", "type", "2", "diabetes", ",", "hypertension", ",", "metabolic", "syndrome", "and", "obstructive", "sleep", "apnea", ",", "and", "it", "may", "be", "recommended", "in", "high", "-", "risk", "individuals", "for", "primary", "prevention", "of", "these", "diseases", ".", "Massive", "obesity", "is", "associated", "with", "excess", "mortality", ",", "especially", "in", "younger", ",", "physically", "inactive", "men", "with", "upper", "-", "body", "-", "segment", "obesity", ".", "It", "is", "widely", "assumed", "that", "weight", "reduction", "will", "lead", "to", "a", "reduction", "of", "excess", "mortality", "in", "these", "individuals", ";", "so", "far", ",", "however", ",", "there", "is", "no", "proof", "for", "this", "assumption", ".", "Non", "-", "medicamentous", "conservative", "therapeutic", "approaches", "to", "weight", "reduction", "have", "the", "advantage", "of", "safety", ",", "even", "though", "their", "long", "-", "term", "efficacy", "is", "generally", "disappointing", ".", "There", "are", "no", "randomized", ",", "controlled", "trials", "to", "prove", "a", "reduction", "of", "morbidity", "or", "mortality", "risks", "and", "of", "therapeutic", "safety", "for", "pharmacological", ",", "invasive", "or", "surgical", "methods", "to", "treat", "obesity", "." ]
[ "umlsterm" ]
aim is an umlsterm, cisplatin is an umlsterm, radiation is an umlsterm, time is an umlsterm, cisplatin is an umlsterm, radiation is an umlsterm, Bone marrow is an umlsterm, female is an umlsterm, mice is an umlsterm, tissue is an umlsterm, Cisplatin is an umlsterm, Cisplatin is an umlsterm, time is an umlsterm, radiation is an umlsterm, Bone marrow is an umlsterm, metaphases is an umlsterm, standard is an umlsterm, procedures is an umlsterm, metaphases is an umlsterm, radiation is an umlsterm, cisplatin is an umlsterm, values is an umlsterm, time is an umlsterm, metaphases is an umlsterm, irradiation is an umlsterm, chromosomes is an umlsterm, cisplatin is an umlsterm, irradiation is an umlsterm, combined treatment is an umlsterm, cisplatin is an umlsterm, radiation is an umlsterm, cisplatin is an umlsterm
Strahlentherapie+Onkologie.01760319.eng.abstr_task0
Sentence: The aim of this study was to quantify the combined effect of cisplatin and radiation on chromosomal damage with emphasis on the time interval between cisplatin and radiation . Bone marrow of female NMRI-nu ( + ) mice was taken as a model system for a highly proliferative tissue irradiated with cobalt-60 ( 1 to 4 Gy ) . Cisplatin was injected intraperitoneally ( ip ) at 1.1 to 36 mg/kg . Cisplatin was given at various time intervals before and after radiation . Bone marrow and metaphases were prepared according to standard procedures . The percentage of aberrant metaphases after radiation or cisplatin alone increased in a dose-dependent manner ( sigmoidal dose-response curve ) . Combining both modalities led to additive values at all time points for the percentage of aberrant metaphases . Borderline significant ( p 0.05 ) supraadditive effects were found 2 hours before or 1 hour after irradiation . However , a supraadditive percentage of aberrant chromosomes was found only at 2 or 1.5 hours with cisplatin before irradiation indicating the dependence of supraadditivity on the chosen parameter . It is doubtful to expect a true supraadditive or " radiosensitizing " effect , e . g . in the clinical setting from combined treatment with cisplatin and radiation . Rather , cisplatin might act as an independent cytotoxic agent . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
The aim of this study was to quantify the combined effect of cisplatin and radiation on chromosomal damage with emphasis on the time interval between cisplatin and radiation . Bone marrow of female NMRI-nu ( + ) mice was taken as a model system for a highly proliferative tissue irradiated with cobalt-60 ( 1 to 4 Gy ) . Cisplatin was injected intraperitoneally ( ip ) at 1.1 to 36 mg/kg . Cisplatin was given at various time intervals before and after radiation . Bone marrow and metaphases were prepared according to standard procedures . The percentage of aberrant metaphases after radiation or cisplatin alone increased in a dose-dependent manner ( sigmoidal dose-response curve ) . Combining both modalities led to additive values at all time points for the percentage of aberrant metaphases . Borderline significant ( p 0.05 ) supraadditive effects were found 2 hours before or 1 hour after irradiation . However , a supraadditive percentage of aberrant chromosomes was found only at 2 or 1.5 hours with cisplatin before irradiation indicating the dependence of supraadditivity on the chosen parameter . It is doubtful to expect a true supraadditive or " radiosensitizing " effect , e . g . in the clinical setting from combined treatment with cisplatin and radiation . Rather , cisplatin might act as an independent cytotoxic agent .
[ "The", "aim", "of", "this", "study", "was", "to", "quantify", "the", "combined", "effect", "of", "cisplatin", "and", "radiation", "on", "chromosomal", "damage", "with", "emphasis", "on", "the", "time", "interval", "between", "cisplatin", "and", "radiation", ".", "Bone", "marrow", "of", "female", "NMRI", "-", "nu", "(", "+", ")", "mice", "was", "taken", "as", "a", "model", "system", "for", "a", "highly", "proliferative", "tissue", "irradiated", "with", "cobalt-60", "(", "1", "to", "4", "Gy", ")", ".", "Cisplatin", "was", "injected", "intraperitoneally", "(", "ip", ")", "at", "1.1", "to", "36", "mg", "/", "kg", ".", "Cisplatin", "was", "given", "at", "various", "time", "intervals", "before", "and", "after", "radiation", ".", "Bone", "marrow", "and", "metaphases", "were", "prepared", "according", "to", "standard", "procedures", ".", "The", "percentage", "of", "aberrant", "metaphases", "after", "radiation", "or", "cisplatin", "alone", "increased", "in", "a", "dose", "-", "dependent", "manner", "(", "sigmoidal", "dose", "-", "response", "curve", ")", ".", "Combining", "both", "modalities", "led", "to", "additive", "values", "at", "all", "time", "points", "for", "the", "percentage", "of", "aberrant", "metaphases", ".", "Borderline", "significant", "(", "p", "0.05", ")", "supraadditive", "effects", "were", "found", "2", "hours", "before", "or", "1", "hour", "after", "irradiation", ".", "However", ",", "a", "supraadditive", "percentage", "of", "aberrant", "chromosomes", "was", "found", "only", "at", "2", "or", "1.5", "hours", "with", "cisplatin", "before", "irradiation", "indicating", "the", "dependence", "of", "supraadditivity", "on", "the", "chosen", "parameter", ".", "It", "is", "doubtful", "to", "expect", "a", "true", "supraadditive", "or", "\"", "radiosensitizing", "\"", "effect", ",", "e", ".", "g", ".", "in", "the", "clinical", "setting", "from", "combined", "treatment", "with", "cisplatin", "and", "radiation", ".", "Rather", ",", "cisplatin", "might", "act", "as", "an", "independent", "cytotoxic", "agent", "." ]
[ "umlsterm" ]
aim is an umlsterm, cisplatin is an umlsterm, radiation is an umlsterm, time is an umlsterm, cisplatin is an umlsterm, radiation is an umlsterm, Bone marrow is an umlsterm, female is an umlsterm, mice is an umlsterm, tissue is an umlsterm, Cisplatin is an umlsterm, Cisplatin is an umlsterm, time is an umlsterm, radiation is an umlsterm, Bone marrow is an umlsterm, metaphases is an umlsterm, standard is an umlsterm, procedures is an umlsterm, metaphases is an umlsterm, radiation is an umlsterm, cisplatin is an umlsterm, values is an umlsterm, time is an umlsterm, metaphases is an umlsterm, irradiation is an umlsterm, chromosomes is an umlsterm, cisplatin is an umlsterm, irradiation is an umlsterm, combined treatment is an umlsterm, cisplatin is an umlsterm, radiation is an umlsterm, cisplatin is an umlsterm
Strahlentherapie+Onkologie.01760319.eng.abstr_task1
Sentence: The aim of this study was to quantify the combined effect of cisplatin and radiation on chromosomal damage with emphasis on the time interval between cisplatin and radiation . Bone marrow of female NMRI-nu ( + ) mice was taken as a model system for a highly proliferative tissue irradiated with cobalt-60 ( 1 to 4 Gy ) . Cisplatin was injected intraperitoneally ( ip ) at 1.1 to 36 mg/kg . Cisplatin was given at various time intervals before and after radiation . Bone marrow and metaphases were prepared according to standard procedures . The percentage of aberrant metaphases after radiation or cisplatin alone increased in a dose-dependent manner ( sigmoidal dose-response curve ) . Combining both modalities led to additive values at all time points for the percentage of aberrant metaphases . Borderline significant ( p 0.05 ) supraadditive effects were found 2 hours before or 1 hour after irradiation . However , a supraadditive percentage of aberrant chromosomes was found only at 2 or 1.5 hours with cisplatin before irradiation indicating the dependence of supraadditivity on the chosen parameter . It is doubtful to expect a true supraadditive or " radiosensitizing " effect , e . g . in the clinical setting from combined treatment with cisplatin and radiation . Rather , cisplatin might act as an independent cytotoxic agent . Instructions: please typing these entity words according to sentence: aim, cisplatin, radiation, time, cisplatin, radiation, Bone marrow, female, mice, tissue, Cisplatin, Cisplatin, time, radiation, Bone marrow, metaphases, standard, procedures, metaphases, radiation, cisplatin, values, time, metaphases, irradiation, chromosomes, cisplatin, irradiation, combined treatment, cisplatin, radiation, cisplatin Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
The aim of this study was to quantify the combined effect of cisplatin and radiation on chromosomal damage with emphasis on the time interval between cisplatin and radiation . Bone marrow of female NMRI-nu ( + ) mice was taken as a model system for a highly proliferative tissue irradiated with cobalt-60 ( 1 to 4 Gy ) . Cisplatin was injected intraperitoneally ( ip ) at 1.1 to 36 mg/kg . Cisplatin was given at various time intervals before and after radiation . Bone marrow and metaphases were prepared according to standard procedures . The percentage of aberrant metaphases after radiation or cisplatin alone increased in a dose-dependent manner ( sigmoidal dose-response curve ) . Combining both modalities led to additive values at all time points for the percentage of aberrant metaphases . Borderline significant ( p 0.05 ) supraadditive effects were found 2 hours before or 1 hour after irradiation . However , a supraadditive percentage of aberrant chromosomes was found only at 2 or 1.5 hours with cisplatin before irradiation indicating the dependence of supraadditivity on the chosen parameter . It is doubtful to expect a true supraadditive or " radiosensitizing " effect , e . g . in the clinical setting from combined treatment with cisplatin and radiation . Rather , cisplatin might act as an independent cytotoxic agent .
[ "The", "aim", "of", "this", "study", "was", "to", "quantify", "the", "combined", "effect", "of", "cisplatin", "and", "radiation", "on", "chromosomal", "damage", "with", "emphasis", "on", "the", "time", "interval", "between", "cisplatin", "and", "radiation", ".", "Bone", "marrow", "of", "female", "NMRI", "-", "nu", "(", "+", ")", "mice", "was", "taken", "as", "a", "model", "system", "for", "a", "highly", "proliferative", "tissue", "irradiated", "with", "cobalt-60", "(", "1", "to", "4", "Gy", ")", ".", "Cisplatin", "was", "injected", "intraperitoneally", "(", "ip", ")", "at", "1.1", "to", "36", "mg", "/", "kg", ".", "Cisplatin", "was", "given", "at", "various", "time", "intervals", "before", "and", "after", "radiation", ".", "Bone", "marrow", "and", "metaphases", "were", "prepared", "according", "to", "standard", "procedures", ".", "The", "percentage", "of", "aberrant", "metaphases", "after", "radiation", "or", "cisplatin", "alone", "increased", "in", "a", "dose", "-", "dependent", "manner", "(", "sigmoidal", "dose", "-", "response", "curve", ")", ".", "Combining", "both", "modalities", "led", "to", "additive", "values", "at", "all", "time", "points", "for", "the", "percentage", "of", "aberrant", "metaphases", ".", "Borderline", "significant", "(", "p", "0.05", ")", "supraadditive", "effects", "were", "found", "2", "hours", "before", "or", "1", "hour", "after", "irradiation", ".", "However", ",", "a", "supraadditive", "percentage", "of", "aberrant", "chromosomes", "was", "found", "only", "at", "2", "or", "1.5", "hours", "with", "cisplatin", "before", "irradiation", "indicating", "the", "dependence", "of", "supraadditivity", "on", "the", "chosen", "parameter", ".", "It", "is", "doubtful", "to", "expect", "a", "true", "supraadditive", "or", "\"", "radiosensitizing", "\"", "effect", ",", "e", ".", "g", ".", "in", "the", "clinical", "setting", "from", "combined", "treatment", "with", "cisplatin", "and", "radiation", ".", "Rather", ",", "cisplatin", "might", "act", "as", "an", "independent", "cytotoxic", "agent", "." ]
[ "umlsterm" ]
aim, cisplatin, radiation, time, cisplatin, radiation, Bone marrow, female, mice, tissue, Cisplatin, Cisplatin, time, radiation, Bone marrow, metaphases, standard, procedures, metaphases, radiation, cisplatin, values, time, metaphases, irradiation, chromosomes, cisplatin, irradiation, combined treatment, cisplatin, radiation, cisplatin
Strahlentherapie+Onkologie.01760319.eng.abstr_task2
Sentence: The aim of this study was to quantify the combined effect of cisplatin and radiation on chromosomal damage with emphasis on the time interval between cisplatin and radiation . Bone marrow of female NMRI-nu ( + ) mice was taken as a model system for a highly proliferative tissue irradiated with cobalt-60 ( 1 to 4 Gy ) . Cisplatin was injected intraperitoneally ( ip ) at 1.1 to 36 mg/kg . Cisplatin was given at various time intervals before and after radiation . Bone marrow and metaphases were prepared according to standard procedures . The percentage of aberrant metaphases after radiation or cisplatin alone increased in a dose-dependent manner ( sigmoidal dose-response curve ) . Combining both modalities led to additive values at all time points for the percentage of aberrant metaphases . Borderline significant ( p 0.05 ) supraadditive effects were found 2 hours before or 1 hour after irradiation . However , a supraadditive percentage of aberrant chromosomes was found only at 2 or 1.5 hours with cisplatin before irradiation indicating the dependence of supraadditivity on the chosen parameter . It is doubtful to expect a true supraadditive or " radiosensitizing " effect , e . g . in the clinical setting from combined treatment with cisplatin and radiation . Rather , cisplatin might act as an independent cytotoxic agent . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
The aim of this study was to quantify the combined effect of cisplatin and radiation on chromosomal damage with emphasis on the time interval between cisplatin and radiation . Bone marrow of female NMRI-nu ( + ) mice was taken as a model system for a highly proliferative tissue irradiated with cobalt-60 ( 1 to 4 Gy ) . Cisplatin was injected intraperitoneally ( ip ) at 1.1 to 36 mg/kg . Cisplatin was given at various time intervals before and after radiation . Bone marrow and metaphases were prepared according to standard procedures . The percentage of aberrant metaphases after radiation or cisplatin alone increased in a dose-dependent manner ( sigmoidal dose-response curve ) . Combining both modalities led to additive values at all time points for the percentage of aberrant metaphases . Borderline significant ( p 0.05 ) supraadditive effects were found 2 hours before or 1 hour after irradiation . However , a supraadditive percentage of aberrant chromosomes was found only at 2 or 1.5 hours with cisplatin before irradiation indicating the dependence of supraadditivity on the chosen parameter . It is doubtful to expect a true supraadditive or " radiosensitizing " effect , e . g . in the clinical setting from combined treatment with cisplatin and radiation . Rather , cisplatin might act as an independent cytotoxic agent .
[ "The", "aim", "of", "this", "study", "was", "to", "quantify", "the", "combined", "effect", "of", "cisplatin", "and", "radiation", "on", "chromosomal", "damage", "with", "emphasis", "on", "the", "time", "interval", "between", "cisplatin", "and", "radiation", ".", "Bone", "marrow", "of", "female", "NMRI", "-", "nu", "(", "+", ")", "mice", "was", "taken", "as", "a", "model", "system", "for", "a", "highly", "proliferative", "tissue", "irradiated", "with", "cobalt-60", "(", "1", "to", "4", "Gy", ")", ".", "Cisplatin", "was", "injected", "intraperitoneally", "(", "ip", ")", "at", "1.1", "to", "36", "mg", "/", "kg", ".", "Cisplatin", "was", "given", "at", "various", "time", "intervals", "before", "and", "after", "radiation", ".", "Bone", "marrow", "and", "metaphases", "were", "prepared", "according", "to", "standard", "procedures", ".", "The", "percentage", "of", "aberrant", "metaphases", "after", "radiation", "or", "cisplatin", "alone", "increased", "in", "a", "dose", "-", "dependent", "manner", "(", "sigmoidal", "dose", "-", "response", "curve", ")", ".", "Combining", "both", "modalities", "led", "to", "additive", "values", "at", "all", "time", "points", "for", "the", "percentage", "of", "aberrant", "metaphases", ".", "Borderline", "significant", "(", "p", "0.05", ")", "supraadditive", "effects", "were", "found", "2", "hours", "before", "or", "1", "hour", "after", "irradiation", ".", "However", ",", "a", "supraadditive", "percentage", "of", "aberrant", "chromosomes", "was", "found", "only", "at", "2", "or", "1.5", "hours", "with", "cisplatin", "before", "irradiation", "indicating", "the", "dependence", "of", "supraadditivity", "on", "the", "chosen", "parameter", ".", "It", "is", "doubtful", "to", "expect", "a", "true", "supraadditive", "or", "\"", "radiosensitizing", "\"", "effect", ",", "e", ".", "g", ".", "in", "the", "clinical", "setting", "from", "combined", "treatment", "with", "cisplatin", "and", "radiation", ".", "Rather", ",", "cisplatin", "might", "act", "as", "an", "independent", "cytotoxic", "agent", "." ]
[ "umlsterm" ]
morphological is an umlsterm, analysis is an umlsterm, method is an umlsterm, heart is an umlsterm, dissection is an umlsterm, angioplasty is an umlsterm, ventricles is an umlsterm, bread - loaf is an umlsterm, formalin - fixation is an umlsterm, serial is an umlsterm, arteries is an umlsterm, distribution is an umlsterm, necrosis is an umlsterm, infarction is an umlsterm, age is an umlsterm, sequelae is an umlsterm, heart is an umlsterm, blood is an umlsterm, arteries is an umlsterm, plaque is an umlsterm, hemorrhage is an umlsterm, thrombi is an umlsterm, complications is an umlsterm, procedures is an umlsterm, surgery is an umlsterm, heart is an umlsterm, sudden cardiac death is an umlsterm, ischemia is an umlsterm, identification is an umlsterm
DerPathologe.50160168.eng.abstr_task0
Sentence: The quality of the morphological analysis of myocardial and coronary alterations depends essentially on the method chosen for the heart dissection . Even if previous postmortem coronary angioplasty is not feasible , the best results are obtained by transverse sectioning of the ventricles in a bread-loaf fashion subsequent to formalin-fixation and serial cross-sectioning of the coronary arteries , with decalcification in addition if necessary . The distribution pattern of disseminated myocardial necrosis , the longitudinal , circumferential and transmural extent of infarction , its age and sequelae and its correlation to the coronary supplying areas can be evaluated with better accuracy than by dissecting the heart chambers according to the flow of blood . Cross-sectioning of coronary arteries with preservation of their luminal shape allows proper examination of the degree and extent of luminal narrowing , plaque hemorrhage , parietal and occluding thrombi and the effects and complications of angioplastic procedures or bypass surgery . Transverse sectioning of the heart is a prerequisite for adequate examination following sudden cardiac death and short-term territorial ischemia . Full-thickness samples of the ventricular walls , taken systematically with respect to coronary narrowing and coronary supplying areas , enable identification of early myocardial damage . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
The quality of the morphological analysis of myocardial and coronary alterations depends essentially on the method chosen for the heart dissection . Even if previous postmortem coronary angioplasty is not feasible , the best results are obtained by transverse sectioning of the ventricles in a bread-loaf fashion subsequent to formalin-fixation and serial cross-sectioning of the coronary arteries , with decalcification in addition if necessary . The distribution pattern of disseminated myocardial necrosis , the longitudinal , circumferential and transmural extent of infarction , its age and sequelae and its correlation to the coronary supplying areas can be evaluated with better accuracy than by dissecting the heart chambers according to the flow of blood . Cross-sectioning of coronary arteries with preservation of their luminal shape allows proper examination of the degree and extent of luminal narrowing , plaque hemorrhage , parietal and occluding thrombi and the effects and complications of angioplastic procedures or bypass surgery . Transverse sectioning of the heart is a prerequisite for adequate examination following sudden cardiac death and short-term territorial ischemia . Full-thickness samples of the ventricular walls , taken systematically with respect to coronary narrowing and coronary supplying areas , enable identification of early myocardial damage .
[ "The", "quality", "of", "the", "morphological", "analysis", "of", "myocardial", "and", "coronary", "alterations", "depends", "essentially", "on", "the", "method", "chosen", "for", "the", "heart", "dissection", ".", "Even", "if", "previous", "postmortem", "coronary", "angioplasty", "is", "not", "feasible", ",", "the", "best", "results", "are", "obtained", "by", "transverse", "sectioning", "of", "the", "ventricles", "in", "a", "bread", "-", "loaf", "fashion", "subsequent", "to", "formalin", "-", "fixation", "and", "serial", "cross", "-", "sectioning", "of", "the", "coronary", "arteries", ",", "with", "decalcification", "in", "addition", "if", "necessary", ".", "The", "distribution", "pattern", "of", "disseminated", "myocardial", "necrosis", ",", "the", "longitudinal", ",", "circumferential", "and", "transmural", "extent", "of", "infarction", ",", "its", "age", "and", "sequelae", "and", "its", "correlation", "to", "the", "coronary", "supplying", "areas", "can", "be", "evaluated", "with", "better", "accuracy", "than", "by", "dissecting", "the", "heart", "chambers", "according", "to", "the", "flow", "of", "blood", ".", "Cross", "-", "sectioning", "of", "coronary", "arteries", "with", "preservation", "of", "their", "luminal", "shape", "allows", "proper", "examination", "of", "the", "degree", "and", "extent", "of", "luminal", "narrowing", ",", "plaque", "hemorrhage", ",", "parietal", "and", "occluding", "thrombi", "and", "the", "effects", "and", "complications", "of", "angioplastic", "procedures", "or", "bypass", "surgery", ".", "Transverse", "sectioning", "of", "the", "heart", "is", "a", "prerequisite", "for", "adequate", "examination", "following", "sudden", "cardiac", "death", "and", "short", "-", "term", "territorial", "ischemia", ".", "Full", "-", "thickness", "samples", "of", "the", "ventricular", "walls", ",", "taken", "systematically", "with", "respect", "to", "coronary", "narrowing", "and", "coronary", "supplying", "areas", ",", "enable", "identification", "of", "early", "myocardial", "damage", "." ]
[ "umlsterm" ]
morphological is an umlsterm, analysis is an umlsterm, method is an umlsterm, heart is an umlsterm, dissection is an umlsterm, angioplasty is an umlsterm, ventricles is an umlsterm, bread - loaf is an umlsterm, formalin - fixation is an umlsterm, serial is an umlsterm, arteries is an umlsterm, distribution is an umlsterm, necrosis is an umlsterm, infarction is an umlsterm, age is an umlsterm, sequelae is an umlsterm, heart is an umlsterm, blood is an umlsterm, arteries is an umlsterm, plaque is an umlsterm, hemorrhage is an umlsterm, thrombi is an umlsterm, complications is an umlsterm, procedures is an umlsterm, surgery is an umlsterm, heart is an umlsterm, sudden cardiac death is an umlsterm, ischemia is an umlsterm, identification is an umlsterm
DerPathologe.50160168.eng.abstr_task1
Sentence: The quality of the morphological analysis of myocardial and coronary alterations depends essentially on the method chosen for the heart dissection . Even if previous postmortem coronary angioplasty is not feasible , the best results are obtained by transverse sectioning of the ventricles in a bread-loaf fashion subsequent to formalin-fixation and serial cross-sectioning of the coronary arteries , with decalcification in addition if necessary . The distribution pattern of disseminated myocardial necrosis , the longitudinal , circumferential and transmural extent of infarction , its age and sequelae and its correlation to the coronary supplying areas can be evaluated with better accuracy than by dissecting the heart chambers according to the flow of blood . Cross-sectioning of coronary arteries with preservation of their luminal shape allows proper examination of the degree and extent of luminal narrowing , plaque hemorrhage , parietal and occluding thrombi and the effects and complications of angioplastic procedures or bypass surgery . Transverse sectioning of the heart is a prerequisite for adequate examination following sudden cardiac death and short-term territorial ischemia . Full-thickness samples of the ventricular walls , taken systematically with respect to coronary narrowing and coronary supplying areas , enable identification of early myocardial damage . Instructions: please typing these entity words according to sentence: morphological, analysis, method, heart, dissection, angioplasty, ventricles, bread - loaf, formalin - fixation, serial, arteries, distribution, necrosis, infarction, age, sequelae, heart, blood, arteries, plaque, hemorrhage, thrombi, complications, procedures, surgery, heart, sudden cardiac death, ischemia, identification Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
The quality of the morphological analysis of myocardial and coronary alterations depends essentially on the method chosen for the heart dissection . Even if previous postmortem coronary angioplasty is not feasible , the best results are obtained by transverse sectioning of the ventricles in a bread-loaf fashion subsequent to formalin-fixation and serial cross-sectioning of the coronary arteries , with decalcification in addition if necessary . The distribution pattern of disseminated myocardial necrosis , the longitudinal , circumferential and transmural extent of infarction , its age and sequelae and its correlation to the coronary supplying areas can be evaluated with better accuracy than by dissecting the heart chambers according to the flow of blood . Cross-sectioning of coronary arteries with preservation of their luminal shape allows proper examination of the degree and extent of luminal narrowing , plaque hemorrhage , parietal and occluding thrombi and the effects and complications of angioplastic procedures or bypass surgery . Transverse sectioning of the heart is a prerequisite for adequate examination following sudden cardiac death and short-term territorial ischemia . Full-thickness samples of the ventricular walls , taken systematically with respect to coronary narrowing and coronary supplying areas , enable identification of early myocardial damage .
[ "The", "quality", "of", "the", "morphological", "analysis", "of", "myocardial", "and", "coronary", "alterations", "depends", "essentially", "on", "the", "method", "chosen", "for", "the", "heart", "dissection", ".", "Even", "if", "previous", "postmortem", "coronary", "angioplasty", "is", "not", "feasible", ",", "the", "best", "results", "are", "obtained", "by", "transverse", "sectioning", "of", "the", "ventricles", "in", "a", "bread", "-", "loaf", "fashion", "subsequent", "to", "formalin", "-", "fixation", "and", "serial", "cross", "-", "sectioning", "of", "the", "coronary", "arteries", ",", "with", "decalcification", "in", "addition", "if", "necessary", ".", "The", "distribution", "pattern", "of", "disseminated", "myocardial", "necrosis", ",", "the", "longitudinal", ",", "circumferential", "and", "transmural", "extent", "of", "infarction", ",", "its", "age", "and", "sequelae", "and", "its", "correlation", "to", "the", "coronary", "supplying", "areas", "can", "be", "evaluated", "with", "better", "accuracy", "than", "by", "dissecting", "the", "heart", "chambers", "according", "to", "the", "flow", "of", "blood", ".", "Cross", "-", "sectioning", "of", "coronary", "arteries", "with", "preservation", "of", "their", "luminal", "shape", "allows", "proper", "examination", "of", "the", "degree", "and", "extent", "of", "luminal", "narrowing", ",", "plaque", "hemorrhage", ",", "parietal", "and", "occluding", "thrombi", "and", "the", "effects", "and", "complications", "of", "angioplastic", "procedures", "or", "bypass", "surgery", ".", "Transverse", "sectioning", "of", "the", "heart", "is", "a", "prerequisite", "for", "adequate", "examination", "following", "sudden", "cardiac", "death", "and", "short", "-", "term", "territorial", "ischemia", ".", "Full", "-", "thickness", "samples", "of", "the", "ventricular", "walls", ",", "taken", "systematically", "with", "respect", "to", "coronary", "narrowing", "and", "coronary", "supplying", "areas", ",", "enable", "identification", "of", "early", "myocardial", "damage", "." ]
[ "umlsterm" ]
morphological, analysis, method, heart, dissection, angioplasty, ventricles, bread - loaf, formalin - fixation, serial, arteries, distribution, necrosis, infarction, age, sequelae, heart, blood, arteries, plaque, hemorrhage, thrombi, complications, procedures, surgery, heart, sudden cardiac death, ischemia, identification
DerPathologe.50160168.eng.abstr_task2
Sentence: The quality of the morphological analysis of myocardial and coronary alterations depends essentially on the method chosen for the heart dissection . Even if previous postmortem coronary angioplasty is not feasible , the best results are obtained by transverse sectioning of the ventricles in a bread-loaf fashion subsequent to formalin-fixation and serial cross-sectioning of the coronary arteries , with decalcification in addition if necessary . The distribution pattern of disseminated myocardial necrosis , the longitudinal , circumferential and transmural extent of infarction , its age and sequelae and its correlation to the coronary supplying areas can be evaluated with better accuracy than by dissecting the heart chambers according to the flow of blood . Cross-sectioning of coronary arteries with preservation of their luminal shape allows proper examination of the degree and extent of luminal narrowing , plaque hemorrhage , parietal and occluding thrombi and the effects and complications of angioplastic procedures or bypass surgery . Transverse sectioning of the heart is a prerequisite for adequate examination following sudden cardiac death and short-term territorial ischemia . Full-thickness samples of the ventricular walls , taken systematically with respect to coronary narrowing and coronary supplying areas , enable identification of early myocardial damage . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
The quality of the morphological analysis of myocardial and coronary alterations depends essentially on the method chosen for the heart dissection . Even if previous postmortem coronary angioplasty is not feasible , the best results are obtained by transverse sectioning of the ventricles in a bread-loaf fashion subsequent to formalin-fixation and serial cross-sectioning of the coronary arteries , with decalcification in addition if necessary . The distribution pattern of disseminated myocardial necrosis , the longitudinal , circumferential and transmural extent of infarction , its age and sequelae and its correlation to the coronary supplying areas can be evaluated with better accuracy than by dissecting the heart chambers according to the flow of blood . Cross-sectioning of coronary arteries with preservation of their luminal shape allows proper examination of the degree and extent of luminal narrowing , plaque hemorrhage , parietal and occluding thrombi and the effects and complications of angioplastic procedures or bypass surgery . Transverse sectioning of the heart is a prerequisite for adequate examination following sudden cardiac death and short-term territorial ischemia . Full-thickness samples of the ventricular walls , taken systematically with respect to coronary narrowing and coronary supplying areas , enable identification of early myocardial damage .
[ "The", "quality", "of", "the", "morphological", "analysis", "of", "myocardial", "and", "coronary", "alterations", "depends", "essentially", "on", "the", "method", "chosen", "for", "the", "heart", "dissection", ".", "Even", "if", "previous", "postmortem", "coronary", "angioplasty", "is", "not", "feasible", ",", "the", "best", "results", "are", "obtained", "by", "transverse", "sectioning", "of", "the", "ventricles", "in", "a", "bread", "-", "loaf", "fashion", "subsequent", "to", "formalin", "-", "fixation", "and", "serial", "cross", "-", "sectioning", "of", "the", "coronary", "arteries", ",", "with", "decalcification", "in", "addition", "if", "necessary", ".", "The", "distribution", "pattern", "of", "disseminated", "myocardial", "necrosis", ",", "the", "longitudinal", ",", "circumferential", "and", "transmural", "extent", "of", "infarction", ",", "its", "age", "and", "sequelae", "and", "its", "correlation", "to", "the", "coronary", "supplying", "areas", "can", "be", "evaluated", "with", "better", "accuracy", "than", "by", "dissecting", "the", "heart", "chambers", "according", "to", "the", "flow", "of", "blood", ".", "Cross", "-", "sectioning", "of", "coronary", "arteries", "with", "preservation", "of", "their", "luminal", "shape", "allows", "proper", "examination", "of", "the", "degree", "and", "extent", "of", "luminal", "narrowing", ",", "plaque", "hemorrhage", ",", "parietal", "and", "occluding", "thrombi", "and", "the", "effects", "and", "complications", "of", "angioplastic", "procedures", "or", "bypass", "surgery", ".", "Transverse", "sectioning", "of", "the", "heart", "is", "a", "prerequisite", "for", "adequate", "examination", "following", "sudden", "cardiac", "death", "and", "short", "-", "term", "territorial", "ischemia", ".", "Full", "-", "thickness", "samples", "of", "the", "ventricular", "walls", ",", "taken", "systematically", "with", "respect", "to", "coronary", "narrowing", "and", "coronary", "supplying", "areas", ",", "enable", "identification", "of", "early", "myocardial", "damage", "." ]
[ "umlsterm" ]
Juan is a NOMBRE_SUJETO_ASISTENCIA, Ferrara Maldonado is a NOMBRE_SUJETO_ASISTENCIA, 7348567 is a ID_SUJETO_ASISTENCIA, 89 56729805 56 is a ID_ASEGURAMIENTO, C/ FInisterre , 3 is a CALLE, Madrid is a TERRITORIO, 28034 is a TERRITORIO, 06/05/1948 is a FECHAS, España is a PAIS, 70 años is a EDAD_SUJETO_ASISTENCIA, 13/06/2018 is a FECHAS, Juan Velásquez López is a NOMBRE_PERSONAL_SANITARIO, 28 28 57748 is a ID_TITULACION_PERSONAL_SANITARIO, masculino is a SEXO_SUJETO_ASISTENCIA, 70 años is a EDAD_SUJETO_ASISTENCIA, Hospital Pablo Tobón Uribe is a HOSPITAL, Juan Velásquez López is a NOMBRE_PERSONAL_SANITARIO, juangvl@gmail.com is a CORREO_ELECTRONICO
71_task0
Sentence: Datos del paciente. Nombre: Juan. Apellidos: Ferrara Maldonado. NHC: 7348567. NASS: 89 56729805 56. Domicilio: C/ FInisterre, 3. Localidad/ Provincia: Madrid. CP: 28034. Datos asistenciales. Fecha de nacimiento: 06/05/1948. País de nacimiento: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 13/06/2018. Médico: Juan Velásquez López NºCol: 28 28 57748. Informe clínico del paciente: paciente masculino de 70 años, quien ingresó en el servicio de urgencias del Hospital Pablo Tobón Uribe, con cuadro de aproximadamente una hora de evolución consistente en opresión torácica, malestar general, astenia y diaforesis; que iniciaron después de haber ingerido 100 mg de sildenafil, niega ingesta de otro estimulante sexual o cocaína y sin relación sexual después de su consumo. El paciente como único antecedente clínico sufría de hipertensión arterial, controlada farmacológicamente y niega episodios previos de angina o consumo de nitratos. El examen clínico y sus signos vitales eran normales; sin embargo, después de la valoración inicial presenta paro cardiorrespiratorio secundario a fibrilación ventricular con respuesta a una única desfibrilación de 200 joules. El electrocardiograma inicial demostró elevación del segmento ST en las derivadas de la cara inferior (II, III y aVF) y de la cara anterior (V2-V4) con cambios recíprocos en aVL, sin demostrarse extensión electrocardiográfica a ventrículo derecho. Las enzimas cardíacas al ingreso revelaron una creatinfosfokinasa (CK) de170 y una creatinfosfokinasa fracción MB (CK-MB) de 6. Los electrolitos, las pruebas de coagulación y los conteos de células sanguíneas fueron normales. El manejo inicial se realizó con aspirina 100 mg, lovastatina 40 mg cada día, metoprolol 25 mg cada 12 horas, enoxaparina 60 mg cada 12 horas, oxígeno a 3 lt/min y estreptoquinasa 1´500.000 unidades administradas en 30 minutos. No se demostraron cambios secundarios a reperfusión. El paciente fue trasladado a la unidad de cuidados intensivos, donde se documentaron durante las primeras horas de evolución, episodios de bloqueo A-V completo con resolución espontánea. El EKG tomado a las 24 horas de evolución reveló QS en cara inferior y una progresión tardía de la onda R en la cara anterior. El seguimiento enzimático demostró aumento de CK y de la fracción MB a las 6 horas (4476 y 165) y a las 12 horas (3839 y 136). Al día siguiente se realizó una coronariografía que mostró enfermedad difusa de la arteria descendente anterior con lesión en el tercio distal del 50% y lesión del 40% en el tercio proximal de la primera rama diagonal. La arteria circunfleja tenía una lesión del 50% en el tercio medio y enfermedad difusa de sus ramas obtusas marginales. La arteria coronaria derecha presentaba una lesión irregular sugestiva de trombo parcialmente resuelto produciendo estenosis máxima del 50%; distalmente la arteria descendente posterior presentaba dos lesiones del 40%. El paciente evolucionó satisfactoriamente sin complicaciones posteriores y libre de dolor. Fue dado de alta para seguimiento ambulatorio. Responsable clínico: Dr. Juan Velásquez López. E-mail: juangvl@gmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO
[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Juan. Apellidos: Ferrara Maldonado. NHC: 7348567. NASS: 89 56729805 56. Domicilio: C/ FInisterre, 3. Localidad/ Provincia: Madrid. CP: 28034. Datos asistenciales. Fecha de nacimiento: 06/05/1948. País de nacimiento: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 13/06/2018. Médico: Juan Velásquez López NºCol: 28 28 57748. Informe clínico del paciente: paciente masculino de 70 años, quien ingresó en el servicio de urgencias del Hospital Pablo Tobón Uribe, con cuadro de aproximadamente una hora de evolución consistente en opresión torácica, malestar general, astenia y diaforesis; que iniciaron después de haber ingerido 100 mg de sildenafil, niega ingesta de otro estimulante sexual o cocaína y sin relación sexual después de su consumo. El paciente como único antecedente clínico sufría de hipertensión arterial, controlada farmacológicamente y niega episodios previos de angina o consumo de nitratos. El examen clínico y sus signos vitales eran normales; sin embargo, después de la valoración inicial presenta paro cardiorrespiratorio secundario a fibrilación ventricular con respuesta a una única desfibrilación de 200 joules. El electrocardiograma inicial demostró elevación del segmento ST en las derivadas de la cara inferior (II, III y aVF) y de la cara anterior (V2-V4) con cambios recíprocos en aVL, sin demostrarse extensión electrocardiográfica a ventrículo derecho. Las enzimas cardíacas al ingreso revelaron una creatinfosfokinasa (CK) de170 y una creatinfosfokinasa fracción MB (CK-MB) de 6. Los electrolitos, las pruebas de coagulación y los conteos de células sanguíneas fueron normales. El manejo inicial se realizó con aspirina 100 mg, lovastatina 40 mg cada día, metoprolol 25 mg cada 12 horas, enoxaparina 60 mg cada 12 horas, oxígeno a 3 lt/min y estreptoquinasa 1´500.000 unidades administradas en 30 minutos. No se demostraron cambios secundarios a reperfusión. El paciente fue trasladado a la unidad de cuidados intensivos, donde se documentaron durante las primeras horas de evolución, episodios de bloqueo A-V completo con resolución espontánea. El EKG tomado a las 24 horas de evolución reveló QS en cara inferior y una progresión tardía de la onda R en la cara anterior. El seguimiento enzimático demostró aumento de CK y de la fracción MB a las 6 horas (4476 y 165) y a las 12 horas (3839 y 136). Al día siguiente se realizó una coronariografía que mostró enfermedad difusa de la arteria descendente anterior con lesión en el tercio distal del 50% y lesión del 40% en el tercio proximal de la primera rama diagonal. La arteria circunfleja tenía una lesión del 50% en el tercio medio y enfermedad difusa de sus ramas obtusas marginales. La arteria coronaria derecha presentaba una lesión irregular sugestiva de trombo parcialmente resuelto produciendo estenosis máxima del 50%; distalmente la arteria descendente posterior presentaba dos lesiones del 40%. El paciente evolucionó satisfactoriamente sin complicaciones posteriores y libre de dolor. Fue dado de alta para seguimiento ambulatorio. Responsable clínico: Dr. Juan Velásquez López. E-mail: juangvl@gmail.com
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Juan", ".", "\n", "Apellidos", ":", "Ferrara", "Maldonado", ".", "\n", "NHC", ":", "7348567", ".", "\n", "NASS", ":", "89", "56729805", "56", ".", "\n", "Domicilio", ":", "C/", "FInisterre", ",", "3", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28034", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "06/05/1948", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "70", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "13/06/2018", ".", "\n", "Médico", ":", "Juan", "Velásquez", "López", "NºCol", ":", "28", "28", "57748", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "paciente", "masculino", "de", "70", "años", ",", "quien", "ingresó", "en", "el", "servicio", "de", "urgencias", "del", "Hospital", "Pablo", "Tobón", "Uribe", ",", "con", "cuadro", "de", "aproximadamente", "una", "hora", "de", "evolución", "consistente", "en", "opresión", "torácica", ",", "malestar", "general", ",", "astenia", "y", "diaforesis", ";", "que", "iniciaron", "después", "de", "haber", "ingerido", "100", "mg", "de", "sildenafil", ",", "niega", "ingesta", "de", "otro", "estimulante", "sexual", "o", "cocaína", "y", "sin", "relación", "sexual", "después", "de", "su", "consumo", ".", "El", "paciente", "como", "único", "antecedente", "clínico", "sufría", "de", "hipertensión", "arterial", ",", "controlada", "farmacológicamente", "y", "niega", "episodios", "previos", "de", "angina", "o", "consumo", "de", "nitratos", ".", "El", "examen", "clínico", "y", "sus", "signos", "vitales", "eran", "normales", ";", "sin", "embargo", ",", "después", "de", "la", "valoración", "inicial", "presenta", "paro", "cardiorrespiratorio", "secundario", "a", "fibrilación", "ventricular", "con", "respuesta", "a", "una", "única", "desfibrilación", "de", "200", "joules", ".", "\n", "El", "electrocardiograma", "inicial", "demostró", "elevación", "del", "segmento", "ST", "en", "las", "derivadas", "de", "la", "cara", "inferior", "(", "II", ",", "III", "y", "aVF", ")", "y", "de", "la", "cara", "anterior", "(", "V2-V4", ")", "con", "cambios", "recíprocos", "en", "aVL", ",", "sin", "demostrarse", "extensión", "electrocardiográfica", "a", "ventrículo", "derecho", ".", "\n", "Las", "enzimas", "cardíacas", "al", "ingreso", "revelaron", "una", "creatinfosfokinasa", "(", "CK", ")", "de170", "y", "una", "creatinfosfokinasa", "fracción", "MB", "(", "CK", "-", "MB", ")", "de", "6", ".", "Los", "electrolitos", ",", "las", "pruebas", "de", "coagulación", "y", "los", "conteos", "de", "células", "sanguíneas", "fueron", "normales", ".", "\n", "El", "manejo", "inicial", "se", "realizó", "con", "aspirina", "100", "mg", ",", "lovastatina", "40", "mg", "cada", "día", ",", "metoprolol", "25", "mg", "cada", "12", "horas", ",", "enoxaparina", "60", "mg", "cada", "12", "horas", ",", "oxígeno", "a", "3", "lt", "/", "min", "y", "estreptoquinasa", "1´500.000", "unidades", "administradas", "en", "30", "minutos", ".", "No", "se", "demostraron", "cambios", "secundarios", "a", "reperfusión", ".", "El", "paciente", "fue", "trasladado", "a", "la", "unidad", "de", "cuidados", "intensivos", ",", "donde", "se", "documentaron", "durante", "las", "primeras", "horas", "de", "evolución", ",", "episodios", "de", "bloqueo", "A", "-", "V", "completo", "con", "resolución", "espontánea", ".", "\n", "El", "EKG", "tomado", "a", "las", "24", "horas", "de", "evolución", "reveló", "QS", "en", "cara", "inferior", "y", "una", "progresión", "tardía", "de", "la", "onda", "R", "en", "la", "cara", "anterior", ".", "El", "seguimiento", "enzimático", "demostró", "aumento", "de", "CK", "y", "de", "la", "fracción", "MB", "a", "las", "6", "horas", "(", "4476", "y", "165", ")", "y", "a", "las", "12", "horas", "(", "3839", "y", "136", ")", ".", "\n", "Al", "día", "siguiente", "se", "realizó", "una", "coronariografía", "que", "mostró", "enfermedad", "difusa", "de", "la", "arteria", "descendente", "anterior", "con", "lesión", "en", "el", "tercio", "distal", "del", "50", "%", "y", "lesión", "del", "40", "%", "en", "el", "tercio", "proximal", "de", "la", "primera", "rama", "diagonal", ".", "La", "arteria", "circunfleja", "tenía", "una", "lesión", "del", "50", "%", "en", "el", "tercio", "medio", "y", "enfermedad", "difusa", "de", "sus", "ramas", "obtusas", "marginales", ".", "La", "arteria", "coronaria", "derecha", "presentaba", "una", "lesión", "irregular", "sugestiva", "de", "trombo", "parcialmente", "resuelto", "produciendo", "estenosis", "máxima", "del", "50", "%", ";", "distalmente", "la", "arteria", "descendente", "posterior", "presentaba", "dos", "lesiones", "del", "40", "%", ".", "\n", "El", "paciente", "evolucionó", "satisfactoriamente", "sin", "complicaciones", "posteriores", "y", "libre", "de", "dolor", ".", "Fue", "dado", "de", "alta", "para", "seguimiento", "ambulatorio", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Juan", "Velásquez", "López", ".", "E", "-", "mail", ":", "juangvl@gmail.com", "\n" ]
[ "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "CALLE", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "SEXO_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO" ]
Juan is a NOMBRE_SUJETO_ASISTENCIA, Ferrara Maldonado is a NOMBRE_SUJETO_ASISTENCIA, 7348567 is a ID_SUJETO_ASISTENCIA, 89 56729805 56 is a ID_ASEGURAMIENTO, C/ FInisterre , 3 is a CALLE, Madrid is a TERRITORIO, 28034 is a TERRITORIO, 06/05/1948 is a FECHAS, España is a PAIS, 70 años is a EDAD_SUJETO_ASISTENCIA, 13/06/2018 is a FECHAS, Juan Velásquez López is a NOMBRE_PERSONAL_SANITARIO, 28 28 57748 is a ID_TITULACION_PERSONAL_SANITARIO, masculino is a SEXO_SUJETO_ASISTENCIA, 70 años is a EDAD_SUJETO_ASISTENCIA, Hospital Pablo Tobón Uribe is a HOSPITAL, Juan Velásquez López is a NOMBRE_PERSONAL_SANITARIO, juangvl@gmail.com is a CORREO_ELECTRONICO
71_task1
Sentence: Datos del paciente. Nombre: Juan. Apellidos: Ferrara Maldonado. NHC: 7348567. NASS: 89 56729805 56. Domicilio: C/ FInisterre, 3. Localidad/ Provincia: Madrid. CP: 28034. Datos asistenciales. Fecha de nacimiento: 06/05/1948. País de nacimiento: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 13/06/2018. Médico: Juan Velásquez López NºCol: 28 28 57748. Informe clínico del paciente: paciente masculino de 70 años, quien ingresó en el servicio de urgencias del Hospital Pablo Tobón Uribe, con cuadro de aproximadamente una hora de evolución consistente en opresión torácica, malestar general, astenia y diaforesis; que iniciaron después de haber ingerido 100 mg de sildenafil, niega ingesta de otro estimulante sexual o cocaína y sin relación sexual después de su consumo. El paciente como único antecedente clínico sufría de hipertensión arterial, controlada farmacológicamente y niega episodios previos de angina o consumo de nitratos. El examen clínico y sus signos vitales eran normales; sin embargo, después de la valoración inicial presenta paro cardiorrespiratorio secundario a fibrilación ventricular con respuesta a una única desfibrilación de 200 joules. El electrocardiograma inicial demostró elevación del segmento ST en las derivadas de la cara inferior (II, III y aVF) y de la cara anterior (V2-V4) con cambios recíprocos en aVL, sin demostrarse extensión electrocardiográfica a ventrículo derecho. Las enzimas cardíacas al ingreso revelaron una creatinfosfokinasa (CK) de170 y una creatinfosfokinasa fracción MB (CK-MB) de 6. Los electrolitos, las pruebas de coagulación y los conteos de células sanguíneas fueron normales. El manejo inicial se realizó con aspirina 100 mg, lovastatina 40 mg cada día, metoprolol 25 mg cada 12 horas, enoxaparina 60 mg cada 12 horas, oxígeno a 3 lt/min y estreptoquinasa 1´500.000 unidades administradas en 30 minutos. No se demostraron cambios secundarios a reperfusión. El paciente fue trasladado a la unidad de cuidados intensivos, donde se documentaron durante las primeras horas de evolución, episodios de bloqueo A-V completo con resolución espontánea. El EKG tomado a las 24 horas de evolución reveló QS en cara inferior y una progresión tardía de la onda R en la cara anterior. El seguimiento enzimático demostró aumento de CK y de la fracción MB a las 6 horas (4476 y 165) y a las 12 horas (3839 y 136). Al día siguiente se realizó una coronariografía que mostró enfermedad difusa de la arteria descendente anterior con lesión en el tercio distal del 50% y lesión del 40% en el tercio proximal de la primera rama diagonal. La arteria circunfleja tenía una lesión del 50% en el tercio medio y enfermedad difusa de sus ramas obtusas marginales. La arteria coronaria derecha presentaba una lesión irregular sugestiva de trombo parcialmente resuelto produciendo estenosis máxima del 50%; distalmente la arteria descendente posterior presentaba dos lesiones del 40%. El paciente evolucionó satisfactoriamente sin complicaciones posteriores y libre de dolor. Fue dado de alta para seguimiento ambulatorio. Responsable clínico: Dr. Juan Velásquez López. E-mail: juangvl@gmail.com Instructions: please typing these entity words according to sentence: Juan, Ferrara Maldonado, 7348567, 89 56729805 56, C/ FInisterre , 3, Madrid, 28034, 06/05/1948, España, 70 años, 13/06/2018, Juan Velásquez López, 28 28 57748, masculino, 70 años, Hospital Pablo Tobón Uribe, Juan Velásquez López, juangvl@gmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO
[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Juan. Apellidos: Ferrara Maldonado. NHC: 7348567. NASS: 89 56729805 56. Domicilio: C/ FInisterre, 3. Localidad/ Provincia: Madrid. CP: 28034. Datos asistenciales. Fecha de nacimiento: 06/05/1948. País de nacimiento: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 13/06/2018. Médico: Juan Velásquez López NºCol: 28 28 57748. Informe clínico del paciente: paciente masculino de 70 años, quien ingresó en el servicio de urgencias del Hospital Pablo Tobón Uribe, con cuadro de aproximadamente una hora de evolución consistente en opresión torácica, malestar general, astenia y diaforesis; que iniciaron después de haber ingerido 100 mg de sildenafil, niega ingesta de otro estimulante sexual o cocaína y sin relación sexual después de su consumo. El paciente como único antecedente clínico sufría de hipertensión arterial, controlada farmacológicamente y niega episodios previos de angina o consumo de nitratos. El examen clínico y sus signos vitales eran normales; sin embargo, después de la valoración inicial presenta paro cardiorrespiratorio secundario a fibrilación ventricular con respuesta a una única desfibrilación de 200 joules. El electrocardiograma inicial demostró elevación del segmento ST en las derivadas de la cara inferior (II, III y aVF) y de la cara anterior (V2-V4) con cambios recíprocos en aVL, sin demostrarse extensión electrocardiográfica a ventrículo derecho. Las enzimas cardíacas al ingreso revelaron una creatinfosfokinasa (CK) de170 y una creatinfosfokinasa fracción MB (CK-MB) de 6. Los electrolitos, las pruebas de coagulación y los conteos de células sanguíneas fueron normales. El manejo inicial se realizó con aspirina 100 mg, lovastatina 40 mg cada día, metoprolol 25 mg cada 12 horas, enoxaparina 60 mg cada 12 horas, oxígeno a 3 lt/min y estreptoquinasa 1´500.000 unidades administradas en 30 minutos. No se demostraron cambios secundarios a reperfusión. El paciente fue trasladado a la unidad de cuidados intensivos, donde se documentaron durante las primeras horas de evolución, episodios de bloqueo A-V completo con resolución espontánea. El EKG tomado a las 24 horas de evolución reveló QS en cara inferior y una progresión tardía de la onda R en la cara anterior. El seguimiento enzimático demostró aumento de CK y de la fracción MB a las 6 horas (4476 y 165) y a las 12 horas (3839 y 136). Al día siguiente se realizó una coronariografía que mostró enfermedad difusa de la arteria descendente anterior con lesión en el tercio distal del 50% y lesión del 40% en el tercio proximal de la primera rama diagonal. La arteria circunfleja tenía una lesión del 50% en el tercio medio y enfermedad difusa de sus ramas obtusas marginales. La arteria coronaria derecha presentaba una lesión irregular sugestiva de trombo parcialmente resuelto produciendo estenosis máxima del 50%; distalmente la arteria descendente posterior presentaba dos lesiones del 40%. El paciente evolucionó satisfactoriamente sin complicaciones posteriores y libre de dolor. Fue dado de alta para seguimiento ambulatorio. Responsable clínico: Dr. Juan Velásquez López. E-mail: juangvl@gmail.com
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Juan", ".", "\n", "Apellidos", ":", "Ferrara", "Maldonado", ".", "\n", "NHC", ":", "7348567", ".", "\n", "NASS", ":", "89", "56729805", "56", ".", "\n", "Domicilio", ":", "C/", "FInisterre", ",", "3", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28034", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "06/05/1948", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "70", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "13/06/2018", ".", "\n", "Médico", ":", "Juan", "Velásquez", "López", "NºCol", ":", "28", "28", "57748", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "paciente", "masculino", "de", "70", "años", ",", "quien", "ingresó", "en", "el", "servicio", "de", "urgencias", "del", "Hospital", "Pablo", "Tobón", "Uribe", ",", "con", "cuadro", "de", "aproximadamente", "una", "hora", "de", "evolución", "consistente", "en", "opresión", "torácica", ",", "malestar", "general", ",", "astenia", "y", "diaforesis", ";", "que", "iniciaron", "después", "de", "haber", "ingerido", "100", "mg", "de", "sildenafil", ",", "niega", "ingesta", "de", "otro", "estimulante", "sexual", "o", "cocaína", "y", "sin", "relación", "sexual", "después", "de", "su", "consumo", ".", "El", "paciente", "como", "único", "antecedente", "clínico", "sufría", "de", "hipertensión", "arterial", ",", "controlada", "farmacológicamente", "y", "niega", "episodios", "previos", "de", "angina", "o", "consumo", "de", "nitratos", ".", "El", "examen", "clínico", "y", "sus", "signos", "vitales", "eran", "normales", ";", "sin", "embargo", ",", "después", "de", "la", "valoración", "inicial", "presenta", "paro", "cardiorrespiratorio", "secundario", "a", "fibrilación", "ventricular", "con", "respuesta", "a", "una", "única", "desfibrilación", "de", "200", "joules", ".", "\n", "El", "electrocardiograma", "inicial", "demostró", "elevación", "del", "segmento", "ST", "en", "las", "derivadas", "de", "la", "cara", "inferior", "(", "II", ",", "III", "y", "aVF", ")", "y", "de", "la", "cara", "anterior", "(", "V2-V4", ")", "con", "cambios", "recíprocos", "en", "aVL", ",", "sin", "demostrarse", "extensión", "electrocardiográfica", "a", "ventrículo", "derecho", ".", "\n", "Las", "enzimas", "cardíacas", "al", "ingreso", "revelaron", "una", "creatinfosfokinasa", "(", "CK", ")", "de170", "y", "una", "creatinfosfokinasa", "fracción", "MB", "(", "CK", "-", "MB", ")", "de", "6", ".", "Los", "electrolitos", ",", "las", "pruebas", "de", "coagulación", "y", "los", "conteos", "de", "células", "sanguíneas", "fueron", "normales", ".", "\n", "El", "manejo", "inicial", "se", "realizó", "con", "aspirina", "100", "mg", ",", "lovastatina", "40", "mg", "cada", "día", ",", "metoprolol", "25", "mg", "cada", "12", "horas", ",", "enoxaparina", "60", "mg", "cada", "12", "horas", ",", "oxígeno", "a", "3", "lt", "/", "min", "y", "estreptoquinasa", "1´500.000", "unidades", "administradas", "en", "30", "minutos", ".", "No", "se", "demostraron", "cambios", "secundarios", "a", "reperfusión", ".", "El", "paciente", "fue", "trasladado", "a", "la", "unidad", "de", "cuidados", "intensivos", ",", "donde", "se", "documentaron", "durante", "las", "primeras", "horas", "de", "evolución", ",", "episodios", "de", "bloqueo", "A", "-", "V", "completo", "con", "resolución", "espontánea", ".", "\n", "El", "EKG", "tomado", "a", "las", "24", "horas", "de", "evolución", "reveló", "QS", "en", "cara", "inferior", "y", "una", "progresión", "tardía", "de", "la", "onda", "R", "en", "la", "cara", "anterior", ".", "El", "seguimiento", "enzimático", "demostró", "aumento", "de", "CK", "y", "de", "la", "fracción", "MB", "a", "las", "6", "horas", "(", "4476", "y", "165", ")", "y", "a", "las", "12", "horas", "(", "3839", "y", "136", ")", ".", "\n", "Al", "día", "siguiente", "se", "realizó", "una", "coronariografía", "que", "mostró", "enfermedad", "difusa", "de", "la", "arteria", "descendente", "anterior", "con", "lesión", "en", "el", "tercio", "distal", "del", "50", "%", "y", "lesión", "del", "40", "%", "en", "el", "tercio", "proximal", "de", "la", "primera", "rama", "diagonal", ".", "La", "arteria", "circunfleja", "tenía", "una", "lesión", "del", "50", "%", "en", "el", "tercio", "medio", "y", "enfermedad", "difusa", "de", "sus", "ramas", "obtusas", "marginales", ".", "La", "arteria", "coronaria", "derecha", "presentaba", "una", "lesión", "irregular", "sugestiva", "de", "trombo", "parcialmente", "resuelto", "produciendo", "estenosis", "máxima", "del", "50", "%", ";", "distalmente", "la", "arteria", "descendente", "posterior", "presentaba", "dos", "lesiones", "del", "40", "%", ".", "\n", "El", "paciente", "evolucionó", "satisfactoriamente", "sin", "complicaciones", "posteriores", "y", "libre", "de", "dolor", ".", "Fue", "dado", "de", "alta", "para", "seguimiento", "ambulatorio", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Juan", "Velásquez", "López", ".", "E", "-", "mail", ":", "juangvl@gmail.com", "\n" ]
[ "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "CALLE", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "SEXO_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO" ]
Juan, Ferrara Maldonado, 7348567, 89 56729805 56, C/ FInisterre , 3, Madrid, 28034, 06/05/1948, España, 70 años, 13/06/2018, Juan Velásquez López, 28 28 57748, masculino, 70 años, Hospital Pablo Tobón Uribe, Juan Velásquez López, juangvl@gmail.com
71_task2
Sentence: Datos del paciente. Nombre: Juan. Apellidos: Ferrara Maldonado. NHC: 7348567. NASS: 89 56729805 56. Domicilio: C/ FInisterre, 3. Localidad/ Provincia: Madrid. CP: 28034. Datos asistenciales. Fecha de nacimiento: 06/05/1948. País de nacimiento: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 13/06/2018. Médico: Juan Velásquez López NºCol: 28 28 57748. Informe clínico del paciente: paciente masculino de 70 años, quien ingresó en el servicio de urgencias del Hospital Pablo Tobón Uribe, con cuadro de aproximadamente una hora de evolución consistente en opresión torácica, malestar general, astenia y diaforesis; que iniciaron después de haber ingerido 100 mg de sildenafil, niega ingesta de otro estimulante sexual o cocaína y sin relación sexual después de su consumo. El paciente como único antecedente clínico sufría de hipertensión arterial, controlada farmacológicamente y niega episodios previos de angina o consumo de nitratos. El examen clínico y sus signos vitales eran normales; sin embargo, después de la valoración inicial presenta paro cardiorrespiratorio secundario a fibrilación ventricular con respuesta a una única desfibrilación de 200 joules. El electrocardiograma inicial demostró elevación del segmento ST en las derivadas de la cara inferior (II, III y aVF) y de la cara anterior (V2-V4) con cambios recíprocos en aVL, sin demostrarse extensión electrocardiográfica a ventrículo derecho. Las enzimas cardíacas al ingreso revelaron una creatinfosfokinasa (CK) de170 y una creatinfosfokinasa fracción MB (CK-MB) de 6. Los electrolitos, las pruebas de coagulación y los conteos de células sanguíneas fueron normales. El manejo inicial se realizó con aspirina 100 mg, lovastatina 40 mg cada día, metoprolol 25 mg cada 12 horas, enoxaparina 60 mg cada 12 horas, oxígeno a 3 lt/min y estreptoquinasa 1´500.000 unidades administradas en 30 minutos. No se demostraron cambios secundarios a reperfusión. El paciente fue trasladado a la unidad de cuidados intensivos, donde se documentaron durante las primeras horas de evolución, episodios de bloqueo A-V completo con resolución espontánea. El EKG tomado a las 24 horas de evolución reveló QS en cara inferior y una progresión tardía de la onda R en la cara anterior. El seguimiento enzimático demostró aumento de CK y de la fracción MB a las 6 horas (4476 y 165) y a las 12 horas (3839 y 136). Al día siguiente se realizó una coronariografía que mostró enfermedad difusa de la arteria descendente anterior con lesión en el tercio distal del 50% y lesión del 40% en el tercio proximal de la primera rama diagonal. La arteria circunfleja tenía una lesión del 50% en el tercio medio y enfermedad difusa de sus ramas obtusas marginales. La arteria coronaria derecha presentaba una lesión irregular sugestiva de trombo parcialmente resuelto produciendo estenosis máxima del 50%; distalmente la arteria descendente posterior presentaba dos lesiones del 40%. El paciente evolucionó satisfactoriamente sin complicaciones posteriores y libre de dolor. Fue dado de alta para seguimiento ambulatorio. Responsable clínico: Dr. Juan Velásquez López. E-mail: juangvl@gmail.com Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]
Datos del paciente. Nombre: Juan. Apellidos: Ferrara Maldonado. NHC: 7348567. NASS: 89 56729805 56. Domicilio: C/ FInisterre, 3. Localidad/ Provincia: Madrid. CP: 28034. Datos asistenciales. Fecha de nacimiento: 06/05/1948. País de nacimiento: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 13/06/2018. Médico: Juan Velásquez López NºCol: 28 28 57748. Informe clínico del paciente: paciente masculino de 70 años, quien ingresó en el servicio de urgencias del Hospital Pablo Tobón Uribe, con cuadro de aproximadamente una hora de evolución consistente en opresión torácica, malestar general, astenia y diaforesis; que iniciaron después de haber ingerido 100 mg de sildenafil, niega ingesta de otro estimulante sexual o cocaína y sin relación sexual después de su consumo. El paciente como único antecedente clínico sufría de hipertensión arterial, controlada farmacológicamente y niega episodios previos de angina o consumo de nitratos. El examen clínico y sus signos vitales eran normales; sin embargo, después de la valoración inicial presenta paro cardiorrespiratorio secundario a fibrilación ventricular con respuesta a una única desfibrilación de 200 joules. El electrocardiograma inicial demostró elevación del segmento ST en las derivadas de la cara inferior (II, III y aVF) y de la cara anterior (V2-V4) con cambios recíprocos en aVL, sin demostrarse extensión electrocardiográfica a ventrículo derecho. Las enzimas cardíacas al ingreso revelaron una creatinfosfokinasa (CK) de170 y una creatinfosfokinasa fracción MB (CK-MB) de 6. Los electrolitos, las pruebas de coagulación y los conteos de células sanguíneas fueron normales. El manejo inicial se realizó con aspirina 100 mg, lovastatina 40 mg cada día, metoprolol 25 mg cada 12 horas, enoxaparina 60 mg cada 12 horas, oxígeno a 3 lt/min y estreptoquinasa 1´500.000 unidades administradas en 30 minutos. No se demostraron cambios secundarios a reperfusión. El paciente fue trasladado a la unidad de cuidados intensivos, donde se documentaron durante las primeras horas de evolución, episodios de bloqueo A-V completo con resolución espontánea. El EKG tomado a las 24 horas de evolución reveló QS en cara inferior y una progresión tardía de la onda R en la cara anterior. El seguimiento enzimático demostró aumento de CK y de la fracción MB a las 6 horas (4476 y 165) y a las 12 horas (3839 y 136). Al día siguiente se realizó una coronariografía que mostró enfermedad difusa de la arteria descendente anterior con lesión en el tercio distal del 50% y lesión del 40% en el tercio proximal de la primera rama diagonal. La arteria circunfleja tenía una lesión del 50% en el tercio medio y enfermedad difusa de sus ramas obtusas marginales. La arteria coronaria derecha presentaba una lesión irregular sugestiva de trombo parcialmente resuelto produciendo estenosis máxima del 50%; distalmente la arteria descendente posterior presentaba dos lesiones del 40%. El paciente evolucionó satisfactoriamente sin complicaciones posteriores y libre de dolor. Fue dado de alta para seguimiento ambulatorio. Responsable clínico: Dr. Juan Velásquez López. E-mail: juangvl@gmail.com
[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Juan", ".", "\n", "Apellidos", ":", "Ferrara", "Maldonado", ".", "\n", "NHC", ":", "7348567", ".", "\n", "NASS", ":", "89", "56729805", "56", ".", "\n", "Domicilio", ":", "C/", "FInisterre", ",", "3", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28034", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "06/05/1948", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "70", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "13/06/2018", ".", "\n", "Médico", ":", "Juan", "Velásquez", "López", "NºCol", ":", "28", "28", "57748", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "paciente", "masculino", "de", "70", "años", ",", "quien", "ingresó", "en", "el", "servicio", "de", "urgencias", "del", "Hospital", "Pablo", "Tobón", "Uribe", ",", "con", "cuadro", "de", "aproximadamente", "una", "hora", "de", "evolución", "consistente", "en", "opresión", "torácica", ",", "malestar", "general", ",", "astenia", "y", "diaforesis", ";", "que", "iniciaron", "después", "de", "haber", "ingerido", "100", "mg", "de", "sildenafil", ",", "niega", "ingesta", "de", "otro", "estimulante", "sexual", "o", "cocaína", "y", "sin", "relación", "sexual", "después", "de", "su", "consumo", ".", "El", "paciente", "como", "único", "antecedente", "clínico", "sufría", "de", "hipertensión", "arterial", ",", "controlada", "farmacológicamente", "y", "niega", "episodios", "previos", "de", "angina", "o", "consumo", "de", "nitratos", ".", "El", "examen", "clínico", "y", "sus", "signos", "vitales", "eran", "normales", ";", "sin", "embargo", ",", "después", "de", "la", "valoración", "inicial", "presenta", "paro", "cardiorrespiratorio", "secundario", "a", "fibrilación", "ventricular", "con", "respuesta", "a", "una", "única", "desfibrilación", "de", "200", "joules", ".", "\n", "El", "electrocardiograma", "inicial", "demostró", "elevación", "del", "segmento", "ST", "en", "las", "derivadas", "de", "la", "cara", "inferior", "(", "II", ",", "III", "y", "aVF", ")", "y", "de", "la", "cara", "anterior", "(", "V2-V4", ")", "con", "cambios", "recíprocos", "en", "aVL", ",", "sin", "demostrarse", "extensión", "electrocardiográfica", "a", "ventrículo", "derecho", ".", "\n", "Las", "enzimas", "cardíacas", "al", "ingreso", "revelaron", "una", "creatinfosfokinasa", "(", "CK", ")", "de170", "y", "una", "creatinfosfokinasa", "fracción", "MB", "(", "CK", "-", "MB", ")", "de", "6", ".", "Los", "electrolitos", ",", "las", "pruebas", "de", "coagulación", "y", "los", "conteos", "de", "células", "sanguíneas", "fueron", "normales", ".", "\n", "El", "manejo", "inicial", "se", "realizó", "con", "aspirina", "100", "mg", ",", "lovastatina", "40", "mg", "cada", "día", ",", "metoprolol", "25", "mg", "cada", "12", "horas", ",", "enoxaparina", "60", "mg", "cada", "12", "horas", ",", "oxígeno", "a", "3", "lt", "/", "min", "y", "estreptoquinasa", "1´500.000", "unidades", "administradas", "en", "30", "minutos", ".", "No", "se", "demostraron", "cambios", "secundarios", "a", "reperfusión", ".", "El", "paciente", "fue", "trasladado", "a", "la", "unidad", "de", "cuidados", "intensivos", ",", "donde", "se", "documentaron", "durante", "las", "primeras", "horas", "de", "evolución", ",", "episodios", "de", "bloqueo", "A", "-", "V", "completo", "con", "resolución", "espontánea", ".", "\n", "El", "EKG", "tomado", "a", "las", "24", "horas", "de", "evolución", "reveló", "QS", "en", "cara", "inferior", "y", "una", "progresión", "tardía", "de", "la", "onda", "R", "en", "la", "cara", "anterior", ".", "El", "seguimiento", "enzimático", "demostró", "aumento", "de", "CK", "y", "de", "la", "fracción", "MB", "a", "las", "6", "horas", "(", "4476", "y", "165", ")", "y", "a", "las", "12", "horas", "(", "3839", "y", "136", ")", ".", "\n", "Al", "día", "siguiente", "se", "realizó", "una", "coronariografía", "que", "mostró", "enfermedad", "difusa", "de", "la", "arteria", "descendente", "anterior", "con", "lesión", "en", "el", "tercio", "distal", "del", "50", "%", "y", "lesión", "del", "40", "%", "en", "el", "tercio", "proximal", "de", "la", "primera", "rama", "diagonal", ".", "La", "arteria", "circunfleja", "tenía", "una", "lesión", "del", "50", "%", "en", "el", "tercio", "medio", "y", "enfermedad", "difusa", "de", "sus", "ramas", "obtusas", "marginales", ".", "La", "arteria", "coronaria", "derecha", "presentaba", "una", "lesión", "irregular", "sugestiva", "de", "trombo", "parcialmente", "resuelto", "produciendo", "estenosis", "máxima", "del", "50", "%", ";", "distalmente", "la", "arteria", "descendente", "posterior", "presentaba", "dos", "lesiones", "del", "40", "%", ".", "\n", "El", "paciente", "evolucionó", "satisfactoriamente", "sin", "complicaciones", "posteriores", "y", "libre", "de", "dolor", ".", "Fue", "dado", "de", "alta", "para", "seguimiento", "ambulatorio", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "Juan", "Velásquez", "López", ".", "E", "-", "mail", ":", "juangvl@gmail.com", "\n" ]
[ "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "CALLE", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "SEXO_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO" ]
operation is an umlsterm, therapeutic is an umlsterm, standard is an umlsterm, colon is an umlsterm, peritonitis is an umlsterm, procedure is an umlsterm, one - stage is an umlsterm, techniques is an umlsterm, postoperative is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, aim is an umlsterm, operation is an umlsterm, Method is an umlsterm, operations is an umlsterm, patients is an umlsterm, diseases caused is an umlsterm, complications is an umlsterm, Peritonitis is an umlsterm, Index is an umlsterm, patients died is an umlsterm, mortality is an umlsterm, patients is an umlsterm, complication is an umlsterm, mortality is an umlsterm, patients is an umlsterm, housing is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, time is an umlsterm, patients is an umlsterm, lives is an umlsterm, Quality of life is an umlsterm, patients is an umlsterm, operation is an umlsterm, patients is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, patients is an umlsterm, lives is an umlsterm, assessment is an umlsterm
DerChirurg.90700049.eng.abstr_task0
Sentence: Background : Although the majority of surgeons regard Hartmann's operation as therapeutic standard in perforations of the colon complicated by peritonitis this procedure has been critically discussed in recent years . Advocates of one-stage techniques criticized bad postoperative results ( high morbidity and mortality ) and long-term outcome ( low rates of intestinal restoration ) . The aim of our study was to investigate whether the late results after Hartmann's operation justify this criticism . Method : From 1982 to 1997 Hartmann's operations were performed in 103 patients for colonic perforations . In 63 % of cases inflammatory diseases caused colonic complications . The average Mannheimer Peritonitis Index ( MPI ) was 19. Seventeen patients died postoperatively ( mortality : 16.5 % ) . In 69 patients ( 80 % ) intestinal restoration could be performed after an average interval of 122 days ( complication rate : 6 % , no mortality ) . On follow-up , patients were asked to give information on their general state , changes of housing , abdominal complaints , and quality of life . Results : Data on 93 % of patients could be obtained . The median follow-up time was 75 months . Eleven patients had died ; the remaining 72 were investigated . 86 % described the quality of their lives as good or very good ; only 11 % indicated severe loss of activity . Quality of life did not differ between patients in whom intestinal continuity had been restored and those in whom it had not been restored . Anastomotic strictures developed in 7 % of cases , always after stapled anastomosis . Conclusions : According to our results , long-term outcome after Hartmann's operation is good . 80 % of patients underwent intestinal restoration with low morbidity ( 6 % ) and no mortality . A great majority of patients indicated the quality of their lives as good or very good : this assessment was not dependent on restoration of intestinal continuity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : Although the majority of surgeons regard Hartmann's operation as therapeutic standard in perforations of the colon complicated by peritonitis this procedure has been critically discussed in recent years . Advocates of one-stage techniques criticized bad postoperative results ( high morbidity and mortality ) and long-term outcome ( low rates of intestinal restoration ) . The aim of our study was to investigate whether the late results after Hartmann's operation justify this criticism . Method : From 1982 to 1997 Hartmann's operations were performed in 103 patients for colonic perforations . In 63 % of cases inflammatory diseases caused colonic complications . The average Mannheimer Peritonitis Index ( MPI ) was 19. Seventeen patients died postoperatively ( mortality : 16.5 % ) . In 69 patients ( 80 % ) intestinal restoration could be performed after an average interval of 122 days ( complication rate : 6 % , no mortality ) . On follow-up , patients were asked to give information on their general state , changes of housing , abdominal complaints , and quality of life . Results : Data on 93 % of patients could be obtained . The median follow-up time was 75 months . Eleven patients had died ; the remaining 72 were investigated . 86 % described the quality of their lives as good or very good ; only 11 % indicated severe loss of activity . Quality of life did not differ between patients in whom intestinal continuity had been restored and those in whom it had not been restored . Anastomotic strictures developed in 7 % of cases , always after stapled anastomosis . Conclusions : According to our results , long-term outcome after Hartmann's operation is good . 80 % of patients underwent intestinal restoration with low morbidity ( 6 % ) and no mortality . A great majority of patients indicated the quality of their lives as good or very good : this assessment was not dependent on restoration of intestinal continuity .
[ "Background", ":", "Although", "the", "majority", "of", "surgeons", "regard", "Hartmann", "'s", "operation", "as", "therapeutic", "standard", "in", "perforations", "of", "the", "colon", "complicated", "by", "peritonitis", "this", "procedure", "has", "been", "critically", "discussed", "in", "recent", "years", ".", "Advocates", "of", "one", "-", "stage", "techniques", "criticized", "bad", "postoperative", "results", "(", "high", "morbidity", "and", "mortality", ")", "and", "long", "-", "term", "outcome", "(", "low", "rates", "of", "intestinal", "restoration", ")", ".", "The", "aim", "of", "our", "study", "was", "to", "investigate", "whether", "the", "late", "results", "after", "Hartmann", "'s", "operation", "justify", "this", "criticism", ".", "Method", ":", "From", "1982", "to", "1997", "Hartmann", "'s", "operations", "were", "performed", "in", "103", "patients", "for", "colonic", "perforations", ".", "In", "63", "%", "of", "cases", "inflammatory", "diseases", "caused", "colonic", "complications", ".", "The", "average", "Mannheimer", "Peritonitis", "Index", "(", "MPI", ")", "was", "19", ".", "Seventeen", "patients", "died", "postoperatively", "(", "mortality", ":", "16.5", "%", ")", ".", "In", "69", "patients", "(", "80", "%", ")", "intestinal", "restoration", "could", "be", "performed", "after", "an", "average", "interval", "of", "122", "days", "(", "complication", "rate", ":", "6", "%", ",", "no", "mortality", ")", ".", "On", "follow", "-", "up", ",", "patients", "were", "asked", "to", "give", "information", "on", "their", "general", "state", ",", "changes", "of", "housing", ",", "abdominal", "complaints", ",", "and", "quality", "of", "life", ".", "Results", ":", "Data", "on", "93", "%", "of", "patients", "could", "be", "obtained", ".", "The", "median", "follow", "-", "up", "time", "was", "75", "months", ".", "Eleven", "patients", "had", "died", ";", "the", "remaining", "72", "were", "investigated", ".", "86", "%", "described", "the", "quality", "of", "their", "lives", "as", "good", "or", "very", "good", ";", "only", "11", "%", "indicated", "severe", "loss", "of", "activity", ".", "Quality", "of", "life", "did", "not", "differ", "between", "patients", "in", "whom", "intestinal", "continuity", "had", "been", "restored", "and", "those", "in", "whom", "it", "had", "not", "been", "restored", ".", "Anastomotic", "strictures", "developed", "in", "7", "%", "of", "cases", ",", "always", "after", "stapled", "anastomosis", ".", "Conclusions", ":", "According", "to", "our", "results", ",", "long", "-", "term", "outcome", "after", "Hartmann", "'s", "operation", "is", "good", ".", "80", "%", "of", "patients", "underwent", "intestinal", "restoration", "with", "low", "morbidity", "(", "6", "%", ")", "and", "no", "mortality", ".", "A", "great", "majority", "of", "patients", "indicated", "the", "quality", "of", "their", "lives", "as", "good", "or", "very", "good", ":", "this", "assessment", "was", "not", "dependent", "on", "restoration", "of", "intestinal", "continuity", "." ]
[ "umlsterm" ]
operation is an umlsterm, therapeutic is an umlsterm, standard is an umlsterm, colon is an umlsterm, peritonitis is an umlsterm, procedure is an umlsterm, one - stage is an umlsterm, techniques is an umlsterm, postoperative is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, aim is an umlsterm, operation is an umlsterm, Method is an umlsterm, operations is an umlsterm, patients is an umlsterm, diseases caused is an umlsterm, complications is an umlsterm, Peritonitis is an umlsterm, Index is an umlsterm, patients died is an umlsterm, mortality is an umlsterm, patients is an umlsterm, complication is an umlsterm, mortality is an umlsterm, patients is an umlsterm, housing is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, time is an umlsterm, patients is an umlsterm, lives is an umlsterm, Quality of life is an umlsterm, patients is an umlsterm, operation is an umlsterm, patients is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, patients is an umlsterm, lives is an umlsterm, assessment is an umlsterm
DerChirurg.90700049.eng.abstr_task1
Sentence: Background : Although the majority of surgeons regard Hartmann's operation as therapeutic standard in perforations of the colon complicated by peritonitis this procedure has been critically discussed in recent years . Advocates of one-stage techniques criticized bad postoperative results ( high morbidity and mortality ) and long-term outcome ( low rates of intestinal restoration ) . The aim of our study was to investigate whether the late results after Hartmann's operation justify this criticism . Method : From 1982 to 1997 Hartmann's operations were performed in 103 patients for colonic perforations . In 63 % of cases inflammatory diseases caused colonic complications . The average Mannheimer Peritonitis Index ( MPI ) was 19. Seventeen patients died postoperatively ( mortality : 16.5 % ) . In 69 patients ( 80 % ) intestinal restoration could be performed after an average interval of 122 days ( complication rate : 6 % , no mortality ) . On follow-up , patients were asked to give information on their general state , changes of housing , abdominal complaints , and quality of life . Results : Data on 93 % of patients could be obtained . The median follow-up time was 75 months . Eleven patients had died ; the remaining 72 were investigated . 86 % described the quality of their lives as good or very good ; only 11 % indicated severe loss of activity . Quality of life did not differ between patients in whom intestinal continuity had been restored and those in whom it had not been restored . Anastomotic strictures developed in 7 % of cases , always after stapled anastomosis . Conclusions : According to our results , long-term outcome after Hartmann's operation is good . 80 % of patients underwent intestinal restoration with low morbidity ( 6 % ) and no mortality . A great majority of patients indicated the quality of their lives as good or very good : this assessment was not dependent on restoration of intestinal continuity . Instructions: please typing these entity words according to sentence: operation, therapeutic, standard, colon, peritonitis, procedure, one - stage, techniques, postoperative, morbidity, mortality, aim, operation, Method, operations, patients, diseases caused, complications, Peritonitis, Index, patients died, mortality, patients, complication, mortality, patients, housing, quality of life, patients, time, patients, lives, Quality of life, patients, operation, patients, morbidity, mortality, patients, lives, assessment Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : Although the majority of surgeons regard Hartmann's operation as therapeutic standard in perforations of the colon complicated by peritonitis this procedure has been critically discussed in recent years . Advocates of one-stage techniques criticized bad postoperative results ( high morbidity and mortality ) and long-term outcome ( low rates of intestinal restoration ) . The aim of our study was to investigate whether the late results after Hartmann's operation justify this criticism . Method : From 1982 to 1997 Hartmann's operations were performed in 103 patients for colonic perforations . In 63 % of cases inflammatory diseases caused colonic complications . The average Mannheimer Peritonitis Index ( MPI ) was 19. Seventeen patients died postoperatively ( mortality : 16.5 % ) . In 69 patients ( 80 % ) intestinal restoration could be performed after an average interval of 122 days ( complication rate : 6 % , no mortality ) . On follow-up , patients were asked to give information on their general state , changes of housing , abdominal complaints , and quality of life . Results : Data on 93 % of patients could be obtained . The median follow-up time was 75 months . Eleven patients had died ; the remaining 72 were investigated . 86 % described the quality of their lives as good or very good ; only 11 % indicated severe loss of activity . Quality of life did not differ between patients in whom intestinal continuity had been restored and those in whom it had not been restored . Anastomotic strictures developed in 7 % of cases , always after stapled anastomosis . Conclusions : According to our results , long-term outcome after Hartmann's operation is good . 80 % of patients underwent intestinal restoration with low morbidity ( 6 % ) and no mortality . A great majority of patients indicated the quality of their lives as good or very good : this assessment was not dependent on restoration of intestinal continuity .
[ "Background", ":", "Although", "the", "majority", "of", "surgeons", "regard", "Hartmann", "'s", "operation", "as", "therapeutic", "standard", "in", "perforations", "of", "the", "colon", "complicated", "by", "peritonitis", "this", "procedure", "has", "been", "critically", "discussed", "in", "recent", "years", ".", "Advocates", "of", "one", "-", "stage", "techniques", "criticized", "bad", "postoperative", "results", "(", "high", "morbidity", "and", "mortality", ")", "and", "long", "-", "term", "outcome", "(", "low", "rates", "of", "intestinal", "restoration", ")", ".", "The", "aim", "of", "our", "study", "was", "to", "investigate", "whether", "the", "late", "results", "after", "Hartmann", "'s", "operation", "justify", "this", "criticism", ".", "Method", ":", "From", "1982", "to", "1997", "Hartmann", "'s", "operations", "were", "performed", "in", "103", "patients", "for", "colonic", "perforations", ".", "In", "63", "%", "of", "cases", "inflammatory", "diseases", "caused", "colonic", "complications", ".", "The", "average", "Mannheimer", "Peritonitis", "Index", "(", "MPI", ")", "was", "19", ".", "Seventeen", "patients", "died", "postoperatively", "(", "mortality", ":", "16.5", "%", ")", ".", "In", "69", "patients", "(", "80", "%", ")", "intestinal", "restoration", "could", "be", "performed", "after", "an", "average", "interval", "of", "122", "days", "(", "complication", "rate", ":", "6", "%", ",", "no", "mortality", ")", ".", "On", "follow", "-", "up", ",", "patients", "were", "asked", "to", "give", "information", "on", "their", "general", "state", ",", "changes", "of", "housing", ",", "abdominal", "complaints", ",", "and", "quality", "of", "life", ".", "Results", ":", "Data", "on", "93", "%", "of", "patients", "could", "be", "obtained", ".", "The", "median", "follow", "-", "up", "time", "was", "75", "months", ".", "Eleven", "patients", "had", "died", ";", "the", "remaining", "72", "were", "investigated", ".", "86", "%", "described", "the", "quality", "of", "their", "lives", "as", "good", "or", "very", "good", ";", "only", "11", "%", "indicated", "severe", "loss", "of", "activity", ".", "Quality", "of", "life", "did", "not", "differ", "between", "patients", "in", "whom", "intestinal", "continuity", "had", "been", "restored", "and", "those", "in", "whom", "it", "had", "not", "been", "restored", ".", "Anastomotic", "strictures", "developed", "in", "7", "%", "of", "cases", ",", "always", "after", "stapled", "anastomosis", ".", "Conclusions", ":", "According", "to", "our", "results", ",", "long", "-", "term", "outcome", "after", "Hartmann", "'s", "operation", "is", "good", ".", "80", "%", "of", "patients", "underwent", "intestinal", "restoration", "with", "low", "morbidity", "(", "6", "%", ")", "and", "no", "mortality", ".", "A", "great", "majority", "of", "patients", "indicated", "the", "quality", "of", "their", "lives", "as", "good", "or", "very", "good", ":", "this", "assessment", "was", "not", "dependent", "on", "restoration", "of", "intestinal", "continuity", "." ]
[ "umlsterm" ]
operation, therapeutic, standard, colon, peritonitis, procedure, one - stage, techniques, postoperative, morbidity, mortality, aim, operation, Method, operations, patients, diseases caused, complications, Peritonitis, Index, patients died, mortality, patients, complication, mortality, patients, housing, quality of life, patients, time, patients, lives, Quality of life, patients, operation, patients, morbidity, mortality, patients, lives, assessment
DerChirurg.90700049.eng.abstr_task2
Sentence: Background : Although the majority of surgeons regard Hartmann's operation as therapeutic standard in perforations of the colon complicated by peritonitis this procedure has been critically discussed in recent years . Advocates of one-stage techniques criticized bad postoperative results ( high morbidity and mortality ) and long-term outcome ( low rates of intestinal restoration ) . The aim of our study was to investigate whether the late results after Hartmann's operation justify this criticism . Method : From 1982 to 1997 Hartmann's operations were performed in 103 patients for colonic perforations . In 63 % of cases inflammatory diseases caused colonic complications . The average Mannheimer Peritonitis Index ( MPI ) was 19. Seventeen patients died postoperatively ( mortality : 16.5 % ) . In 69 patients ( 80 % ) intestinal restoration could be performed after an average interval of 122 days ( complication rate : 6 % , no mortality ) . On follow-up , patients were asked to give information on their general state , changes of housing , abdominal complaints , and quality of life . Results : Data on 93 % of patients could be obtained . The median follow-up time was 75 months . Eleven patients had died ; the remaining 72 were investigated . 86 % described the quality of their lives as good or very good ; only 11 % indicated severe loss of activity . Quality of life did not differ between patients in whom intestinal continuity had been restored and those in whom it had not been restored . Anastomotic strictures developed in 7 % of cases , always after stapled anastomosis . Conclusions : According to our results , long-term outcome after Hartmann's operation is good . 80 % of patients underwent intestinal restoration with low morbidity ( 6 % ) and no mortality . A great majority of patients indicated the quality of their lives as good or very good : this assessment was not dependent on restoration of intestinal continuity . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : Although the majority of surgeons regard Hartmann's operation as therapeutic standard in perforations of the colon complicated by peritonitis this procedure has been critically discussed in recent years . Advocates of one-stage techniques criticized bad postoperative results ( high morbidity and mortality ) and long-term outcome ( low rates of intestinal restoration ) . The aim of our study was to investigate whether the late results after Hartmann's operation justify this criticism . Method : From 1982 to 1997 Hartmann's operations were performed in 103 patients for colonic perforations . In 63 % of cases inflammatory diseases caused colonic complications . The average Mannheimer Peritonitis Index ( MPI ) was 19. Seventeen patients died postoperatively ( mortality : 16.5 % ) . In 69 patients ( 80 % ) intestinal restoration could be performed after an average interval of 122 days ( complication rate : 6 % , no mortality ) . On follow-up , patients were asked to give information on their general state , changes of housing , abdominal complaints , and quality of life . Results : Data on 93 % of patients could be obtained . The median follow-up time was 75 months . Eleven patients had died ; the remaining 72 were investigated . 86 % described the quality of their lives as good or very good ; only 11 % indicated severe loss of activity . Quality of life did not differ between patients in whom intestinal continuity had been restored and those in whom it had not been restored . Anastomotic strictures developed in 7 % of cases , always after stapled anastomosis . Conclusions : According to our results , long-term outcome after Hartmann's operation is good . 80 % of patients underwent intestinal restoration with low morbidity ( 6 % ) and no mortality . A great majority of patients indicated the quality of their lives as good or very good : this assessment was not dependent on restoration of intestinal continuity .
[ "Background", ":", "Although", "the", "majority", "of", "surgeons", "regard", "Hartmann", "'s", "operation", "as", "therapeutic", "standard", "in", "perforations", "of", "the", "colon", "complicated", "by", "peritonitis", "this", "procedure", "has", "been", "critically", "discussed", "in", "recent", "years", ".", "Advocates", "of", "one", "-", "stage", "techniques", "criticized", "bad", "postoperative", "results", "(", "high", "morbidity", "and", "mortality", ")", "and", "long", "-", "term", "outcome", "(", "low", "rates", "of", "intestinal", "restoration", ")", ".", "The", "aim", "of", "our", "study", "was", "to", "investigate", "whether", "the", "late", "results", "after", "Hartmann", "'s", "operation", "justify", "this", "criticism", ".", "Method", ":", "From", "1982", "to", "1997", "Hartmann", "'s", "operations", "were", "performed", "in", "103", "patients", "for", "colonic", "perforations", ".", "In", "63", "%", "of", "cases", "inflammatory", "diseases", "caused", "colonic", "complications", ".", "The", "average", "Mannheimer", "Peritonitis", "Index", "(", "MPI", ")", "was", "19", ".", "Seventeen", "patients", "died", "postoperatively", "(", "mortality", ":", "16.5", "%", ")", ".", "In", "69", "patients", "(", "80", "%", ")", "intestinal", "restoration", "could", "be", "performed", "after", "an", "average", "interval", "of", "122", "days", "(", "complication", "rate", ":", "6", "%", ",", "no", "mortality", ")", ".", "On", "follow", "-", "up", ",", "patients", "were", "asked", "to", "give", "information", "on", "their", "general", "state", ",", "changes", "of", "housing", ",", "abdominal", "complaints", ",", "and", "quality", "of", "life", ".", "Results", ":", "Data", "on", "93", "%", "of", "patients", "could", "be", "obtained", ".", "The", "median", "follow", "-", "up", "time", "was", "75", "months", ".", "Eleven", "patients", "had", "died", ";", "the", "remaining", "72", "were", "investigated", ".", "86", "%", "described", "the", "quality", "of", "their", "lives", "as", "good", "or", "very", "good", ";", "only", "11", "%", "indicated", "severe", "loss", "of", "activity", ".", "Quality", "of", "life", "did", "not", "differ", "between", "patients", "in", "whom", "intestinal", "continuity", "had", "been", "restored", "and", "those", "in", "whom", "it", "had", "not", "been", "restored", ".", "Anastomotic", "strictures", "developed", "in", "7", "%", "of", "cases", ",", "always", "after", "stapled", "anastomosis", ".", "Conclusions", ":", "According", "to", "our", "results", ",", "long", "-", "term", "outcome", "after", "Hartmann", "'s", "operation", "is", "good", ".", "80", "%", "of", "patients", "underwent", "intestinal", "restoration", "with", "low", "morbidity", "(", "6", "%", ")", "and", "no", "mortality", ".", "A", "great", "majority", "of", "patients", "indicated", "the", "quality", "of", "their", "lives", "as", "good", "or", "very", "good", ":", "this", "assessment", "was", "not", "dependent", "on", "restoration", "of", "intestinal", "continuity", "." ]
[ "umlsterm" ]
Nabelschnurbluttransplantationen is an umlsterm, Transplantationen is an umlsterm, Restblut is an umlsterm, Vorlaeuferzellen is an umlsterm, Restblut is an umlsterm, Nabelschnurbluttransplantate is an umlsterm, Leukozyten is an umlsterm, familiengerichtete is an umlsterm, Transplantate is an umlsterm, Stickstoff is an umlsterm, Nabelschnurblutvene is an umlsterm, Geburten is an umlsterm, Methoden is an umlsterm, HLA - Typisierung is an umlsterm, Sterilitaet is an umlsterm, Vorlaeuferzellen is an umlsterm, Zellen is an umlsterm, Analyse is an umlsterm, Mutter is an umlsterm, Mutter is an umlsterm, Hepatitis B is an umlsterm, EBV is an umlsterm, Toxoplasmose is an umlsterm
PerinatalMedizin.60080093.ger.abstr_task0
Sentence: Zusammenfassung . Wie bereits an ueber 44 Nabelschnurbluttransplantationen bei Geschwistern ( 34 HLA-identisch , 10 mit 1-3 HLA-Locus-Mismatchen ) und 6 unverwandten ( 1 HLA-identisch , 5 mit 1-3 HLA-Locus-Mismatchen ) Transplantationen gezeigt , ist das plazentare Restblut eine reiche Quelle haematopoetischer Stamm- und Vorlaeuferzellen . Aus diesem Grund wurde hier eine Pilotstudie gestartet , um aus plazentarem Restblut die Definition , Charakterisierung und Standardisierung fuer entsprechende Stammzelltransplantate erstellen zu koennen . Bisher wurden 372 Nabelschnurbluttransplantate ( Stand 10. 05. 1995 ) mit einer mittleren Volumenmenge von 78 +/- 32 ml und 8,4 +/- 5 - 108 Leukozyten fuer familiengerichtete Transplantate ( n=12) und als unverwandte Stammzellasservate ( n=360) abgenommen , charakterisiert und unsepariert in fluessigem Stickstoff gelagert . Die Abnahme des Plazentarestblutes ( PR ) erfolgte aus der Nabelschnurblutvene nach normalen Geburten ( n=302) oder nach einem Kaiserschnitt ( n=70). Sowohl fuer die serologische als auch fuer die molekulargenetische HLA-Klasse-I- und -II-Typisierung wurden Methoden entwickelt , die eine komplette HLA-Typisierung aus 1,5 ml PR ermoeglichen . Zusaetzlich werden nur 3,5 ml fuer die Kontrolle der Sterilitaet , fuer die Bestimmung der Vorlaeuferzellen ueber Koloniebildungstests und CD 34 sowie die Testung auf kontaminierende muetterliche Zellen mit Hilfe der simultanen immunphaenotypischen und genotypischen Analyse oder der PCR-SSP fuer das nicht vererbte HLA-Allel der Mutter benoetigt . Die Seren der Mutter werden auf Hepatitis B , A , C , HIV1, HIV2, EBV , VCA , HTLVI-II , CMV , Toxoplasmose und TPHA getestet . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Zusammenfassung . Wie bereits an ueber 44 Nabelschnurbluttransplantationen bei Geschwistern ( 34 HLA-identisch , 10 mit 1-3 HLA-Locus-Mismatchen ) und 6 unverwandten ( 1 HLA-identisch , 5 mit 1-3 HLA-Locus-Mismatchen ) Transplantationen gezeigt , ist das plazentare Restblut eine reiche Quelle haematopoetischer Stamm- und Vorlaeuferzellen . Aus diesem Grund wurde hier eine Pilotstudie gestartet , um aus plazentarem Restblut die Definition , Charakterisierung und Standardisierung fuer entsprechende Stammzelltransplantate erstellen zu koennen . Bisher wurden 372 Nabelschnurbluttransplantate ( Stand 10. 05. 1995 ) mit einer mittleren Volumenmenge von 78 +/- 32 ml und 8,4 +/- 5 - 108 Leukozyten fuer familiengerichtete Transplantate ( n=12) und als unverwandte Stammzellasservate ( n=360) abgenommen , charakterisiert und unsepariert in fluessigem Stickstoff gelagert . Die Abnahme des Plazentarestblutes ( PR ) erfolgte aus der Nabelschnurblutvene nach normalen Geburten ( n=302) oder nach einem Kaiserschnitt ( n=70). Sowohl fuer die serologische als auch fuer die molekulargenetische HLA-Klasse-I- und -II-Typisierung wurden Methoden entwickelt , die eine komplette HLA-Typisierung aus 1,5 ml PR ermoeglichen . Zusaetzlich werden nur 3,5 ml fuer die Kontrolle der Sterilitaet , fuer die Bestimmung der Vorlaeuferzellen ueber Koloniebildungstests und CD 34 sowie die Testung auf kontaminierende muetterliche Zellen mit Hilfe der simultanen immunphaenotypischen und genotypischen Analyse oder der PCR-SSP fuer das nicht vererbte HLA-Allel der Mutter benoetigt . Die Seren der Mutter werden auf Hepatitis B , A , C , HIV1, HIV2, EBV , VCA , HTLVI-II , CMV , Toxoplasmose und TPHA getestet .
[ "Zusammenfassung", ".", "Wie", "bereits", "an", "ueber", "44", "Nabelschnurbluttransplantationen", "bei", "Geschwistern", "(", "34", "HLA", "-", "identisch", ",", "10", "mit", "1", "-", "3", "HLA", "-", "Locus", "-", "Mismatchen", ")", "und", "6", "unverwandten", "(", "1", "HLA", "-", "identisch", ",", "5", "mit", "1", "-", "3", "HLA", "-", "Locus", "-", "Mismatchen", ")", "Transplantationen", "gezeigt", ",", "ist", "das", "plazentare", "Restblut", "eine", "reiche", "Quelle", "haematopoetischer", "Stamm-", "und", "Vorlaeuferzellen", ".", "Aus", "diesem", "Grund", "wurde", "hier", "eine", "Pilotstudie", "gestartet", ",", "um", "aus", "plazentarem", "Restblut", "die", "Definition", ",", "Charakterisierung", "und", "Standardisierung", "fuer", "entsprechende", "Stammzelltransplantate", "erstellen", "zu", "koennen", ".", "Bisher", "wurden", "372", "Nabelschnurbluttransplantate", "(", "Stand", "10", ".", "05", ".", "1995", ")", "mit", "einer", "mittleren", "Volumenmenge", "von", "78", "+", "/-", "32", "ml", "und", "8,4", "+", "/-", "5", "-", "108", "Leukozyten", "fuer", "familiengerichtete", "Transplantate", "(", "n=12", ")", "und", "als", "unverwandte", "Stammzellasservate", "(", "n=360", ")", "abgenommen", ",", "charakterisiert", "und", "unsepariert", "in", "fluessigem", "Stickstoff", "gelagert", ".", "Die", "Abnahme", "des", "Plazentarestblutes", "(", "PR", ")", "erfolgte", "aus", "der", "Nabelschnurblutvene", "nach", "normalen", "Geburten", "(", "n=302", ")", "oder", "nach", "einem", "Kaiserschnitt", "(", "n=70", ")", ".", "Sowohl", "fuer", "die", "serologische", "als", "auch", "fuer", "die", "molekulargenetische", "HLA", "-", "Klasse", "-", "I-", "und", "-II", "-", "Typisierung", "wurden", "Methoden", "entwickelt", ",", "die", "eine", "komplette", "HLA", "-", "Typisierung", "aus", "1,5", "ml", "PR", "ermoeglichen", ".", "Zusaetzlich", "werden", "nur", "3,5", "ml", "fuer", "die", "Kontrolle", "der", "Sterilitaet", ",", "fuer", "die", "Bestimmung", "der", "Vorlaeuferzellen", "ueber", "Koloniebildungstests", "und", "CD", "34", "sowie", "die", "Testung", "auf", "kontaminierende", "muetterliche", "Zellen", "mit", "Hilfe", "der", "simultanen", "immunphaenotypischen", "und", "genotypischen", "Analyse", "oder", "der", "PCR", "-", "SSP", "fuer", "das", "nicht", "vererbte", "HLA", "-", "Allel", "der", "Mutter", "benoetigt", ".", "Die", "Seren", "der", "Mutter", "werden", "auf", "Hepatitis", "B", ",", "A", ",", "C", ",", "HIV1", ",", "HIV2", ",", "EBV", ",", "VCA", ",", "HTLVI", "-", "II", ",", "CMV", ",", "Toxoplasmose", "und", "TPHA", "getestet", "." ]
[ "umlsterm" ]
Nabelschnurbluttransplantationen is an umlsterm, Transplantationen is an umlsterm, Restblut is an umlsterm, Vorlaeuferzellen is an umlsterm, Restblut is an umlsterm, Nabelschnurbluttransplantate is an umlsterm, Leukozyten is an umlsterm, familiengerichtete is an umlsterm, Transplantate is an umlsterm, Stickstoff is an umlsterm, Nabelschnurblutvene is an umlsterm, Geburten is an umlsterm, Methoden is an umlsterm, HLA - Typisierung is an umlsterm, Sterilitaet is an umlsterm, Vorlaeuferzellen is an umlsterm, Zellen is an umlsterm, Analyse is an umlsterm, Mutter is an umlsterm, Mutter is an umlsterm, Hepatitis B is an umlsterm, EBV is an umlsterm, Toxoplasmose is an umlsterm
PerinatalMedizin.60080093.ger.abstr_task1
Sentence: Zusammenfassung . Wie bereits an ueber 44 Nabelschnurbluttransplantationen bei Geschwistern ( 34 HLA-identisch , 10 mit 1-3 HLA-Locus-Mismatchen ) und 6 unverwandten ( 1 HLA-identisch , 5 mit 1-3 HLA-Locus-Mismatchen ) Transplantationen gezeigt , ist das plazentare Restblut eine reiche Quelle haematopoetischer Stamm- und Vorlaeuferzellen . Aus diesem Grund wurde hier eine Pilotstudie gestartet , um aus plazentarem Restblut die Definition , Charakterisierung und Standardisierung fuer entsprechende Stammzelltransplantate erstellen zu koennen . Bisher wurden 372 Nabelschnurbluttransplantate ( Stand 10. 05. 1995 ) mit einer mittleren Volumenmenge von 78 +/- 32 ml und 8,4 +/- 5 - 108 Leukozyten fuer familiengerichtete Transplantate ( n=12) und als unverwandte Stammzellasservate ( n=360) abgenommen , charakterisiert und unsepariert in fluessigem Stickstoff gelagert . Die Abnahme des Plazentarestblutes ( PR ) erfolgte aus der Nabelschnurblutvene nach normalen Geburten ( n=302) oder nach einem Kaiserschnitt ( n=70). Sowohl fuer die serologische als auch fuer die molekulargenetische HLA-Klasse-I- und -II-Typisierung wurden Methoden entwickelt , die eine komplette HLA-Typisierung aus 1,5 ml PR ermoeglichen . Zusaetzlich werden nur 3,5 ml fuer die Kontrolle der Sterilitaet , fuer die Bestimmung der Vorlaeuferzellen ueber Koloniebildungstests und CD 34 sowie die Testung auf kontaminierende muetterliche Zellen mit Hilfe der simultanen immunphaenotypischen und genotypischen Analyse oder der PCR-SSP fuer das nicht vererbte HLA-Allel der Mutter benoetigt . Die Seren der Mutter werden auf Hepatitis B , A , C , HIV1, HIV2, EBV , VCA , HTLVI-II , CMV , Toxoplasmose und TPHA getestet . Instructions: please typing these entity words according to sentence: Nabelschnurbluttransplantationen, Transplantationen, Restblut, Vorlaeuferzellen, Restblut, Nabelschnurbluttransplantate, Leukozyten, familiengerichtete, Transplantate, Stickstoff, Nabelschnurblutvene, Geburten, Methoden, HLA - Typisierung, Sterilitaet, Vorlaeuferzellen, Zellen, Analyse, Mutter, Mutter, Hepatitis B, EBV, Toxoplasmose Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Zusammenfassung . Wie bereits an ueber 44 Nabelschnurbluttransplantationen bei Geschwistern ( 34 HLA-identisch , 10 mit 1-3 HLA-Locus-Mismatchen ) und 6 unverwandten ( 1 HLA-identisch , 5 mit 1-3 HLA-Locus-Mismatchen ) Transplantationen gezeigt , ist das plazentare Restblut eine reiche Quelle haematopoetischer Stamm- und Vorlaeuferzellen . Aus diesem Grund wurde hier eine Pilotstudie gestartet , um aus plazentarem Restblut die Definition , Charakterisierung und Standardisierung fuer entsprechende Stammzelltransplantate erstellen zu koennen . Bisher wurden 372 Nabelschnurbluttransplantate ( Stand 10. 05. 1995 ) mit einer mittleren Volumenmenge von 78 +/- 32 ml und 8,4 +/- 5 - 108 Leukozyten fuer familiengerichtete Transplantate ( n=12) und als unverwandte Stammzellasservate ( n=360) abgenommen , charakterisiert und unsepariert in fluessigem Stickstoff gelagert . Die Abnahme des Plazentarestblutes ( PR ) erfolgte aus der Nabelschnurblutvene nach normalen Geburten ( n=302) oder nach einem Kaiserschnitt ( n=70). Sowohl fuer die serologische als auch fuer die molekulargenetische HLA-Klasse-I- und -II-Typisierung wurden Methoden entwickelt , die eine komplette HLA-Typisierung aus 1,5 ml PR ermoeglichen . Zusaetzlich werden nur 3,5 ml fuer die Kontrolle der Sterilitaet , fuer die Bestimmung der Vorlaeuferzellen ueber Koloniebildungstests und CD 34 sowie die Testung auf kontaminierende muetterliche Zellen mit Hilfe der simultanen immunphaenotypischen und genotypischen Analyse oder der PCR-SSP fuer das nicht vererbte HLA-Allel der Mutter benoetigt . Die Seren der Mutter werden auf Hepatitis B , A , C , HIV1, HIV2, EBV , VCA , HTLVI-II , CMV , Toxoplasmose und TPHA getestet .
[ "Zusammenfassung", ".", "Wie", "bereits", "an", "ueber", "44", "Nabelschnurbluttransplantationen", "bei", "Geschwistern", "(", "34", "HLA", "-", "identisch", ",", "10", "mit", "1", "-", "3", "HLA", "-", "Locus", "-", "Mismatchen", ")", "und", "6", "unverwandten", "(", "1", "HLA", "-", "identisch", ",", "5", "mit", "1", "-", "3", "HLA", "-", "Locus", "-", "Mismatchen", ")", "Transplantationen", "gezeigt", ",", "ist", "das", "plazentare", "Restblut", "eine", "reiche", "Quelle", "haematopoetischer", "Stamm-", "und", "Vorlaeuferzellen", ".", "Aus", "diesem", "Grund", "wurde", "hier", "eine", "Pilotstudie", "gestartet", ",", "um", "aus", "plazentarem", "Restblut", "die", "Definition", ",", "Charakterisierung", "und", "Standardisierung", "fuer", "entsprechende", "Stammzelltransplantate", "erstellen", "zu", "koennen", ".", "Bisher", "wurden", "372", "Nabelschnurbluttransplantate", "(", "Stand", "10", ".", "05", ".", "1995", ")", "mit", "einer", "mittleren", "Volumenmenge", "von", "78", "+", "/-", "32", "ml", "und", "8,4", "+", "/-", "5", "-", "108", "Leukozyten", "fuer", "familiengerichtete", "Transplantate", "(", "n=12", ")", "und", "als", "unverwandte", "Stammzellasservate", "(", "n=360", ")", "abgenommen", ",", "charakterisiert", "und", "unsepariert", "in", "fluessigem", "Stickstoff", "gelagert", ".", "Die", "Abnahme", "des", "Plazentarestblutes", "(", "PR", ")", "erfolgte", "aus", "der", "Nabelschnurblutvene", "nach", "normalen", "Geburten", "(", "n=302", ")", "oder", "nach", "einem", "Kaiserschnitt", "(", "n=70", ")", ".", "Sowohl", "fuer", "die", "serologische", "als", "auch", "fuer", "die", "molekulargenetische", "HLA", "-", "Klasse", "-", "I-", "und", "-II", "-", "Typisierung", "wurden", "Methoden", "entwickelt", ",", "die", "eine", "komplette", "HLA", "-", "Typisierung", "aus", "1,5", "ml", "PR", "ermoeglichen", ".", "Zusaetzlich", "werden", "nur", "3,5", "ml", "fuer", "die", "Kontrolle", "der", "Sterilitaet", ",", "fuer", "die", "Bestimmung", "der", "Vorlaeuferzellen", "ueber", "Koloniebildungstests", "und", "CD", "34", "sowie", "die", "Testung", "auf", "kontaminierende", "muetterliche", "Zellen", "mit", "Hilfe", "der", "simultanen", "immunphaenotypischen", "und", "genotypischen", "Analyse", "oder", "der", "PCR", "-", "SSP", "fuer", "das", "nicht", "vererbte", "HLA", "-", "Allel", "der", "Mutter", "benoetigt", ".", "Die", "Seren", "der", "Mutter", "werden", "auf", "Hepatitis", "B", ",", "A", ",", "C", ",", "HIV1", ",", "HIV2", ",", "EBV", ",", "VCA", ",", "HTLVI", "-", "II", ",", "CMV", ",", "Toxoplasmose", "und", "TPHA", "getestet", "." ]
[ "umlsterm" ]
Nabelschnurbluttransplantationen, Transplantationen, Restblut, Vorlaeuferzellen, Restblut, Nabelschnurbluttransplantate, Leukozyten, familiengerichtete, Transplantate, Stickstoff, Nabelschnurblutvene, Geburten, Methoden, HLA - Typisierung, Sterilitaet, Vorlaeuferzellen, Zellen, Analyse, Mutter, Mutter, Hepatitis B, EBV, Toxoplasmose
PerinatalMedizin.60080093.ger.abstr_task2
Sentence: Zusammenfassung . Wie bereits an ueber 44 Nabelschnurbluttransplantationen bei Geschwistern ( 34 HLA-identisch , 10 mit 1-3 HLA-Locus-Mismatchen ) und 6 unverwandten ( 1 HLA-identisch , 5 mit 1-3 HLA-Locus-Mismatchen ) Transplantationen gezeigt , ist das plazentare Restblut eine reiche Quelle haematopoetischer Stamm- und Vorlaeuferzellen . Aus diesem Grund wurde hier eine Pilotstudie gestartet , um aus plazentarem Restblut die Definition , Charakterisierung und Standardisierung fuer entsprechende Stammzelltransplantate erstellen zu koennen . Bisher wurden 372 Nabelschnurbluttransplantate ( Stand 10. 05. 1995 ) mit einer mittleren Volumenmenge von 78 +/- 32 ml und 8,4 +/- 5 - 108 Leukozyten fuer familiengerichtete Transplantate ( n=12) und als unverwandte Stammzellasservate ( n=360) abgenommen , charakterisiert und unsepariert in fluessigem Stickstoff gelagert . Die Abnahme des Plazentarestblutes ( PR ) erfolgte aus der Nabelschnurblutvene nach normalen Geburten ( n=302) oder nach einem Kaiserschnitt ( n=70). Sowohl fuer die serologische als auch fuer die molekulargenetische HLA-Klasse-I- und -II-Typisierung wurden Methoden entwickelt , die eine komplette HLA-Typisierung aus 1,5 ml PR ermoeglichen . Zusaetzlich werden nur 3,5 ml fuer die Kontrolle der Sterilitaet , fuer die Bestimmung der Vorlaeuferzellen ueber Koloniebildungstests und CD 34 sowie die Testung auf kontaminierende muetterliche Zellen mit Hilfe der simultanen immunphaenotypischen und genotypischen Analyse oder der PCR-SSP fuer das nicht vererbte HLA-Allel der Mutter benoetigt . Die Seren der Mutter werden auf Hepatitis B , A , C , HIV1, HIV2, EBV , VCA , HTLVI-II , CMV , Toxoplasmose und TPHA getestet . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Zusammenfassung . Wie bereits an ueber 44 Nabelschnurbluttransplantationen bei Geschwistern ( 34 HLA-identisch , 10 mit 1-3 HLA-Locus-Mismatchen ) und 6 unverwandten ( 1 HLA-identisch , 5 mit 1-3 HLA-Locus-Mismatchen ) Transplantationen gezeigt , ist das plazentare Restblut eine reiche Quelle haematopoetischer Stamm- und Vorlaeuferzellen . Aus diesem Grund wurde hier eine Pilotstudie gestartet , um aus plazentarem Restblut die Definition , Charakterisierung und Standardisierung fuer entsprechende Stammzelltransplantate erstellen zu koennen . Bisher wurden 372 Nabelschnurbluttransplantate ( Stand 10. 05. 1995 ) mit einer mittleren Volumenmenge von 78 +/- 32 ml und 8,4 +/- 5 - 108 Leukozyten fuer familiengerichtete Transplantate ( n=12) und als unverwandte Stammzellasservate ( n=360) abgenommen , charakterisiert und unsepariert in fluessigem Stickstoff gelagert . Die Abnahme des Plazentarestblutes ( PR ) erfolgte aus der Nabelschnurblutvene nach normalen Geburten ( n=302) oder nach einem Kaiserschnitt ( n=70). Sowohl fuer die serologische als auch fuer die molekulargenetische HLA-Klasse-I- und -II-Typisierung wurden Methoden entwickelt , die eine komplette HLA-Typisierung aus 1,5 ml PR ermoeglichen . Zusaetzlich werden nur 3,5 ml fuer die Kontrolle der Sterilitaet , fuer die Bestimmung der Vorlaeuferzellen ueber Koloniebildungstests und CD 34 sowie die Testung auf kontaminierende muetterliche Zellen mit Hilfe der simultanen immunphaenotypischen und genotypischen Analyse oder der PCR-SSP fuer das nicht vererbte HLA-Allel der Mutter benoetigt . Die Seren der Mutter werden auf Hepatitis B , A , C , HIV1, HIV2, EBV , VCA , HTLVI-II , CMV , Toxoplasmose und TPHA getestet .
[ "Zusammenfassung", ".", "Wie", "bereits", "an", "ueber", "44", "Nabelschnurbluttransplantationen", "bei", "Geschwistern", "(", "34", "HLA", "-", "identisch", ",", "10", "mit", "1", "-", "3", "HLA", "-", "Locus", "-", "Mismatchen", ")", "und", "6", "unverwandten", "(", "1", "HLA", "-", "identisch", ",", "5", "mit", "1", "-", "3", "HLA", "-", "Locus", "-", "Mismatchen", ")", "Transplantationen", "gezeigt", ",", "ist", "das", "plazentare", "Restblut", "eine", "reiche", "Quelle", "haematopoetischer", "Stamm-", "und", "Vorlaeuferzellen", ".", "Aus", "diesem", "Grund", "wurde", "hier", "eine", "Pilotstudie", "gestartet", ",", "um", "aus", "plazentarem", "Restblut", "die", "Definition", ",", "Charakterisierung", "und", "Standardisierung", "fuer", "entsprechende", "Stammzelltransplantate", "erstellen", "zu", "koennen", ".", "Bisher", "wurden", "372", "Nabelschnurbluttransplantate", "(", "Stand", "10", ".", "05", ".", "1995", ")", "mit", "einer", "mittleren", "Volumenmenge", "von", "78", "+", "/-", "32", "ml", "und", "8,4", "+", "/-", "5", "-", "108", "Leukozyten", "fuer", "familiengerichtete", "Transplantate", "(", "n=12", ")", "und", "als", "unverwandte", "Stammzellasservate", "(", "n=360", ")", "abgenommen", ",", "charakterisiert", "und", "unsepariert", "in", "fluessigem", "Stickstoff", "gelagert", ".", "Die", "Abnahme", "des", "Plazentarestblutes", "(", "PR", ")", "erfolgte", "aus", "der", "Nabelschnurblutvene", "nach", "normalen", "Geburten", "(", "n=302", ")", "oder", "nach", "einem", "Kaiserschnitt", "(", "n=70", ")", ".", "Sowohl", "fuer", "die", "serologische", "als", "auch", "fuer", "die", "molekulargenetische", "HLA", "-", "Klasse", "-", "I-", "und", "-II", "-", "Typisierung", "wurden", "Methoden", "entwickelt", ",", "die", "eine", "komplette", "HLA", "-", "Typisierung", "aus", "1,5", "ml", "PR", "ermoeglichen", ".", "Zusaetzlich", "werden", "nur", "3,5", "ml", "fuer", "die", "Kontrolle", "der", "Sterilitaet", ",", "fuer", "die", "Bestimmung", "der", "Vorlaeuferzellen", "ueber", "Koloniebildungstests", "und", "CD", "34", "sowie", "die", "Testung", "auf", "kontaminierende", "muetterliche", "Zellen", "mit", "Hilfe", "der", "simultanen", "immunphaenotypischen", "und", "genotypischen", "Analyse", "oder", "der", "PCR", "-", "SSP", "fuer", "das", "nicht", "vererbte", "HLA", "-", "Allel", "der", "Mutter", "benoetigt", ".", "Die", "Seren", "der", "Mutter", "werden", "auf", "Hepatitis", "B", ",", "A", ",", "C", ",", "HIV1", ",", "HIV2", ",", "EBV", ",", "VCA", ",", "HTLVI", "-", "II", ",", "CMV", ",", "Toxoplasmose", "und", "TPHA", "getestet", "." ]
[ "umlsterm" ]
whiplash is an umlsterm, therapeutic is an umlsterm, Patients is an umlsterm, patients is an umlsterm, neurologic deficits is an umlsterm, therapeutic is an umlsterm
DerOrthopaede.80270841.eng.abstr_task0
Sentence: In the case of typical whiplash after low- energy rear-end collision we recommend a clear and structured therapeutic regimen to overcome and prevent neuromuscular deficits . Patients with bony and discoligamentous lesions have to be excluded , as well as patients with distinct neurologic deficits . A therapeutic rationale is the basis of full neuromuscular recovery ad integrum . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In the case of typical whiplash after low- energy rear-end collision we recommend a clear and structured therapeutic regimen to overcome and prevent neuromuscular deficits . Patients with bony and discoligamentous lesions have to be excluded , as well as patients with distinct neurologic deficits . A therapeutic rationale is the basis of full neuromuscular recovery ad integrum .
[ "In", "the", "case", "of", "typical", "whiplash", "after", "low-", "energy", "rear", "-", "end", "collision", "we", "recommend", "a", "clear", "and", "structured", "therapeutic", "regimen", "to", "overcome", "and", "prevent", "neuromuscular", "deficits", ".", "Patients", "with", "bony", "and", "discoligamentous", "lesions", "have", "to", "be", "excluded", ",", "as", "well", "as", "patients", "with", "distinct", "neurologic", "deficits", ".", "A", "therapeutic", "rationale", "is", "the", "basis", "of", "full", "neuromuscular", "recovery", "ad", "integrum", "." ]
[ "umlsterm" ]
whiplash is an umlsterm, therapeutic is an umlsterm, Patients is an umlsterm, patients is an umlsterm, neurologic deficits is an umlsterm, therapeutic is an umlsterm
DerOrthopaede.80270841.eng.abstr_task1
Sentence: In the case of typical whiplash after low- energy rear-end collision we recommend a clear and structured therapeutic regimen to overcome and prevent neuromuscular deficits . Patients with bony and discoligamentous lesions have to be excluded , as well as patients with distinct neurologic deficits . A therapeutic rationale is the basis of full neuromuscular recovery ad integrum . Instructions: please typing these entity words according to sentence: whiplash, therapeutic, Patients, patients, neurologic deficits, therapeutic Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In the case of typical whiplash after low- energy rear-end collision we recommend a clear and structured therapeutic regimen to overcome and prevent neuromuscular deficits . Patients with bony and discoligamentous lesions have to be excluded , as well as patients with distinct neurologic deficits . A therapeutic rationale is the basis of full neuromuscular recovery ad integrum .
[ "In", "the", "case", "of", "typical", "whiplash", "after", "low-", "energy", "rear", "-", "end", "collision", "we", "recommend", "a", "clear", "and", "structured", "therapeutic", "regimen", "to", "overcome", "and", "prevent", "neuromuscular", "deficits", ".", "Patients", "with", "bony", "and", "discoligamentous", "lesions", "have", "to", "be", "excluded", ",", "as", "well", "as", "patients", "with", "distinct", "neurologic", "deficits", ".", "A", "therapeutic", "rationale", "is", "the", "basis", "of", "full", "neuromuscular", "recovery", "ad", "integrum", "." ]
[ "umlsterm" ]
whiplash, therapeutic, Patients, patients, neurologic deficits, therapeutic
DerOrthopaede.80270841.eng.abstr_task2
Sentence: In the case of typical whiplash after low- energy rear-end collision we recommend a clear and structured therapeutic regimen to overcome and prevent neuromuscular deficits . Patients with bony and discoligamentous lesions have to be excluded , as well as patients with distinct neurologic deficits . A therapeutic rationale is the basis of full neuromuscular recovery ad integrum . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In the case of typical whiplash after low- energy rear-end collision we recommend a clear and structured therapeutic regimen to overcome and prevent neuromuscular deficits . Patients with bony and discoligamentous lesions have to be excluded , as well as patients with distinct neurologic deficits . A therapeutic rationale is the basis of full neuromuscular recovery ad integrum .
[ "In", "the", "case", "of", "typical", "whiplash", "after", "low-", "energy", "rear", "-", "end", "collision", "we", "recommend", "a", "clear", "and", "structured", "therapeutic", "regimen", "to", "overcome", "and", "prevent", "neuromuscular", "deficits", ".", "Patients", "with", "bony", "and", "discoligamentous", "lesions", "have", "to", "be", "excluded", ",", "as", "well", "as", "patients", "with", "distinct", "neurologic", "deficits", ".", "A", "therapeutic", "rationale", "is", "the", "basis", "of", "full", "neuromuscular", "recovery", "ad", "integrum", "." ]
[ "umlsterm" ]
recovery times is a Outcome_Other, desflurane is a Intervention_Pharmacological, isoflurane is a Intervention_Pharmacological, outpatient anesthesia is a Participant_Condition, recovery and discharge times is a Outcome_Other, procedures greater than 2 hours in length is a Participant_Condition, Thirty - three is a Participant_Sample-size, 18 to 70 is a Participant_Age, propofol is a Intervention_Pharmacological, time to emergence and time to meeting discharge criteria . is a Outcome_Other, intraoperative vital signs and postoperative emesis and opioid requirements is a Outcome_Physical
92978_task0
Sentence: A comparison of the recovery times of desflurane and isoflurane in outpatient anesthesia . The low solubility of desflurane has been shown to contribute to faster awakening from anesthesia when compared with other anesthetics in common use . However , research has failed to consistently demonstrate faster discharge times from the postanesthesia care unit following the use of desflurane . This study was undertaken to compare the recovery and discharge times of outpatients undergoing procedures greater than 2 hours in length . Thirty-three patients aged 18 to 70 years were randomized to receive either desflurane or isoflurane following a standard intravenous induction with propofol . Patients received premedication and opioids consistent with institutional practice , and inhalation agents were titrated to effect during anesthetic maintenance . Following surgery , patients were evaluated for time to emergence and time to meeting discharge criteria . The results demonstrated no differences between the emergence or discharge times following desflurane or isoflurane . In addition , measured parameters , such as intraoperative vital signs and postoperative emesis and opioid requirements , were not different between the groups . The use of desflurane as part of a balanced anesthetic technique did not speed the emergence or discharge time when compared with isoflurane . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A comparison of the recovery times of desflurane and isoflurane in outpatient anesthesia . The low solubility of desflurane has been shown to contribute to faster awakening from anesthesia when compared with other anesthetics in common use . However , research has failed to consistently demonstrate faster discharge times from the postanesthesia care unit following the use of desflurane . This study was undertaken to compare the recovery and discharge times of outpatients undergoing procedures greater than 2 hours in length . Thirty-three patients aged 18 to 70 years were randomized to receive either desflurane or isoflurane following a standard intravenous induction with propofol . Patients received premedication and opioids consistent with institutional practice , and inhalation agents were titrated to effect during anesthetic maintenance . Following surgery , patients were evaluated for time to emergence and time to meeting discharge criteria . The results demonstrated no differences between the emergence or discharge times following desflurane or isoflurane . In addition , measured parameters , such as intraoperative vital signs and postoperative emesis and opioid requirements , were not different between the groups . The use of desflurane as part of a balanced anesthetic technique did not speed the emergence or discharge time when compared with isoflurane .
[ "A", "comparison", "of", "the", "recovery", "times", "of", "desflurane", "and", "isoflurane", "in", "outpatient", "anesthesia", ".", "The", "low", "solubility", "of", "desflurane", "has", "been", "shown", "to", "contribute", "to", "faster", "awakening", "from", "anesthesia", "when", "compared", "with", "other", "anesthetics", "in", "common", "use", ".", "However", ",", "research", "has", "failed", "to", "consistently", "demonstrate", "faster", "discharge", "times", "from", "the", "postanesthesia", "care", "unit", "following", "the", "use", "of", "desflurane", ".", "This", "study", "was", "undertaken", "to", "compare", "the", "recovery", "and", "discharge", "times", "of", "outpatients", "undergoing", "procedures", "greater", "than", "2", "hours", "in", "length", ".", "Thirty", "-", "three", "patients", "aged", "18", "to", "70", "years", "were", "randomized", "to", "receive", "either", "desflurane", "or", "isoflurane", "following", "a", "standard", "intravenous", "induction", "with", "propofol", ".", "Patients", "received", "premedication", "and", "opioids", "consistent", "with", "institutional", "practice", ",", "and", "inhalation", "agents", "were", "titrated", "to", "effect", "during", "anesthetic", "maintenance", ".", "Following", "surgery", ",", "patients", "were", "evaluated", "for", "time", "to", "emergence", "and", "time", "to", "meeting", "discharge", "criteria", ".", "The", "results", "demonstrated", "no", "differences", "between", "the", "emergence", "or", "discharge", "times", "following", "desflurane", "or", "isoflurane", ".", "In", "addition", ",", "measured", "parameters", ",", "such", "as", "intraoperative", "vital", "signs", "and", "postoperative", "emesis", "and", "opioid", "requirements", ",", "were", "not", "different", "between", "the", "groups", ".", "The", "use", "of", "desflurane", "as", "part", "of", "a", "balanced", "anesthetic", "technique", "did", "not", "speed", "the", "emergence", "or", "discharge", "time", "when", "compared", "with", "isoflurane", "." ]
[ "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Participant_Sample-size", "Intervention_Pharmacological", "Participant_Age" ]
recovery times is a Outcome_Other, desflurane is a Intervention_Pharmacological, isoflurane is a Intervention_Pharmacological, outpatient anesthesia is a Participant_Condition, recovery and discharge times is a Outcome_Other, procedures greater than 2 hours in length is a Participant_Condition, Thirty - three is a Participant_Sample-size, 18 to 70 is a Participant_Age, propofol is a Intervention_Pharmacological, time to emergence and time to meeting discharge criteria . is a Outcome_Other, intraoperative vital signs and postoperative emesis and opioid requirements is a Outcome_Physical
92978_task1
Sentence: A comparison of the recovery times of desflurane and isoflurane in outpatient anesthesia . The low solubility of desflurane has been shown to contribute to faster awakening from anesthesia when compared with other anesthetics in common use . However , research has failed to consistently demonstrate faster discharge times from the postanesthesia care unit following the use of desflurane . This study was undertaken to compare the recovery and discharge times of outpatients undergoing procedures greater than 2 hours in length . Thirty-three patients aged 18 to 70 years were randomized to receive either desflurane or isoflurane following a standard intravenous induction with propofol . Patients received premedication and opioids consistent with institutional practice , and inhalation agents were titrated to effect during anesthetic maintenance . Following surgery , patients were evaluated for time to emergence and time to meeting discharge criteria . The results demonstrated no differences between the emergence or discharge times following desflurane or isoflurane . In addition , measured parameters , such as intraoperative vital signs and postoperative emesis and opioid requirements , were not different between the groups . The use of desflurane as part of a balanced anesthetic technique did not speed the emergence or discharge time when compared with isoflurane . Instructions: please typing these entity words according to sentence: recovery times, desflurane, isoflurane, outpatient anesthesia, recovery and discharge times, procedures greater than 2 hours in length, Thirty - three, 18 to 70, propofol, time to emergence and time to meeting discharge criteria ., intraoperative vital signs and postoperative emesis and opioid requirements Options: Intervention_Pharmacological, Participant_Condition, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A comparison of the recovery times of desflurane and isoflurane in outpatient anesthesia . The low solubility of desflurane has been shown to contribute to faster awakening from anesthesia when compared with other anesthetics in common use . However , research has failed to consistently demonstrate faster discharge times from the postanesthesia care unit following the use of desflurane . This study was undertaken to compare the recovery and discharge times of outpatients undergoing procedures greater than 2 hours in length . Thirty-three patients aged 18 to 70 years were randomized to receive either desflurane or isoflurane following a standard intravenous induction with propofol . Patients received premedication and opioids consistent with institutional practice , and inhalation agents were titrated to effect during anesthetic maintenance . Following surgery , patients were evaluated for time to emergence and time to meeting discharge criteria . The results demonstrated no differences between the emergence or discharge times following desflurane or isoflurane . In addition , measured parameters , such as intraoperative vital signs and postoperative emesis and opioid requirements , were not different between the groups . The use of desflurane as part of a balanced anesthetic technique did not speed the emergence or discharge time when compared with isoflurane .
[ "A", "comparison", "of", "the", "recovery", "times", "of", "desflurane", "and", "isoflurane", "in", "outpatient", "anesthesia", ".", "The", "low", "solubility", "of", "desflurane", "has", "been", "shown", "to", "contribute", "to", "faster", "awakening", "from", "anesthesia", "when", "compared", "with", "other", "anesthetics", "in", "common", "use", ".", "However", ",", "research", "has", "failed", "to", "consistently", "demonstrate", "faster", "discharge", "times", "from", "the", "postanesthesia", "care", "unit", "following", "the", "use", "of", "desflurane", ".", "This", "study", "was", "undertaken", "to", "compare", "the", "recovery", "and", "discharge", "times", "of", "outpatients", "undergoing", "procedures", "greater", "than", "2", "hours", "in", "length", ".", "Thirty", "-", "three", "patients", "aged", "18", "to", "70", "years", "were", "randomized", "to", "receive", "either", "desflurane", "or", "isoflurane", "following", "a", "standard", "intravenous", "induction", "with", "propofol", ".", "Patients", "received", "premedication", "and", "opioids", "consistent", "with", "institutional", "practice", ",", "and", "inhalation", "agents", "were", "titrated", "to", "effect", "during", "anesthetic", "maintenance", ".", "Following", "surgery", ",", "patients", "were", "evaluated", "for", "time", "to", "emergence", "and", "time", "to", "meeting", "discharge", "criteria", ".", "The", "results", "demonstrated", "no", "differences", "between", "the", "emergence", "or", "discharge", "times", "following", "desflurane", "or", "isoflurane", ".", "In", "addition", ",", "measured", "parameters", ",", "such", "as", "intraoperative", "vital", "signs", "and", "postoperative", "emesis", "and", "opioid", "requirements", ",", "were", "not", "different", "between", "the", "groups", ".", "The", "use", "of", "desflurane", "as", "part", "of", "a", "balanced", "anesthetic", "technique", "did", "not", "speed", "the", "emergence", "or", "discharge", "time", "when", "compared", "with", "isoflurane", "." ]
[ "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Participant_Sample-size", "Intervention_Pharmacological", "Participant_Age" ]
recovery times, desflurane, isoflurane, outpatient anesthesia, recovery and discharge times, procedures greater than 2 hours in length, Thirty - three, 18 to 70, propofol, time to emergence and time to meeting discharge criteria ., intraoperative vital signs and postoperative emesis and opioid requirements
92978_task2
Sentence: A comparison of the recovery times of desflurane and isoflurane in outpatient anesthesia . The low solubility of desflurane has been shown to contribute to faster awakening from anesthesia when compared with other anesthetics in common use . However , research has failed to consistently demonstrate faster discharge times from the postanesthesia care unit following the use of desflurane . This study was undertaken to compare the recovery and discharge times of outpatients undergoing procedures greater than 2 hours in length . Thirty-three patients aged 18 to 70 years were randomized to receive either desflurane or isoflurane following a standard intravenous induction with propofol . Patients received premedication and opioids consistent with institutional practice , and inhalation agents were titrated to effect during anesthetic maintenance . Following surgery , patients were evaluated for time to emergence and time to meeting discharge criteria . The results demonstrated no differences between the emergence or discharge times following desflurane or isoflurane . In addition , measured parameters , such as intraoperative vital signs and postoperative emesis and opioid requirements , were not different between the groups . The use of desflurane as part of a balanced anesthetic technique did not speed the emergence or discharge time when compared with isoflurane . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A comparison of the recovery times of desflurane and isoflurane in outpatient anesthesia . The low solubility of desflurane has been shown to contribute to faster awakening from anesthesia when compared with other anesthetics in common use . However , research has failed to consistently demonstrate faster discharge times from the postanesthesia care unit following the use of desflurane . This study was undertaken to compare the recovery and discharge times of outpatients undergoing procedures greater than 2 hours in length . Thirty-three patients aged 18 to 70 years were randomized to receive either desflurane or isoflurane following a standard intravenous induction with propofol . Patients received premedication and opioids consistent with institutional practice , and inhalation agents were titrated to effect during anesthetic maintenance . Following surgery , patients were evaluated for time to emergence and time to meeting discharge criteria . The results demonstrated no differences between the emergence or discharge times following desflurane or isoflurane . In addition , measured parameters , such as intraoperative vital signs and postoperative emesis and opioid requirements , were not different between the groups . The use of desflurane as part of a balanced anesthetic technique did not speed the emergence or discharge time when compared with isoflurane .
[ "A", "comparison", "of", "the", "recovery", "times", "of", "desflurane", "and", "isoflurane", "in", "outpatient", "anesthesia", ".", "The", "low", "solubility", "of", "desflurane", "has", "been", "shown", "to", "contribute", "to", "faster", "awakening", "from", "anesthesia", "when", "compared", "with", "other", "anesthetics", "in", "common", "use", ".", "However", ",", "research", "has", "failed", "to", "consistently", "demonstrate", "faster", "discharge", "times", "from", "the", "postanesthesia", "care", "unit", "following", "the", "use", "of", "desflurane", ".", "This", "study", "was", "undertaken", "to", "compare", "the", "recovery", "and", "discharge", "times", "of", "outpatients", "undergoing", "procedures", "greater", "than", "2", "hours", "in", "length", ".", "Thirty", "-", "three", "patients", "aged", "18", "to", "70", "years", "were", "randomized", "to", "receive", "either", "desflurane", "or", "isoflurane", "following", "a", "standard", "intravenous", "induction", "with", "propofol", ".", "Patients", "received", "premedication", "and", "opioids", "consistent", "with", "institutional", "practice", ",", "and", "inhalation", "agents", "were", "titrated", "to", "effect", "during", "anesthetic", "maintenance", ".", "Following", "surgery", ",", "patients", "were", "evaluated", "for", "time", "to", "emergence", "and", "time", "to", "meeting", "discharge", "criteria", ".", "The", "results", "demonstrated", "no", "differences", "between", "the", "emergence", "or", "discharge", "times", "following", "desflurane", "or", "isoflurane", ".", "In", "addition", ",", "measured", "parameters", ",", "such", "as", "intraoperative", "vital", "signs", "and", "postoperative", "emesis", "and", "opioid", "requirements", ",", "were", "not", "different", "between", "the", "groups", ".", "The", "use", "of", "desflurane", "as", "part", "of", "a", "balanced", "anesthetic", "technique", "did", "not", "speed", "the", "emergence", "or", "discharge", "time", "when", "compared", "with", "isoflurane", "." ]
[ "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Participant_Sample-size", "Intervention_Pharmacological", "Participant_Age" ]
BMP is a protein-family, BMPs is a protein-family, BMP is a protein-family, noggin is a protein, follistatin is a protein, BMPs is a protein-family
1.0alpha7.train.656_task0
Sentence: BMP signaling is determined by expression patterns of BMPs, their receptors, and soluble BMP antagonists, such as noggin and follistatin, which directly bind BMPs and prevent functional receptor/ligand interaction (for review, see Cho and Blitz, 1998). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein
[ "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
BMP signaling is determined by expression patterns of BMPs, their receptors, and soluble BMP antagonists, such as noggin and follistatin, which directly bind BMPs and prevent functional receptor/ligand interaction (for review, see Cho and Blitz, 1998).
[ "BMP", "signaling", "is", "determined", "by", "expression", "patterns", "of", "BMPs", ",", "their", "receptors", ",", "and", "soluble", "BMP", "antagonists", ",", "such", "as", "noggin", "and", "follistatin", ",", "which", "directly", "bind", "BMPs", "and", "prevent", "functional", "receptor", "/", "ligand", "interaction", "(", "for", "review", ",", "see", "Cho", "and", "Blitz", ",", "1998", ")", "." ]
[ "protein", "protein-family" ]
BMP is a protein-family, BMPs is a protein-family, BMP is a protein-family, noggin is a protein, follistatin is a protein, BMPs is a protein-family
1.0alpha7.train.656_task1
Sentence: BMP signaling is determined by expression patterns of BMPs, their receptors, and soluble BMP antagonists, such as noggin and follistatin, which directly bind BMPs and prevent functional receptor/ligand interaction (for review, see Cho and Blitz, 1998). Instructions: please typing these entity words according to sentence: BMP, BMPs, BMP, noggin, follistatin, BMPs Options: protein-family, protein
[ "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
BMP signaling is determined by expression patterns of BMPs, their receptors, and soluble BMP antagonists, such as noggin and follistatin, which directly bind BMPs and prevent functional receptor/ligand interaction (for review, see Cho and Blitz, 1998).
[ "BMP", "signaling", "is", "determined", "by", "expression", "patterns", "of", "BMPs", ",", "their", "receptors", ",", "and", "soluble", "BMP", "antagonists", ",", "such", "as", "noggin", "and", "follistatin", ",", "which", "directly", "bind", "BMPs", "and", "prevent", "functional", "receptor", "/", "ligand", "interaction", "(", "for", "review", ",", "see", "Cho", "and", "Blitz", ",", "1998", ")", "." ]
[ "protein", "protein-family" ]
BMP, BMPs, BMP, noggin, follistatin, BMPs
1.0alpha7.train.656_task2
Sentence: BMP signaling is determined by expression patterns of BMPs, their receptors, and soluble BMP antagonists, such as noggin and follistatin, which directly bind BMPs and prevent functional receptor/ligand interaction (for review, see Cho and Blitz, 1998). Instructions: please extract entity words from the input sentence
[ "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
BMP signaling is determined by expression patterns of BMPs, their receptors, and soluble BMP antagonists, such as noggin and follistatin, which directly bind BMPs and prevent functional receptor/ligand interaction (for review, see Cho and Blitz, 1998).
[ "BMP", "signaling", "is", "determined", "by", "expression", "patterns", "of", "BMPs", ",", "their", "receptors", ",", "and", "soluble", "BMP", "antagonists", ",", "such", "as", "noggin", "and", "follistatin", ",", "which", "directly", "bind", "BMPs", "and", "prevent", "functional", "receptor", "/", "ligand", "interaction", "(", "for", "review", ",", "see", "Cho", "and", "Blitz", ",", "1998", ")", "." ]
[ "protein", "protein-family" ]
supervised multimodal exercise intervention is a Intervention_Physical, chemotherapy is a Intervention_Physical, cancer - related fatigue . is a Participant_Condition, Cancer related fatigue ( CRF ) is a Outcome_Physical, adjunct to chemotherapy and standard care is a Intervention_Physical, CRF level is a Outcome_Physical, into is a Participant_Condition, intervention group is a Intervention_Physical, wait - list control group is a Intervention_Control, Fatigue score ( CRF ) is a Outcome_Physical, Functional Assessment of Cancer Therapy - Anaemia Questionnaire ( FACT - An- ) ( FACT - G score & FACT - An Anemia subscale ) is a Outcome_Physical, Supervised exercise , comprising high - intensity cardiovascular and heavy resistance training , relaxation- and body awareness training and massage is a Intervention_Physical, Fatigue score reduction is a Outcome_Physical, FACT - An score is a Outcome_Physical, FACT - An Toi is a Outcome_Physical, Anaemia - ANS is a Outcome_Physical, General Quality of Life score is a Outcome_Other, individual wellbeing scores ; Physical is a Outcome_Physical, Emotional is a Outcome_Physical, Social is a Outcome_Physical, self - reported CRF is a Outcome_Physical
56983_task0
Sentence: The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue . PURPOSE Cancer related fatigue ( CRF ) is a common problem for cancer patients across diagnoses during chemotherapy and is associated with physical inactivity , lower functional level and lack of energy . Few RCT exercise intervention studies have included cancer patients undergoing chemotherapy . The objective of this study is to evaluate whether a six-week supervised multimodal exercise intervention , adjunct to chemotherapy and standard care , can reduce the patient 's CRF level . METHODS Data is based on analyses of a prospective randomised controlled trial 'The Body & Cancer Trial ' . 213 cancer patients with different diagnoses were randomised into an intervention group or wait-list control group . The primary outcome , Fatigue score ( CRF ) , was evaluated by the Functional Assessment of Cancer Therapy-Anaemia Questionnaire ( FACT-An- ) ( FACT-G score & FACT-An Anemia subscale ) . INTERVENTION Supervised exercise , comprising high-intensity cardiovascular and heavy resistance training , relaxation- and body awareness training and massage , 9 h weekly for 6 weeks . RESULTS CRF was significantly reduced in the intervention group , corresponding to a Fatigue score reduction of 3.04 ( effect size of 0.44 , 95 % CI 0.17-0.72 ) ( P = .002 ) , the FACT-An score by 5.40 ( P = .015 ) , the FACT-An Toi score by 5.22 ( P = .009 ) and the Anaemia-ANS by 3.76 ( P = .002 ) . There was no statistically significant effect on the General Quality of Life score ( FACT-G ) or on any of the individual wellbeing scores ; Physical ( P = .13 ) , Emotional ( P = .87 ) , Social ( P = .83 ) and Functional ( P = .26 ) . CONCLUSION In summary , this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other
[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]
The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue . PURPOSE Cancer related fatigue ( CRF ) is a common problem for cancer patients across diagnoses during chemotherapy and is associated with physical inactivity , lower functional level and lack of energy . Few RCT exercise intervention studies have included cancer patients undergoing chemotherapy . The objective of this study is to evaluate whether a six-week supervised multimodal exercise intervention , adjunct to chemotherapy and standard care , can reduce the patient 's CRF level . METHODS Data is based on analyses of a prospective randomised controlled trial 'The Body & Cancer Trial ' . 213 cancer patients with different diagnoses were randomised into an intervention group or wait-list control group . The primary outcome , Fatigue score ( CRF ) , was evaluated by the Functional Assessment of Cancer Therapy-Anaemia Questionnaire ( FACT-An- ) ( FACT-G score & FACT-An Anemia subscale ) . INTERVENTION Supervised exercise , comprising high-intensity cardiovascular and heavy resistance training , relaxation- and body awareness training and massage , 9 h weekly for 6 weeks . RESULTS CRF was significantly reduced in the intervention group , corresponding to a Fatigue score reduction of 3.04 ( effect size of 0.44 , 95 % CI 0.17-0.72 ) ( P = .002 ) , the FACT-An score by 5.40 ( P = .015 ) , the FACT-An Toi score by 5.22 ( P = .009 ) and the Anaemia-ANS by 3.76 ( P = .002 ) . There was no statistically significant effect on the General Quality of Life score ( FACT-G ) or on any of the individual wellbeing scores ; Physical ( P = .13 ) , Emotional ( P = .87 ) , Social ( P = .83 ) and Functional ( P = .26 ) . CONCLUSION In summary , this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy .
[ "The", "effects", "of", "a", "six", "-", "week", "supervised", "multimodal", "exercise", "intervention", "during", "chemotherapy", "on", "cancer", "-", "related", "fatigue", ".", "PURPOSE", "Cancer", "related", "fatigue", "(", "CRF", ")", "is", "a", "common", "problem", "for", "cancer", "patients", "across", "diagnoses", "during", "chemotherapy", "and", "is", "associated", "with", "physical", "inactivity", ",", "lower", "functional", "level", "and", "lack", "of", "energy", ".", "Few", "RCT", "exercise", "intervention", "studies", "have", "included", "cancer", "patients", "undergoing", "chemotherapy", ".", "The", "objective", "of", "this", "study", "is", "to", "evaluate", "whether", "a", "six", "-", "week", "supervised", "multimodal", "exercise", "intervention", ",", "adjunct", "to", "chemotherapy", "and", "standard", "care", ",", "can", "reduce", "the", "patient", "'", "s", "CRF", "level", ".", "METHODS", "Data", "is", "based", "on", "analyses", "of", "a", "prospective", "randomised", "controlled", "trial", "'", "The", "Body", "&", "Cancer", "Trial", "'", ".", "213", "cancer", "patients", "with", "different", "diagnoses", "were", "randomised", "into", "an", "intervention", "group", "or", "wait", "-", "list", "control", "group", ".", "The", "primary", "outcome", ",", "Fatigue", "score", "(", "CRF", ")", ",", "was", "evaluated", "by", "the", "Functional", "Assessment", "of", "Cancer", "Therapy", "-", "Anaemia", "Questionnaire", "(", "FACT", "-", "An-", ")", "(", "FACT", "-", "G", "score", "&", "FACT", "-", "An", "Anemia", "subscale", ")", ".", "INTERVENTION", "Supervised", "exercise", ",", "comprising", "high", "-", "intensity", "cardiovascular", "and", "heavy", "resistance", "training", ",", "relaxation-", "and", "body", "awareness", "training", "and", "massage", ",", "9", "h", "weekly", "for", "6", "weeks", ".", "RESULTS", "CRF", "was", "significantly", "reduced", "in", "the", "intervention", "group", ",", "corresponding", "to", "a", "Fatigue", "score", "reduction", "of", "3.04", "(", "effect", "size", "of", "0.44", ",", "95", "%", "CI", "0.17", "-", "0.72", ")", "(", "P", "=", ".002", ")", ",", "the", "FACT", "-", "An", "score", "by", "5.40", "(", "P", "=", ".015", ")", ",", "the", "FACT", "-", "An", "Toi", "score", "by", "5.22", "(", "P", "=", ".009", ")", "and", "the", "Anaemia", "-", "ANS", "by", "3.76", "(", "P", "=", ".002", ")", ".", "There", "was", "no", "statistically", "significant", "effect", "on", "the", "General", "Quality", "of", "Life", "score", "(", "FACT", "-", "G", ")", "or", "on", "any", "of", "the", "individual", "wellbeing", "scores", ";", "Physical", "(", "P", "=", ".13", ")", ",", "Emotional", "(", "P", "=", ".87", ")", ",", "Social", "(", "P", "=", ".83", ")", "and", "Functional", "(", "P", "=", ".26", ")", ".", "CONCLUSION", "In", "summary", ",", "this", "six", "-", "week", "supervised", "multimodal", "exercise", "intervention", "can", "lead", "to", "significant", "reduction", "in", "self", "-", "reported", "CRF", "in", "cancer", "patients", "undergoing", "chemotherapy", "." ]
[ "Intervention_Physical", "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Control" ]
supervised multimodal exercise intervention is a Intervention_Physical, chemotherapy is a Intervention_Physical, cancer - related fatigue . is a Participant_Condition, Cancer related fatigue ( CRF ) is a Outcome_Physical, adjunct to chemotherapy and standard care is a Intervention_Physical, CRF level is a Outcome_Physical, into is a Participant_Condition, intervention group is a Intervention_Physical, wait - list control group is a Intervention_Control, Fatigue score ( CRF ) is a Outcome_Physical, Functional Assessment of Cancer Therapy - Anaemia Questionnaire ( FACT - An- ) ( FACT - G score & FACT - An Anemia subscale ) is a Outcome_Physical, Supervised exercise , comprising high - intensity cardiovascular and heavy resistance training , relaxation- and body awareness training and massage is a Intervention_Physical, Fatigue score reduction is a Outcome_Physical, FACT - An score is a Outcome_Physical, FACT - An Toi is a Outcome_Physical, Anaemia - ANS is a Outcome_Physical, General Quality of Life score is a Outcome_Other, individual wellbeing scores ; Physical is a Outcome_Physical, Emotional is a Outcome_Physical, Social is a Outcome_Physical, self - reported CRF is a Outcome_Physical
56983_task1
Sentence: The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue . PURPOSE Cancer related fatigue ( CRF ) is a common problem for cancer patients across diagnoses during chemotherapy and is associated with physical inactivity , lower functional level and lack of energy . Few RCT exercise intervention studies have included cancer patients undergoing chemotherapy . The objective of this study is to evaluate whether a six-week supervised multimodal exercise intervention , adjunct to chemotherapy and standard care , can reduce the patient 's CRF level . METHODS Data is based on analyses of a prospective randomised controlled trial 'The Body & Cancer Trial ' . 213 cancer patients with different diagnoses were randomised into an intervention group or wait-list control group . The primary outcome , Fatigue score ( CRF ) , was evaluated by the Functional Assessment of Cancer Therapy-Anaemia Questionnaire ( FACT-An- ) ( FACT-G score & FACT-An Anemia subscale ) . INTERVENTION Supervised exercise , comprising high-intensity cardiovascular and heavy resistance training , relaxation- and body awareness training and massage , 9 h weekly for 6 weeks . RESULTS CRF was significantly reduced in the intervention group , corresponding to a Fatigue score reduction of 3.04 ( effect size of 0.44 , 95 % CI 0.17-0.72 ) ( P = .002 ) , the FACT-An score by 5.40 ( P = .015 ) , the FACT-An Toi score by 5.22 ( P = .009 ) and the Anaemia-ANS by 3.76 ( P = .002 ) . There was no statistically significant effect on the General Quality of Life score ( FACT-G ) or on any of the individual wellbeing scores ; Physical ( P = .13 ) , Emotional ( P = .87 ) , Social ( P = .83 ) and Functional ( P = .26 ) . CONCLUSION In summary , this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy . Instructions: please typing these entity words according to sentence: supervised multimodal exercise intervention, chemotherapy, cancer - related fatigue ., Cancer related fatigue ( CRF ), adjunct to chemotherapy and standard care, CRF level, into, intervention group, wait - list control group, Fatigue score ( CRF ), Functional Assessment of Cancer Therapy - Anaemia Questionnaire ( FACT - An- ) ( FACT - G score & FACT - An Anemia subscale ), Supervised exercise , comprising high - intensity cardiovascular and heavy resistance training , relaxation- and body awareness training and massage, Fatigue score reduction, FACT - An score, FACT - An Toi, Anaemia - ANS, General Quality of Life score, individual wellbeing scores ; Physical, Emotional, Social, self - reported CRF Options: Intervention_Physical, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other
[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]
The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue . PURPOSE Cancer related fatigue ( CRF ) is a common problem for cancer patients across diagnoses during chemotherapy and is associated with physical inactivity , lower functional level and lack of energy . Few RCT exercise intervention studies have included cancer patients undergoing chemotherapy . The objective of this study is to evaluate whether a six-week supervised multimodal exercise intervention , adjunct to chemotherapy and standard care , can reduce the patient 's CRF level . METHODS Data is based on analyses of a prospective randomised controlled trial 'The Body & Cancer Trial ' . 213 cancer patients with different diagnoses were randomised into an intervention group or wait-list control group . The primary outcome , Fatigue score ( CRF ) , was evaluated by the Functional Assessment of Cancer Therapy-Anaemia Questionnaire ( FACT-An- ) ( FACT-G score & FACT-An Anemia subscale ) . INTERVENTION Supervised exercise , comprising high-intensity cardiovascular and heavy resistance training , relaxation- and body awareness training and massage , 9 h weekly for 6 weeks . RESULTS CRF was significantly reduced in the intervention group , corresponding to a Fatigue score reduction of 3.04 ( effect size of 0.44 , 95 % CI 0.17-0.72 ) ( P = .002 ) , the FACT-An score by 5.40 ( P = .015 ) , the FACT-An Toi score by 5.22 ( P = .009 ) and the Anaemia-ANS by 3.76 ( P = .002 ) . There was no statistically significant effect on the General Quality of Life score ( FACT-G ) or on any of the individual wellbeing scores ; Physical ( P = .13 ) , Emotional ( P = .87 ) , Social ( P = .83 ) and Functional ( P = .26 ) . CONCLUSION In summary , this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy .
[ "The", "effects", "of", "a", "six", "-", "week", "supervised", "multimodal", "exercise", "intervention", "during", "chemotherapy", "on", "cancer", "-", "related", "fatigue", ".", "PURPOSE", "Cancer", "related", "fatigue", "(", "CRF", ")", "is", "a", "common", "problem", "for", "cancer", "patients", "across", "diagnoses", "during", "chemotherapy", "and", "is", "associated", "with", "physical", "inactivity", ",", "lower", "functional", "level", "and", "lack", "of", "energy", ".", "Few", "RCT", "exercise", "intervention", "studies", "have", "included", "cancer", "patients", "undergoing", "chemotherapy", ".", "The", "objective", "of", "this", "study", "is", "to", "evaluate", "whether", "a", "six", "-", "week", "supervised", "multimodal", "exercise", "intervention", ",", "adjunct", "to", "chemotherapy", "and", "standard", "care", ",", "can", "reduce", "the", "patient", "'", "s", "CRF", "level", ".", "METHODS", "Data", "is", "based", "on", "analyses", "of", "a", "prospective", "randomised", "controlled", "trial", "'", "The", "Body", "&", "Cancer", "Trial", "'", ".", "213", "cancer", "patients", "with", "different", "diagnoses", "were", "randomised", "into", "an", "intervention", "group", "or", "wait", "-", "list", "control", "group", ".", "The", "primary", "outcome", ",", "Fatigue", "score", "(", "CRF", ")", ",", "was", "evaluated", "by", "the", "Functional", "Assessment", "of", "Cancer", "Therapy", "-", "Anaemia", "Questionnaire", "(", "FACT", "-", "An-", ")", "(", "FACT", "-", "G", "score", "&", "FACT", "-", "An", "Anemia", "subscale", ")", ".", "INTERVENTION", "Supervised", "exercise", ",", "comprising", "high", "-", "intensity", "cardiovascular", "and", "heavy", "resistance", "training", ",", "relaxation-", "and", "body", "awareness", "training", "and", "massage", ",", "9", "h", "weekly", "for", "6", "weeks", ".", "RESULTS", "CRF", "was", "significantly", "reduced", "in", "the", "intervention", "group", ",", "corresponding", "to", "a", "Fatigue", "score", "reduction", "of", "3.04", "(", "effect", "size", "of", "0.44", ",", "95", "%", "CI", "0.17", "-", "0.72", ")", "(", "P", "=", ".002", ")", ",", "the", "FACT", "-", "An", "score", "by", "5.40", "(", "P", "=", ".015", ")", ",", "the", "FACT", "-", "An", "Toi", "score", "by", "5.22", "(", "P", "=", ".009", ")", "and", "the", "Anaemia", "-", "ANS", "by", "3.76", "(", "P", "=", ".002", ")", ".", "There", "was", "no", "statistically", "significant", "effect", "on", "the", "General", "Quality", "of", "Life", "score", "(", "FACT", "-", "G", ")", "or", "on", "any", "of", "the", "individual", "wellbeing", "scores", ";", "Physical", "(", "P", "=", ".13", ")", ",", "Emotional", "(", "P", "=", ".87", ")", ",", "Social", "(", "P", "=", ".83", ")", "and", "Functional", "(", "P", "=", ".26", ")", ".", "CONCLUSION", "In", "summary", ",", "this", "six", "-", "week", "supervised", "multimodal", "exercise", "intervention", "can", "lead", "to", "significant", "reduction", "in", "self", "-", "reported", "CRF", "in", "cancer", "patients", "undergoing", "chemotherapy", "." ]
[ "Intervention_Physical", "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Control" ]
supervised multimodal exercise intervention, chemotherapy, cancer - related fatigue ., Cancer related fatigue ( CRF ), adjunct to chemotherapy and standard care, CRF level, into, intervention group, wait - list control group, Fatigue score ( CRF ), Functional Assessment of Cancer Therapy - Anaemia Questionnaire ( FACT - An- ) ( FACT - G score & FACT - An Anemia subscale ), Supervised exercise , comprising high - intensity cardiovascular and heavy resistance training , relaxation- and body awareness training and massage, Fatigue score reduction, FACT - An score, FACT - An Toi, Anaemia - ANS, General Quality of Life score, individual wellbeing scores ; Physical, Emotional, Social, self - reported CRF
56983_task2
Sentence: The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue . PURPOSE Cancer related fatigue ( CRF ) is a common problem for cancer patients across diagnoses during chemotherapy and is associated with physical inactivity , lower functional level and lack of energy . Few RCT exercise intervention studies have included cancer patients undergoing chemotherapy . The objective of this study is to evaluate whether a six-week supervised multimodal exercise intervention , adjunct to chemotherapy and standard care , can reduce the patient 's CRF level . METHODS Data is based on analyses of a prospective randomised controlled trial 'The Body & Cancer Trial ' . 213 cancer patients with different diagnoses were randomised into an intervention group or wait-list control group . The primary outcome , Fatigue score ( CRF ) , was evaluated by the Functional Assessment of Cancer Therapy-Anaemia Questionnaire ( FACT-An- ) ( FACT-G score & FACT-An Anemia subscale ) . INTERVENTION Supervised exercise , comprising high-intensity cardiovascular and heavy resistance training , relaxation- and body awareness training and massage , 9 h weekly for 6 weeks . RESULTS CRF was significantly reduced in the intervention group , corresponding to a Fatigue score reduction of 3.04 ( effect size of 0.44 , 95 % CI 0.17-0.72 ) ( P = .002 ) , the FACT-An score by 5.40 ( P = .015 ) , the FACT-An Toi score by 5.22 ( P = .009 ) and the Anaemia-ANS by 3.76 ( P = .002 ) . There was no statistically significant effect on the General Quality of Life score ( FACT-G ) or on any of the individual wellbeing scores ; Physical ( P = .13 ) , Emotional ( P = .87 ) , Social ( P = .83 ) and Functional ( P = .26 ) . CONCLUSION In summary , this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]
The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue . PURPOSE Cancer related fatigue ( CRF ) is a common problem for cancer patients across diagnoses during chemotherapy and is associated with physical inactivity , lower functional level and lack of energy . Few RCT exercise intervention studies have included cancer patients undergoing chemotherapy . The objective of this study is to evaluate whether a six-week supervised multimodal exercise intervention , adjunct to chemotherapy and standard care , can reduce the patient 's CRF level . METHODS Data is based on analyses of a prospective randomised controlled trial 'The Body & Cancer Trial ' . 213 cancer patients with different diagnoses were randomised into an intervention group or wait-list control group . The primary outcome , Fatigue score ( CRF ) , was evaluated by the Functional Assessment of Cancer Therapy-Anaemia Questionnaire ( FACT-An- ) ( FACT-G score & FACT-An Anemia subscale ) . INTERVENTION Supervised exercise , comprising high-intensity cardiovascular and heavy resistance training , relaxation- and body awareness training and massage , 9 h weekly for 6 weeks . RESULTS CRF was significantly reduced in the intervention group , corresponding to a Fatigue score reduction of 3.04 ( effect size of 0.44 , 95 % CI 0.17-0.72 ) ( P = .002 ) , the FACT-An score by 5.40 ( P = .015 ) , the FACT-An Toi score by 5.22 ( P = .009 ) and the Anaemia-ANS by 3.76 ( P = .002 ) . There was no statistically significant effect on the General Quality of Life score ( FACT-G ) or on any of the individual wellbeing scores ; Physical ( P = .13 ) , Emotional ( P = .87 ) , Social ( P = .83 ) and Functional ( P = .26 ) . CONCLUSION In summary , this six-week supervised multimodal exercise intervention can lead to significant reduction in self-reported CRF in cancer patients undergoing chemotherapy .
[ "The", "effects", "of", "a", "six", "-", "week", "supervised", "multimodal", "exercise", "intervention", "during", "chemotherapy", "on", "cancer", "-", "related", "fatigue", ".", "PURPOSE", "Cancer", "related", "fatigue", "(", "CRF", ")", "is", "a", "common", "problem", "for", "cancer", "patients", "across", "diagnoses", "during", "chemotherapy", "and", "is", "associated", "with", "physical", "inactivity", ",", "lower", "functional", "level", "and", "lack", "of", "energy", ".", "Few", "RCT", "exercise", "intervention", "studies", "have", "included", "cancer", "patients", "undergoing", "chemotherapy", ".", "The", "objective", "of", "this", "study", "is", "to", "evaluate", "whether", "a", "six", "-", "week", "supervised", "multimodal", "exercise", "intervention", ",", "adjunct", "to", "chemotherapy", "and", "standard", "care", ",", "can", "reduce", "the", "patient", "'", "s", "CRF", "level", ".", "METHODS", "Data", "is", "based", "on", "analyses", "of", "a", "prospective", "randomised", "controlled", "trial", "'", "The", "Body", "&", "Cancer", "Trial", "'", ".", "213", "cancer", "patients", "with", "different", "diagnoses", "were", "randomised", "into", "an", "intervention", "group", "or", "wait", "-", "list", "control", "group", ".", "The", "primary", "outcome", ",", "Fatigue", "score", "(", "CRF", ")", ",", "was", "evaluated", "by", "the", "Functional", "Assessment", "of", "Cancer", "Therapy", "-", "Anaemia", "Questionnaire", "(", "FACT", "-", "An-", ")", "(", "FACT", "-", "G", "score", "&", "FACT", "-", "An", "Anemia", "subscale", ")", ".", "INTERVENTION", "Supervised", "exercise", ",", "comprising", "high", "-", "intensity", "cardiovascular", "and", "heavy", "resistance", "training", ",", "relaxation-", "and", "body", "awareness", "training", "and", "massage", ",", "9", "h", "weekly", "for", "6", "weeks", ".", "RESULTS", "CRF", "was", "significantly", "reduced", "in", "the", "intervention", "group", ",", "corresponding", "to", "a", "Fatigue", "score", "reduction", "of", "3.04", "(", "effect", "size", "of", "0.44", ",", "95", "%", "CI", "0.17", "-", "0.72", ")", "(", "P", "=", ".002", ")", ",", "the", "FACT", "-", "An", "score", "by", "5.40", "(", "P", "=", ".015", ")", ",", "the", "FACT", "-", "An", "Toi", "score", "by", "5.22", "(", "P", "=", ".009", ")", "and", "the", "Anaemia", "-", "ANS", "by", "3.76", "(", "P", "=", ".002", ")", ".", "There", "was", "no", "statistically", "significant", "effect", "on", "the", "General", "Quality", "of", "Life", "score", "(", "FACT", "-", "G", ")", "or", "on", "any", "of", "the", "individual", "wellbeing", "scores", ";", "Physical", "(", "P", "=", ".13", ")", ",", "Emotional", "(", "P", "=", ".87", ")", ",", "Social", "(", "P", "=", ".83", ")", "and", "Functional", "(", "P", "=", ".26", ")", ".", "CONCLUSION", "In", "summary", ",", "this", "six", "-", "week", "supervised", "multimodal", "exercise", "intervention", "can", "lead", "to", "significant", "reduction", "in", "self", "-", "reported", "CRF", "in", "cancer", "patients", "undergoing", "chemotherapy", "." ]
[ "Intervention_Physical", "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Control" ]
Blutgefaesse is an umlsterm, weiblichen is an umlsterm, Wundheilung is an umlsterm, Tumorwachstum is an umlsterm, Gewebe is an umlsterm, Gefaessneubildung is an umlsterm, Neubildung is an umlsterm, Kapillaren is an umlsterm, Embryo is an umlsterm, erwachsenen is an umlsterm, Gefaessneubildung is an umlsterm, Vorlaeuferzellen is an umlsterm
Herz.00250611.ger.abstr_task0
Sentence: Die Bildung neuer Blutgefaesse ist bei einer Vielzahl von Vorgaengen , wie zum Beispiel der Embryogenese , dem weiblichen Reproduktionszyklus , der Wundheilung , dem Tumorwachstum und der Neovaskularisation ischaemischer Gewebe , von Bedeutung . Zwei unterschiedliche Mechanismen sind an der Gefaessneubildung beteiligt : Vaskulogenese und Angiogenese . Die Angiogenese beschreibt die Neubildung von Gefaessen aus bestehenden Kapillaren im Embryo und im erwachsenen Organismus . Die Vaskulogenese definiert die Gefaessneubildung aus sich in situ differenzierenden endothelialen Vorlaeuferzellen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Die Bildung neuer Blutgefaesse ist bei einer Vielzahl von Vorgaengen , wie zum Beispiel der Embryogenese , dem weiblichen Reproduktionszyklus , der Wundheilung , dem Tumorwachstum und der Neovaskularisation ischaemischer Gewebe , von Bedeutung . Zwei unterschiedliche Mechanismen sind an der Gefaessneubildung beteiligt : Vaskulogenese und Angiogenese . Die Angiogenese beschreibt die Neubildung von Gefaessen aus bestehenden Kapillaren im Embryo und im erwachsenen Organismus . Die Vaskulogenese definiert die Gefaessneubildung aus sich in situ differenzierenden endothelialen Vorlaeuferzellen .
[ "Die", "Bildung", "neuer", "Blutgefaesse", "ist", "bei", "einer", "Vielzahl", "von", "Vorgaengen", ",", "wie", "zum", "Beispiel", "der", "Embryogenese", ",", "dem", "weiblichen", "Reproduktionszyklus", ",", "der", "Wundheilung", ",", "dem", "Tumorwachstum", "und", "der", "Neovaskularisation", "ischaemischer", "Gewebe", ",", "von", "Bedeutung", ".", "Zwei", "unterschiedliche", "Mechanismen", "sind", "an", "der", "Gefaessneubildung", "beteiligt", ":", "Vaskulogenese", "und", "Angiogenese", ".", "Die", "Angiogenese", "beschreibt", "die", "Neubildung", "von", "Gefaessen", "aus", "bestehenden", "Kapillaren", "im", "Embryo", "und", "im", "erwachsenen", "Organismus", ".", "Die", "Vaskulogenese", "definiert", "die", "Gefaessneubildung", "aus", "sich", "in", "situ", "differenzierenden", "endothelialen", "Vorlaeuferzellen", "." ]
[ "umlsterm" ]
Blutgefaesse is an umlsterm, weiblichen is an umlsterm, Wundheilung is an umlsterm, Tumorwachstum is an umlsterm, Gewebe is an umlsterm, Gefaessneubildung is an umlsterm, Neubildung is an umlsterm, Kapillaren is an umlsterm, Embryo is an umlsterm, erwachsenen is an umlsterm, Gefaessneubildung is an umlsterm, Vorlaeuferzellen is an umlsterm
Herz.00250611.ger.abstr_task1
Sentence: Die Bildung neuer Blutgefaesse ist bei einer Vielzahl von Vorgaengen , wie zum Beispiel der Embryogenese , dem weiblichen Reproduktionszyklus , der Wundheilung , dem Tumorwachstum und der Neovaskularisation ischaemischer Gewebe , von Bedeutung . Zwei unterschiedliche Mechanismen sind an der Gefaessneubildung beteiligt : Vaskulogenese und Angiogenese . Die Angiogenese beschreibt die Neubildung von Gefaessen aus bestehenden Kapillaren im Embryo und im erwachsenen Organismus . Die Vaskulogenese definiert die Gefaessneubildung aus sich in situ differenzierenden endothelialen Vorlaeuferzellen . Instructions: please typing these entity words according to sentence: Blutgefaesse, weiblichen, Wundheilung, Tumorwachstum, Gewebe, Gefaessneubildung, Neubildung, Kapillaren, Embryo, erwachsenen, Gefaessneubildung, Vorlaeuferzellen Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Die Bildung neuer Blutgefaesse ist bei einer Vielzahl von Vorgaengen , wie zum Beispiel der Embryogenese , dem weiblichen Reproduktionszyklus , der Wundheilung , dem Tumorwachstum und der Neovaskularisation ischaemischer Gewebe , von Bedeutung . Zwei unterschiedliche Mechanismen sind an der Gefaessneubildung beteiligt : Vaskulogenese und Angiogenese . Die Angiogenese beschreibt die Neubildung von Gefaessen aus bestehenden Kapillaren im Embryo und im erwachsenen Organismus . Die Vaskulogenese definiert die Gefaessneubildung aus sich in situ differenzierenden endothelialen Vorlaeuferzellen .
[ "Die", "Bildung", "neuer", "Blutgefaesse", "ist", "bei", "einer", "Vielzahl", "von", "Vorgaengen", ",", "wie", "zum", "Beispiel", "der", "Embryogenese", ",", "dem", "weiblichen", "Reproduktionszyklus", ",", "der", "Wundheilung", ",", "dem", "Tumorwachstum", "und", "der", "Neovaskularisation", "ischaemischer", "Gewebe", ",", "von", "Bedeutung", ".", "Zwei", "unterschiedliche", "Mechanismen", "sind", "an", "der", "Gefaessneubildung", "beteiligt", ":", "Vaskulogenese", "und", "Angiogenese", ".", "Die", "Angiogenese", "beschreibt", "die", "Neubildung", "von", "Gefaessen", "aus", "bestehenden", "Kapillaren", "im", "Embryo", "und", "im", "erwachsenen", "Organismus", ".", "Die", "Vaskulogenese", "definiert", "die", "Gefaessneubildung", "aus", "sich", "in", "situ", "differenzierenden", "endothelialen", "Vorlaeuferzellen", "." ]
[ "umlsterm" ]
Blutgefaesse, weiblichen, Wundheilung, Tumorwachstum, Gewebe, Gefaessneubildung, Neubildung, Kapillaren, Embryo, erwachsenen, Gefaessneubildung, Vorlaeuferzellen
Herz.00250611.ger.abstr_task2
Sentence: Die Bildung neuer Blutgefaesse ist bei einer Vielzahl von Vorgaengen , wie zum Beispiel der Embryogenese , dem weiblichen Reproduktionszyklus , der Wundheilung , dem Tumorwachstum und der Neovaskularisation ischaemischer Gewebe , von Bedeutung . Zwei unterschiedliche Mechanismen sind an der Gefaessneubildung beteiligt : Vaskulogenese und Angiogenese . Die Angiogenese beschreibt die Neubildung von Gefaessen aus bestehenden Kapillaren im Embryo und im erwachsenen Organismus . Die Vaskulogenese definiert die Gefaessneubildung aus sich in situ differenzierenden endothelialen Vorlaeuferzellen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Die Bildung neuer Blutgefaesse ist bei einer Vielzahl von Vorgaengen , wie zum Beispiel der Embryogenese , dem weiblichen Reproduktionszyklus , der Wundheilung , dem Tumorwachstum und der Neovaskularisation ischaemischer Gewebe , von Bedeutung . Zwei unterschiedliche Mechanismen sind an der Gefaessneubildung beteiligt : Vaskulogenese und Angiogenese . Die Angiogenese beschreibt die Neubildung von Gefaessen aus bestehenden Kapillaren im Embryo und im erwachsenen Organismus . Die Vaskulogenese definiert die Gefaessneubildung aus sich in situ differenzierenden endothelialen Vorlaeuferzellen .
[ "Die", "Bildung", "neuer", "Blutgefaesse", "ist", "bei", "einer", "Vielzahl", "von", "Vorgaengen", ",", "wie", "zum", "Beispiel", "der", "Embryogenese", ",", "dem", "weiblichen", "Reproduktionszyklus", ",", "der", "Wundheilung", ",", "dem", "Tumorwachstum", "und", "der", "Neovaskularisation", "ischaemischer", "Gewebe", ",", "von", "Bedeutung", ".", "Zwei", "unterschiedliche", "Mechanismen", "sind", "an", "der", "Gefaessneubildung", "beteiligt", ":", "Vaskulogenese", "und", "Angiogenese", ".", "Die", "Angiogenese", "beschreibt", "die", "Neubildung", "von", "Gefaessen", "aus", "bestehenden", "Kapillaren", "im", "Embryo", "und", "im", "erwachsenen", "Organismus", ".", "Die", "Vaskulogenese", "definiert", "die", "Gefaessneubildung", "aus", "sich", "in", "situ", "differenzierenden", "endothelialen", "Vorlaeuferzellen", "." ]
[ "umlsterm" ]
Zinc is an umlsterm, micronutrient is an umlsterm, zinc is an umlsterm, deficiency is an umlsterm, older is an umlsterm, people is an umlsterm, Zinc is an umlsterm, role is an umlsterm, wound healing is an umlsterm, infections is an umlsterm, immune system is an umlsterm, cardiovascular disease is an umlsterm, investigators is an umlsterm, intervention studies is an umlsterm, zinc is an umlsterm, older is an umlsterm, people is an umlsterm, paper is an umlsterm, zinc is an umlsterm, deficiency is an umlsterm, zinc is an umlsterm, supplementation is an umlsterm, older is an umlsterm, people is an umlsterm
ZfuerGerontologie+Geriatrie.9032s075.eng.abstr_task0
Sentence: Zinc is an essential micronutrient . Several studies have shown that zinc deficiency is common in older people . Zinc has been extensively studied with regard to its role in wound healing , infections , immune system , cardiovascular disease , and several other medical conditions . Several investigators have published intervention studies using zinc supplements in older people with favorable outcomes . This paper will briefly review the pathophysicologic effects of zinc , nutritional deficiency , and effects of zinc supplementation in older people . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]
Zinc is an essential micronutrient . Several studies have shown that zinc deficiency is common in older people . Zinc has been extensively studied with regard to its role in wound healing , infections , immune system , cardiovascular disease , and several other medical conditions . Several investigators have published intervention studies using zinc supplements in older people with favorable outcomes . This paper will briefly review the pathophysicologic effects of zinc , nutritional deficiency , and effects of zinc supplementation in older people .
[ "Zinc", "is", "an", "essential", "micronutrient", ".", "Several", "studies", "have", "shown", "that", "zinc", "deficiency", "is", "common", "in", "older", "people", ".", "Zinc", "has", "been", "extensively", "studied", "with", "regard", "to", "its", "role", "in", "wound", "healing", ",", "infections", ",", "immune", "system", ",", "cardiovascular", "disease", ",", "and", "several", "other", "medical", "conditions", ".", "Several", "investigators", "have", "published", "intervention", "studies", "using", "zinc", "supplements", "in", "older", "people", "with", "favorable", "outcomes", ".", "This", "paper", "will", "briefly", "review", "the", "pathophysicologic", "effects", "of", "zinc", ",", "nutritional", "deficiency", ",", "and", "effects", "of", "zinc", "supplementation", "in", "older", "people", "." ]
[ "umlsterm" ]
Zinc is an umlsterm, micronutrient is an umlsterm, zinc is an umlsterm, deficiency is an umlsterm, older is an umlsterm, people is an umlsterm, Zinc is an umlsterm, role is an umlsterm, wound healing is an umlsterm, infections is an umlsterm, immune system is an umlsterm, cardiovascular disease is an umlsterm, investigators is an umlsterm, intervention studies is an umlsterm, zinc is an umlsterm, older is an umlsterm, people is an umlsterm, paper is an umlsterm, zinc is an umlsterm, deficiency is an umlsterm, zinc is an umlsterm, supplementation is an umlsterm, older is an umlsterm, people is an umlsterm
ZfuerGerontologie+Geriatrie.9032s075.eng.abstr_task1
Sentence: Zinc is an essential micronutrient . Several studies have shown that zinc deficiency is common in older people . Zinc has been extensively studied with regard to its role in wound healing , infections , immune system , cardiovascular disease , and several other medical conditions . Several investigators have published intervention studies using zinc supplements in older people with favorable outcomes . This paper will briefly review the pathophysicologic effects of zinc , nutritional deficiency , and effects of zinc supplementation in older people . Instructions: please typing these entity words according to sentence: Zinc, micronutrient, zinc, deficiency, older, people, Zinc, role, wound healing, infections, immune system, cardiovascular disease, investigators, intervention studies, zinc, older, people, paper, zinc, deficiency, zinc, supplementation, older, people Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]
Zinc is an essential micronutrient . Several studies have shown that zinc deficiency is common in older people . Zinc has been extensively studied with regard to its role in wound healing , infections , immune system , cardiovascular disease , and several other medical conditions . Several investigators have published intervention studies using zinc supplements in older people with favorable outcomes . This paper will briefly review the pathophysicologic effects of zinc , nutritional deficiency , and effects of zinc supplementation in older people .
[ "Zinc", "is", "an", "essential", "micronutrient", ".", "Several", "studies", "have", "shown", "that", "zinc", "deficiency", "is", "common", "in", "older", "people", ".", "Zinc", "has", "been", "extensively", "studied", "with", "regard", "to", "its", "role", "in", "wound", "healing", ",", "infections", ",", "immune", "system", ",", "cardiovascular", "disease", ",", "and", "several", "other", "medical", "conditions", ".", "Several", "investigators", "have", "published", "intervention", "studies", "using", "zinc", "supplements", "in", "older", "people", "with", "favorable", "outcomes", ".", "This", "paper", "will", "briefly", "review", "the", "pathophysicologic", "effects", "of", "zinc", ",", "nutritional", "deficiency", ",", "and", "effects", "of", "zinc", "supplementation", "in", "older", "people", "." ]
[ "umlsterm" ]
Zinc, micronutrient, zinc, deficiency, older, people, Zinc, role, wound healing, infections, immune system, cardiovascular disease, investigators, intervention studies, zinc, older, people, paper, zinc, deficiency, zinc, supplementation, older, people
ZfuerGerontologie+Geriatrie.9032s075.eng.abstr_task2
Sentence: Zinc is an essential micronutrient . Several studies have shown that zinc deficiency is common in older people . Zinc has been extensively studied with regard to its role in wound healing , infections , immune system , cardiovascular disease , and several other medical conditions . Several investigators have published intervention studies using zinc supplements in older people with favorable outcomes . This paper will briefly review the pathophysicologic effects of zinc , nutritional deficiency , and effects of zinc supplementation in older people . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]
Zinc is an essential micronutrient . Several studies have shown that zinc deficiency is common in older people . Zinc has been extensively studied with regard to its role in wound healing , infections , immune system , cardiovascular disease , and several other medical conditions . Several investigators have published intervention studies using zinc supplements in older people with favorable outcomes . This paper will briefly review the pathophysicologic effects of zinc , nutritional deficiency , and effects of zinc supplementation in older people .
[ "Zinc", "is", "an", "essential", "micronutrient", ".", "Several", "studies", "have", "shown", "that", "zinc", "deficiency", "is", "common", "in", "older", "people", ".", "Zinc", "has", "been", "extensively", "studied", "with", "regard", "to", "its", "role", "in", "wound", "healing", ",", "infections", ",", "immune", "system", ",", "cardiovascular", "disease", ",", "and", "several", "other", "medical", "conditions", ".", "Several", "investigators", "have", "published", "intervention", "studies", "using", "zinc", "supplements", "in", "older", "people", "with", "favorable", "outcomes", ".", "This", "paper", "will", "briefly", "review", "the", "pathophysicologic", "effects", "of", "zinc", ",", "nutritional", "deficiency", ",", "and", "effects", "of", "zinc", "supplementation", "in", "older", "people", "." ]
[ "umlsterm" ]
Chirurgie is an umlsterm, Nasendefekten is an umlsterm, Tumorresektion is an umlsterm, Patienten is an umlsterm, tumorbedingten is an umlsterm, Nasendefekten is an umlsterm, Gesichtsteile is an umlsterm, Silikonepithesen is an umlsterm, PMMA is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Intraoperative Komplikationen is an umlsterm, Nachsorge is an umlsterm, Entzuendungen is an umlsterm, Knochenarealen is an umlsterm, Knochenarealen is an umlsterm, Knochenarealen is an umlsterm, knochenverankerte is an umlsterm, tumorbedingter is an umlsterm, Nasendefekte is an umlsterm, Patienten is an umlsterm
HNO.90470623.ger.abstr_task0
Sentence: Die plastisch-rekonstruktive Chirurgie von Nasendefekten nach Tumorresektion ist nicht immer moeglich oder sinnvoll . Hier bietet sich als Alternative die epithetische Versorgung an . 37 Patienten mit tumorbedingten Nasendefekten wurden seit 1991 im Berliner Zentrum fuer kuenstliche Gesichtsteile epithetisch versorgt . Es wurden 28 weiche " Silikonepithesen " und 9 " harte " Epithesen aus Polymethylmetacrylat ( PMMA ) gefertigt . Bei 35 Patienten wurde die Epithese knochenverankert : bei 12 Patienten mit Brånemark-Implantaten und bei 23 Patienten mit einem Epitec-Geruest . Lediglich 2 Patienten erhielten eine Klebeepithese . Intraoperative Komplikationen bei der Implantatsetzung traten nicht auf . In der Nachsorge sahen wir nur leichte periimplantaere Entzuendungen , die lokal behandelt werden konnten . Die Implantaterfolgsrate lag bei den Brånemark-Implantaten bei 78% ( 89,7% in nicht bestrahlten Knochenarealen und 50% in bestrahlten Knochenarealen ) und beim Epitec-System in bestrahlten und in nicht bestrahlten Knochenarealen bei 100% . Die Untersuchung zeigt , dass bei richtiger Indikationsstellung die knochenverankerte epithetische Versorgung tumorbedingter Nasendefekte sicher , kosmetisch guenstig , komplikationsarm und fuer den Patienten wenig belastend ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Die plastisch-rekonstruktive Chirurgie von Nasendefekten nach Tumorresektion ist nicht immer moeglich oder sinnvoll . Hier bietet sich als Alternative die epithetische Versorgung an . 37 Patienten mit tumorbedingten Nasendefekten wurden seit 1991 im Berliner Zentrum fuer kuenstliche Gesichtsteile epithetisch versorgt . Es wurden 28 weiche " Silikonepithesen " und 9 " harte " Epithesen aus Polymethylmetacrylat ( PMMA ) gefertigt . Bei 35 Patienten wurde die Epithese knochenverankert : bei 12 Patienten mit Brånemark-Implantaten und bei 23 Patienten mit einem Epitec-Geruest . Lediglich 2 Patienten erhielten eine Klebeepithese . Intraoperative Komplikationen bei der Implantatsetzung traten nicht auf . In der Nachsorge sahen wir nur leichte periimplantaere Entzuendungen , die lokal behandelt werden konnten . Die Implantaterfolgsrate lag bei den Brånemark-Implantaten bei 78% ( 89,7% in nicht bestrahlten Knochenarealen und 50% in bestrahlten Knochenarealen ) und beim Epitec-System in bestrahlten und in nicht bestrahlten Knochenarealen bei 100% . Die Untersuchung zeigt , dass bei richtiger Indikationsstellung die knochenverankerte epithetische Versorgung tumorbedingter Nasendefekte sicher , kosmetisch guenstig , komplikationsarm und fuer den Patienten wenig belastend ist .
[ "Die", "plastisch", "-", "rekonstruktive", "Chirurgie", "von", "Nasendefekten", "nach", "Tumorresektion", "ist", "nicht", "immer", "moeglich", "oder", "sinnvoll", ".", "Hier", "bietet", "sich", "als", "Alternative", "die", "epithetische", "Versorgung", "an", ".", "37", "Patienten", "mit", "tumorbedingten", "Nasendefekten", "wurden", "seit", "1991", "im", "Berliner", "Zentrum", "fuer", "kuenstliche", "Gesichtsteile", "epithetisch", "versorgt", ".", "Es", "wurden", "28", "weiche", "\"", "Silikonepithesen", "\"", "und", "9", "\"", "harte", "\"", "Epithesen", "aus", "Polymethylmetacrylat", "(", "PMMA", ")", "gefertigt", ".", "Bei", "35", "Patienten", "wurde", "die", "Epithese", "knochenverankert", ":", "bei", "12", "Patienten", "mit", "Brånemark", "-", "Implantaten", "und", "bei", "23", "Patienten", "mit", "einem", "Epitec", "-", "Geruest", ".", "Lediglich", "2", "Patienten", "erhielten", "eine", "Klebeepithese", ".", "Intraoperative", "Komplikationen", "bei", "der", "Implantatsetzung", "traten", "nicht", "auf", ".", "In", "der", "Nachsorge", "sahen", "wir", "nur", "leichte", "periimplantaere", "Entzuendungen", ",", "die", "lokal", "behandelt", "werden", "konnten", ".", "Die", "Implantaterfolgsrate", "lag", "bei", "den", "Brånemark", "-", "Implantaten", "bei", "78", "%", "(", "89,7", "%", "in", "nicht", "bestrahlten", "Knochenarealen", "und", "50", "%", "in", "bestrahlten", "Knochenarealen", ")", "und", "beim", "Epitec", "-", "System", "in", "bestrahlten", "und", "in", "nicht", "bestrahlten", "Knochenarealen", "bei", "100", "%", ".", "Die", "Untersuchung", "zeigt", ",", "dass", "bei", "richtiger", "Indikationsstellung", "die", "knochenverankerte", "epithetische", "Versorgung", "tumorbedingter", "Nasendefekte", "sicher", ",", "kosmetisch", "guenstig", ",", "komplikationsarm", "und", "fuer", "den", "Patienten", "wenig", "belastend", "ist", "." ]
[ "umlsterm" ]
Chirurgie is an umlsterm, Nasendefekten is an umlsterm, Tumorresektion is an umlsterm, Patienten is an umlsterm, tumorbedingten is an umlsterm, Nasendefekten is an umlsterm, Gesichtsteile is an umlsterm, Silikonepithesen is an umlsterm, PMMA is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Intraoperative Komplikationen is an umlsterm, Nachsorge is an umlsterm, Entzuendungen is an umlsterm, Knochenarealen is an umlsterm, Knochenarealen is an umlsterm, Knochenarealen is an umlsterm, knochenverankerte is an umlsterm, tumorbedingter is an umlsterm, Nasendefekte is an umlsterm, Patienten is an umlsterm
HNO.90470623.ger.abstr_task1
Sentence: Die plastisch-rekonstruktive Chirurgie von Nasendefekten nach Tumorresektion ist nicht immer moeglich oder sinnvoll . Hier bietet sich als Alternative die epithetische Versorgung an . 37 Patienten mit tumorbedingten Nasendefekten wurden seit 1991 im Berliner Zentrum fuer kuenstliche Gesichtsteile epithetisch versorgt . Es wurden 28 weiche " Silikonepithesen " und 9 " harte " Epithesen aus Polymethylmetacrylat ( PMMA ) gefertigt . Bei 35 Patienten wurde die Epithese knochenverankert : bei 12 Patienten mit Brånemark-Implantaten und bei 23 Patienten mit einem Epitec-Geruest . Lediglich 2 Patienten erhielten eine Klebeepithese . Intraoperative Komplikationen bei der Implantatsetzung traten nicht auf . In der Nachsorge sahen wir nur leichte periimplantaere Entzuendungen , die lokal behandelt werden konnten . Die Implantaterfolgsrate lag bei den Brånemark-Implantaten bei 78% ( 89,7% in nicht bestrahlten Knochenarealen und 50% in bestrahlten Knochenarealen ) und beim Epitec-System in bestrahlten und in nicht bestrahlten Knochenarealen bei 100% . Die Untersuchung zeigt , dass bei richtiger Indikationsstellung die knochenverankerte epithetische Versorgung tumorbedingter Nasendefekte sicher , kosmetisch guenstig , komplikationsarm und fuer den Patienten wenig belastend ist . Instructions: please typing these entity words according to sentence: Chirurgie, Nasendefekten, Tumorresektion, Patienten, tumorbedingten, Nasendefekten, Gesichtsteile, Silikonepithesen, PMMA, Patienten, Patienten, Patienten, Patienten, Intraoperative Komplikationen, Nachsorge, Entzuendungen, Knochenarealen, Knochenarealen, Knochenarealen, knochenverankerte, tumorbedingter, Nasendefekte, Patienten Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Die plastisch-rekonstruktive Chirurgie von Nasendefekten nach Tumorresektion ist nicht immer moeglich oder sinnvoll . Hier bietet sich als Alternative die epithetische Versorgung an . 37 Patienten mit tumorbedingten Nasendefekten wurden seit 1991 im Berliner Zentrum fuer kuenstliche Gesichtsteile epithetisch versorgt . Es wurden 28 weiche " Silikonepithesen " und 9 " harte " Epithesen aus Polymethylmetacrylat ( PMMA ) gefertigt . Bei 35 Patienten wurde die Epithese knochenverankert : bei 12 Patienten mit Brånemark-Implantaten und bei 23 Patienten mit einem Epitec-Geruest . Lediglich 2 Patienten erhielten eine Klebeepithese . Intraoperative Komplikationen bei der Implantatsetzung traten nicht auf . In der Nachsorge sahen wir nur leichte periimplantaere Entzuendungen , die lokal behandelt werden konnten . Die Implantaterfolgsrate lag bei den Brånemark-Implantaten bei 78% ( 89,7% in nicht bestrahlten Knochenarealen und 50% in bestrahlten Knochenarealen ) und beim Epitec-System in bestrahlten und in nicht bestrahlten Knochenarealen bei 100% . Die Untersuchung zeigt , dass bei richtiger Indikationsstellung die knochenverankerte epithetische Versorgung tumorbedingter Nasendefekte sicher , kosmetisch guenstig , komplikationsarm und fuer den Patienten wenig belastend ist .
[ "Die", "plastisch", "-", "rekonstruktive", "Chirurgie", "von", "Nasendefekten", "nach", "Tumorresektion", "ist", "nicht", "immer", "moeglich", "oder", "sinnvoll", ".", "Hier", "bietet", "sich", "als", "Alternative", "die", "epithetische", "Versorgung", "an", ".", "37", "Patienten", "mit", "tumorbedingten", "Nasendefekten", "wurden", "seit", "1991", "im", "Berliner", "Zentrum", "fuer", "kuenstliche", "Gesichtsteile", "epithetisch", "versorgt", ".", "Es", "wurden", "28", "weiche", "\"", "Silikonepithesen", "\"", "und", "9", "\"", "harte", "\"", "Epithesen", "aus", "Polymethylmetacrylat", "(", "PMMA", ")", "gefertigt", ".", "Bei", "35", "Patienten", "wurde", "die", "Epithese", "knochenverankert", ":", "bei", "12", "Patienten", "mit", "Brånemark", "-", "Implantaten", "und", "bei", "23", "Patienten", "mit", "einem", "Epitec", "-", "Geruest", ".", "Lediglich", "2", "Patienten", "erhielten", "eine", "Klebeepithese", ".", "Intraoperative", "Komplikationen", "bei", "der", "Implantatsetzung", "traten", "nicht", "auf", ".", "In", "der", "Nachsorge", "sahen", "wir", "nur", "leichte", "periimplantaere", "Entzuendungen", ",", "die", "lokal", "behandelt", "werden", "konnten", ".", "Die", "Implantaterfolgsrate", "lag", "bei", "den", "Brånemark", "-", "Implantaten", "bei", "78", "%", "(", "89,7", "%", "in", "nicht", "bestrahlten", "Knochenarealen", "und", "50", "%", "in", "bestrahlten", "Knochenarealen", ")", "und", "beim", "Epitec", "-", "System", "in", "bestrahlten", "und", "in", "nicht", "bestrahlten", "Knochenarealen", "bei", "100", "%", ".", "Die", "Untersuchung", "zeigt", ",", "dass", "bei", "richtiger", "Indikationsstellung", "die", "knochenverankerte", "epithetische", "Versorgung", "tumorbedingter", "Nasendefekte", "sicher", ",", "kosmetisch", "guenstig", ",", "komplikationsarm", "und", "fuer", "den", "Patienten", "wenig", "belastend", "ist", "." ]
[ "umlsterm" ]
Chirurgie, Nasendefekten, Tumorresektion, Patienten, tumorbedingten, Nasendefekten, Gesichtsteile, Silikonepithesen, PMMA, Patienten, Patienten, Patienten, Patienten, Intraoperative Komplikationen, Nachsorge, Entzuendungen, Knochenarealen, Knochenarealen, Knochenarealen, knochenverankerte, tumorbedingter, Nasendefekte, Patienten
HNO.90470623.ger.abstr_task2
Sentence: Die plastisch-rekonstruktive Chirurgie von Nasendefekten nach Tumorresektion ist nicht immer moeglich oder sinnvoll . Hier bietet sich als Alternative die epithetische Versorgung an . 37 Patienten mit tumorbedingten Nasendefekten wurden seit 1991 im Berliner Zentrum fuer kuenstliche Gesichtsteile epithetisch versorgt . Es wurden 28 weiche " Silikonepithesen " und 9 " harte " Epithesen aus Polymethylmetacrylat ( PMMA ) gefertigt . Bei 35 Patienten wurde die Epithese knochenverankert : bei 12 Patienten mit Brånemark-Implantaten und bei 23 Patienten mit einem Epitec-Geruest . Lediglich 2 Patienten erhielten eine Klebeepithese . Intraoperative Komplikationen bei der Implantatsetzung traten nicht auf . In der Nachsorge sahen wir nur leichte periimplantaere Entzuendungen , die lokal behandelt werden konnten . Die Implantaterfolgsrate lag bei den Brånemark-Implantaten bei 78% ( 89,7% in nicht bestrahlten Knochenarealen und 50% in bestrahlten Knochenarealen ) und beim Epitec-System in bestrahlten und in nicht bestrahlten Knochenarealen bei 100% . Die Untersuchung zeigt , dass bei richtiger Indikationsstellung die knochenverankerte epithetische Versorgung tumorbedingter Nasendefekte sicher , kosmetisch guenstig , komplikationsarm und fuer den Patienten wenig belastend ist . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Die plastisch-rekonstruktive Chirurgie von Nasendefekten nach Tumorresektion ist nicht immer moeglich oder sinnvoll . Hier bietet sich als Alternative die epithetische Versorgung an . 37 Patienten mit tumorbedingten Nasendefekten wurden seit 1991 im Berliner Zentrum fuer kuenstliche Gesichtsteile epithetisch versorgt . Es wurden 28 weiche " Silikonepithesen " und 9 " harte " Epithesen aus Polymethylmetacrylat ( PMMA ) gefertigt . Bei 35 Patienten wurde die Epithese knochenverankert : bei 12 Patienten mit Brånemark-Implantaten und bei 23 Patienten mit einem Epitec-Geruest . Lediglich 2 Patienten erhielten eine Klebeepithese . Intraoperative Komplikationen bei der Implantatsetzung traten nicht auf . In der Nachsorge sahen wir nur leichte periimplantaere Entzuendungen , die lokal behandelt werden konnten . Die Implantaterfolgsrate lag bei den Brånemark-Implantaten bei 78% ( 89,7% in nicht bestrahlten Knochenarealen und 50% in bestrahlten Knochenarealen ) und beim Epitec-System in bestrahlten und in nicht bestrahlten Knochenarealen bei 100% . Die Untersuchung zeigt , dass bei richtiger Indikationsstellung die knochenverankerte epithetische Versorgung tumorbedingter Nasendefekte sicher , kosmetisch guenstig , komplikationsarm und fuer den Patienten wenig belastend ist .
[ "Die", "plastisch", "-", "rekonstruktive", "Chirurgie", "von", "Nasendefekten", "nach", "Tumorresektion", "ist", "nicht", "immer", "moeglich", "oder", "sinnvoll", ".", "Hier", "bietet", "sich", "als", "Alternative", "die", "epithetische", "Versorgung", "an", ".", "37", "Patienten", "mit", "tumorbedingten", "Nasendefekten", "wurden", "seit", "1991", "im", "Berliner", "Zentrum", "fuer", "kuenstliche", "Gesichtsteile", "epithetisch", "versorgt", ".", "Es", "wurden", "28", "weiche", "\"", "Silikonepithesen", "\"", "und", "9", "\"", "harte", "\"", "Epithesen", "aus", "Polymethylmetacrylat", "(", "PMMA", ")", "gefertigt", ".", "Bei", "35", "Patienten", "wurde", "die", "Epithese", "knochenverankert", ":", "bei", "12", "Patienten", "mit", "Brånemark", "-", "Implantaten", "und", "bei", "23", "Patienten", "mit", "einem", "Epitec", "-", "Geruest", ".", "Lediglich", "2", "Patienten", "erhielten", "eine", "Klebeepithese", ".", "Intraoperative", "Komplikationen", "bei", "der", "Implantatsetzung", "traten", "nicht", "auf", ".", "In", "der", "Nachsorge", "sahen", "wir", "nur", "leichte", "periimplantaere", "Entzuendungen", ",", "die", "lokal", "behandelt", "werden", "konnten", ".", "Die", "Implantaterfolgsrate", "lag", "bei", "den", "Brånemark", "-", "Implantaten", "bei", "78", "%", "(", "89,7", "%", "in", "nicht", "bestrahlten", "Knochenarealen", "und", "50", "%", "in", "bestrahlten", "Knochenarealen", ")", "und", "beim", "Epitec", "-", "System", "in", "bestrahlten", "und", "in", "nicht", "bestrahlten", "Knochenarealen", "bei", "100", "%", ".", "Die", "Untersuchung", "zeigt", ",", "dass", "bei", "richtiger", "Indikationsstellung", "die", "knochenverankerte", "epithetische", "Versorgung", "tumorbedingter", "Nasendefekte", "sicher", ",", "kosmetisch", "guenstig", ",", "komplikationsarm", "und", "fuer", "den", "Patienten", "wenig", "belastend", "ist", "." ]
[ "umlsterm" ]
laser is an umlsterm, attention is an umlsterm, angina is an umlsterm, symptoms is an umlsterm, patients is an umlsterm, therapy is an umlsterm, up - regulation is an umlsterm, growth factors is an umlsterm, laser is an umlsterm, myocardium is an umlsterm, injury is an umlsterm
Herz.00250579.eng.abstr_task0
Sentence: The clinical and experimental data relevant to the theoretical mechanisms and clinical results of laser myocardial " revascularization " are reviewed . Both transmyocardial ( TMR ) and percutaneous ( PMR ) approaches are considered . Special attention is paid to the issue of TMR-induced angiogenesis . Both TMR and PMR result in a reduction in angina symptoms in patients refractory to conventional therapy and are likely to act through common pathways . TMR-induced angiogenesis appears to result from the up-regulation of vascular growth factors . However , the available data suggest that the angiogenic response is not a unique consequence of laser revascularization . Rather , the angiogenesis associated with TMR is likely to be a non-specific response of the myocardium to injury . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
The clinical and experimental data relevant to the theoretical mechanisms and clinical results of laser myocardial " revascularization " are reviewed . Both transmyocardial ( TMR ) and percutaneous ( PMR ) approaches are considered . Special attention is paid to the issue of TMR-induced angiogenesis . Both TMR and PMR result in a reduction in angina symptoms in patients refractory to conventional therapy and are likely to act through common pathways . TMR-induced angiogenesis appears to result from the up-regulation of vascular growth factors . However , the available data suggest that the angiogenic response is not a unique consequence of laser revascularization . Rather , the angiogenesis associated with TMR is likely to be a non-specific response of the myocardium to injury .
[ "The", "clinical", "and", "experimental", "data", "relevant", "to", "the", "theoretical", "mechanisms", "and", "clinical", "results", "of", "laser", "myocardial", "\"", "revascularization", "\"", "are", "reviewed", ".", "Both", "transmyocardial", "(", "TMR", ")", "and", "percutaneous", "(", "PMR", ")", "approaches", "are", "considered", ".", "Special", "attention", "is", "paid", "to", "the", "issue", "of", "TMR", "-", "induced", "angiogenesis", ".", "Both", "TMR", "and", "PMR", "result", "in", "a", "reduction", "in", "angina", "symptoms", "in", "patients", "refractory", "to", "conventional", "therapy", "and", "are", "likely", "to", "act", "through", "common", "pathways", ".", "TMR", "-", "induced", "angiogenesis", "appears", "to", "result", "from", "the", "up", "-", "regulation", "of", "vascular", "growth", "factors", ".", "However", ",", "the", "available", "data", "suggest", "that", "the", "angiogenic", "response", "is", "not", "a", "unique", "consequence", "of", "laser", "revascularization", ".", "Rather", ",", "the", "angiogenesis", "associated", "with", "TMR", "is", "likely", "to", "be", "a", "non", "-", "specific", "response", "of", "the", "myocardium", "to", "injury", "." ]
[ "umlsterm" ]